US6054561A
(en)
*
|
1984-02-08 |
2000-04-25 |
Chiron Corporation |
Antigen-binding sites of antibody molecules specific for cancer antigens
|
US5571714A
(en)
*
|
1988-12-22 |
1996-11-05 |
Celtrix Pharmaceuticals, Inc. |
Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
|
US20040049014A1
(en)
*
|
1988-12-28 |
2004-03-11 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
GB9020282D0
(en)
*
|
1990-09-17 |
1990-10-31 |
Gorman Scott D |
Altered antibodies and their preparation
|
US5811267A
(en)
*
|
1990-10-29 |
1998-09-22 |
Chiron Corporation |
Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens
|
US5948647A
(en)
*
|
1990-10-29 |
1999-09-07 |
Chiron Corporation |
Nucleic acids encoding antigen-binding sites specific for cancer antigens
|
US5849877A
(en)
*
|
1990-10-29 |
1998-12-15 |
Chiron Corporation |
Antigen-binding sites of antibody molecules specific for cancer antigens
|
WO1994004679A1
(en)
*
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
GB9115364D0
(en)
*
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
US6329509B1
(en)
*
|
1991-08-14 |
2001-12-11 |
Genentech, Inc. |
Anti-IgE antibodies
|
US6699472B2
(en)
|
1991-08-14 |
2004-03-02 |
Genentech, Inc. |
Method of treating allergic disorders
|
US5869619A
(en)
*
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
ES2202310T3
(es)
*
|
1991-12-13 |
2004-04-01 |
Xoma Corporation |
Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
EP0578515A3
(en)
*
|
1992-05-26 |
1995-05-10 |
Bristol Myers Squibb Co |
Humanized monoclonal antibodies.
|
AU687755B2
(en)
*
|
1992-08-21 |
1998-03-05 |
Genentech Inc. |
Method for treating an LFA-1-mediated disorder
|
US5958708A
(en)
*
|
1992-09-25 |
1999-09-28 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
US6066718A
(en)
*
|
1992-09-25 |
2000-05-23 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
EP0804235A4
(en)
*
|
1993-05-04 |
2001-09-19 |
Aeres Biomedical Ltd |
ANTIBODIES AGAINST SELECTIN P AND USES THEREOF
|
US20040067157A1
(en)
*
|
1993-07-22 |
2004-04-08 |
Clearant, Inc. |
Methods for sterilizing biological materials
|
US6057287A
(en)
|
1994-01-11 |
2000-05-02 |
Dyax Corp. |
Kallikrein-binding "Kunitz domain" proteins and analogues thereof
|
US5753230A
(en)
*
|
1994-03-18 |
1998-05-19 |
The Scripps Research Institute |
Methods and compositions useful for inhibition of angiogenesis
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
JPH10504971A
(ja)
*
|
1994-09-08 |
1998-05-19 |
カイロン コーポレイション |
インスリン様増殖因子の改善された生産方法
|
US5712249A
(en)
*
|
1994-09-08 |
1998-01-27 |
Ciba-Geigy Corporation |
Use of insulin-like growth factors I and II for inhibition of inflammatory response
|
US5874540A
(en)
*
|
1994-10-05 |
1999-02-23 |
Immunomedics, Inc. |
CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
|
US7803904B2
(en)
*
|
1995-09-01 |
2010-09-28 |
Millennium Pharmaceuticals, Inc. |
Mucosal vascular addressing and uses thereof
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US5573762A
(en)
|
1995-04-24 |
1996-11-12 |
Genentech, Inc. |
Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
|
JPH11507535A
(ja)
*
|
1995-06-07 |
1999-07-06 |
イムクローン システムズ インコーポレイテッド |
腫瘍の成長を抑制する抗体および抗体フラグメント類
|
US7060808B1
(en)
|
1995-06-07 |
2006-06-13 |
Imclone Systems Incorporated |
Humanized anti-EGF receptor monoclonal antibody
|
EP2258726A1
(en)
|
1995-06-14 |
2010-12-08 |
The Regents of the University of California |
High affinity human antibodies to c-erbB-2
|
US6685940B2
(en)
*
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
SI2275119T1
(sl)
|
1995-07-27 |
2013-12-31 |
Genentech, Inc. |
Stabilna izotonična liofilizirana proteinska formulacija
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
GB9601081D0
(en)
*
|
1995-10-06 |
1996-03-20 |
Cambridge Antibody Tech |
Specific binding members for human transforming growth factor beta;materials and methods
|
EP1378525A3
(en)
|
1996-06-07 |
2004-01-14 |
Neorx Corporation |
Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods
|
JP3819436B2
(ja)
*
|
1996-07-11 |
2006-09-06 |
タカラバイオ株式会社 |
部位特異的変異導入方法
|
US7129061B1
(en)
*
|
1996-08-07 |
2006-10-31 |
Biogen Idec Ma Inc. |
Tumor necrosis factor related ligand
|
US7147851B1
(en)
*
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
US7371376B1
(en)
*
|
1996-10-18 |
2008-05-13 |
Genentech, Inc. |
Anti-ErbB2 antibodies
|
AU736287B2
(en)
*
|
1997-03-21 |
2001-07-26 |
Sankyo Company Limited |
Humanized anti-human Fas antibody
|
WO1999021999A2
(en)
|
1997-10-29 |
1999-05-06 |
Genentech, Inc. |
Wnt-1 inducible genes
|
US7083786B2
(en)
|
1997-04-03 |
2006-08-01 |
Jensenius Jens Chr |
MASP-2, a complement-fixing enzyme, and uses for it
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US7365166B2
(en)
|
1997-04-07 |
2008-04-29 |
Genentech, Inc. |
Anti-VEGF antibodies
|
BRPI9809388B8
(pt)
*
|
1997-04-07 |
2021-05-25 |
Genentech Inc |
anticorpos humanizados e métodos para a formação de anticorpos humanizados.
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
NZ500078A
(en)
|
1997-04-07 |
2001-10-26 |
Genentech Inc |
Humanized anti-VEGF antibodies and their use in inhibiting VEGF-induced angiogenesis in mammals
|
DE69834257T2
(de)
*
|
1997-04-30 |
2007-01-04 |
Klingemann, Hans |
Natürliche killerzelllinien und verfahren zu ihrer verwendung
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
DK0979281T3
(da)
|
1997-05-02 |
2005-11-21 |
Genentech Inc |
Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
WO1998055607A2
(en)
|
1997-06-04 |
1998-12-10 |
Oxford Biomedica (Uk) Limited |
Tumor targeted vector
|
US7276488B2
(en)
|
1997-06-04 |
2007-10-02 |
Oxford Biomedica (Uk) Limited |
Vector system
|
US6991790B1
(en)
|
1997-06-13 |
2006-01-31 |
Genentech, Inc. |
Antibody formulation
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
US6172213B1
(en)
|
1997-07-02 |
2001-01-09 |
Genentech, Inc. |
Anti-IgE antibodies and method of improving polypeptides
|
US5994511A
(en)
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
US20020192659A1
(en)
*
|
1997-09-17 |
2002-12-19 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US20030082541A1
(en)
*
|
1997-09-17 |
2003-05-01 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
US6455283B1
(en)
|
1998-03-17 |
2002-09-24 |
Genentech, Inc. |
Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E)
|
ES2313756T3
(es)
|
1997-10-29 |
2009-03-01 |
Genentech, Inc. |
Usos de polipeptido secretado wisp-1 inducido por wnt-1.
|
DE69829995T2
(de)
*
|
1997-12-01 |
2006-02-23 |
Fang, Fang, San Diego |
Multivalente rekombinante antikörper zur behandlung von hrv infektionen
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US7179892B2
(en)
*
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US7964192B1
(en)
*
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US6761888B1
(en)
*
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
US6617171B2
(en)
*
|
1998-02-27 |
2003-09-09 |
The General Hospital Corporation |
Methods for diagnosing and treating autoimmune disease
|
US20030224001A1
(en)
*
|
1998-03-19 |
2003-12-04 |
Goldstein Neil I. |
Antibody and antibody fragments for inhibiting the growth of tumors
|
US7244826B1
(en)
|
1998-04-24 |
2007-07-17 |
The Regents Of The University Of California |
Internalizing ERB2 antibodies
|
DK1308456T3
(da)
*
|
1998-05-06 |
2007-12-27 |
Genentech Inc |
Antistofoprensning ved ionbytterkromatografi
|
AU2003200709B2
(en)
*
|
1998-05-06 |
2006-06-29 |
Genentech, Inc. |
Protein purification
|
DK1308455T3
(da)
*
|
1998-05-06 |
2006-07-31 |
Genentech Inc |
Sammensætning omfattende anti-HER2-antistoffer
|
ZA200007412B
(en)
*
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
US7387772B1
(en)
*
|
1999-06-22 |
2008-06-17 |
Immunimedics, Inc. |
Chimeric, human and humanized anti-CSAP monoclonal antibodies
|
GB9815909D0
(en)
*
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
EP1150688A4
(en)
*
|
1998-10-19 |
2004-06-16 |
Yeda Res & Dev |
TREATING SYSTEMIC LUPUS ERYTHEMATODES BY REGULATING THE AUTOIMMUNE RESPONSE TO AUTOANTIGENS
|
AU1727500A
(en)
*
|
1998-11-17 |
2000-06-05 |
Tanox, Inc. |
Bispecific molecules cross-linking itim and itam for therapy
|
AU1728800A
(en)
*
|
1998-11-18 |
2000-06-05 |
Genentech Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
EP1151012A4
(en)
*
|
1998-11-19 |
2003-01-08 |
Smithkline Beecham Corp |
ANTAGONIST ANTIBODIES OF RHAMM
|
US20030035798A1
(en)
*
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
SK10042001A3
(sk)
|
1999-01-15 |
2001-12-03 |
Biogen, Inc. |
Farmaceutická kompozícia obsahujúca činidlo blokujúce proteín tweak alebo receptor tweak
|
US6599710B1
(en)
|
1999-03-10 |
2003-07-29 |
The General Hospital Corporation |
Treatment of autoimmune disease
|
IL145674A0
(en)
*
|
1999-04-06 |
2002-06-30 |
Genentech Inc |
USE OF ERbB RECEPTOR LIGANDS IN TREATING DIABETES
|
EP2042194A3
(en)
*
|
1999-05-14 |
2009-04-22 |
Imclone Systems, Inc. |
Treatment of refractory human tumors with epidermal growth factor receptor antagonists
|
CA2374085C
(en)
*
|
1999-05-14 |
2015-12-29 |
Genentech, Inc. |
Tumour treatment with anti-erbb2 antibodies
|
NZ515686A
(en)
|
1999-06-01 |
2005-01-28 |
Biogen Inc |
A blocking monoclonal antibody to integrin VLA-1 and its use for the treatment of inflammatory disorders such as arthritis
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
ES2282120T3
(es)
*
|
1999-06-25 |
2007-10-16 |
Genentech, Inc. |
Tratamiento del cancer de prostata con anticuerpos anti-erbb2.
|
IL146954A0
(en)
|
1999-06-25 |
2002-08-14 |
Genentech Inc |
HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
ES2466715T3
(es)
|
1999-06-25 |
2014-06-11 |
Immunogen, Inc. |
Métodos de tratamiento usando conjugados de anticuerpo anti-ErbB-maitansinoide
|
US20020068066A1
(en)
*
|
1999-08-20 |
2002-06-06 |
Wenyuan Shi |
Method for the treatment and prevention of dental caries
|
PL202369B1
(pl)
|
1999-08-27 |
2009-06-30 |
Genentech Inc |
Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało
|
CA2385528C
(en)
|
1999-10-01 |
2013-12-10 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
US7947496B2
(en)
|
1999-10-08 |
2011-05-24 |
Hoffmann-La Roche Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD44
|
US6346249B1
(en)
*
|
1999-10-22 |
2002-02-12 |
Ludwig Institute For Cancer Research |
Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
|
US20020028178A1
(en)
*
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
JP2003515323A
(ja)
|
1999-11-18 |
2003-05-07 |
オックスフォード バイオメディカ(ユーケイ)リミテッド |
抗 体
|
US20060228364A1
(en)
*
|
1999-12-24 |
2006-10-12 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
US20050287153A1
(en)
*
|
2002-06-28 |
2005-12-29 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
US20040001827A1
(en)
*
|
2002-06-28 |
2004-01-01 |
Dennis Mark S. |
Serum albumin binding peptides for tumor targeting
|
CA2390691C
(en)
*
|
1999-12-24 |
2016-05-10 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
US6632979B2
(en)
|
2000-03-16 |
2003-10-14 |
Genentech, Inc. |
Rodent HER2 tumor model
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
JP2003527439A
(ja)
|
2000-03-17 |
2003-09-16 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
抗cd18抗体と抗ccr2抗体の混合物を用いる狭窄および再狭窄を抑制する方法
|
DK2857516T3
(en)
|
2000-04-11 |
2017-08-07 |
Genentech Inc |
Multivalent antibodies and uses thereof
|
US20010046496A1
(en)
*
|
2000-04-14 |
2001-11-29 |
Brettman Lee R. |
Method of administering an antibody
|
EP1881004B1
(en)
|
2000-04-21 |
2012-07-25 |
Fuso Pharmaceutical Industries, Ltd. |
Novel collectin
|
JP2003531178A
(ja)
*
|
2000-04-25 |
2003-10-21 |
アイデック ファーマスーティカルズ コーポレイション |
中枢神経系リンパ腫治療用のリツキシマブのクモ膜下投与
|
EP1280923A2
(en)
*
|
2000-04-28 |
2003-02-05 |
Millennium Pharmaceuticals, Inc. |
14094, a human trypsin family member and uses thereof
|
CN101711868A
(zh)
*
|
2000-05-19 |
2010-05-26 |
杰南技术公司 |
用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
|
US6656700B2
(en)
|
2000-05-26 |
2003-12-02 |
Amersham Plc |
Isoforms of human pregnancy-associated protein-E
|
US6686188B2
(en)
|
2000-05-26 |
2004-02-03 |
Amersham Plc |
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
|
AU2001268363B2
(en)
|
2000-06-20 |
2006-08-17 |
Biogen Idec Inc. |
Treatment of B cell associated diseases
|
EP2792747A1
(en)
|
2000-06-23 |
2014-10-22 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
CA2648051A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
AU2001295002B2
(en)
*
|
2000-08-09 |
2007-05-31 |
Imclone Systems Incorporated |
Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
|
US6984494B2
(en)
|
2000-08-15 |
2006-01-10 |
Genentech, Inc. |
Analytical method
|
JP5113314B2
(ja)
*
|
2000-09-01 |
2013-01-09 |
ザ センター フォー ブラッド リサーチ インク |
所望のコンホメーションで安定させた改変ポリペプチド及び該ポリペプチドの作製方法
|
US20020119148A1
(en)
*
|
2000-09-01 |
2002-08-29 |
Gerritsen Mary E. |
ErbB4 antagonists
|
US20030017491A1
(en)
*
|
2000-09-14 |
2003-01-23 |
Zuo-Rong Shi |
Chromogenic in situ hybridization methods, kits, and compositions
|
DE60139944D1
(de)
|
2000-10-12 |
2009-10-29 |
Genentech Inc |
Niederviskose konzentrierte proteinformulierungen
|
WO2002046208A2
(en)
*
|
2000-11-01 |
2002-06-13 |
Elusys Therapeutics, Inc. |
Method of producing biospecific molecules by protein trans-splicing
|
US20040018194A1
(en)
*
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
PE20020574A1
(es)
*
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
US6979556B2
(en)
*
|
2000-12-14 |
2005-12-27 |
Genentech, Inc. |
Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
|
US20030049800A1
(en)
*
|
2000-12-15 |
2003-03-13 |
Saravis Calvin A. |
Compositions and methods for producing antibodies to low molecular weight analytes
|
US7132510B2
(en)
|
2000-12-29 |
2006-11-07 |
Bio-Technology General (Israel) Ltd. |
Specific human antibodies for selective cancer therapy
|
US20040002450A1
(en)
*
|
2000-12-29 |
2004-01-01 |
Janette Lazarovits |
Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
|
US20040001822A1
(en)
*
|
2000-12-29 |
2004-01-01 |
Avigdor Levanon |
Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
|
US20040001839A1
(en)
*
|
2000-12-29 |
2004-01-01 |
Avigdor Levanon |
Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
|
BRPI0116728B1
(pt)
|
2001-01-05 |
2018-10-30 |
Abgenix Inc |
anticorpos para receptor de fator de crescimento i semelhante à insulina
|
US20070065436A1
(en)
*
|
2001-01-31 |
2007-03-22 |
Biogen Idec Inc. |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
EP1372724A2
(en)
|
2001-01-31 |
2004-01-02 |
Idec Pharmaceuticals Corporation |
Use of immunoregulatory antibodies in the treatment of neoplastic disorders
|
KR20080087184A
(ko)
|
2001-01-31 |
2008-09-30 |
바이오겐 아이덱 인크. |
종양질환 치료를 위한 cd23 길항제의 용도
|
US20020159996A1
(en)
*
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20030211107A1
(en)
*
|
2002-01-31 |
2003-11-13 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
KR20030074839A
(ko)
*
|
2001-02-19 |
2003-09-19 |
메르크 파텐트 게엠베하 |
감소된 면역원성을 갖는 개질 항-egfr 항체
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
AU2002247826A1
(en)
*
|
2001-03-13 |
2002-09-24 |
University College London |
Specific binding members
|
US20080008704A1
(en)
*
|
2001-03-16 |
2008-01-10 |
Mark Rubin |
Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
|
CA2441228A1
(en)
|
2001-03-23 |
2002-10-03 |
Aphton Corporation |
Combination treatment of pancreatic cancer
|
WO2002081649A2
(en)
*
|
2001-04-06 |
2002-10-17 |
The Trustees Of The University Of Pennsylvania |
ErbB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF
|
KR100927670B1
(ko)
|
2001-04-13 |
2009-11-20 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Vla-1에 대한 항체들
|
AU2002316855B2
(en)
|
2001-04-24 |
2008-03-13 |
Merck Patent Gmbh |
Combination therapy using anti-angiogenic agents and TNFalpha
|
US20090191232A1
(en)
|
2001-05-04 |
2009-07-30 |
Gevas Philip C |
Combination therapy for the treatment of tumors
|
US6972324B2
(en)
|
2001-05-18 |
2005-12-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Antibodies specific for CD44v6
|
EP1395275B1
(en)
|
2001-05-22 |
2008-11-12 |
Merck & Co., Inc. |
Beta-secretase substrate and uses thereof
|
WO2002096458A1
(en)
|
2001-05-30 |
2002-12-05 |
Genentech, Inc. |
Anti-ngf antibodies for the treatment of various disorders
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
CA2817619A1
(en)
*
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
DK1399186T3
(da)
|
2001-06-13 |
2010-03-29 |
Armbruster Biotechnology Gmbh |
Lægemiddel til behandling af tumorer og disses metastaser under anvendelse af et bindemolekyle mod knogle-sialoprotein
|
DE50213368D1
(de)
*
|
2001-06-13 |
2009-04-30 |
Immundiagnostik Ag |
Bestimmung von bone-sialoprotein in körperflüssigkeiten für onkologische fragestellungen
|
WO2002102972A2
(en)
|
2001-06-20 |
2002-12-27 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
KR100628425B1
(ko)
|
2001-06-20 |
2006-09-28 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
US7393656B2
(en)
|
2001-07-10 |
2008-07-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for risk stratification
|
CA2491864C
(en)
|
2001-07-12 |
2012-09-11 |
Jefferson Foote |
Super humanized antibodies
|
CA2898314A1
(en)
|
2001-07-19 |
2003-07-31 |
Perian Therapeutics, Inc. |
Multimeric proteins and methods of making and using same
|
US20040078837A1
(en)
*
|
2001-08-02 |
2004-04-22 |
Shannon Mark E. |
Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12
|
US7662374B2
(en)
*
|
2001-08-03 |
2010-02-16 |
The Trustees Of The University Of Pennsylvania |
Monoclonal antibodies to activated erbB family members and methods of use thereof
|
US20050070689A1
(en)
*
|
2001-08-03 |
2005-03-31 |
Genentech, Inc. |
Taci and br3 polypeptides and uses thereof
|
MXPA04001566A
(es)
*
|
2001-08-27 |
2004-05-17 |
Genentech Inc |
Un sistema para expresion y ensamblado de anticuerpos.
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
AU2002330015B2
(en)
|
2001-09-18 |
2008-02-07 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
DK1461300T3
(da)
|
2001-11-30 |
2011-10-24 |
Biogen Idec Inc |
Antistoffer mod kemotaktiske monocytproteiner
|
CA2471431A1
(en)
|
2002-01-02 |
2003-07-17 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
CA2476654A1
(en)
*
|
2002-02-21 |
2003-09-04 |
Wyeth |
Follistatin domain containing proteins
|
US20040009169A1
(en)
|
2002-02-25 |
2004-01-15 |
Julie Taylor |
Administration of agents for the treatment of inflammation
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US8093357B2
(en)
*
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20100311954A1
(en)
*
|
2002-03-01 |
2010-12-09 |
Xencor, Inc. |
Optimized Proteins that Target Ep-CAM
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
MY139983A
(en)
*
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
EP2287199B1
(en)
|
2002-03-13 |
2017-08-02 |
Biogen MA Inc. |
Anti-alpha V beta 6 antibodies
|
US20030180292A1
(en)
*
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
JP2005520854A
(ja)
*
|
2002-03-19 |
2005-07-14 |
アブジェニックス・インコーポレーテッド |
慢性閉塞性肺疾患(copd)を治療するための方法
|
EP1494713A4
(en)
|
2002-04-09 |
2005-12-28 |
Biogen Idec Inc |
PROCESS FOR TREATING TWEAK-RELATED CONDITIONS
|
ES2401428T3
(es)
*
|
2002-04-10 |
2013-04-19 |
Genentech, Inc. |
Variantes de anticuerpos anti-HER2
|
AU2003230874A1
(en)
|
2002-04-16 |
2003-11-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US6916904B2
(en)
*
|
2002-04-24 |
2005-07-12 |
Zolaris Biosciences, Llc |
Inhibition of immune complex formation
|
JP3885658B2
(ja)
*
|
2002-05-13 |
2007-02-21 |
住友電気工業株式会社 |
ヘテロ接合バイポーラトランジスタ
|
AU2003233662B2
(en)
|
2002-05-23 |
2010-04-01 |
Trustees Of The University Of Pennsylvania |
Fas peptide mimetics and uses thereof
|
EP1513879B1
(en)
*
|
2002-06-03 |
2018-08-22 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US7153829B2
(en)
|
2002-06-07 |
2006-12-26 |
Dyax Corp. |
Kallikrein-inhibitor therapies
|
ATE477020T1
(de)
|
2002-06-07 |
2010-08-15 |
Dyax Corp |
Prevention und verringerung von ischemia
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
AU2003243651B2
(en)
*
|
2002-06-17 |
2008-10-16 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Specificity grafting of a murine antibody onto a human framework
|
US7582313B2
(en)
*
|
2002-06-27 |
2009-09-01 |
The General Hospital Corporation |
Methods of organ regeneration using Hox 11-expressing pluripotent cells
|
US7628988B2
(en)
|
2002-06-27 |
2009-12-08 |
The General Hospital Corporation |
Methods and compositions for treating type 1 diabetes
|
US20040208877A1
(en)
*
|
2002-07-01 |
2004-10-21 |
Avigdor Levanon |
Antibodies and uses thereof
|
US20040202665A1
(en)
*
|
2002-07-01 |
2004-10-14 |
Janette Lazarovits |
Compositions and methods for therapeutic treatment
|
EP2263691B1
(en)
*
|
2002-07-15 |
2012-08-29 |
F.Hoffmann-La Roche Ag |
Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
|
US7435419B2
(en)
|
2002-07-19 |
2008-10-14 |
Beth Israel Deaconess Medical Center |
Methods of diagnosing and treating pre-eclampsia or eclampsia
|
PT2305301E
(pt)
|
2002-07-19 |
2015-04-21 |
Beth Israel Hospital |
Métodos de tratamento de pré-eclâmpsia
|
US7794716B2
(en)
|
2002-07-25 |
2010-09-14 |
Glenveigh Pharmaceuticals, Llc |
Antibody composition and passive immunization against pregnancy-induced hypertension
|
MXPA05000940A
(es)
*
|
2002-07-25 |
2005-05-16 |
Genentech Inc |
Anticuerpos taci y su uso.
|
US7659241B2
(en)
|
2002-07-31 |
2010-02-09 |
Seattle Genetics, Inc. |
Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
|
US7425620B2
(en)
|
2002-08-14 |
2008-09-16 |
Scott Koenig |
FcγRIIB-specific antibodies and methods of use thereof
|
PT2386310T
(pt)
*
|
2002-08-28 |
2019-02-05 |
Dyax Corp |
Métodos para preservar órgãos e tecidos
|
AU2003273299B2
(en)
*
|
2002-09-05 |
2010-04-01 |
Medimmune, Llc |
Methods of preventing or treating cell malignancies by administering CD2 antagonists
|
US20060140931A1
(en)
*
|
2002-09-16 |
2006-06-29 |
Nehal Mohamed |
Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
BR0315164A
(pt)
*
|
2002-10-08 |
2005-08-23 |
Rinat Neuroscience Corp |
Métodos para tratar dor pós-cirúrgica administrando um antagonista de fator de crescimento nervoso e composições contendo o mesmo
|
WO2005000194A2
(en)
*
|
2002-10-08 |
2005-01-06 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
|
RU2349340C2
(ru)
|
2002-10-10 |
2009-03-20 |
Мерк Патент Гмбх |
Биспецифические антитела к erb-b и их применение для лечения опухолей
|
DE60336406D1
(de)
|
2002-10-16 |
2011-04-28 |
Purdue Pharma Lp |
Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
|
AR047392A1
(es)
|
2002-10-22 |
2006-01-18 |
Wyeth Corp |
Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
|
US20040223966A1
(en)
*
|
2002-10-25 |
2004-11-11 |
Wolfman Neil M. |
ActRIIB fusion polypeptides and uses therefor
|
WO2004042017A2
(en)
*
|
2002-10-31 |
2004-05-21 |
Genentech, Inc. |
Methods and compositions for increasing antibody production
|
TW200509968A
(en)
|
2002-11-01 |
2005-03-16 |
Elan Pharm Inc |
Prevention and treatment of synucleinopathic disease
|
US8506959B2
(en)
|
2002-11-01 |
2013-08-13 |
Neotope Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
WO2004045376A2
(en)
*
|
2002-11-15 |
2004-06-03 |
The General Hospital Corporation |
Screening methods to identify treatments for autoimmune disease
|
US8505468B2
(en)
*
|
2002-11-19 |
2013-08-13 |
Sharp Kabushiki Kaisha |
Substrate accommodating tray
|
JP2006516117A
(ja)
*
|
2002-11-21 |
2006-06-22 |
ジェネンテック・インコーポレーテッド |
抗ErbB2抗体を用いた非悪性疾病または疾患の治療
|
EP2314676A1
(en)
*
|
2002-11-26 |
2011-04-27 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
WO2004050836A2
(en)
*
|
2002-11-27 |
2004-06-17 |
Biogen Idec Ma Inc. |
Humanized antibodies against monocyte chemotactic proteins
|
EP2301966A1
(en)
*
|
2002-12-16 |
2011-03-30 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
ATE471946T1
(de)
*
|
2002-12-17 |
2010-07-15 |
Merck Patent Gmbh |
Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
|
ATE431157T1
(de)
*
|
2002-12-23 |
2009-05-15 |
Rinat Neuroscience Corp |
Verfahren zur behandlung von durch taxol induzierter sensorischer neuropathie
|
SI1575517T1
(sl)
|
2002-12-24 |
2012-06-29 |
Rinat Neuroscience Corp |
Protitelesa proti ĺ˝iväśnemu rastnemu dejavniku in metode njihove uporabe
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
CA2510003A1
(en)
*
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US7488475B2
(en)
|
2003-01-21 |
2009-02-10 |
Arius Research, Inc. |
Antibody therapy of tumors
|
US7575893B2
(en)
*
|
2003-01-23 |
2009-08-18 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
WO2004066931A2
(en)
|
2003-01-24 |
2004-08-12 |
Elan Pharmaceuticals Inc. |
Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
|
NZ567324A
(en)
*
|
2003-02-01 |
2009-08-28 |
Wyeth Corp |
Active immunization to generate antibodies to soluble A-beta
|
JP3803790B2
(ja)
*
|
2003-02-17 |
2006-08-02 |
株式会社東北テクノアーチ |
新規なダイアボディ型二重特異性抗体
|
ATE491444T1
(de)
|
2003-02-19 |
2011-01-15 |
Rinat Neuroscience Corp |
Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor- antagonisten und eines nsaid und diese enthaltende zusammensetzung
|
US20070275460A1
(en)
*
|
2003-03-03 |
2007-11-29 |
Xencor.Inc. |
Fc Variants With Optimized Fc Receptor Binding Properties
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
EP2526960A1
(en)
|
2003-03-12 |
2012-11-28 |
Genentech, Inc. |
Use of BV8 and/or EG-VEGF to promote hematopoiesis
|
WO2004084836A2
(en)
*
|
2003-03-20 |
2004-10-07 |
Rinat Neuroscience Corp. |
Methods for treating taxol-induced gut disorder
|
EP1622941A2
(en)
*
|
2003-03-20 |
2006-02-08 |
ImClone Systems Incorporated |
Method of producing an antibody to epidermal growth factor receptor
|
EP1615946B1
(en)
*
|
2003-03-26 |
2020-05-06 |
Sudhir Paul |
Proteolytic and covalent antibodies
|
EP1610808A4
(en)
|
2003-03-26 |
2011-04-06 |
Sudhir Paul |
COVALENT BINDING OF LIGANDS TO NUCLEOPHILIC PROTEINS UNDER GUIDANCE BY NONCOVALENT BINDING
|
EP1613643A4
(en)
*
|
2003-03-27 |
2009-10-28 |
Sudhir Paul |
LUPUS ANTIBODIES FOR PASSIVE IMMUNOTHERAPY AGAINST HIV / AIDS
|
JP4689597B2
(ja)
*
|
2003-03-28 |
2011-05-25 |
レセプター バイオロジックス インク. |
ガストリンホルモン免疫アッセイ
|
PT1610820E
(pt)
|
2003-04-04 |
2010-12-16 |
Novartis Ag |
Formulações de elevada concentração de anticorpos e proteínas
|
JP2006522811A
(ja)
|
2003-04-09 |
2006-10-05 |
ジェネンテック・インコーポレーテッド |
TNFαインヒビターに対して不十分な反応を示す患者の自己免疫疾患治療法
|
WO2004091510A2
(en)
|
2003-04-11 |
2004-10-28 |
Medimmune, Inc. |
Recombinant il-9 antibodies and uses thereof
|
US20060140963A1
(en)
*
|
2003-04-14 |
2006-06-29 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD59
|
US20080213169A1
(en)
*
|
2003-04-14 |
2008-09-04 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD59
|
US20080025977A1
(en)
*
|
2003-04-14 |
2008-01-31 |
Arius Research, Inc. |
Cytotoxicity mediation of cells evidencing surface expression of CD59
|
US7321065B2
(en)
|
2003-04-18 |
2008-01-22 |
The Regents Of The University Of California |
Thyronamine derivatives and analogs and methods of use thereof
|
US20040208876A1
(en)
|
2003-04-18 |
2004-10-21 |
Kim Kyung Jin |
Monoclonal antibodies to hepatocyte growth factor
|
WO2004094463A2
(en)
*
|
2003-04-18 |
2004-11-04 |
University Of Florida Research Foundation, Inc. |
Peptide inhibitors of autophosphorylation protein kinases
|
US8613922B2
(en)
|
2003-04-24 |
2013-12-24 |
The University Of North Carolina At Chapel Hill |
Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
WO2004100985A2
(en)
*
|
2003-05-12 |
2004-11-25 |
University Of Florida Research Foundation, Inc. |
Materials and methods for immunizing against fiv infection
|
US7658927B2
(en)
*
|
2003-05-12 |
2010-02-09 |
University Of Florida Research Foundation, Inc. |
Materials and methods for immunizing against FIV infection
|
PT2374819T
(pt)
|
2003-05-12 |
2017-07-04 |
Helion Biotech Aps |
Anticorpos para masp-2
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
SI2361928T1
(sl)
|
2003-05-19 |
2017-07-31 |
Prothena Biosciences Limited |
Skrajšani fragmenti alfa-sinukleina pri bolezni Lewyjevih telesc
|
US7358331B2
(en)
|
2003-05-19 |
2008-04-15 |
Elan Pharmaceuticals, Inc. |
Truncated fragments of alpha-synuclein in Lewy body disease
|
WO2005000896A2
(en)
*
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Polypeptides that bind an anti-tissue factor antibody and uses thereof
|
PE20050627A1
(es)
|
2003-05-30 |
2005-08-10 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido beta amiloideo
|
US7405274B2
(en)
|
2003-06-04 |
2008-07-29 |
Fibrogen, Inc. |
Connective tissue growth factor antibodies
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
ES2537738T3
(es)
|
2003-06-05 |
2015-06-11 |
Genentech, Inc. |
Terapia de combinación para trastornos de células B
|
CN1279056C
(zh)
*
|
2003-06-06 |
2006-10-11 |
马菁 |
肿瘤相关抗原sm5-1的特异性抗体及其应用
|
DE602004029252D1
(de)
|
2003-06-13 |
2010-11-04 |
Biogen Idec Inc |
Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen
|
US20050069955A1
(en)
*
|
2003-06-30 |
2005-03-31 |
Daniel Plaksin |
Antibodies and uses thereof
|
US7825085B2
(en)
*
|
2003-06-30 |
2010-11-02 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Fragments of NKp44 and NKp46 for targeting viral-infected and tumor cells
|
US20050266009A1
(en)
*
|
2003-06-30 |
2005-12-01 |
Savient Pharmaceuticals, Inc. |
Antibodies and uses thereof
|
US20050152906A1
(en)
*
|
2003-06-30 |
2005-07-14 |
Avigdor Levanon |
Specific human antibodies
|
MX341074B
(es)
|
2003-07-08 |
2016-08-05 |
Genentech Inc |
Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
|
WO2005010163A2
(en)
*
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv)
|
WO2005010040A1
(en)
*
|
2003-07-15 |
2005-02-03 |
Barros Research Institute |
Eimeria tenella antigen for immunotherapy of coccidiosis
|
TWI476206B
(zh)
*
|
2003-07-18 |
2015-03-11 |
Amgen Inc |
對肝細胞生長因子具專一性之結合劑
|
EP1648940B1
(en)
|
2003-07-28 |
2016-04-27 |
Genentech, Inc. |
Reducing protein a leaching during protein a affinity chromatography
|
US7758859B2
(en)
*
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
JP2007511738A
(ja)
|
2003-08-08 |
2007-05-10 |
ジーンニュース インコーポレーテッド |
変形性関節症のバイオマーカー及びその使用
|
JP4934426B2
(ja)
*
|
2003-08-18 |
2012-05-16 |
メディミューン,エルエルシー |
抗体のヒト化
|
US20060228350A1
(en)
*
|
2003-08-18 |
2006-10-12 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
JP2007528723A
(ja)
*
|
2003-08-22 |
2007-10-18 |
メディミューン,インコーポレーテッド |
抗体のヒト化
|
US20050152894A1
(en)
*
|
2003-09-05 |
2005-07-14 |
Genentech, Inc. |
Antibodies with altered effector functions
|
GB2406094B
(en)
*
|
2003-09-17 |
2007-06-06 |
Antisoma Plc |
Modified antibody comprising an amino acid substitution mutation which confers increased stability
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US8883147B2
(en)
|
2004-10-21 |
2014-11-11 |
Xencor, Inc. |
Immunoglobulins insertions, deletions, and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20060134105A1
(en)
*
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
AU2004283850C1
(en)
|
2003-10-16 |
2011-11-03 |
Amgen Research (Munich) Gmbh |
Multispecific deimmunized CD3-binders
|
US20050176028A1
(en)
*
|
2003-10-16 |
2005-08-11 |
Robert Hofmeister |
Deimmunized binding molecules to CD3
|
BR122018071808B8
(pt)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugado
|
AR046833A1
(es)
|
2003-11-10 |
2005-12-28 |
Schering Corp |
Anticuerpos anti-interleuquina-10
|
CA2541709C
(en)
*
|
2003-11-13 |
2013-06-04 |
California Pacific Medical Center |
Anti-pecam therapy for metastasis suppression
|
SI2295073T1
(sl)
|
2003-11-17 |
2014-07-31 |
Genentech, Inc. |
Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
|
AU2004293471C1
(en)
|
2003-11-25 |
2011-02-24 |
The Government Of The United States, As Represented By The Secretary Of Health And Human Services |
Mutated anti-CD22 antibodies and immunoconjugates
|
EP1697741A4
(en)
*
|
2003-12-04 |
2008-02-13 |
Xencor Inc |
PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF
|
US20060003412A1
(en)
*
|
2003-12-08 |
2006-01-05 |
Xencor, Inc. |
Protein engineering with analogous contact environments
|
US20070249809A1
(en)
*
|
2003-12-08 |
2007-10-25 |
Xencor, Inc. |
Protein engineering with analogous contact environments
|
CA2549840C
(en)
|
2003-12-09 |
2012-03-20 |
Engeneic Molecular Delivery Pty Ltd. |
Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells
|
ZA200604864B
(en)
*
|
2003-12-19 |
2007-10-31 |
Genentech Inc |
Monovalent antibody fragments useful as therapeutics
|
WO2005077981A2
(en)
*
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
BRPI0417270A
(pt)
*
|
2003-12-23 |
2007-03-27 |
Rinat Neuroscience Corp |
anticorpos agonistas antitrkc e métodos para utilização dos mesmos
|
ITRM20030601A1
(it)
*
|
2003-12-24 |
2005-06-25 |
Lay Line Genomics Spa |
Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
|
PE20051053A1
(es)
|
2004-01-09 |
2005-12-12 |
Pfizer |
ANTICUERPOS CONTRA MAdCAM
|
WO2005072479A2
(en)
*
|
2004-01-27 |
2005-08-11 |
University Of Southern California |
Polymer-bound antibody concer therapeutic agent
|
WO2005079854A1
(en)
|
2004-02-02 |
2005-09-01 |
Engeneic Molecular Delivery Pty Ltd. |
Compositions and methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells
|
JP5155564B2
(ja)
|
2004-02-03 |
2013-03-06 |
ディアデクサス インコーポレーテッド |
Lp−PLA2活性を検出する方法
|
AU2005210695A1
(en)
*
|
2004-02-06 |
2005-08-18 |
Nymox Corporation |
Humanized anti-AF-20 monoclonal antibody
|
WO2005079479A2
(en)
*
|
2004-02-17 |
2005-09-01 |
Absalus, Inc. |
Super-humanized antibodies against respiratory syncytial virus
|
ES2337473T3
(es)
|
2004-02-19 |
2010-04-26 |
Genentech, Inc. |
Anticuerpos reparadores con cdr.
|
WO2006074418A2
(en)
|
2005-01-07 |
2006-07-13 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
US7875598B2
(en)
|
2004-03-04 |
2011-01-25 |
The Regents Of The University Of California |
Compositions useful for the treatment of microbial infections
|
CN1950394B
(zh)
*
|
2004-03-10 |
2014-04-02 |
三一治疗公司 |
在受试者中抑制免疫复合物形成的方法
|
WO2005086875A2
(en)
*
|
2004-03-11 |
2005-09-22 |
City Of Hope |
A humanized anti-cea t84.66 antibody and uses thereof
|
CN103007279B
(zh)
*
|
2004-03-19 |
2017-01-11 |
英克隆有限责任公司 |
人抗表皮生长因子受体抗体
|
US7276585B2
(en)
*
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
WO2005097832A2
(en)
*
|
2004-03-31 |
2005-10-20 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
MY162179A
(en)
|
2004-04-01 |
2017-05-31 |
Elan Pharm Inc |
Steroid sparing agents and methods of using same
|
ES2338344T3
(es)
*
|
2004-04-07 |
2010-05-06 |
Rinat Neuroscience Corporation |
Procedimiento de tratamiento del dolor de cancer de hueso mediante la administracion de una antagonista del factor de crecimiento neuronal.
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
AU2005232657B2
(en)
*
|
2004-04-08 |
2010-12-16 |
David B. Agus |
ErbB antagonists for pain therapy
|
US7785903B2
(en)
*
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
BRPI0509412A
(pt)
*
|
2004-04-16 |
2007-09-04 |
Genentech Inc |
método de tratamento de policondrite ou mononeurite multiplex em mamìferos e artigo industrializado
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
WO2005113003A2
(en)
*
|
2004-04-16 |
2005-12-01 |
Genentech, Inc. |
Method for augmenting b cell depletion
|
EP2286844A3
(en)
|
2004-06-01 |
2012-08-22 |
Genentech, Inc. |
Antibody-drug conjugates and methods
|
CN102512675A
(zh)
|
2004-06-04 |
2012-06-27 |
健泰科生物技术公司 |
用于治疗多发性硬化的方法
|
US20090098142A1
(en)
*
|
2004-06-09 |
2009-04-16 |
Kasaian Marion T |
Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
|
US7501121B2
(en)
*
|
2004-06-17 |
2009-03-10 |
Wyeth |
IL-13 binding agents
|
AR049390A1
(es)
*
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
US7919094B2
(en)
*
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
GT200500155A
(es)
*
|
2004-06-16 |
2006-05-15 |
|
Terapia del càncer resistente al platino
|
US20060019342A1
(en)
*
|
2004-06-25 |
2006-01-26 |
Medimmune, Inc. |
Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
|
US7973134B2
(en)
*
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
SI2471813T1
(sl)
|
2004-07-15 |
2015-03-31 |
Xencor, Inc. |
Optimirane Fc variante
|
US6986264B1
(en)
*
|
2004-07-15 |
2006-01-17 |
Carrier Corporation |
Economized dehumidification system
|
SI1771474T1
(sl)
|
2004-07-20 |
2010-06-30 |
Genentech Inc |
Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
|
SI1771482T1
(sl)
|
2004-07-22 |
2014-12-31 |
Genentech, Inc. |
Sestavek HER2 protitelesa
|
GEP20105059B
(en)
|
2004-07-26 |
2010-08-10 |
Biogen Idec Inc |
Anti-cd154 antibodies
|
JP5042828B2
(ja)
*
|
2004-07-30 |
2012-10-03 |
ライナット ニューロサイエンス コーポレイション |
アミロイド−ベータ・ペプチドに対して向けられる抗体、および該抗体を用いる方法
|
RS51326B
(sr)
*
|
2004-08-05 |
2010-12-31 |
Genentech Inc. |
Humanizovani anti-cmet antagonisti
|
JP5237638B2
(ja)
|
2004-08-06 |
2013-07-17 |
ジェネンテック, インコーポレイテッド |
バイオマーカーを用いたアッセイおよび方法
|
CN101061238B
(zh)
|
2004-08-06 |
2013-11-20 |
健泰科生物技术公司 |
使用生物标志的测定法和方法
|
EA013752B1
(ru)
|
2004-08-09 |
2010-06-30 |
Элан Фармасьютикалз, Инк. |
Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
|
KR20070057839A
(ko)
*
|
2004-08-19 |
2007-06-07 |
제넨테크, 인크. |
변경된 이펙터 기능을 갖는 폴리펩티드 변이체
|
CA2478458A1
(en)
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
SI2386640T1
(sl)
|
2004-08-26 |
2015-06-30 |
Engeneic Molecular Delivery Pty Ltd |
Dostava funkcionalnih nukleinskih kislin celicam sesalcev preko bakterijsko izvirajočih, intaktnih minicelic
|
US7662926B2
(en)
*
|
2004-09-02 |
2010-02-16 |
Genentech, Inc. |
Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
|
AU2005282700A1
(en)
*
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
CA2577405A1
(en)
*
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Anti-fc-gamma riib receptor antibody and uses therefor
|
US7655229B2
(en)
*
|
2004-09-02 |
2010-02-02 |
Chan Andrew C |
Anti-FC-gamma RIIB receptor antibody and uses therefor
|
CN103304667B
(zh)
|
2004-09-03 |
2015-04-08 |
健泰科生物技术公司 |
人源化的抗-β7拮抗剂及其应用
|
US20060074225A1
(en)
*
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
CA2580921C
(en)
|
2004-09-21 |
2016-04-12 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
CA2580965C
(en)
|
2004-09-22 |
2014-04-08 |
Receptor Biologix, Inc. |
Monoclonal antibodies to progastrin
|
NZ553500A
(en)
|
2004-09-23 |
2009-11-27 |
Genentech Inc Genentech Inc |
Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
DE602005024850D1
(de)
|
2004-09-24 |
2010-12-30 |
Beth Israel Hospital |
Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
|
US7235530B2
(en)
|
2004-09-27 |
2007-06-26 |
Dyax Corporation |
Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
|
JP4937127B2
(ja)
|
2004-10-04 |
2012-05-23 |
ジェネンテック, インコーポレイテッド |
肝細胞成長因子活性化物質のモジュレータ
|
US7935790B2
(en)
*
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
MX2007003907A
(es)
*
|
2004-10-05 |
2007-05-21 |
Genentech Inc |
Agentes terapeuticos con toxicidad reducida.
|
JO3000B1
(ar)
*
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
EP2311433A3
(en)
|
2004-10-21 |
2011-08-10 |
Genentech, Inc. |
Method for treating intraocular neovascular diseases
|
EP2422811A2
(en)
|
2004-10-27 |
2012-02-29 |
MedImmune, LLC |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
CA2585849A1
(en)
*
|
2004-10-29 |
2006-05-11 |
Elusys Therapeutics, Inc. |
Use of cr1-binding molecules in clearance and induction of immune responses
|
US8367805B2
(en)
*
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
*
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US20060222653A1
(en)
*
|
2004-11-12 |
2006-10-05 |
Xencor, Inc. |
Antibodies operably linked to selected chemoattractants
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
AU2005304624B2
(en)
|
2004-11-12 |
2010-10-07 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
AU2005332660A1
(en)
*
|
2004-11-12 |
2006-12-14 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the N terminus
|
WO2006055638A2
(en)
|
2004-11-17 |
2006-05-26 |
Abgenix, Inc. |
Fully human monoclonal antibodies to il-13
|
CN101102792A
(zh)
|
2004-11-19 |
2008-01-09 |
比奥根艾迪克Ma公司 |
治疗多发性硬化
|
GB0425713D0
(en)
*
|
2004-11-23 |
2004-12-22 |
Baker Matthew |
Immunogencity testing and antibody selection methods
|
WO2006060533A2
(en)
|
2004-12-01 |
2006-06-08 |
Genentech, Inc. |
Conjugates of 1, 8-bis-naphthalimides with an antibody
|
US20070134243A1
(en)
*
|
2004-12-01 |
2007-06-14 |
Gazzard Lewis J |
Antibody drug conjugates and methods
|
CA2589379A1
(en)
*
|
2004-12-03 |
2006-06-08 |
Biogen Idec Ma Inc. |
Delaying or preventing onset of multiple sclerosis
|
CN101115849A
(zh)
*
|
2004-12-07 |
2008-01-30 |
健泰科生物技术公司 |
选择her抑制剂疗法的患者
|
AR051800A1
(es)
*
|
2004-12-15 |
2007-02-07 |
Wyeth Corp |
Anticuerpos a beta usados en mejorar la cognicion
|
AR052051A1
(es)
|
2004-12-15 |
2007-02-28 |
Neuralab Ltd |
Anticuerpos ab humanizados usados en mejorar la cognicion
|
ES2396555T3
(es)
|
2004-12-15 |
2013-02-22 |
Janssen Alzheimer Immunotherapy |
Anticuerpos que reconocen péptido beta amiloide
|
US7807789B2
(en)
*
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
US8080391B2
(en)
*
|
2004-12-22 |
2011-12-20 |
Ambrx, Inc. |
Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
|
JP2008525041A
(ja)
|
2004-12-22 |
2008-07-17 |
ジェネンテック・インコーポレーテッド |
可溶性多膜貫通型タンパク質の産生方法
|
KR100950635B1
(ko)
*
|
2004-12-23 |
2010-04-01 |
에프. 호프만-라 로슈 아게 |
실험동물의 치료용 항체의 검출
|
EP1838736B1
(en)
|
2005-01-05 |
2013-03-06 |
Biogen Idec MA Inc. |
Cripto binding molecules
|
CA2595169A1
(en)
*
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
GT200600020A
(es)
*
|
2005-01-13 |
2006-11-08 |
|
Procedimiento de tratamiento
|
US20080102054A1
(en)
*
|
2005-01-18 |
2008-05-01 |
Faustman Denise L |
Compositions Containing Agm Cells And Methods Of Use Thereof
|
US7449184B2
(en)
*
|
2005-01-21 |
2008-11-11 |
Genentech, Inc. |
Fixed dosing of HER antibodies
|
US20080161251A1
(en)
|
2005-01-21 |
2008-07-03 |
Astex Therapeutics Limited |
Pharmaceutical Compounds
|
US8029783B2
(en)
*
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
NZ556673A
(en)
|
2005-02-03 |
2010-03-26 |
Gen Hospital Corp |
Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
|
ES2417133T3
(es)
|
2005-02-03 |
2013-08-06 |
Antitope Limited |
Anticuerpos y proteínas humanas
|
JP5265923B2
(ja)
|
2005-02-07 |
2013-08-14 |
ジーンニュース インコーポレーテッド |
軽度の変形性関節症のバイオマーカーおよびその使用
|
SI1871805T1
(sl)
|
2005-02-07 |
2020-02-28 |
Roche Glycart Ag |
Antigen vezavne molekule, ki vežejo EGFR, vektorji, ki te kodirajo in uporabe le-teh
|
EP3520815B1
(en)
|
2005-02-08 |
2021-11-17 |
Genzyme Corporation |
Antibodies to tgfbeta
|
RU2007133660A
(ru)
*
|
2005-02-09 |
2009-03-20 |
Дженентек, Инк. (Us) |
Ингибирование шеддинга her2 антагонистами матриксной металлопротеиназы
|
CN103920142A
(zh)
|
2005-02-14 |
2014-07-16 |
爱荷华大学研究基金会 |
治疗和诊断年龄相关性黄斑变性的方法和试剂
|
WO2006089133A2
(en)
|
2005-02-15 |
2006-08-24 |
Duke University |
Anti-cd19 antibodies and uses in oncology
|
US20090124993A1
(en)
|
2005-02-17 |
2009-05-14 |
Burkly Linda C |
Treating neurological disorders
|
EP1850874B1
(en)
|
2005-02-23 |
2013-10-16 |
Genentech, Inc. |
Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
|
US20060193849A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Antisoma Plc |
Biological materials and uses thereof
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
ATE478707T1
(de)
|
2005-03-02 |
2010-09-15 |
Biogen Idec Inc |
Kim-1-antikörper zur behandlung von th2- vermittelten erkrankungen
|
US20090142338A1
(en)
*
|
2005-03-04 |
2009-06-04 |
Curedm, Inc. |
Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
|
AU2006220709B2
(en)
*
|
2005-03-04 |
2012-09-06 |
Biogen Ma Inc. |
Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
|
US8211430B2
(en)
*
|
2005-03-04 |
2012-07-03 |
Curedm Group Holdings, Llc |
Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
|
TW200642695A
(en)
*
|
2005-03-08 |
2006-12-16 |
Genentech Inc |
Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
|
CA2601400A1
(en)
|
2005-03-19 |
2006-09-28 |
Medical Research Council |
Improvements in or relating to treatment and prevention of viral infections
|
BRPI0609449A2
(pt)
*
|
2005-03-23 |
2010-04-06 |
Wyeth Corp |
detecção de agentes de modulação de gdf-8
|
WO2006105021A2
(en)
|
2005-03-25 |
2006-10-05 |
Tolerrx, Inc. |
Gitr binding molecules and uses therefor
|
KR20070119710A
(ko)
|
2005-03-31 |
2007-12-20 |
더 제너럴 하스피탈 코포레이션 |
Hgf/hgfr 활성의 모니터링 및 조정
|
EP1872136B9
(en)
|
2005-04-04 |
2023-02-08 |
Biogen MA Inc. |
Methods and products for evaluating an immune response to a therapeutic protein
|
US20090099340A1
(en)
*
|
2007-10-12 |
2009-04-16 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
US9889197B2
(en)
|
2005-04-15 |
2018-02-13 |
Macrogenics, Inc. |
Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
|
AU2006236439B2
(en)
|
2005-04-15 |
2012-05-03 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
AR054260A1
(es)
*
|
2005-04-26 |
2007-06-13 |
Rinat Neuroscience Corp |
Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
|
UY29504A1
(es)
|
2005-04-29 |
2006-10-31 |
Rinat Neuroscience Corp |
Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
|
EP1885396A2
(en)
|
2005-05-04 |
2008-02-13 |
Quark Pharmaceuticals, Inc. |
Recombinant antibodies against cd55 and cd59 and uses thereof
|
CA2607281C
(en)
|
2005-05-05 |
2023-10-03 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
MX2007013609A
(es)
|
2005-05-06 |
2008-01-24 |
Zymogenetics Inc |
Anticuerpos monoclonales de il-31 y meodos de uso.
|
US8088908B2
(en)
*
|
2005-05-10 |
2012-01-03 |
City Of Hope |
Humanized anti-prostate stem cell antigen monoclonal antibody
|
EP1885388B1
(en)
|
2005-05-10 |
2013-09-11 |
Biogen Idec MA Inc. |
Treating and evaluating inflammatory disorders
|
WO2006122150A1
(en)
|
2005-05-10 |
2006-11-16 |
Incyte Corporation |
Modulators of indoleamine 2,3-dioxygenase and methods of using the same
|
JP2006316040A
(ja)
|
2005-05-13 |
2006-11-24 |
Genentech Inc |
Herceptin(登録商標)補助療法
|
US7393919B2
(en)
|
2005-05-25 |
2008-07-01 |
Cure Dm, Inc. |
Peptides, derivatives and analogs thereof, and methods of using same
|
SI2460831T1
(sl)
*
|
2005-05-27 |
2017-01-31 |
Biogen Ma Inc. |
Protitelesa, ki se vežejo na TWEAK
|
NZ563341A
(en)
|
2005-06-06 |
2009-10-30 |
Genentech Inc |
Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide
|
KR101457223B1
(ko)
|
2005-06-07 |
2014-11-04 |
에스바테크 - 어 노바티스 컴파니 엘엘씨 |
TNFα를 억제하는 안정적이고 가용성인 항체
|
ITRM20050290A1
(it)
|
2005-06-07 |
2006-12-08 |
Lay Line Genomics Spa |
Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
|
WO2006138219A2
(en)
|
2005-06-13 |
2006-12-28 |
Biogen Idec Ma Inc. |
Methods of diagnosis / prognosis of inflammatory conditions
|
US8901281B2
(en)
|
2005-06-17 |
2014-12-02 |
Merck Sharp & Dohme Corp. |
ILT3 binding molecules and uses therefor
|
US20070110757A1
(en)
|
2005-06-23 |
2007-05-17 |
Ziping Wei |
Antibody formulations having optimized aggregation and fragmentation profiles
|
MY157955A
(en)
*
|
2005-07-06 |
2016-08-30 |
Hoffmann La Roche |
Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
|
WO2007008848A2
(en)
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
|
WO2007008603A1
(en)
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
|
US7557190B2
(en)
|
2005-07-08 |
2009-07-07 |
Xencor, Inc. |
Optimized proteins that target Ep-CAM
|
CN104072614B
(zh)
|
2005-07-08 |
2017-04-26 |
生物基因Ma公司 |
抗-αvβ6 抗体及其用途
|
PE20070207A1
(es)
*
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
US7456259B2
(en)
|
2005-08-02 |
2008-11-25 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7494648B2
(en)
*
|
2005-08-02 |
2009-02-24 |
Hoffmann-La Roche Inc. |
Cancerous disease modifying antibodies
|
US7452978B2
(en)
*
|
2005-08-02 |
2008-11-18 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7411046B2
(en)
|
2005-08-02 |
2008-08-12 |
Arius Research Inc |
Cancerous disease modifying antibodies
|
US7452979B2
(en)
|
2005-08-02 |
2008-11-18 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7456258B2
(en)
|
2005-08-02 |
2008-11-25 |
Arius Research, Inc. |
Cancerous disease modifying antibodies
|
US7700299B2
(en)
|
2005-08-12 |
2010-04-20 |
Hoffmann-La Roche Inc. |
Method for predicting the response to a treatment
|
CA2619577A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
ATE533058T1
(de)
|
2005-08-16 |
2011-11-15 |
Genentech Inc |
Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe
|
SI1915397T1
(sl)
|
2005-08-19 |
2015-05-29 |
Wyeth Llc |
Antagonistična protitelesa proti GDF-8 in uporabe pri zdravljenju ALS in drugih obolenj, povezanih z GDF-8
|
US20100151495A9
(en)
*
|
2005-08-31 |
2010-06-17 |
Cell Signaling Technolgy, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
WO2007027906A2
(en)
*
|
2005-08-31 |
2007-03-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
US20080187490A1
(en)
*
|
2005-09-06 |
2008-08-07 |
Bodie Neil M |
Methods for Treating Amyotrophic Lateral Sclerosis
|
US8945573B2
(en)
|
2005-09-08 |
2015-02-03 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Targeted identification of immunogenic peptides
|
DK1931709T3
(en)
|
2005-10-03 |
2017-03-13 |
Xencor Inc |
FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
|
EP1951757B1
(en)
|
2005-10-06 |
2014-05-14 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
EP3178850B1
(en)
|
2005-10-11 |
2021-01-13 |
Amgen Research (Munich) GmbH |
Compositions comprising cross-species-specific antibodies and uses thereof
|
ATE518007T1
(de)
|
2005-10-21 |
2011-08-15 |
Genenews Inc |
Verfahren und vorrichtung zur korrelierung der ebenen von biomarker-produkten mit erkrankungen
|
AR058140A1
(es)
*
|
2005-10-24 |
2008-01-23 |
Wyeth Corp |
Metodo de produccion proteica utilizando compuestos anti-senescencia
|
UA99591C2
(ru)
*
|
2005-11-04 |
2012-09-10 |
Дженентек, Инк. |
Применение ингибиторов пути комплемента для лечения глазных болезней
|
KR101354828B1
(ko)
|
2005-11-04 |
2014-02-18 |
와이어쓰 엘엘씨 |
mTOR 저해자, 헤르셉틴, 및/또는 HKI-272의항신생물성 조합
|
EP2465870A1
(en)
|
2005-11-07 |
2012-06-20 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
|
US20070161089A1
(en)
*
|
2005-11-08 |
2007-07-12 |
Genentech, Inc. |
Method of Producing Pan-Specific Antibodies
|
BRPI0618705B8
(pt)
|
2005-11-14 |
2021-05-25 |
Labrys Biologics Inc |
anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
US20070122404A1
(en)
*
|
2005-11-17 |
2007-05-31 |
O'keefe Theresa L |
Humanized immunoglobulin reactive with alpha4beta7 integrin
|
JP2009516514A
(ja)
|
2005-11-21 |
2009-04-23 |
ジェネンテック・インコーポレーテッド |
新規遺伝子破壊、それらに関する組成物および方法
|
AU2006318537A1
(en)
|
2005-11-22 |
2007-05-31 |
The Trustees Of The University Of Pennsylvania |
Antibody treatment of Alzheimer's and related diseases
|
JP6088723B2
(ja)
*
|
2005-11-23 |
2017-03-01 |
ジェネンテック, インコーポレイテッド |
B細胞アッセイに関する組成物及び方法。
|
US20070237764A1
(en)
*
|
2005-12-02 |
2007-10-11 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
KR101434682B1
(ko)
*
|
2005-12-02 |
2014-08-27 |
제넨테크, 인크. |
결합 폴리펩티드 및 이들의 용도
|
DOP2006000277A
(es)
|
2005-12-12 |
2007-08-31 |
Bayer Pharmaceuticals Corp |
Anticuerpos anti mn y métodos para su utilización
|
EP3309170B1
(en)
|
2005-12-15 |
2019-05-22 |
Genentech, Inc. |
Polyubiquitin antibodies
|
WO2007071426A1
(en)
|
2005-12-21 |
2007-06-28 |
Micromet Ag |
Pharmaceutical compositions with resistance to soluble cea
|
EA015173B1
(ru)
*
|
2006-01-04 |
2011-06-30 |
Мерк Патент Гмбх |
Комбинированная терапия с использованием антител к egfr и her2
|
KR101589391B1
(ko)
|
2006-01-05 |
2016-01-29 |
제넨테크, 인크. |
항-ephb4 항체 및 그의 사용 방법
|
TWI428143B
(zh)
|
2006-01-18 |
2014-03-01 |
Gen Hospital Corp |
增加淋巴功能之方法
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
US20070175313A1
(en)
*
|
2006-01-31 |
2007-08-02 |
Kevin Vandervliet |
MP3 player holder assembly
|
ZA200807714B
(en)
|
2006-02-17 |
2010-01-27 |
Genentech Inc |
Gene disruptions, compositions and methods relating thereto
|
US7750116B1
(en)
*
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-22(il-22)之抗體及其用途
|
US8021839B2
(en)
*
|
2006-02-24 |
2011-09-20 |
Investigen, Inc. |
Methods and compositions for detecting polynucleotides
|
EP2650306A1
(en)
|
2006-03-06 |
2013-10-16 |
Aeres Biomedical Limited |
Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
WO2007106585A1
(en)
|
2006-03-15 |
2007-09-20 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
AR059900A1
(es)
|
2006-03-17 |
2008-05-07 |
Genentech Inc |
Anticuerpos anti-tat226 e inmunoconjugados
|
HUE025989T2
(hu)
|
2006-03-21 |
2016-05-30 |
Genentech Inc |
Alfa5béta1-antagonistákat magában foglaló kombinációs terápia
|
TW200812615A
(en)
|
2006-03-22 |
2008-03-16 |
Hoffmann La Roche |
Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
|
CA2647107A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
US9315578B2
(en)
|
2006-03-23 |
2016-04-19 |
Tohoku Univeristy |
High functional bispecific antibody
|
JP4419976B2
(ja)
|
2006-03-24 |
2010-02-24 |
オンキヨー株式会社 |
スピーカー振動板およびスピーカー
|
AR059922A1
(es)
*
|
2006-04-01 |
2008-05-07 |
Galaxy Biotech Llc |
Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
|
CA2647277A1
(en)
|
2006-04-05 |
2007-11-08 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
NZ571300A
(en)
|
2006-04-07 |
2011-12-22 |
Warner Chilcott Co Llc |
Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
CA2649387A1
(en)
|
2006-04-19 |
2008-03-27 |
Genentech, Inc. |
Novel gene disruptions, compositions and methods relating thereto
|
WO2007127335A2
(en)
*
|
2006-04-27 |
2007-11-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in atm and atr kinase signaling pathways
|
AR060871A1
(es)
*
|
2006-05-09 |
2008-07-16 |
Genentech Inc |
Union de polipeptidos con supercontigos optimizados
|
US7745584B2
(en)
|
2006-05-22 |
2010-06-29 |
California Institute Of Technology |
Antibodies to sulfated carbohydrates
|
JP5496658B2
(ja)
*
|
2006-05-25 |
2014-05-21 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
脳卒中を処置する方法
|
EP2447282B1
(en)
|
2006-05-30 |
2016-01-27 |
Genentech, Inc. |
Anti-CD22 Antibodies, their Immunoconjugates and uses thereof
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
JP2009539841A
(ja)
*
|
2006-06-06 |
2009-11-19 |
トラークス,インコーポレイテッド |
自己免疫疾患の治療における抗cd3抗体の投与
|
TW200817435A
(en)
*
|
2006-06-06 |
2008-04-16 |
Genentech Inc |
Compositions and methods for modulating vascular development
|
AU2007319672B2
(en)
*
|
2006-06-06 |
2011-06-30 |
Genentech, Inc. |
Anti-DLL4 antibodies and methods using same
|
CA2652703C
(en)
*
|
2006-06-07 |
2018-08-28 |
Bioalliance C.V. |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
CA2655080A1
(en)
|
2006-06-14 |
2007-12-21 |
Macrogenics, Inc. |
Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
|
CA2655504A1
(en)
|
2006-06-15 |
2007-12-21 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
JP5597793B2
(ja)
|
2006-06-19 |
2014-10-01 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Ilt3結合分子およびその使用
|
US9878043B2
(en)
|
2006-06-23 |
2018-01-30 |
Engeneic Molecular Delivery Pty Ltd |
Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells
|
EP2032159B1
(en)
|
2006-06-26 |
2015-01-07 |
MacroGenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
US8440625B2
(en)
*
|
2006-06-26 |
2013-05-14 |
University Of British Columbia |
Secreted protein acidic and rich in cysteine (SPARC) as chemotherapeutic sensitizers
|
ES2599319T3
(es)
|
2006-06-26 |
2017-02-01 |
Macrogenics, Inc. |
Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
|
US7749772B1
(en)
|
2006-06-29 |
2010-07-06 |
Varian, Inc. |
Antibody and immunoassays for determining the presence of Δ9-Tetrahydrocannabinol
|
BRPI0712953B8
(pt)
|
2006-06-30 |
2021-05-25 |
Novo Nordisk As |
anticorpos anti-nkg2a, seu uso, e composição farmacêutica
|
AU2007269714A1
(en)
|
2006-07-03 |
2008-01-10 |
Charles David Adair |
Composition for modulating the expression of cell adhesion molecules
|
SG173364A1
(en)
|
2006-07-10 |
2011-08-29 |
Biogen Idec Inc |
Compositions and methods for inhibiting growth of smad4-deficient cancers
|
MX2009000709A
(es)
|
2006-07-18 |
2009-02-04 |
Sanofi Aventis |
Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
PT2511301T
(pt)
|
2006-08-04 |
2018-03-08 |
Medimmune Ltd |
Anticorpos humanos para erbb2
|
EP2057465A4
(en)
|
2006-08-09 |
2010-04-21 |
Homestead Clinical Corp |
SPECIFIC ORGAN PROTEINS AND METHODS OF USE
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
US7939636B2
(en)
*
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
EP2056709A4
(en)
|
2006-08-11 |
2013-05-01 |
Univ New Jersey Med |
DOUBLE-SENSITIZER WITH LUMINESCENCE COMPOUNDS, CONJUGATES AND USE
|
PL2059536T3
(pl)
|
2006-08-14 |
2014-07-31 |
Xencor Inc |
Zoptymalizowane przeciwciała ukierunkowane na CD19
|
US20080050385A1
(en)
|
2006-08-21 |
2008-02-28 |
Thomas Friess |
Tumor therapy with an anti-vegf antibody
|
US8058402B2
(en)
|
2006-08-28 |
2011-11-15 |
Kyowa Hakko Kirin |
Antagonistic human LIGHT-specific human monoclonal antibodies
|
EP2471816A1
(en)
|
2006-08-30 |
2012-07-04 |
Genentech, Inc. |
Multispecific antibodies
|
US20090258442A1
(en)
*
|
2006-08-31 |
2009-10-15 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
PT2594586E
(pt)
|
2006-09-01 |
2014-11-26 |
Zymogenetics Inc |
Anticorpos monoclonais de il-31 e métodos de utilização
|
PL2061810T3
(pl)
|
2006-09-05 |
2015-05-29 |
Alexion Pharma Inc |
Sposoby i kompozycje do leczenia neuropatii zależnych od przeciwciał
|
WO2008030988A2
(en)
|
2006-09-06 |
2008-03-13 |
The Regents Of The University Of California |
Selectively targeted antimicrobial peptides and the use thereof
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
RU2495882C2
(ru)
|
2006-09-08 |
2013-10-20 |
Медиммун, Ллк. |
Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
|
ES2372217T3
(es)
|
2006-09-12 |
2012-01-17 |
Genentech, Inc. |
Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
|
CA2660795C
(en)
|
2006-09-18 |
2014-11-18 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
WO2008042941A2
(en)
*
|
2006-10-04 |
2008-04-10 |
Medimmune, Llc |
Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
|
US9382327B2
(en)
|
2006-10-10 |
2016-07-05 |
Vaccinex, Inc. |
Anti-CD20 antibodies and methods of use
|
AU2007306102B2
(en)
*
|
2006-10-11 |
2012-02-23 |
Antitope Limited |
T cell epitope databases
|
KR20090069330A
(ko)
*
|
2006-10-12 |
2009-06-30 |
와이어쓰 |
유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화
|
EP2073807A1
(en)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
JP5528806B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
AR063257A1
(es)
|
2006-10-12 |
2009-01-14 |
Genentech Inc |
Anticuerpos anti-linfotoxina alfa
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
PL2087002T3
(pl)
*
|
2006-10-27 |
2015-02-27 |
Lpath Inc |
Kompozycje i sposoby do wiązania sfingozyno-1 fosforanu
|
PL2845866T3
(pl)
|
2006-10-27 |
2017-10-31 |
Genentech Inc |
Przeciwciała i immunokoniugaty oraz ich zastosowanie
|
JP5732182B2
(ja)
*
|
2006-10-27 |
2015-06-10 |
エルパス・インコーポレイテッドLpath, Inc. |
眼疾患と症状を処置するための組成物および方法
|
PL2097455T3
(pl)
|
2006-11-02 |
2015-04-30 |
Genentech Inc |
Humanizowane przeciwciała przeciw czynnikowi D
|
CA2666317C
(en)
|
2006-11-03 |
2013-08-06 |
Wyeth |
Glycolysis-inhibiting substances in cell culture
|
CN101595213A
(zh)
*
|
2006-11-13 |
2009-12-02 |
霍夫曼-拉罗奇有限公司 |
修饰癌性疾病的抗体
|
CN101535470A
(zh)
*
|
2006-11-13 |
2009-09-16 |
霍夫曼-拉罗奇有限公司 |
修饰癌性疾病的抗体180706-01
|
KR20090101886A
(ko)
*
|
2006-11-13 |
2009-09-29 |
에프. 호프만-라 로슈 아게 |
암 질환 조절 항체
|
CA2669095A1
(en)
*
|
2006-11-15 |
2008-05-29 |
Functional Genetics, Inc. |
Anti-tsg101 antibodies and their uses for treatment of viral infections
|
EP2121743B1
(en)
|
2006-11-22 |
2015-06-03 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
|
US8785400B2
(en)
*
|
2006-11-22 |
2014-07-22 |
Curedm Group Holdings, Llc |
Methods and compositions relating to islet cell neogenesis
|
JP5391073B2
(ja)
|
2006-11-27 |
2014-01-15 |
ディアデクサス インコーポレーテッド |
Ovr110抗体組成物および使用方法
|
US8945565B2
(en)
|
2006-12-01 |
2015-02-03 |
Selexys Pharmaceuticals Corporation |
Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies
|
US20110212096A1
(en)
|
2006-12-01 |
2011-09-01 |
Scott Rollins |
Anti-p-selectin antibodies and methods of their use and identification
|
EP2097105A4
(en)
|
2006-12-01 |
2010-09-15 |
Selexys Pharmaceuticals Corp |
ANTI-P-SELECTINE ANTIBODIES AND METHODS FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES
|
US8288110B2
(en)
*
|
2006-12-04 |
2012-10-16 |
Perkinelmer Health Sciences, Inc. |
Biomarkers for detecting cancer
|
CN101678100A
(zh)
|
2006-12-06 |
2010-03-24 |
米迪缪尼有限公司 |
治疗系统性红斑狼疮的方法
|
MX2009006659A
(es)
*
|
2006-12-20 |
2009-10-12 |
Mmr Information Systems Inc |
Anticuerpos y metodos de elaboracion y uso.
|
ES2673153T3
(es)
|
2007-01-09 |
2018-06-20 |
Biogen Ma Inc. |
Anticuerpos Sp35 y usos de los mismos
|
DE102007001370A1
(de)
*
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
EP2111553B1
(en)
|
2007-01-24 |
2018-09-19 |
Carnegie Mellon University |
Optical biosensors
|
US20100119526A1
(en)
*
|
2007-01-26 |
2010-05-13 |
Bioinvent International Ab |
DLL4 Signaling Inhibitors and Uses Thereof
|
ATE516814T1
(de)
|
2007-02-02 |
2011-08-15 |
Bristol Myers Squibb Co |
10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
|
NZ578701A
(en)
|
2007-02-09 |
2012-02-24 |
Genentech Inc |
Anti-robo4 antibodies and uses therefor
|
PL2125889T3
(pl)
|
2007-02-21 |
2014-06-30 |
Univ Massachusetts |
Ludzkie przeciwciała przeciwko wirusowi żółtaczki typu C (HCV) i ich zastosowania
|
WO2008103702A2
(en)
*
|
2007-02-23 |
2008-08-28 |
Investigen, Inc. |
Methods and compositions for rapid light-activated isolation and detection of analytes
|
ES2546863T3
(es)
|
2007-02-23 |
2015-09-29 |
Prothena Biosciences Limited |
Prevención y tratamiento de enfermedad sinucleinopática y amiloidogénica
|
EP2118300B1
(en)
|
2007-02-23 |
2015-05-27 |
Prothena Biosciences Limited |
Prevention and treatment of synucleinopathic and amyloidogenic disease
|
CN103432580A
(zh)
*
|
2007-03-02 |
2013-12-11 |
健泰科生物技术公司 |
基于低her3表达预测对her二聚化抑制剂的响应
|
EP1972639A3
(en)
|
2007-03-07 |
2008-12-03 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
AR065687A1
(es)
|
2007-03-13 |
2009-06-24 |
Amgen Inc |
Metodo para determinar la presencia o no de una mutacion k-ras y terapia con anticuerpos anti-egfr
|
CL2008000716A1
(es)
|
2007-03-13 |
2008-09-22 |
Amgen Inc |
Metodo para pronosticar si un paciente sera no respondedor al tratamiento con un agente de union especifica a un polipeptido de egfr que comprende determinar la presencia o ausencia de una mutacion de k-ras y b-raf en un tumor del paciente.
|
EP2474556A3
(en)
|
2007-03-14 |
2012-10-17 |
Novartis AG |
APCDD1 inhibitors for treating, diagnosing or detecting cancer
|
WO2008116103A2
(en)
*
|
2007-03-22 |
2008-09-25 |
Imclone Llc |
Stable antibody formulations
|
JP5721951B2
(ja)
|
2007-03-22 |
2015-05-20 |
バイオジェン アイデック マサチューセッツ インコーポレイテッド |
抗体、抗体誘導体、および抗体断片を含む、cd154に特異的に結合する結合タンパク質ならびにその使用
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
EP1975184A3
(en)
|
2007-03-26 |
2008-11-26 |
Cell Signaling Technology, Inc. |
Serine or threonine phosphorylation sites
|
US20080238709A1
(en)
*
|
2007-03-28 |
2008-10-02 |
Faramarz Vaziri |
One-way communication apparatus with dynamic key generation
|
US20110130544A1
(en)
|
2007-03-30 |
2011-06-02 |
Medimmune, Llc |
Antibodies with decreased deamidation profiles
|
US20100291024A1
(en)
*
|
2007-03-30 |
2010-11-18 |
Xuebin Qin |
Methods and compositions for the treatment of proliferative and pathogenic diseases
|
DK2865755T3
(en)
|
2007-03-30 |
2017-05-15 |
Engeneic Molecular Delivery Pty Ltd |
BACTERIAL DERIVATIVE INTACT MINICELLS WITH REGULATORY RNA
|
WO2008119566A2
(en)
*
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific bispecific binders
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
EP1983003A3
(en)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
EP1983002A3
(en)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
TW200902708A
(en)
*
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
RU2009140134A
(ru)
*
|
2007-04-23 |
2011-05-27 |
Вайет (Us) |
Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
EP2164868B1
(en)
|
2007-05-04 |
2015-03-25 |
Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA |
Engineered rabbit antibody variable domains and uses thereof
|
US20080279851A1
(en)
|
2007-05-07 |
2008-11-13 |
Medlmmune, Llc |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
SI3072525T1
(en)
|
2007-05-14 |
2018-06-29 |
Astrazeneca Ab |
Procedures for lowering the levels of basophiles
|
US8318163B2
(en)
|
2007-05-17 |
2012-11-27 |
Genentech, Inc. |
Anti-pan neuropilin antibody and binding fragments thereof
|
LT2164514T
(lt)
|
2007-05-21 |
2017-03-10 |
Alderbio Holdings Llc |
Il-6 antikūnai ir jų naudojimas
|
US20090304590A1
(en)
*
|
2007-05-29 |
2009-12-10 |
Wyeth |
Therapeutic compositions and methods
|
WO2008150485A2
(en)
*
|
2007-05-29 |
2008-12-11 |
Wyeth |
Erbb2 binding proteins and use thereof
|
US8158124B2
(en)
*
|
2007-05-30 |
2012-04-17 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
US9163091B2
(en)
*
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
US20110064744A1
(en)
*
|
2007-05-30 |
2011-03-17 |
Sabbadini Roger A |
Prevention and treatment of pain using antibodies to lysophosphatidic acid
|
US8604172B2
(en)
*
|
2009-04-17 |
2013-12-10 |
Lpath, Inc. |
Humanized antibody compositions and methods for binding lysophosphatidic acid
|
PE20090321A1
(es)
|
2007-06-04 |
2009-04-20 |
Genentech Inc |
Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
|
US9551033B2
(en)
|
2007-06-08 |
2017-01-24 |
Genentech, Inc. |
Gene expression markers of tumor resistance to HER2 inhibitor treatment
|
WO2008154249A2
(en)
*
|
2007-06-08 |
2008-12-18 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
PT2170389E
(pt)
|
2007-06-12 |
2015-02-10 |
Genentech Inc |
Anticorpos humanizados contra amilóide beta
|
CN101778640A
(zh)
*
|
2007-06-14 |
2010-07-14 |
比奥根艾迪克Ma公司 |
抗体制剂
|
WO2008151819A2
(en)
*
|
2007-06-15 |
2008-12-18 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Treatment of tumors using specific anti-l1 antibody
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
AU2008265984B2
(en)
|
2007-06-21 |
2014-07-17 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
CL2008001887A1
(es)
|
2007-06-29 |
2008-10-03 |
Amgen Inc |
Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
|
US20090053786A1
(en)
|
2007-07-09 |
2009-02-26 |
Yung-Hsiang Kao |
Prevention of disulfide bond reduction during recombinant production of polypeptides
|
JP5932217B2
(ja)
|
2007-07-12 |
2016-06-08 |
ジーアイティーアール, インコーポレイテッド |
Gitr結合分子を使用する併用療法
|
US8329421B2
(en)
|
2007-07-13 |
2012-12-11 |
Ventana Medical Systems, Inc. |
Methods of predicting response of a neoplasm to an EGFR inhibitor and detecting interactions between EGFR and an EGFR regulatory protein
|
PE20090481A1
(es)
|
2007-07-16 |
2009-05-18 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
|
CR20190516A
(es)
|
2007-07-16 |
2020-02-18 |
Genentech Inc |
ANTICUERPOS ANTI-CD79B E INMUNOCONJUGADOS (Divisional 2015-0040)
|
JP5889529B2
(ja)
|
2007-07-27 |
2016-03-22 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
アミロイド原性疾患の処置
|
EP2069401A4
(en)
|
2007-07-31 |
2011-02-23 |
Medimmune Llc |
MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
|
EP2185594B1
(en)
*
|
2007-08-13 |
2016-04-06 |
VasGene Therapeutics, Inc. |
Cancer treatment using humanized antibodies that bind to ephb4
|
JP2010536371A
(ja)
|
2007-08-21 |
2010-12-02 |
ノダリティ,インコーポレイテッド |
診断方法、予後および治療方法
|
EP2190861A4
(en)
|
2007-08-22 |
2011-03-30 |
Univ California |
ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
|
AU2013203265B2
(en)
*
|
2007-08-29 |
2016-06-23 |
Sanofi |
Humanized anti-CXCR5 antibodies, derivatives thereof and their uses
|
MX346172B
(es)
*
|
2007-08-29 |
2017-03-10 |
Sanofi - Aventis |
Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
|
KR20100080519A
(ko)
|
2007-08-30 |
2010-07-08 |
큐어디엠 인코포레이티드 |
프로섬 펩타이드 및 이의 유사체의 조성물 및 이의 이용 방법
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
CN101842388B
(zh)
|
2007-09-13 |
2013-09-04 |
德勒尼克斯治疗股份公司 |
针对β淀粉样肽的人源化抗体
|
SG193868A1
(en)
|
2007-09-26 |
2013-10-30 |
Chugai Pharmaceutical Co Ltd |
Modified antibody constant region
|
EP3181228B1
(en)
|
2007-10-02 |
2020-07-29 |
Labrador Diagnostics LLC |
Modular point-of-care devices and uses thereof
|
BRPI0818623A2
(pt)
|
2007-10-05 |
2017-05-23 |
Ac Immune Sa |
composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
|
WO2009050444A1
(en)
*
|
2007-10-15 |
2009-04-23 |
King's College London |
Diagnostic methods for hiv infection
|
AU2008312406B2
(en)
|
2007-10-16 |
2014-03-06 |
Ares Trading S.A. |
Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
ES2576650T3
(es)
|
2007-10-18 |
2016-07-08 |
Cell Signaling Technology, Inc. |
Translocación y ROS quinasa mutante en el carcinoma pulmonar no microcítico humano
|
WO2009055074A2
(en)
*
|
2007-10-25 |
2009-04-30 |
Wyeth |
Erbb2 binding proteins and use thereof
|
US8361465B2
(en)
*
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
SI2215117T2
(en)
|
2007-10-30 |
2018-04-30 |
Genentech, Inc. |
Purification of the antibody by cation exchange chromatography
|
WO2009059317A2
(en)
|
2007-11-01 |
2009-05-07 |
University Of Iowa Research Foundation |
Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715
|
AU2008324800B2
(en)
|
2007-11-05 |
2014-03-27 |
Astrazeneca Ab |
Methods of treating scleroderma
|
MX2010005080A
(es)
|
2007-11-07 |
2010-07-28 |
Genentech Inc |
Metodos y composiciones para determinar la sensibilidad de linfoma de celula b al tratamiento con anticuerpos anti-cd40.
|
DK2224954T3
(en)
|
2007-11-07 |
2014-03-03 |
Celldex Therapeutics Inc |
Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
|
WO2010008411A1
(en)
|
2007-11-09 |
2010-01-21 |
The Salk Institute For Biological Studies |
Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
|
MX2010005244A
(es)
*
|
2007-11-12 |
2010-10-25 |
Theraclone Sciences Inc |
Composiciones y métodos para la terapia y el diagnóstico de influenza.
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
EP2062920A3
(en)
|
2007-11-21 |
2009-06-17 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signalling pathways
|
WO2009068625A2
(en)
|
2007-11-27 |
2009-06-04 |
Ablynx N.V. |
Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
|
JP5490714B2
(ja)
*
|
2007-11-28 |
2014-05-14 |
メディミューン,エルエルシー |
タンパク質製剤
|
US8912149B1
(en)
|
2007-11-28 |
2014-12-16 |
California Institute Of Technology |
Glycosaminoglycan mimetics
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
EP2796466B1
(en)
|
2007-12-07 |
2017-11-22 |
ZymoGenetics, Inc. |
Humanized antibody molecules specific for IL-31
|
CA3102704A1
(en)
|
2007-12-14 |
2009-06-25 |
Novo Nordisk A/S |
Antibodies against human nkg2d and uses thereof
|
KR20130087632A
(ko)
|
2007-12-17 |
2013-08-06 |
화이자 리미티드 |
간질성 방광염의 치료
|
NZ585959A
(en)
|
2007-12-18 |
2012-09-28 |
Bioalliance Cv |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
KR101620539B1
(ko)
|
2007-12-21 |
2016-05-13 |
메디뮨 리미티드 |
인터루킨-4 수용체 알파(IL-4Rα)에 대한 결합 구성원-173
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
CN101932333A
(zh)
*
|
2007-12-26 |
2010-12-29 |
瓦西尼斯公司 |
抗c35抗体联合疗法和方法
|
MX2010007101A
(es)
*
|
2007-12-26 |
2011-07-01 |
Biotest Ag |
Metodos y agentes para mejorar el reconocimiento de celulas de tumor que expresan cd138.
|
DK2238168T3
(da)
*
|
2007-12-26 |
2014-08-25 |
Biotest Ag |
Midler, der er målrettet mod cd138 og anvendelser deraf
|
EP4269443A3
(en)
|
2007-12-26 |
2023-12-27 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
PT2242772E
(pt)
*
|
2007-12-26 |
2015-02-09 |
Biotest Ag |
Imunoconjugados dirigidos contra cd138 e as suas utilizações
|
US8454960B2
(en)
*
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
GEP20156390B
(en)
|
2008-01-03 |
2015-11-10 |
Scripps Research Inst |
Antibody targeting through a modular recognition domain
|
US8557243B2
(en)
*
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
US8557242B2
(en)
*
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
EP2244729B1
(en)
|
2008-01-18 |
2016-11-02 |
MedImmune, LLC |
Cysteine engineered antibodies for site-specific conjugation
|
CN101952317B
(zh)
|
2008-01-24 |
2015-07-22 |
诺沃-诺迪斯克有限公司 |
人化抗-人nkg2a单克隆抗体
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
CN101981055B
(zh)
|
2008-01-31 |
2016-03-09 |
健泰科生物技术公司 |
抗cd79b抗体和免疫偶联物及使用方法
|
US9131671B2
(en)
|
2008-02-01 |
2015-09-15 |
Entogenetics, Inc. |
Methods, compositions and systems for production of recombinant spider silk polypeptides
|
CA2952055C
(en)
|
2008-02-01 |
2020-07-21 |
Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health |
Monoclonal antibodies for ebola and marburg viruses
|
EP2641612A1
(en)
|
2008-02-05 |
2013-09-25 |
Bristol-Myers Squibb Company |
Alpha 5 - beta 1 antibodies and their uses
|
CA2713981C
(en)
|
2008-02-08 |
2016-11-01 |
Medimmune, Llc |
Anti-ifnar1 antibodies with reduced fc ligand affinity
|
US20090220991A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
MX2010009724A
(es)
|
2008-03-04 |
2010-09-28 |
Pfizer Ltd |
Procedimientos de tratamiento del dolor inflamatorio-.
|
CA2716424C
(en)
|
2008-03-04 |
2015-04-28 |
Pfizer Limited |
Methods of treating chronic pain
|
EP2260056A1
(en)
*
|
2008-03-06 |
2010-12-15 |
Genentech, Inc. |
Combination therapy with c-met and her antagonists
|
US7982012B2
(en)
|
2008-03-10 |
2011-07-19 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of cytomegalovirus
|
KR20110015516A
(ko)
|
2008-03-14 |
2011-02-16 |
옵셰스트보 스 오그라니첸노이 오트베츠벤노스티유 "이니티움-파름" |
혈관신생억제 작용을 갖는 항종양 테르페노이드 약학적 조성물 ‘아비실린’
|
EP3692988A3
(en)
|
2008-03-18 |
2020-10-14 |
Genentech, Inc. |
Combinations of an anti-her2 antibody-drug conjugate and 5-fu, anti-vegf antibody, carboplatin or abt-869 and methods of use
|
SI2274008T1
(sl)
|
2008-03-27 |
2014-08-29 |
Zymogenetics, Inc. |
Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
|
AU2009231991B2
(en)
*
|
2008-04-02 |
2014-09-25 |
Macrogenics, Inc. |
HER2/neu-specific antibodies and methods of using same
|
EP3023502A1
(en)
|
2008-04-10 |
2016-05-25 |
Cell Signaling Technology, Inc. |
Compositions and methods for detecting egfr mutations in cancer
|
AU2008201871A1
(en)
*
|
2008-04-16 |
2009-11-26 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Inhibition of angiogenesis and tumor metastasis
|
CA2722082C
(en)
|
2008-04-25 |
2021-11-09 |
Christopher Tenhoor |
Fc receptor binding proteins
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
EP2282769A4
(en)
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
EP2274331B1
(en)
|
2008-05-02 |
2013-11-06 |
Novartis AG |
Improved fibronectin-based binding molecules and uses thereof
|
EP2291399B1
(en)
|
2008-05-22 |
2014-06-25 |
Bristol-Myers Squibb Company |
Multivalent fibronectin based scaffold domain proteins
|
JP2011523560A
(ja)
|
2008-06-02 |
2011-08-18 |
ダナ−ファーバー キャンサー インスティテュート インク. |
Xbp1ペプチド、cd138ペプチドおよびcs1ペプチド
|
JP5723769B2
(ja)
|
2008-06-03 |
2015-05-27 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
EP2297209A4
(en)
|
2008-06-03 |
2012-08-01 |
Abbott Lab |
IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
|
EP2133433A1
(en)
|
2008-06-09 |
2009-12-16 |
Centre Georges François Leclerc |
A method for predicting responsiveness to a treatment with an anti-HER2 antibody
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
BRPI0812682A2
(pt)
|
2008-06-16 |
2010-06-22 |
Genentech Inc |
tratamento de cáncer de mama metastático
|
EP3730139B1
(en)
|
2008-06-17 |
2023-08-16 |
Wyeth LLC |
Antineoplastic combinations containing hki-272 and vinorelbine
|
KR102007492B1
(ko)
*
|
2008-06-25 |
2019-08-05 |
에스바테크 - 어 노바티스 컴파니 엘엘씨 |
보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
|
PT2307457T
(pt)
|
2008-06-25 |
2018-10-16 |
Esbatech Alcon Biomed Res Unit |
Anticorpos estáveis e solúveis que inibem o tnf
|
EP3216803B1
(en)
|
2008-06-25 |
2020-03-11 |
Novartis Ag |
Stable and soluble antibodies inhibiting vegf
|
AU2009269149B2
(en)
|
2008-06-30 |
2016-03-17 |
Mesoblast, Inc. |
Treatment of eye diseases and excessive neovascularization using a combined therapy
|
LT2824100T
(lt)
|
2008-07-08 |
2018-05-10 |
Incyte Holdings Corporation |
1,2,5-oksadiazolai, kaip indolamino 2,3-dioksigenazės inhibitoriai
|
EP2321422A4
(en)
|
2008-07-08 |
2013-06-19 |
Abbvie Inc |
PROSTAGLANDINE E2 VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
|
US8900589B2
(en)
|
2008-07-15 |
2014-12-02 |
Genetech, Inc. |
Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
MY160699A
(en)
*
|
2008-07-18 |
2017-03-15 |
Trinity Therapeutics Inc |
Methods for treating immune-mediated dengue fever infections and antibody-dependent enhancement of dengue fever infections, including dengue hemorrhagic fever and dengue shock syndrome
|
US8148088B2
(en)
*
|
2008-07-18 |
2012-04-03 |
Abgent |
Regulation of autophagy pathway phosphorylation and uses thereof
|
KR101434009B1
(ko)
|
2008-08-04 |
2014-08-25 |
와이어쓰 엘엘씨 |
4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
WO2010027981A1
(en)
|
2008-09-03 |
2010-03-11 |
Genentech, Inc. |
Multispecific antibodies
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
US8192738B2
(en)
|
2008-09-19 |
2012-06-05 |
Medimmune, Llc |
Targeted antibodies directed to DLL4
|
JP2012504939A
(ja)
|
2008-09-23 |
2012-03-01 |
ワイス・エルエルシー |
架橋結合タンパク質による活性化シグナルの産生を予測するための方法
|
US10981998B2
(en)
|
2008-10-01 |
2021-04-20 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
PT2356153T
(pt)
|
2008-10-01 |
2016-07-15 |
Amgen Res (Munich) Gmbh |
Anticorpo biespecífico, de cadeia única, amepxcd3, específico interespécies
|
PE20110707A1
(es)
|
2008-10-14 |
2011-10-11 |
Genentech Inc |
Variantes de inmunoglobulinas
|
US20100261620A1
(en)
*
|
2008-10-14 |
2010-10-14 |
Juan Carlos Almagro |
Methods of Humanizing and Affinity-Maturing Antibodies
|
JP2012505900A
(ja)
|
2008-10-14 |
2012-03-08 |
ダイアクス コーポレーション |
全身性強皮症に伴う肺線維症の治療および予防のためのigf−ii/igf−iie結合タンパク質の使用
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
WO2010050528A1
(ja)
*
|
2008-10-28 |
2010-05-06 |
塩野義製薬株式会社 |
抗muc1抗体
|
CN104740631B
(zh)
|
2008-10-29 |
2019-04-16 |
阿布林克斯公司 |
单域抗原结合性分子的制剂
|
JP6113404B2
(ja)
|
2008-10-29 |
2017-04-12 |
アブリンクス エン.ヴェー. |
単一ドメイン抗原結合分子の精製方法
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
CN105601742A
(zh)
|
2008-10-31 |
2016-05-25 |
詹森生物科技公司 |
Toll样受体3拮抗剂
|
AU2009308707A1
(en)
|
2008-10-31 |
2010-05-06 |
Biogen Idec Ma Inc. |
LIGHT targeting molecules and uses thereof
|
BRPI0921845A2
(pt)
|
2008-11-12 |
2019-09-17 |
Medimmune Llc |
formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
|
CA2743306A1
(en)
*
|
2008-11-12 |
2010-05-20 |
Theraclone Sciences, Inc. |
Human m2e peptide immunogens
|
US8309306B2
(en)
*
|
2008-11-12 |
2012-11-13 |
Nodality, Inc. |
Detection composition
|
WO2010065079A2
(en)
|
2008-11-25 |
2010-06-10 |
Alder Biopharmaceuticals, Inc. |
Antibodies to il-6 and use thereof
|
US20110229471A1
(en)
|
2008-11-26 |
2011-09-22 |
Cedars-Sinai Medical Center |
Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
|
WO2010062857A1
(en)
*
|
2008-11-26 |
2010-06-03 |
Allergan, Inc. |
Klk-13 antibody inhibitor for treating dry eye
|
EP2191841A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
EP2191842A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
|
EP2191840A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
EP2191843A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
|
EP2370092A1
(en)
|
2008-12-03 |
2011-10-05 |
Research Development Foundation |
Modulation of olfml-3 mediated angiogenesis
|
CN104940928B
(zh)
|
2008-12-05 |
2018-03-30 |
阿布拉西斯生物科学有限责任公司 |
结合SPARC的scFv
|
CA2745899C
(en)
|
2008-12-05 |
2015-04-28 |
Vuong Trieu |
Albumin binding peptide-mediated disease targeting
|
JP2012511026A
(ja)
*
|
2008-12-05 |
2012-05-17 |
エルパス・インコーポレイテッド |
抗脂抗体結晶構造を用いた抗体設計
|
US8401799B2
(en)
*
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
CN102245640B
(zh)
|
2008-12-09 |
2014-12-31 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
AU2009335788A1
(en)
|
2008-12-17 |
2011-07-07 |
Genentech, Inc. |
Hepatitis C virus combination therapy
|
BRPI0918122A8
(pt)
|
2008-12-19 |
2017-01-24 |
Macrogenics Inc |
molécula de diabody, diabody, e mólecula dart
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
US20120114667A1
(en)
|
2008-12-23 |
2012-05-10 |
Medimmune Limited |
TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
|
EP3318573A1
(en)
|
2008-12-23 |
2018-05-09 |
F. Hoffmann-La Roche AG |
Mmunoglobulin variants with altered binding to protein a
|
CN102341411A
(zh)
|
2008-12-31 |
2012-02-01 |
比奥根艾迪克Ma公司 |
抗-淋巴细胞毒素抗体
|
AU2010203712A1
(en)
|
2009-01-06 |
2010-07-15 |
Dyax Corp. |
Treatment of mucositis with kallikrein inhibitors
|
ES2630226T3
(es)
|
2009-01-06 |
2017-08-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Un agente agotador de células B para el tratamiento de la aterosclerosis
|
CN106995495A
(zh)
*
|
2009-01-12 |
2017-08-01 |
希托马克斯医疗有限责任公司 |
修饰抗体组合物及其制备和使用方法
|
EP2387584A1
(en)
|
2009-01-14 |
2011-11-23 |
IQ Therapeutics BV |
Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
|
WO2010087927A2
(en)
|
2009-02-02 |
2010-08-05 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
EP2394159B1
(en)
*
|
2009-02-04 |
2018-09-26 |
Molecular Innovations |
Assays for detecting prorenin, and antibodies used therein
|
US20100233733A1
(en)
*
|
2009-02-10 |
2010-09-16 |
Nodality, Inc., A Delaware Corporation |
Multiple mechanisms for modulation of the pi3 kinase pathway
|
EP2396652B1
(en)
|
2009-02-11 |
2017-12-13 |
Cedars-Sinai Medical Center |
Diagnosis of inflammatory bowel syndrome based on cytolethal distending toxin
|
SI2881402T1
(sl)
|
2009-02-12 |
2017-12-29 |
Cell Signaling Technology, Inc. |
Ekspresija mutantnega ros pri humanem raku jeter
|
JP2012518072A
(ja)
|
2009-02-18 |
2012-08-09 |
カーネギー メロン ユニバーシティ |
明検出のためのクエンチャー付加デンドリマー色素
|
JP5861223B2
(ja)
*
|
2009-02-23 |
2016-02-16 |
サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. |
プロタンパク質およびその使用方法
|
US20100292443A1
(en)
*
|
2009-02-26 |
2010-11-18 |
Sabbadini Roger A |
Humanized platelet activating factor antibody design using anti-lipid antibody templates
|
US20100248265A1
(en)
*
|
2009-02-27 |
2010-09-30 |
The Salk Institute For Biological Studies |
Compositions and methods for diagnosis and treatment of cancer
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
WO2010107752A2
(en)
|
2009-03-20 |
2010-09-23 |
Amgen Inc. |
Alpha-4-beta-7 heterodimer specific antagonist antibody
|
MX2011009729A
(es)
*
|
2009-03-20 |
2011-10-14 |
Genentech Inc |
Anticuerpos anti-her.
|
US8242248B2
(en)
*
|
2009-03-23 |
2012-08-14 |
Nodality, Inc. |
Kits for multiparametric phospho analysis
|
RU2011142974A
(ru)
|
2009-03-25 |
2013-04-27 |
Дженентек, Инк. |
НОВЫЕ АНТИТЕЛА ПРОТИВ α5β1 И ИХ ПРИМЕНЕНИЕ
|
US9315584B2
(en)
|
2009-03-25 |
2016-04-19 |
Tohoku University |
LH-type bispecific antibody
|
SG174904A1
(en)
|
2009-03-25 |
2011-11-28 |
Genentech Inc |
Anti-fgfr3 antibodies and methods using same
|
EP2413967A1
(en)
|
2009-04-01 |
2012-02-08 |
F. Hoffmann-La Roche AG |
Treatment of insulin-resistant disorders
|
CA2757382A1
(en)
|
2009-04-01 |
2010-10-21 |
Kristi Elkins |
Anti-fcrh5 antibodies and immunoconjugates
|
SG175004A1
(en)
|
2009-04-02 |
2011-11-28 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
ES2363358B1
(es)
|
2009-04-03 |
2012-06-21 |
FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al |
Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
|
JP5992325B2
(ja)
|
2009-04-06 |
2016-09-14 |
ワイス・エルエルシー |
乳癌のための、ネラチニブを活用する治療計画
|
JP5612663B2
(ja)
|
2009-04-07 |
2014-10-22 |
ロシュ グリクアート アクチェンゲゼルシャフト |
二重特異性抗ErbB−1/抗c−Met抗体
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
CA2758548A1
(en)
*
|
2009-04-17 |
2010-10-21 |
Biogen Idec Ma Inc. |
Compositions and methods to treat acute myelogenous leukemia
|
CA2758523C
(en)
|
2009-04-18 |
2019-03-12 |
Genentech, Inc. |
Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
|
NZ595792A
(en)
|
2009-04-20 |
2014-01-31 |
Oxford Biotherapeutics Ltd |
Antibodies specific to cadherin-17
|
US8609101B2
(en)
*
|
2009-04-23 |
2013-12-17 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies
|
AU2010241706B2
(en)
|
2009-04-29 |
2015-07-09 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
ERG monoclonal antibodies
|
SG175396A1
(en)
|
2009-04-29 |
2011-12-29 |
Centocor Ortho Biotech Inc |
Toll-like receptor 3 antagonists
|
TWI529247B
(zh)
|
2009-05-13 |
2016-04-11 |
建新公司 |
抗人類cd52免疫球蛋白
|
AU2010249787A1
(en)
|
2009-05-20 |
2011-12-22 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
GB0908613D0
(en)
|
2009-05-20 |
2009-06-24 |
Immunocore Ltd |
T Cell Reseptors
|
KR20120024794A
(ko)
*
|
2009-05-28 |
2012-03-14 |
아브락시스 바이오사이언스, 엘엘씨 |
화학요법에 대한 반응을 예측하는 2 항-sparc 항체의 용도
|
WO2010136569A1
(en)
|
2009-05-29 |
2010-12-02 |
F. Hoffmann-La Roche Ag |
Modulators for her2 signaling in her2 expressing patients with gastric cancer
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
MX2012000121A
(es)
|
2009-06-22 |
2012-03-07 |
Medimmune Llc |
Regiones fc modificadas para la conjugacion especifica del sitio.
|
TWI513465B
(zh)
|
2009-06-25 |
2015-12-21 |
Regeneron Pharma |
以dll4拮抗劑與化學治療劑治療癌症之方法
|
SG176947A1
(en)
|
2009-07-03 |
2012-01-30 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
NZ597458A
(en)
|
2009-07-03 |
2014-01-31 |
Bionor Immuno As |
Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
|
WO2011004899A1
(en)
|
2009-07-06 |
2011-01-13 |
Takeda Pharmaceutical Company Limited |
Cancerous disease modifying antibodies
|
WO2011005715A1
(en)
|
2009-07-07 |
2011-01-13 |
Genentech, Inc. |
Diagnosis and treatment of autoimmune demyelinating diseases
|
US20120226119A1
(en)
|
2009-07-09 |
2012-09-06 |
Hoffmann-La Roche Inc. |
Vivo tumor vasculature imaging
|
JP6095367B2
(ja)
|
2009-07-13 |
2017-03-15 |
ジェネンテック, インコーポレイテッド |
癌治療のための診断方法および組成物
|
EP2454368A4
(en)
|
2009-07-17 |
2013-01-09 |
Aaron Thomas Tabor |
COMPOSITIONS AND METHOD FOR THE GENETIC MODIFICATION OF COSMETIC FUNCTION CELLS FOR IMPROVING THE COSMETIC APPEARANCE PICTURE
|
BRPI1010068A2
(pt)
|
2009-07-24 |
2016-03-15 |
Hoffmann La Roche |
"sistema agitador, dispositivo, método para cultivo de células animais, método para produzir um polipeptídeo, uso de um sistema agitador e dispositivos para cultivar células animais"
|
AU2010275774B2
(en)
|
2009-07-24 |
2016-03-31 |
F. Hoffmann-La Roche Ag |
Optimizing the production of antibodies
|
TW201106972A
(en)
|
2009-07-27 |
2011-03-01 |
Genentech Inc |
Combination treatments
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
EP2459591B1
(en)
|
2009-07-31 |
2014-08-20 |
Genentech, Inc. |
Inhibition of tumor metastasis using anti-g-csf-antibodies
|
MX2012001283A
(es)
|
2009-07-31 |
2012-06-12 |
Amgen Inc |
Polipeptidos que se enlazan al inhibidor de tejidos de metaloproteinasa tipo tres (timp-3) composiciones y metodos.
|
NZ597809A
(en)
|
2009-08-06 |
2014-05-30 |
Genentech Inc |
Method to improve virus removal in protein purification
|
US20110039300A1
(en)
|
2009-08-10 |
2011-02-17 |
Robert Bayer |
Antibodies with enhanced adcc functions
|
LT2464725T
(lt)
|
2009-08-11 |
2020-06-10 |
F. Hoffmann-La Roche Ag |
Baltymų gamyba ląstelių mitybinėje terpėje, kurioje nėra glutamino
|
WO2011019679A1
(en)
|
2009-08-11 |
2011-02-17 |
Allergan, Inc. |
Ccr2 inhibitors for treating conditions of the eye
|
WO2011020024A2
(en)
|
2009-08-13 |
2011-02-17 |
The Johns Hopkins University |
Methods of modulating immune function
|
EP2464744A1
(en)
|
2009-08-14 |
2012-06-20 |
F. Hoffmann-La Roche AG |
Biological markers for monitoring patient response to vegf antagonists
|
WO2011019622A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Cell culture methods to make antibodies with enhanced adcc function
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
JP5925678B2
(ja)
|
2009-08-18 |
2016-05-25 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
増殖性および病原性疾患の治療のための方法および組成物
|
RU2535074C2
(ru)
|
2009-08-28 |
2014-12-10 |
Лэйбрис Байолоджикс, Инк. |
Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина
|
SG178602A1
(en)
|
2009-09-01 |
2012-04-27 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
WO2011028945A1
(en)
|
2009-09-03 |
2011-03-10 |
Genentech, Inc. |
Methods for treating, diagnosing, and monitoring rheumatoid arthritis
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
US8936792B2
(en)
|
2009-09-11 |
2015-01-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Pseudomonas exotoxin a with reduced immunogenicity
|
CN102597776A
(zh)
|
2009-09-11 |
2012-07-18 |
霍夫曼-拉罗奇有限公司 |
鉴定响应抗癌剂的可能性升高的患者的方法
|
RU2573915C2
(ru)
|
2009-09-16 |
2016-01-27 |
Дженентек, Инк. |
Содержащие суперспираль и/или привязку белковые комплексы и их применение
|
CN102612566B
(zh)
|
2009-09-17 |
2016-02-17 |
霍夫曼-拉罗奇有限公司 |
用于癌症患者中诊断学用途的方法和组合物
|
JP2013505268A
(ja)
|
2009-09-18 |
2013-02-14 |
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー |
癌の治療におけるsparc微小環境シグネチャの使用
|
US8926976B2
(en)
*
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
CN102574913A
(zh)
|
2009-10-01 |
2012-07-11 |
弗·哈夫曼-拉罗切有限公司 |
多步骤的最终过滤
|
UY32914A
(es)
|
2009-10-02 |
2011-04-29 |
Sanofi Aventis |
Anticuerpos que se usan específicamente al receptor epha2
|
US8518405B2
(en)
|
2009-10-08 |
2013-08-27 |
The University Of North Carolina At Charlotte |
Tumor specific antibodies and uses therefor
|
CA2776756A1
(en)
|
2009-10-11 |
2011-04-14 |
Biogen Idec Ma Inc. |
Anti-vla-4 related assays
|
EP2470569A1
(en)
|
2009-10-13 |
2012-07-04 |
Oxford Biotherapeutics Ltd. |
Antibodies against epha10
|
WO2011047262A2
(en)
|
2009-10-15 |
2011-04-21 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
PT2488873E
(pt)
|
2009-10-16 |
2015-11-19 |
Novartis Ag |
Biomarcadores da resposta farmacodinâmica de tumores
|
PT2488203T
(pt)
*
|
2009-10-16 |
2017-03-10 |
Univ Leicester |
Métodos para tratamento de coagulação intravascular disseminada através da inibição da activação do complemento dependente de masp-2
|
MX2012002013A
(es)
|
2009-10-19 |
2012-03-16 |
Genentech Inc |
Moduladores de activador del factor de crecimiento de hepatocitos.
|
ES2564207T3
(es)
|
2009-10-22 |
2016-03-18 |
F. Hoffmann-La Roche Ag |
Métodos y composiciones para modular la activación con hepsina de la proteína estimuladora de macrófagos
|
AR078716A1
(es)
|
2009-10-22 |
2011-11-30 |
Genentech Inc |
Anticuerpos antihepsina y metodos para su uso
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056561A1
(en)
|
2009-10-27 |
2011-05-12 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the generation and use of conformation-specific antibodies
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
ES2728115T3
(es)
|
2009-10-30 |
2019-10-22 |
Janssen Biotech Inc |
Antagonistas de IL-17A
|
WO2011051327A2
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Small antibody-like single chain proteins
|
JP5956342B2
(ja)
|
2009-11-03 |
2016-07-27 |
シティ・オブ・ホープCity of Hope |
形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt)
|
AU2010314798B2
(en)
|
2009-11-05 |
2013-10-24 |
Teva Pharmaceuticals Australia Pty Ltd |
Treatment of cancer involving mutated KRAS or BRAF genes
|
JP5818003B2
(ja)
|
2009-11-18 |
2015-11-18 |
国立大学法人東北大学 |
ヒト型化抗egfr抗体可変領域の高機能性変異体
|
MX359551B
(es)
|
2009-11-24 |
2018-10-02 |
Medimmune Ltd |
Agentes de union diana contra b7-h1.
|
EP3002297B1
(en)
|
2009-11-30 |
2020-04-08 |
F. Hoffmann-La Roche AG |
Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211)
|
CN102811736B
(zh)
|
2009-11-30 |
2016-01-20 |
生物测试股份公司 |
治疗系统性红斑狼疮(sle)的人源化抗il-10抗体
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
TW201129380A
(en)
|
2009-12-04 |
2011-09-01 |
Genentech Inc |
Methods of treating metastatic breast cancer with trastuzumab-MCC-DM1
|
CN107337734A
(zh)
|
2009-12-04 |
2017-11-10 |
弗·哈夫曼-拉罗切有限公司 |
多特异性抗体、抗体类似物、组合物和方法
|
NZ600470A
(en)
|
2009-12-09 |
2015-02-27 |
Bayer Pharma AG |
Anti-c4.4a antibodies and uses thereof
|
ES2595376T3
(es)
|
2009-12-10 |
2016-12-29 |
Regeneron Pharmaceuticals, Inc. |
Ratones que producen anticuerpos de cadena pesada
|
ES2565208T3
(es)
|
2009-12-11 |
2016-04-01 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-VEGF-C y métodos de uso de los mismos
|
WO2011084496A1
(en)
*
|
2009-12-16 |
2011-07-14 |
Abbott Biotherapeutics Corp. |
Anti-her2 antibodies and their uses
|
US8765432B2
(en)
|
2009-12-18 |
2014-07-01 |
Oligasis, Llc |
Targeted drug phosphorylcholine polymer conjugates
|
AU2010336029B2
(en)
|
2009-12-23 |
2011-10-13 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them 2
|
CN103068849B
(zh)
|
2009-12-23 |
2016-04-06 |
霍夫曼-拉罗奇有限公司 |
抗Bv8抗体及其用途
|
WO2011079283A1
(en)
*
|
2009-12-23 |
2011-06-30 |
Bioalliance C.V. |
Anti-epcam antibodies that induce apoptosis of cancer cells and methods using same
|
WO2011082187A1
(en)
|
2009-12-30 |
2011-07-07 |
Genentech, Inc. |
Methods for modulating a pdgf-aa mediated biological response
|
JP6037841B2
(ja)
|
2010-01-06 |
2016-12-07 |
ダイアックス コーポレーション |
血漿カリクレイン結合タンパク質
|
WO2011088193A2
(en)
|
2010-01-13 |
2011-07-21 |
University Of Medicine And Dentistry Of New Jersey |
Fluorophore chelated lanthanide luminiscent probes with improved quantum efficiency
|
US20120288499A1
(en)
|
2010-01-15 |
2012-11-15 |
Armand Bensussan |
Methods for diagnosis and treatment of cutaneous t cell lymphomas
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
EP2525813B1
(en)
|
2010-01-20 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Anti-ilt5 antibodies and ilt5-binding antibody fragments
|
EP2525822B1
(en)
|
2010-01-20 |
2017-05-10 |
Merck Sharp & Dohme Corp. |
Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
|
US20110189178A1
(en)
*
|
2010-02-04 |
2011-08-04 |
Xencor, Inc. |
Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
|
WO2011097527A2
(en)
|
2010-02-04 |
2011-08-11 |
Xencor, Inc. |
Immunoprotection of therapeutic moieties using enhanced fc regions
|
WO2011100403A1
(en)
|
2010-02-10 |
2011-08-18 |
Immunogen, Inc |
Cd20 antibodies and uses thereof
|
WO2011101328A2
(en)
|
2010-02-18 |
2011-08-25 |
Roche Glycart Ag |
Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
|
CN102892779B
(zh)
|
2010-02-18 |
2016-12-21 |
基因泰克公司 |
神经调节蛋白拮抗剂及其在治疗癌症中的用途
|
AR080243A1
(es)
|
2010-02-23 |
2012-03-21 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
CN102167742B
(zh)
*
|
2010-02-25 |
2014-05-14 |
上海百迈博制药有限公司 |
一种全人源抗her2单克隆抗体、其制备方法及用途
|
US20110212088A1
(en)
*
|
2010-02-26 |
2011-09-01 |
Sabbadini Roger A |
Anti-paf antibodies
|
JP6066732B2
(ja)
|
2010-03-05 |
2017-01-25 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
標的免疫調節抗体および融合タンパク質に基づく組成物および方法
|
GB201003701D0
(en)
|
2010-03-05 |
2010-04-21 |
Cilian Ag |
System for the expression of a protein
|
CN102858362A
(zh)
|
2010-03-11 |
2013-01-02 |
阿布拉西斯生物科学有限责任公司 |
Sparc 血管生成结构域和使用方法
|
EP3513810A1
(en)
|
2010-03-22 |
2019-07-24 |
F. Hoffmann-La Roche AG |
Compositions and methods useful for stabilizing protein- containing formulations
|
AU2011232514A1
(en)
|
2010-03-24 |
2012-08-30 |
Genentech, Inc. |
Anti-LRP6 antibodies
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
AU2011230537C1
(en)
|
2010-03-26 |
2018-08-02 |
Trustees Of Dartmouth College |
Vista regulatory T cell mediator protein, vista binding agents and use thereof
|
EP2552959B1
(en)
|
2010-03-26 |
2017-01-11 |
Memorial Sloan-Kettering Cancer Center |
Antibodies to muc16 and methods of use thereof
|
AR081750A1
(es)
|
2010-03-31 |
2012-10-17 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd40
|
TWI653333B
(zh)
|
2010-04-01 |
2019-03-11 |
安進研究(慕尼黑)有限責任公司 |
跨物種專一性之PSMAxCD3雙專一性單鏈抗體
|
EP2371860A1
(en)
|
2010-04-05 |
2011-10-05 |
Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron |
Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
|
CA2795279C
(en)
|
2010-04-08 |
2020-05-05 |
Jn Biosciences Llc |
Antibodies to cd122
|
CN103154027B
(zh)
|
2010-04-09 |
2016-06-29 |
重症监护诊断股份有限公司 |
可溶性人st-2抗体和分析法
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
WO2011130434A2
(en)
|
2010-04-13 |
2011-10-20 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
US8349585B2
(en)
|
2010-04-15 |
2013-01-08 |
Alper Biotech, Llc |
Monoclonal antibodies against HER2 antigens, and uses therefor
|
PL2558499T3
(pl)
|
2010-04-16 |
2017-10-31 |
Biogen Ma Inc |
Przeciwciała anty-VLA-4
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
ES2617777T5
(es)
|
2010-04-23 |
2022-10-13 |
Hoffmann La Roche |
Producción de proteínas heteromultiméricas
|
WO2011137245A2
(en)
|
2010-04-30 |
2011-11-03 |
Esperance Pharmaceuticals, Inc. |
Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
|
KR20130079384A
(ko)
|
2010-05-03 |
2013-07-10 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
BR112012027828A2
(pt)
|
2010-05-03 |
2016-08-09 |
Genentech Inc |
composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
|
DK2568976T3
(en)
|
2010-05-10 |
2016-01-11 |
Academia Sinica |
Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
WO2011145085A2
(en)
|
2010-05-21 |
2011-11-24 |
Procognia (Israel) Ltd |
Novel antibodies and methods of use for the treatment and diagnosis of cancer
|
WO2011150079A1
(en)
|
2010-05-25 |
2011-12-01 |
Carnegie Mellon University |
Targeted probes of cellular physiology
|
PL2575847T5
(pl)
|
2010-05-25 |
2022-07-18 |
F.Hoffmann-La Roche Ag |
Sposoby oczyszczania polipeptydów
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
JO3340B1
(ar)
|
2010-05-26 |
2019-03-13 |
Regeneron Pharma |
مضادات حيوية لـعامل تمايز النمو 8 البشري
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
EP2577310B1
(en)
|
2010-06-03 |
2018-11-14 |
F.Hoffmann-La Roche Ag |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
US9193782B2
(en)
|
2010-06-03 |
2015-11-24 |
Abraxis Bioscience, Llc |
Use of the SPARC microenvironment signature in the treatment of cancer
|
EP2579897A1
(en)
|
2010-06-08 |
2013-04-17 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
JO3330B1
(ar)
*
|
2010-06-10 |
2019-03-13 |
Lilly Co Eli |
الأجسام المضادة cgrp
|
US20110311527A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
RU2577986C2
(ru)
|
2010-06-18 |
2016-03-20 |
Дженентек, Инк. |
Антитела против axl и способы их применения
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
US20130189268A1
(en)
|
2010-06-22 |
2013-07-25 |
Precision Biologics, Inc. |
Colon and pancreas cancer specific antigens and antibodies
|
MX339666B
(es)
|
2010-06-24 |
2016-06-03 |
Genentech Inc * |
Composiciones y metodos para estabilizar formulaciones que contienen proteinas.
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
WO2012006552A1
(en)
|
2010-07-09 |
2012-01-12 |
Exelixis, Inc. |
Combinations of kinase inhibitors for the treatment of cancer
|
RU2571226C2
(ru)
|
2010-07-09 |
2015-12-20 |
Дженентек, Инк. |
Антитела против нейропилина и способы их применения
|
US20120100166A1
(en)
|
2010-07-15 |
2012-04-26 |
Zyngenia, Inc. |
Ang-2 Binding Complexes and Uses Thereof
|
CN108314733A
(zh)
|
2010-07-16 |
2018-07-24 |
埃博灵克斯股份有限公司 |
修饰的单结构域抗原结合分子及其应用
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
KR102080704B1
(ko)
|
2010-07-29 |
2020-02-24 |
세센 바이오, 아이엔씨. |
키메라 il-1 수용체 유형 i 항진제 및 길항제들
|
AU2011283694B2
(en)
|
2010-07-29 |
2017-04-13 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
CN103403027A
(zh)
|
2010-07-30 |
2013-11-20 |
诺华有限公司 |
纤连蛋白摇篮分子和其库
|
US8747844B2
(en)
|
2010-07-30 |
2014-06-10 |
Saint Louis University |
Methods of treating pain
|
JP2013537415A
(ja)
|
2010-08-03 |
2013-10-03 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
BR112013002535A2
(pt)
|
2010-08-03 |
2019-09-24 |
Hoffmann La Roche |
biomarcadores de leucemia linfocítica crônica (cll)
|
CA2807440A1
(en)
|
2010-08-04 |
2012-02-09 |
Cizzle Biotechnology Limited |
Methods and compounds for the diagnosis and treatment of cancer
|
CN103209709A
(zh)
|
2010-08-05 |
2013-07-17 |
弗·哈夫曼-拉罗切有限公司 |
抗mhc抗体抗病毒性细胞因子融合蛋白
|
US20120101108A1
(en)
|
2010-08-06 |
2012-04-26 |
Cell Signaling Technology, Inc. |
Anaplastic Lymphoma Kinase In Kidney Cancer
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
AU2011289275A1
(en)
|
2010-08-12 |
2013-02-21 |
Theraclone Sciences, Inc. |
Anti-hemagglutinin antibody compositions and methods of use thereof
|
JP2012034668A
(ja)
|
2010-08-12 |
2012-02-23 |
Tohoku Univ |
ヒト型化抗egfr抗体リジン置換可変領域断片及びその利用
|
CN103154032A
(zh)
|
2010-08-13 |
2013-06-12 |
弗·哈夫曼-拉罗切有限公司 |
用于疾病治疗的针对IL-1β和IL-18的抗体
|
RU2584597C2
(ru)
|
2010-08-13 |
2016-05-20 |
Рош Гликарт Аг |
Антитела против а2 тенасцина с и способы их применения
|
NZ703653A
(en)
|
2010-08-13 |
2016-09-30 |
Roche Glycart Ag |
Anti-fap antibodies and methods of use
|
CA2808382A1
(en)
|
2010-08-16 |
2012-02-23 |
Amgen Inc. |
Antibodies that bind myostatin, compositions and methods
|
RU2603284C2
(ru)
|
2010-08-17 |
2016-11-27 |
Ф.Хоффманн-Ля Рош Аг |
АНТИТЕЛА ПРОТИВ IgG1 ЧЕЛОВЕКА
|
ES2665954T3
(es)
|
2010-08-19 |
2018-04-30 |
Zoetis Belgium S.A. |
Anticuerpos anti-NGF y su uso
|
CA2807278A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann - La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
US11077212B2
(en)
|
2010-08-24 |
2021-08-03 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Molecular imaging of cancer cells in vivo
|
WO2012027494A1
(en)
|
2010-08-24 |
2012-03-01 |
Regents Of The University Of Minnesota |
Bispecific targeting reagents
|
KR101603001B1
(ko)
|
2010-08-25 |
2016-03-11 |
에프. 호프만-라 로슈 아게 |
Il-18r1에 대한 항체 및 그의 용도
|
CA2809433A1
(en)
|
2010-08-26 |
2012-03-01 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
AU2011295919A1
(en)
|
2010-08-31 |
2013-03-07 |
Genentech, Inc. |
Biomarkers and methods of treatment
|
ES2774369T3
(es)
|
2010-08-31 |
2020-07-20 |
Theraclone Science Int |
Anticuerpo de neutralización del virus de la inmunodeficiencia humana
|
CA3182320A1
(en)
|
2010-09-23 |
2012-03-29 |
Precision Biologics, Inc. |
Colon and pancreas cancer peptidomimetics
|
AR083044A1
(es)
|
2010-09-27 |
2013-01-30 |
Regeneron Pharma |
Anticuerpos anti-cd48 y usos de los mismos
|
US9228023B2
(en)
|
2010-10-01 |
2016-01-05 |
Oxford Biotherapeutics Ltd. |
Anti-ROR1 antibodies and methods of use for treatment of cancer
|
CA2813738A1
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
AR083495A1
(es)
|
2010-10-22 |
2013-02-27 |
Esbatech Alcon Biomed Res Unit |
Anticuerpos estables y solubles
|
EP3326645B1
(en)
|
2010-10-25 |
2020-03-18 |
Biogen MA Inc. |
Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
|
EP3214442A1
(en)
|
2010-10-25 |
2017-09-06 |
F. Hoffmann-La Roche AG |
Treatment of gastrointestinal inflammation and psoriasis and asthmainflammation and psoriasis a
|
EP3456740A1
(en)
|
2010-11-04 |
2019-03-20 |
Boehringer Ingelheim International GmbH |
Anti-il-23 antibodies
|
SG189475A1
(en)
|
2010-11-05 |
2013-05-31 |
Transbio Ltd |
Markers of endothelial progenitor cells and uses thereof
|
EP2638070B1
(en)
|
2010-11-10 |
2016-10-19 |
F.Hoffmann-La Roche Ag |
Methods and compositions for neural disease immunotherapy
|
EP2640727B1
(en)
|
2010-11-17 |
2015-05-13 |
Genentech, Inc. |
Alaninyl maytansinol antibody conjugates
|
EP2640744A4
(en)
|
2010-11-19 |
2014-05-28 |
Eisai R&D Man Co Ltd |
NEUTRALIZATION OF ANTIBODIES TO CCL20
|
DK2643018T3
(da)
|
2010-11-23 |
2021-01-18 |
Vitaeris Inc |
Anti-il-6-antistoffer til behandling af oral mucositis
|
US20130245233A1
(en)
|
2010-11-24 |
2013-09-19 |
Ming Lei |
Multispecific Molecules
|
US9783602B2
(en)
|
2010-12-01 |
2017-10-10 |
Alderbio Holdings Llc |
Anti-NGF compositions and use thereof
|
WO2012075173A2
(en)
|
2010-12-01 |
2012-06-07 |
Board Of Regents The University Of Texas System |
Compositions and method for deimmunization of proteins
|
KR20230057485A
(ko)
|
2010-12-06 |
2023-04-28 |
씨젠 인크. |
Liv-1에 대한 인간화 항체 및 이의 암을 치료하기 위한 용도
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
EA201790664A1
(ru)
|
2010-12-20 |
2017-07-31 |
Дженентек, Инк. |
Антитела против мезотелина и иммуноконъюгаты
|
SG190891A1
(en)
|
2010-12-21 |
2013-07-31 |
Hoffmann La Roche |
Chromatography equipment characterization
|
JP5838221B2
(ja)
|
2010-12-21 |
2016-01-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
アイソフォーム濃縮抗体調製物及びこれを得る方法
|
WO2012088313A1
(en)
|
2010-12-22 |
2012-06-28 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
CN103384681B
(zh)
|
2010-12-23 |
2018-05-18 |
霍夫曼-拉罗奇有限公司 |
结合剂
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
WO2012093068A1
(en)
|
2011-01-03 |
2012-07-12 |
F. Hoffmann-La Roche Ag |
A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide
|
US20120171195A1
(en)
|
2011-01-03 |
2012-07-05 |
Ravindranath Mepur H |
Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
|
AU2012204202A1
(en)
|
2011-01-06 |
2013-07-11 |
Dyax Corp. |
Plasma kallikrein binding proteins
|
RU2620922C2
(ru)
|
2011-01-21 |
2017-05-30 |
Теранос, Инк. |
Системы и методы оптимизации использования образца
|
WO2012103240A2
(en)
|
2011-01-25 |
2012-08-02 |
Eleven Biotherapeutics, Inc. |
Receptor binding agents
|
DK2668210T3
(da)
|
2011-01-26 |
2020-08-24 |
Celldex Therapeutics Inc |
Anti-kit antistoffer og anvendelser deraf
|
CA2825894C
(en)
|
2011-02-02 |
2021-11-30 |
Amgen Inc. |
Prognosis of cancer using a circulating biomarker
|
EP3263125A3
(en)
|
2011-02-02 |
2018-03-14 |
Emory University |
Antagonism of the vip signaling pathway
|
EP2670776B1
(en)
|
2011-02-04 |
2018-11-21 |
F. Hoffmann-La Roche AG |
Fc VARIANTS AND METHODS FOR THEIR PRODUCTION
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
US9527905B2
(en)
|
2011-02-08 |
2016-12-27 |
Medimmune, Llc |
Antibodies that specifically bind Staphylococcus aureus alpha toxin and methods of use
|
UA117294C2
(uk)
|
2011-02-10 |
2018-07-10 |
Рош Глікарт Аг |
Імунокон'югат
|
CN103476433A
(zh)
|
2011-02-10 |
2013-12-25 |
罗切格利卡特公司 |
改良的免疫疗法
|
EP2675478A4
(en)
|
2011-02-14 |
2015-06-10 |
Theraclone Sciences Inc |
COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF GRIP
|
BR112013021725A2
(pt)
|
2011-02-28 |
2016-11-01 |
Genentech Inc |
marcadores biológicos e métodos para prever resposta aos antagonistas de células b
|
CA2824824A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
RU2607038C2
(ru)
|
2011-02-28 |
2017-01-10 |
Ф. Хоффманн-Ля Рош Аг |
Антигенсвязывающие белки
|
WO2012119989A2
(en)
|
2011-03-04 |
2012-09-13 |
Oryzon Genomics, S.A. |
Methods and antibodies for the diagnosis and treatment of cancer
|
JP2014515598A
(ja)
|
2011-03-10 |
2014-07-03 |
エイチシーオー アンティボディ, インク. |
二重特異性三鎖抗体様分子
|
WO2012122512A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Recombinant production of mixtures of single chain antibodies
|
CN103533929A
(zh)
|
2011-03-15 |
2014-01-22 |
特罗科隆科学有限公司 |
用于流行性感冒的治疗和诊断的组合物和方法
|
CA2812739A1
(en)
|
2011-03-25 |
2012-10-04 |
Glenmark Pharmaceuticals S.A. |
Hetero-dimeric immunoglobulins
|
ES2692268T3
(es)
|
2011-03-29 |
2018-12-03 |
Roche Glycart Ag |
Variantes de Fc de anticuerpo
|
CN106039306A
(zh)
|
2011-03-30 |
2016-10-26 |
埃博灵克斯股份有限公司 |
使用针对TNFα的单结构域抗体治疗免疫病症的方法
|
MX2013011130A
(es)
|
2011-03-31 |
2013-10-30 |
Genentech Inc |
Metodos de administracion de antagonistas de integrina beta7.
|
HUE036513T2
(hu)
|
2011-04-01 |
2018-07-30 |
Genentech Inc |
AKT inhibitor vegyület és abirateron kombinációja terápiás kezelésekben való alkalmazásra
|
RU2013143358A
(ru)
|
2011-04-07 |
2015-05-20 |
Дженентек, Инк. |
Анти-fgfr4 антитела и способы их применения
|
EP2696898A4
(en)
|
2011-04-07 |
2014-10-01 |
Univ Emory |
COMPOSITIONS COMPRISING SACCHARIDE BINDING FRACTIONS AND METHODS FOR TARGETED THERAPY
|
US9644035B2
(en)
|
2011-04-08 |
2017-05-09 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
CA3076975C
(en)
|
2011-04-08 |
2024-06-18 |
Omeros Corporation |
Methods for treating conditions associated with masp-2 dependent complement activation
|
TR201905909T4
(tr)
|
2011-04-19 |
2019-05-21 |
Pfizer |
Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
|
EP2699264B1
(en)
|
2011-04-20 |
2018-03-14 |
Medlmmune, LLC |
Antibodies and other molecules that bind b7-h1 and pd-1
|
CA2833404A1
(en)
|
2011-04-21 |
2012-10-26 |
Garvan Institute Of Medical Research |
Modified variable domain molecules and methods for producing and using them b
|
US10487114B2
(en)
|
2011-04-27 |
2019-11-26 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
|
WO2012146630A1
(en)
|
2011-04-29 |
2012-11-01 |
F. Hoffmann-La Roche Ag |
N-terminal acylated polypeptides, methods for their production and uses thereof
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
EP2704742B1
(en)
|
2011-05-02 |
2017-07-12 |
Millennium Pharmaceuticals, Inc. |
Formulation for anti- 4 7 antibody
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
WO2012151317A1
(en)
|
2011-05-03 |
2012-11-08 |
Genentech, Inc. |
Vascular disruption agents and uses thereof
|
JP6169561B2
(ja)
|
2011-05-06 |
2017-07-26 |
ザ ガバメント オブ ザ ユナイテツド ステイツ オブ アメリカ アズ リプリゼンテツド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒユーマン サービシズ |
メソテリンを標的とする組換え免疫毒素
|
MX2013013054A
(es)
|
2011-05-12 |
2014-02-20 |
Genentech Inc |
Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
|
AU2012255881C1
(en)
|
2011-05-16 |
2015-11-26 |
Genentech, Inc. |
FGFR1 agonists and methods of use
|
SI2710033T1
(sl)
|
2011-05-17 |
2021-05-31 |
The Rockefeller University |
Virus humane imunske pomanjkljivosti nevtralizirajoča protitelesa in metode njihove uporabe
|
EP2709662B1
(en)
|
2011-05-20 |
2019-07-31 |
AlderBio Holdings LLC |
Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
|
LT2710039T
(lt)
|
2011-05-20 |
2019-04-25 |
Alderbio Holdings Llc |
Anti-cgrp kompozicijos ir jų panaudojimas
|
CA2836800A1
(en)
|
2011-05-20 |
2012-11-29 |
Alderbio Holdings Llc |
Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
|
SG195073A1
(en)
|
2011-05-21 |
2013-12-30 |
Macrogenics Inc |
Deimmunized serum-binding domains and their use for extending serum half-life
|
CA2837169C
(en)
|
2011-05-24 |
2021-11-09 |
Zyngenia, Inc. |
Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
|
KR102046666B1
(ko)
|
2011-05-25 |
2019-11-19 |
이나뜨 파르마 |
염증성 장애의 치료를 위한 항-kir 항체
|
JP6104897B2
(ja)
|
2011-06-02 |
2017-04-05 |
ダイアックス コーポレーション |
Fcレセプター結合タンパク質
|
JP6305919B2
(ja)
|
2011-06-06 |
2018-04-04 |
プロセナ バイオサイエンシーズ リミテッド |
Mcamアンタゴニスト及び治療の方法
|
BR112013031590A2
(pt)
|
2011-06-10 |
2016-11-22 |
Corimmun Gmbh |
compostos de ligação ao adrenorreceptor beta1 humano (beta1-ar) e seu uso na medida de anticorpos auto-anti-beta1-ar
|
EP2720718A4
(en)
*
|
2011-06-14 |
2015-01-21 |
Mayo Foundation |
ANTI-CD3 THERAPIES
|
RU2013158627A
(ru)
|
2011-06-15 |
2015-07-20 |
Ф. Хоффманн-Ля Рош Аг |
Антитела к рецептору человеческого эритропоэтина и способы их применения
|
US20130011394A1
(en)
|
2011-06-22 |
2013-01-10 |
Hoffmann-La Roche Inc. |
Complexes comprising mhc class i fusion polypeptides and antigen-specific antibodies and methods of use
|
EP2537933A1
(en)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
JP6247209B2
(ja)
|
2011-06-28 |
2017-12-13 |
オックスフォード ビオトヘラペウトイクス エルティーディー. |
Adpリボシルシクラーゼ2に対する抗体
|
CA2835242A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
DK2739310T3
(en)
|
2011-08-05 |
2018-07-16 |
Res Found Dev |
Improved methods and compositions for modulating OLFML3-mediated angiogenesis
|
JP6120848B2
(ja)
|
2011-08-15 |
2017-04-26 |
メディミューン,エルエルシー |
抗b7−h4抗体およびその使用
|
MX2014001736A
(es)
|
2011-08-17 |
2014-03-31 |
Genentech Inc |
Inhibicion de angiogenesis en tumores refractarios.
|
JP2014526891A
(ja)
|
2011-08-17 |
2014-10-09 |
ジェネンテック, インコーポレイテッド |
ニューレグリン抗体とその使用
|
AU2012299195B9
(en)
|
2011-08-19 |
2018-05-10 |
Regeneron Pharmaceuticals, Inc |
Anti-Tie2 antibodies uses thereof
|
WO2013026837A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
AR087601A1
(es)
|
2011-08-23 |
2014-04-03 |
Roche Glycart Ag |
Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de utilizacion
|
US9309306B2
(en)
|
2011-08-23 |
2016-04-12 |
Roche Glycart Ag |
Anti-MCSP antibodies
|
WO2013026839A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
NO2748201T3
(xx)
|
2011-08-23 |
2018-05-12 |
|
|
RS57744B1
(sr)
|
2011-08-23 |
2018-12-31 |
Roche Glycart Ag |
Bispecifični antigen vezujući molekuli
|
CA2843158A1
(en)
|
2011-08-26 |
2013-03-07 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
CA2845179A1
(en)
|
2011-08-31 |
2013-03-07 |
Genentech, Inc. |
Diagnostic markers
|
CN104159610A
(zh)
|
2011-09-12 |
2014-11-19 |
詹森生物科技公司 |
用于治疗代谢和心血管疾病的3型toll样受体拮抗剂
|
US8840838B2
(en)
|
2011-09-25 |
2014-09-23 |
Theranos, Inc. |
Centrifuge configurations
|
US9632102B2
(en)
|
2011-09-25 |
2017-04-25 |
Theranos, Inc. |
Systems and methods for multi-purpose analysis
|
US8475739B2
(en)
|
2011-09-25 |
2013-07-02 |
Theranos, Inc. |
Systems and methods for fluid handling
|
US9268915B2
(en)
|
2011-09-25 |
2016-02-23 |
Theranos, Inc. |
Systems and methods for diagnosis or treatment
|
US9664702B2
(en)
|
2011-09-25 |
2017-05-30 |
Theranos, Inc. |
Fluid handling apparatus and configurations
|
US8435738B2
(en)
|
2011-09-25 |
2013-05-07 |
Theranos, Inc. |
Systems and methods for multi-analysis
|
US20140170735A1
(en)
|
2011-09-25 |
2014-06-19 |
Elizabeth A. Holmes |
Systems and methods for multi-analysis
|
US9619627B2
(en)
|
2011-09-25 |
2017-04-11 |
Theranos, Inc. |
Systems and methods for collecting and transmitting assay results
|
EP2756300A1
(en)
|
2011-09-15 |
2014-07-23 |
F.Hoffmann-La Roche Ag |
Methods of promoting differentiation
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
CN103930111A
(zh)
|
2011-09-19 |
2014-07-16 |
霍夫曼-拉罗奇有限公司 |
包含c-met拮抗剂和b-raf拮抗剂的组合治疗
|
MX2014003313A
(es)
|
2011-09-23 |
2014-07-09 |
Amgen Res Munich Gmbh |
Moleculas de union biespecificas para 5t4 y cd3.
|
CN103958542A
(zh)
|
2011-09-23 |
2014-07-30 |
抗菌技术,生物技术研究与发展股份有限公司 |
经修饰的白蛋白结合结构域及其用于改善药代动力学的用途
|
US10012664B2
(en)
|
2011-09-25 |
2018-07-03 |
Theranos Ip Company, Llc |
Systems and methods for fluid and component handling
|
US9250229B2
(en)
|
2011-09-25 |
2016-02-02 |
Theranos, Inc. |
Systems and methods for multi-analysis
|
US9810704B2
(en)
|
2013-02-18 |
2017-11-07 |
Theranos, Inc. |
Systems and methods for multi-analysis
|
CA2849508C
(en)
|
2011-09-30 |
2020-12-22 |
Regeneron Pharmaceuticals, Inc. |
Anti-erbb3 antibodies and uses thereof
|
EP4176871A1
(en)
|
2011-10-03 |
2023-05-10 |
Canqura Oncology Ab |
Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
|
US9663573B2
(en)
|
2011-10-05 |
2017-05-30 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
KR20130036993A
(ko)
*
|
2011-10-05 |
2013-04-15 |
삼성전자주식회사 |
c-Met의 SEMA 도메인 내의 에피토프에 특이적으로 결합하는 항체
|
JP6310394B2
(ja)
|
2011-10-10 |
2018-04-11 |
ゼンコア インコーポレイテッド |
抗体を精製する方法
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
AU2012323864A1
(en)
|
2011-10-13 |
2013-05-16 |
The Regents Of The University Of California |
Treatment of breast cancer with companion diagnostic
|
CN104039351A
(zh)
|
2011-10-13 |
2014-09-10 |
阿尔皮奥治疗学股份有限公司 |
用于治疗血管渗漏综合征和癌症的方法
|
HUE039133T2
(hu)
|
2011-10-14 |
2018-12-28 |
Hoffmann La Roche |
Anti-HtrA1 antitestek és felhasználási módszerek
|
SI2766040T1
(sl)
|
2011-10-14 |
2019-08-30 |
F. Hoffmann-La Roche Ag |
Pertuzumab, Trastuzumab, Docetaxel in Carboplatin za zdravljenje zgodnjega raka dojke
|
MX2014004426A
(es)
|
2011-10-15 |
2014-07-09 |
Genentech Inc |
Metodos de uso de antagonistas de scd1.
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
WO2013057290A1
(en)
|
2011-10-21 |
2013-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A m-dc8+ monocyte depleting agent for the prevention or the treatment of a condition associated with a chronic hyperactivation of the immune system
|
US9327023B2
(en)
|
2011-10-25 |
2016-05-03 |
The Regents Of The University Of Michigan |
HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
CN104039340B
(zh)
|
2011-10-28 |
2017-04-05 |
霍夫曼-拉罗奇有限公司 |
治疗黑素瘤的方法及治疗剂组合
|
KR101600733B1
(ko)
|
2011-10-28 |
2016-03-09 |
프로테나 바이오사이언시즈 리미티드 |
알파-시누클레인을 인식하는 인간화된 항체
|
BR112014010406A2
(pt)
|
2011-11-02 |
2017-04-25 |
Genentech Inc |
cromatografia de sobrecarga e eluto
|
WO2013067492A1
(en)
|
2011-11-03 |
2013-05-10 |
The Trustees Of The University Of Pennsylvania |
Isolated b7-h4 specific compositions and methods of use thereof
|
WO2013070468A1
(en)
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
EP2776470A2
(en)
|
2011-11-11 |
2014-09-17 |
Rinat Neuroscience Corporation |
Antibodies specific for trop-2 and their uses
|
US8871209B2
(en)
|
2011-11-14 |
2014-10-28 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
CN107007833B
(zh)
|
2011-11-16 |
2020-12-11 |
勃林格殷格翰国际有限公司 |
抗il-36r抗体
|
CA2854477A1
(en)
|
2011-11-21 |
2013-05-30 |
Genentech, Inc. |
Purification of anti-c-met antibodies
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
BR112014012590A8
(pt)
|
2011-11-23 |
2017-12-19 |
Igenica Inc |
Anticorpos anti-cd98 e métodos de uso dos mesmos
|
CN108424456B
(zh)
|
2011-11-23 |
2022-04-26 |
医学免疫有限责任公司 |
特异于her3的结合分子及其用途
|
PT2785375T
(pt)
|
2011-11-28 |
2020-10-29 |
Merck Patent Gmbh |
Anticorpos anti-pd-l1 e usos destes
|
CA2857114A1
(en)
|
2011-11-30 |
2013-06-06 |
Genentech, Inc. |
Erbb3 mutations in cancer
|
SG11201402737SA
(en)
|
2011-12-05 |
2014-06-27 |
Hoffmann La Roche |
Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
|
EP2788024A1
(en)
|
2011-12-06 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Antibody formulation
|
EP2788500A1
(en)
|
2011-12-09 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
WO2013087913A1
(en)
|
2011-12-16 |
2013-06-20 |
Synthon Biopharmaceuticals B.V. |
Compounds and methods for treating inflammatory diseases
|
CA2854249C
(en)
|
2011-12-22 |
2022-05-03 |
F. Hoffmann-La Roche Ag |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
BR112014013035A2
(pt)
|
2011-12-22 |
2018-10-09 |
Hoffmann La Roche |
métodos de seleção de células, conjuntos de expressão bicistrônica, células eucarióticas, vetores lentivirais, uso de vetor lentiviral, bibliotecas de ventores lentivirais e de células eucarióticas, métodos de seleção de células, fluxos de trabalho e uso de célula
|
JP2015502165A
(ja)
|
2011-12-22 |
2015-01-22 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
発現ベクター構成、新規の産生細胞生成法、およびポリペプチドの組換え産生のためのそれらの使用
|
WO2013093122A2
(en)
|
2011-12-23 |
2013-06-27 |
Phenoquest Ag |
Antibodies for the treatment and diagnosis of affective and anxiety disorders
|
EP2793949B1
(en)
|
2011-12-23 |
2018-08-22 |
Innate Pharma |
Enzymatic conjugation of antibodies
|
ES2721882T3
(es)
|
2011-12-23 |
2019-08-06 |
Pfizer |
Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
US9988439B2
(en)
|
2011-12-23 |
2018-06-05 |
Nicholas B. Lydon |
Immunoglobulins and variants directed against pathogenic microbes
|
EP2793941A1
(en)
|
2011-12-23 |
2014-10-29 |
F.Hoffmann-La Roche Ag |
Articles of manufacture and methods for co-administration of antibodies
|
EP2793944A4
(en)
|
2011-12-23 |
2015-09-02 |
Nicholas B Lydon |
IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES
|
TWI443107B
(zh)
|
2011-12-29 |
2014-07-01 |
Ind Tech Res Inst |
人源化之抗人類細胞表面抗原cd34之單株抗體及其應用
|
US9120870B2
(en)
|
2011-12-30 |
2015-09-01 |
Abbvie Inc. |
Dual specific binding proteins directed against IL-13 and IL-17
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
AU2013208007A1
(en)
|
2012-01-09 |
2014-07-31 |
The Scripps Research Institute |
Humanized antibodies with ultralong CDR3
|
CA2863224A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
US10800847B2
(en)
|
2012-01-11 |
2020-10-13 |
Dr. Mepur Ravindranath |
Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
|
US20130177574A1
(en)
|
2012-01-11 |
2013-07-11 |
Paul I. Terasaki Foundation Laboratory |
ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
|
WO2013104798A1
(en)
|
2012-01-12 |
2013-07-18 |
Cemm - Center For Molecular Medicine Of The Austrian Academy Of Sciences |
Modulators of immune responses
|
SG11201403927XA
(en)
|
2012-01-13 |
2014-08-28 |
Genentech Inc |
Biological markers for identifying patients for treatment with vegf antagonists
|
BR112014017626A2
(pt)
|
2012-01-18 |
2018-05-22 |
Genentech Inc |
métodos para tratar uma doença ou disfunção, métodos de identificação de um indivíduo, método para prever se um indivíduo com uma doença ou disfunção tem mais ou menos probabilidade para desenvolver toxicidade ao tratamento, método para determinar se um indivíduo com uma doença ou disfunção deve continuar ou suspender o tratamento que compreende um modulador de fgf19, método de otimização de eficácia terapêutica e método de ensaio
|
TW201335187A
(zh)
|
2012-01-18 |
2013-09-01 |
Genentech Inc |
抗lrp5抗體及使用方法
|
DK2807188T3
(da)
|
2012-01-27 |
2019-10-07 |
Prothena Biosciences Ltd |
Humaniserede antistoffer, der genkender alpha-synuclein
|
EP2809773B1
(en)
|
2012-01-30 |
2020-09-02 |
Dr. Reddy's Laboratories Limited |
Process of modulating man5 and/or afucosylation content of glycoprotein composition
|
WO2013113641A1
(en)
|
2012-01-31 |
2013-08-08 |
Roche Glycart Ag |
Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
|
EP2809684A1
(en)
|
2012-01-31 |
2014-12-10 |
Genentech, Inc. |
Anti-ig-e m1' antibodies and methods using same
|
KR102091297B1
(ko)
|
2012-02-03 |
2020-03-20 |
에프. 호프만-라 로슈 아게 |
항원-형질감염된 t 세포와 함께 사용되는 이중특이적 항체 분자 및 의약에서의 이들의 용도
|
JP6486686B2
(ja)
|
2012-02-10 |
2019-03-20 |
ジェネンテック, インコーポレイテッド |
単鎖抗体及び他のヘテロ多量体
|
MX366804B
(es)
|
2012-02-11 |
2019-07-25 |
Genentech Inc |
Translocaciones de la r-espondina y sus metodos de uso.
|
MX360352B
(es)
|
2012-02-15 |
2018-10-30 |
Hoffmann La Roche |
Cromatografia de afinidad basada en receptores fc.
|
ES2732243T3
(es)
|
2012-02-16 |
2019-11-21 |
Santarus Inc |
Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
|
TWI613215B
(zh)
|
2012-02-22 |
2018-02-01 |
再生元醫藥公司 |
抗-大-內皮素-1(big-et-1)抗體及其用途
|
MX353608B
(es)
*
|
2012-02-24 |
2018-01-19 |
Alteogen Inc |
Anticuerpo modificado en el que el tema que comprende residuos de cisteina esta ligado, conjugado de farmaco de anticuerpo modificado que comprende el anticuerpo modificado y metodo de produccion para el mismo.
|
JP6407726B2
(ja)
|
2012-03-01 |
2018-10-24 |
アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH |
長寿命ポリペプチド結合分子
|
CA2860369A1
(en)
|
2012-03-02 |
2013-09-06 |
Roche Glycart Ag |
Predicitive biomarker for cancer treatment with adcc enhanced antibodies
|
CN104379602B
(zh)
|
2012-03-08 |
2017-05-03 |
哈洛齐梅公司 |
具有条件活性的抗表皮生长因子受体抗体及其使用方法
|
PT2825558T
(pt)
|
2012-03-13 |
2019-07-11 |
Hoffmann La Roche |
Terapêutica combinada para o tratamento do cancro do ovário
|
EP2638916A1
(en)
|
2012-03-16 |
2013-09-18 |
Covagen AG |
Novel binding molecules with antitumoral activity
|
ES2731757T3
(es)
|
2012-03-20 |
2019-11-18 |
Biogen Ma Inc |
Anticuerpos neutralizantes de JCV
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
WO2013148315A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
JP6209206B2
(ja)
|
2012-03-27 |
2017-10-04 |
グリーン・クロス・コーポレイションGreen Cross Corp. |
上皮成長因子受容体の表面抗原上のエピトープおよびその用途
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
SG11201406184XA
(en)
|
2012-03-30 |
2014-10-30 |
Genentech Inc |
Diagnostic methods and compositions for treatment of cancer
|
EP2833900B1
(en)
|
2012-04-01 |
2018-09-19 |
Technion Research & Development Foundation Limited |
Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
|
TWI619729B
(zh)
|
2012-04-02 |
2018-04-01 |
再生元醫藥公司 |
抗-hla-b*27抗體及其用途
|
US10385395B2
(en)
|
2012-04-11 |
2019-08-20 |
The Regents Of The University Of California |
Diagnostic tools for response to 6-thiopurine therapy
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
HUE037856T2
(hu)
|
2012-04-18 |
2018-09-28 |
Cell Signaling Technology Inc |
EGFR és ROS1 rákban
|
SG11201407106XA
(en)
|
2012-05-01 |
2014-11-27 |
Genentech Inc |
Anti-pmel17 antibodies and immunoconjugates
|
EP4039275A1
(en)
|
2012-05-03 |
2022-08-10 |
Boehringer Ingelheim International GmbH |
Anti-il-23p19 antibodies
|
US9441039B2
(en)
|
2012-05-07 |
2016-09-13 |
Amgen Inc. |
Anti-erythropoietin antibodies
|
KR101505157B1
(ko)
|
2012-05-08 |
2015-03-24 |
주식회사 종근당 |
항―ErbB2 항체 변이체
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
ES2924722T3
(es)
|
2012-05-18 |
2022-10-10 |
Aptevo Res & Development Llc |
Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3
|
MX2014014086A
(es)
|
2012-05-23 |
2015-01-26 |
Genentech Inc |
Metodo de seleccion para agentes terapeuticos.
|
EP3967323A3
(en)
|
2012-06-06 |
2022-05-04 |
Bionor Immuno AS |
Hiv vaccine
|
WO2013184871A1
(en)
|
2012-06-06 |
2013-12-12 |
Zoetis Llc |
Caninized anti-ngf antibodies and methods thereof
|
CN104379163A
(zh)
|
2012-06-08 |
2015-02-25 |
霍夫曼-拉罗奇有限公司 |
用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
|
AU2013270684B2
(en)
|
2012-06-08 |
2018-04-19 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
AR091462A1
(es)
|
2012-06-15 |
2015-02-04 |
Genentech Inc |
Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso
|
PE20150223A1
(es)
|
2012-06-15 |
2015-02-11 |
Pfizer |
Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
|
CN104582736A
(zh)
|
2012-06-21 |
2015-04-29 |
印第安纳大学研究及科技有限公司 |
Fc效应子功能改变的肠降血糖素受体配体多肽Fc区融合多肽和缀合物
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
BR112014032276A2
(pt)
|
2012-06-22 |
2017-11-28 |
King S College London |
construtos de vista-ig e o uso de vista-ig para o tratamento de distúrbios autoimunes, alérgicos e inflamatórios
|
TWI641619B
(zh)
|
2012-06-25 |
2018-11-21 |
美商再生元醫藥公司 |
抗-egfr抗體及其用途
|
JP2015522815A
(ja)
|
2012-06-26 |
2015-08-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
乳癌の治療用ベバシズマブ併用療法の血漿バイオマーカー
|
CN104395339A
(zh)
|
2012-06-27 |
2015-03-04 |
弗·哈夫曼-拉罗切有限公司 |
用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途
|
BR112014029888A2
(pt)
|
2012-06-27 |
2020-05-12 |
Hoffmann La Roche |
Métodos de produção de um anticorpo, de determinação de uma combinação de sítios de ligação e de tratamento de um indivíduo com câncer, formulação farmacêutica, anticorpo e uso de um anticorpo
|
WO2014004549A2
(en)
|
2012-06-27 |
2014-01-03 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
CA2871882A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
CN107973856B
(zh)
|
2012-07-04 |
2021-11-23 |
弗·哈夫曼-拉罗切有限公司 |
共价连接的抗原-抗体缀合物
|
RU2017128512A
(ru)
|
2012-07-04 |
2019-02-15 |
Ф. Хоффманн-Ля Рош Аг |
Антитела к теофиллину и способы их применения
|
CN104411725B
(zh)
|
2012-07-04 |
2018-09-28 |
弗·哈夫曼-拉罗切有限公司 |
抗生物素抗体及使用方法
|
US10656156B2
(en)
|
2012-07-05 |
2020-05-19 |
Mepur Ravindranath |
Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
|
MX356162B
(es)
|
2012-07-05 |
2018-05-16 |
Genentech Inc |
Sistema de expresion y secrecion.
|
US20140030279A1
(en)
|
2012-07-09 |
2014-01-30 |
Spirogen Sarl |
Anti-cd22 antibodies and immunoconjugates
|
JP2015523380A
(ja)
|
2012-07-09 |
2015-08-13 |
ジェネンテック, インコーポレイテッド |
抗cd79b抗体を含む免疫複合体
|
WO2014011521A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti - cd79b antibodies
|
TW201408696A
(zh)
|
2012-07-09 |
2014-03-01 |
Genentech Inc |
抗cd22抗體及免疫結合物
|
EP2872894B1
(en)
|
2012-07-13 |
2019-04-17 |
Innate Pharma |
Screening of conjugated antibodies
|
RS62509B1
(sr)
|
2012-07-13 |
2021-11-30 |
Roche Glycart Ag |
Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti
|
ES2786263T3
(es)
|
2012-07-13 |
2020-10-09 |
Univ Pennsylvania |
Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico
|
SG11201500489YA
(en)
|
2012-07-25 |
2015-02-27 |
Kolltan Pharmaceuticals Inc |
Anti-kit antibodies and uses thereof
|
PL2880170T3
(pl)
|
2012-08-02 |
2017-02-28 |
F.Hoffmann-La Roche Ag |
SPOSÓB WYTWARZANIA ROZPUSZCZALNEGO FcR JAKO FUZJI Fc Z OBOJĘTNYM REGIONEM Fc IMMUNOGLOBULINY I JEGO ZASTOSOWANIA
|
SG10201800535XA
(en)
|
2012-08-07 |
2018-02-27 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
KR20190088571A
(ko)
|
2012-08-07 |
2019-07-26 |
제넨테크, 인크. |
교모세포종의 치료를 위한 조합 요법
|
WO2014023673A1
(en)
|
2012-08-08 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-10 fusion proteins and uses thereof
|
WO2014026033A1
(en)
|
2012-08-08 |
2014-02-13 |
University Of Florida Research Foundation, Inc. |
Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats
|
CA2878626A1
(en)
|
2012-08-09 |
2014-02-13 |
Roche Glycart Ag |
Asgpr antibodies and uses thereof
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
WO2014028939A2
(en)
|
2012-08-17 |
2014-02-20 |
California Institute Of Technology |
Targeting phosphofructokinase and its glycosylation form for cancer
|
WO2014031498A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
CA2883168A1
(en)
|
2012-08-21 |
2014-02-27 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
PT2892560T
(pt)
|
2012-09-06 |
2019-10-18 |
Adelaide Research&Innovation Pty Ltd |
Métodos e produtos para prevenção e/ou tratamento do cancro metastático
|
CN105246507B
(zh)
|
2012-09-07 |
2019-01-25 |
达特茅斯大学理事会 |
用于诊断和治疗癌症的vista调节剂
|
TWI660972B
(zh)
|
2012-09-10 |
2019-06-01 |
愛爾蘭商尼歐托普生物科學公司 |
抗mcam抗體及相關使用方法
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
IN2015MN00139A
(xx)
|
2012-09-25 |
2015-10-16 |
Glenmark Pharmaceuticals Sa |
|
WO2014055442A2
(en)
|
2012-10-01 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
WO2014055771A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
UA118441C2
(uk)
|
2012-10-08 |
2019-01-25 |
Протена Біосаєнсиз Лімітед |
Антитіло, що розпізнає альфа-синуклеїн
|
US10087250B2
(en)
|
2012-10-08 |
2018-10-02 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
CA2887129A1
(en)
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
CA2883264A1
(en)
|
2012-10-15 |
2014-04-24 |
Universitat Zurich Prorektorat Mnw |
Bispecific her2 ligands for cancer therapy
|
EP2719706A1
(en)
|
2012-10-15 |
2014-04-16 |
Universität Zürich |
Bispecific HER2 ligands for cancer therapy
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
AU2013331049B2
(en)
|
2012-10-18 |
2018-11-15 |
California Institute Of Technology |
Broadly-neutralizing anti-HIV antibodies
|
CA2888345C
(en)
|
2012-10-24 |
2020-04-21 |
Research Development Foundation |
Jam-c antibodies and methods for treatment of cancer
|
AU2013334493B2
(en)
|
2012-10-26 |
2018-11-29 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
KR102460297B1
(ko)
*
|
2012-10-30 |
2022-10-28 |
에스퍼란스 파마슈티컬스, 인코포레이티드 |
항체/약물 컨쥬게이트 및 이의 사용 방법
|
BR112015009961B1
(pt)
|
2012-11-01 |
2020-10-20 |
Abbvie Inc. |
proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende
|
EP3919069A1
(en)
|
2012-11-05 |
2021-12-08 |
Dana-Farber Cancer Institute, Inc. |
Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
|
CA2890207A1
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
SG11201502538TA
(en)
|
2012-11-08 |
2015-05-28 |
Hoffmann La Roche |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
EP2916872B1
(en)
|
2012-11-09 |
2019-02-27 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
CA2890669A1
(en)
|
2012-11-13 |
2014-05-22 |
Genetech, Inc. |
Anti-hemagglutinin antibodies and methods of use
|
AR093445A1
(es)
|
2012-11-14 |
2015-06-10 |
Regeneron Pharma |
Metodos para tratar el cancer de ovario con antagonistas de dll4
|
US9810670B2
(en)
|
2012-11-15 |
2017-11-07 |
Genentech, Inc. |
Ionic strength-mediated pH gradient ion exchange chromatography
|
WO2014078866A2
(en)
|
2012-11-19 |
2014-05-22 |
Xencor, Inc. |
Engineered immunoglobulins with extended in vivo half-life
|
PL2922875T3
(pl)
|
2012-11-20 |
2017-08-31 |
Sanofi |
Przeciwciała anty-CEACAM5 i ich zastosowanie
|
WO2014080251A1
(en)
|
2012-11-24 |
2014-05-30 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
US9474803B2
(en)
|
2012-11-27 |
2016-10-25 |
Alteogen Inc. |
Composition for stabilizing fusion protein in which protein and FC domain are fused
|
MX363188B
(es)
|
2012-11-30 |
2019-03-13 |
Hoffmann La Roche |
Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
UA118255C2
(uk)
|
2012-12-07 |
2018-12-26 |
Санофі |
Композиція, яка містить антитіло до cd38 і леналідомід
|
US9902775B2
(en)
|
2012-12-10 |
2018-02-27 |
Biogen Ma Inc. |
Anti-blood dendritic cell antigen 2 antibodies and uses thereof
|
EP2934575A2
(en)
|
2012-12-19 |
2015-10-28 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
JP6359031B2
(ja)
|
2012-12-21 |
2018-07-18 |
メディミューン,エルエルシー |
抗h7cr抗体
|
PL2935328T3
(pl)
|
2012-12-21 |
2019-02-28 |
Hoffmann La Roche |
Połączone wiązaniem dwusiarczkowym wielowartościowe białka wielofunkcyjne zawierające MHC klasy I
|
EA201591219A1
(ru)
|
2012-12-27 |
2015-12-30 |
Санофи |
Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
|
EP2938633B1
(en)
|
2012-12-28 |
2018-02-07 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
JO3405B1
(ar)
|
2013-01-09 |
2019-10-20 |
Regeneron Pharma |
الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
|
US10717965B2
(en)
|
2013-01-10 |
2020-07-21 |
Gloriana Therapeutics, Inc. |
Mammalian cell culture-produced neublastin antibodies
|
US9180185B2
(en)
|
2013-01-11 |
2015-11-10 |
Hoffman-La Roche Inc. |
Combination therapy of anti-HER3 antibodies
|
EP3620473A1
(en)
|
2013-01-14 |
2020-03-11 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
SI2946206T1
(sl)
|
2013-01-20 |
2019-06-28 |
Dyax Corp. |
Ocenjevanje, testi in zdravljenje motenj, pri katerih posreduje PKA
|
ES2692408T3
(es)
|
2013-01-20 |
2018-12-03 |
Dyax Corp. |
Evaluación y tratamiento de trastornos mediados por bradiquinina
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
WO2014114595A1
(en)
|
2013-01-23 |
2014-07-31 |
Roche Glycart Ag |
Predictive biomarker for cancer treatment with adcc-enhanced antibodies
|
US9834610B2
(en)
|
2013-01-31 |
2017-12-05 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector T cells
|
EP2951205B1
(en)
|
2013-02-01 |
2021-08-11 |
Santa Maria Biotherapeutics, Inc. |
Anti-activin-a compounds for the treatment of ovarian cancer
|
EP3936137A1
(en)
|
2013-02-07 |
2022-01-12 |
The General Hospital Corporation |
Methods for expansion or depletion of t-regulatory cells
|
AU2014216959A1
(en)
|
2013-02-15 |
2015-10-01 |
Perseus Proteomics Inc. |
Anti-CDH3 humanized antibody, drug conjugate thereof, and use thereof
|
KR102313997B1
(ko)
|
2013-02-20 |
2021-10-20 |
노파르티스 아게 |
인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료
|
EP3744736A1
(en)
|
2013-02-20 |
2020-12-02 |
Novartis AG |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
BR112015018418A2
(pt)
|
2013-02-22 |
2017-07-18 |
Hoffmann La Roche |
métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
|
CN105247072B
(zh)
|
2013-02-25 |
2019-10-15 |
基因泰克公司 |
检测和治疗抗药性akt突变体的方法和组合物
|
KR102282761B1
(ko)
|
2013-02-26 |
2021-07-30 |
로슈 글리카트 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
MX2015010843A
(es)
|
2013-02-26 |
2016-04-04 |
Roche Glycart Ag |
Moleculas biespecificas de union al antigeno que activan celulas t.
|
CA2896370A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
RU2015140921A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Антитела к mcsp
|
JP2016510751A
(ja)
|
2013-03-06 |
2016-04-11 |
ジェネンテック, インコーポレイテッド |
抗がん剤耐性を治療及び予防する方法
|
KR20150143458A
(ko)
|
2013-03-06 |
2015-12-23 |
메리맥 파마슈티컬즈, 인크. |
항-C-MET 탠덤 Fc 이중특이적 항체
|
ES2858472T3
(es)
|
2013-03-11 |
2021-09-30 |
Amgen Inc |
Formulaciones proteínicas
|
SG10201707464SA
(en)
|
2013-03-13 |
2017-10-30 |
Sanofi Sa |
Compositions comprising anti-cd38 antibodies and carfilzomib
|
JO3532B1
(ar)
|
2013-03-13 |
2020-07-05 |
Regeneron Pharma |
الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
|
US9649390B2
(en)
|
2013-03-13 |
2017-05-16 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
US10501531B2
(en)
|
2013-03-13 |
2019-12-10 |
Prothena Biosciences Limited |
Tau immunotherapy
|
NZ710745A
(en)
|
2013-03-13 |
2019-03-29 |
Genentech Inc |
Pyrrolobenzodiazepines and conjugates thereof
|
JP6450364B2
(ja)
|
2013-03-13 |
2019-01-09 |
セセン バイオ, インコーポレイテッド |
眼送達のためのキメラサイトカイン製剤
|
WO2014153056A2
(en)
|
2013-03-14 |
2014-09-25 |
Parkash Gill |
Cancer treatment using antibodies that bing cell surface grp78
|
BR112015022604A2
(pt)
|
2013-03-14 |
2017-10-24 |
Genentech Inc |
usos de um modulador de modificador de cromatina e um antagonista de egfr
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
EP3299391B1
(en)
|
2013-03-14 |
2019-12-04 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
MX2015010854A
(es)
|
2013-03-14 |
2016-07-20 |
Genentech Inc |
Combinaciones de un compuesto inhibidor de mek con un compuesto inhibidor de her3/egfr y metodos de uso.
|
PT2968552T
(pt)
|
2013-03-14 |
2020-05-18 |
Scripps Research Inst |
Anticorpo dos agentes alvo, combinações e uso para os mesmos
|
WO2014144280A2
(en)
|
2013-03-15 |
2014-09-18 |
Abbvie Inc. |
DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
|
AU2014232501C1
(en)
|
2013-03-15 |
2021-04-22 |
Xencor, Inc. |
Heterodimeric proteins
|
AR095199A1
(es)
|
2013-03-15 |
2015-09-30 |
Genzyme Corp |
Anticuerpos anti-cd52
|
EA201591806A1
(ru)
|
2013-03-15 |
2016-01-29 |
Байоджен Ма Инк. |
Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
US10035860B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
WO2014144850A1
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
CN105283196B
(zh)
|
2013-03-15 |
2018-10-12 |
贝丝以色列女执事医疗中心 |
用于产生和使用构象-特异性抗体的方法和组合物
|
US9446105B2
(en)
|
2013-03-15 |
2016-09-20 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor specific for folate receptor β
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
WO2014144466A1
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
MX2015012326A
(es)
|
2013-03-15 |
2016-03-08 |
Genentech Inc |
Anticuerpos anti-crth2 y su uso.
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
BR112015023752B1
(pt)
|
2013-03-15 |
2023-11-14 |
Zyngenia, Inc. |
Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
|
MX364591B
(es)
|
2013-03-15 |
2019-05-02 |
Regeneron Pharma |
Antagonistas de il-33 y usos de estos.
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
EP2970452A2
(en)
|
2013-03-15 |
2016-01-20 |
AC Immune S.A. |
Anti-tau antibodies and methods of use
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
SG10201701380TA
(en)
|
2013-03-15 |
2017-04-27 |
Genentech Inc |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
US9550829B2
(en)
|
2013-03-15 |
2017-01-24 |
Genentech, Inc. |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
LT2970422T
(lt)
|
2013-03-15 |
2018-06-25 |
F. Hoffmann-La Roche Ag |
Il-22 polipeptidai ir il-22 su fc sulieti baltymai bei panaudojimo būdai
|
US9260527B2
(en)
|
2013-03-15 |
2016-02-16 |
Sdix, Llc |
Anti-human CXCR4 antibodies and methods of making same
|
JP6469644B2
(ja)
|
2013-03-15 |
2019-02-13 |
アムジエン・インコーポレーテツド |
抗ccr7抗原結合タンパク質に関係する方法および組成物
|
EP2968582B1
(en)
|
2013-03-15 |
2020-07-01 |
Innate Pharma |
Solid phase tgase-mediated conjugation of antibodies
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
DK2976361T3
(en)
|
2013-03-18 |
2018-10-01 |
Biocerox Prod Bv |
HUMANIZED ANTI-CD134- (0X40) ANTIBODIES AND APPLICATIONS THEREOF
|
CN105143876B
(zh)
|
2013-03-27 |
2018-04-20 |
豪夫迈·罗氏有限公司 |
生物标志物用于评估用β7整联蛋白拮抗剂治疗胃肠炎性病症的用途
|
AU2014241162A1
(en)
|
2013-03-27 |
2015-10-22 |
Cedars-Sinai Medical Center |
Mitigation and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways
|
WO2014163558A1
(en)
|
2013-04-01 |
2014-10-09 |
Moreinx Ab |
Nanoparticles, composed of sterol and saponin from quillaja saponaria molina process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
CA3071678A1
(en)
|
2013-04-16 |
2014-10-23 |
Genentech,Inc. |
Pertuzumab variants and evaluation thereof
|
US20140314741A1
(en)
*
|
2013-04-18 |
2014-10-23 |
Developmen Center For Biotechnology |
Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
|
KR20150145260A
(ko)
|
2013-04-19 |
2015-12-29 |
싸이튠 파마 |
감소된 혈관 누출 증후근에 대한 사이토카인 유도체 치료
|
BR112015027385A2
(pt)
|
2013-04-29 |
2017-08-29 |
Hoffmann La Roche |
Anticorpos modificados de ligação ao fcrn humano e métodos de uso
|
JP6618893B2
(ja)
|
2013-04-29 |
2019-12-11 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Fc受容体結合が変更された非対称抗体および使用方法
|
CN105164158A
(zh)
|
2013-04-29 |
2015-12-16 |
豪夫迈·罗氏有限公司 |
消除对FcRn-结合的抗-IGF-1R抗体及其在血管性眼病治疗中的用途
|
US10501802B2
(en)
|
2013-04-30 |
2019-12-10 |
Universite De Montreal |
Biomarkers for acute myeloid leukemia
|
US10239951B2
(en)
*
|
2013-05-08 |
2019-03-26 |
Zymeworks Inc. |
Bispecific HER2 and HER3 antigen binding constructs
|
KR101453462B1
(ko)
|
2013-05-16 |
2014-10-23 |
앱클론(주) |
Her2에 특이적으로 결합하는 항체
|
CA2908743C
(en)
|
2013-05-20 |
2024-06-25 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
KR20160129698A
(ko)
|
2013-05-24 |
2016-11-09 |
메디뮨 엘엘씨 |
항-b7-h5 항체 및 이의 용도
|
BR112015029754A2
(pt)
|
2013-05-31 |
2017-09-26 |
Genentech Inc |
anticorpos anti-teicoico da parede e conjugados
|
CA2913370C
(en)
|
2013-05-31 |
2022-12-13 |
Zymeworks Inc. |
Heteromultimers with reduced or silenced effector function
|
ES2793174T3
(es)
|
2013-05-31 |
2020-11-13 |
Genentech Inc |
Anticuerpos antiteicoicos de pared y conjugados
|
SG10201708143QA
(en)
|
2013-06-06 |
2017-11-29 |
Pierre Fabre Médicament |
Anti-c10orf54 antibodies and uses thereof
|
US20160130661A1
(en)
|
2013-06-13 |
2016-05-12 |
University Of South Australia |
Methods for detecting prostate cancer
|
RU2016100892A
(ru)
|
2013-06-14 |
2017-07-19 |
Байер Фарма Акциенгезельшафт |
Антитела против tweakr и их применение
|
EP3010547B1
(en)
|
2013-06-20 |
2021-04-21 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
CN105517577A
(zh)
|
2013-06-21 |
2016-04-20 |
先天制药公司 |
多肽的酶促偶联
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
US10513555B2
(en)
|
2013-07-04 |
2019-12-24 |
Prothena Biosciences Limited |
Antibody formulations and methods
|
UA119646C2
(uk)
|
2013-07-05 |
2019-07-25 |
Ґенмаб А/С |
Гуманізоване антитіло, що зв`язується з сd3 людини
|
JP6450381B2
(ja)
|
2013-07-05 |
2019-01-09 |
ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション |
がんを処置するための可溶性mic中和モノクローナル抗体
|
EP3019522B1
(en)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
US9951131B2
(en)
|
2013-07-12 |
2018-04-24 |
Prothena Biosciences Limited |
Antibodies that recognize IAPP
|
WO2015006686A1
(en)
|
2013-07-12 |
2015-01-15 |
Genentech, Inc. |
Elucidation of ion exchange chromatography input optimization
|
US9850302B2
(en)
|
2013-07-12 |
2017-12-26 |
Prothena Biosciences Limited |
Antibodies that recognize IAPP
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
EP3022224A2
(en)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
CN105814074B
(zh)
|
2013-07-18 |
2020-04-21 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
US10316083B2
(en)
|
2013-07-19 |
2019-06-11 |
Cedars-Sinai Medical Center |
Signature of TL1A (TNFSF15) signaling pathway
|
WO2015007337A1
(en)
|
2013-07-19 |
2015-01-22 |
Bionor Immuno As |
Method for the vaccination against hiv
|
US11161906B2
(en)
|
2013-07-25 |
2021-11-02 |
Cytomx Therapeutics, Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
TW201920262A
(zh)
|
2013-07-30 |
2019-06-01 |
美商再生元醫藥公司 |
抗活化素a之抗體及其用途
|
CA2919583C
(en)
|
2013-07-31 |
2018-09-11 |
Rinat Neuroscience Corp. |
Engineered polypeptide conjugates
|
NZ715201A
(en)
|
2013-08-01 |
2021-12-24 |
Five Prime Therapeutics Inc |
Afucosylated anti-fgfr2iiib antibodies
|
US10227370B2
(en)
|
2013-08-02 |
2019-03-12 |
California Institute Of Technology |
Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
|
US9770461B2
(en)
|
2013-08-02 |
2017-09-26 |
California Institute Of Technology |
Tailored glycopolymers as anticoagulant heparin mimetics
|
BR112016002685A2
(pt)
|
2013-08-07 |
2018-01-30 |
Astute Medical Inc |
ensaios para timp2 que apresentam melhor desempenho em amostras biológicas
|
KR20180021234A
(ko)
|
2013-08-12 |
2018-02-28 |
제넨테크, 인크. |
보체-연관 상태의 치료를 위한 조성물 및 방법
|
WO2015023355A1
(en)
|
2013-08-12 |
2015-02-19 |
Genentech, Inc. |
1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
|
PL3036320T5
(pl)
|
2013-08-19 |
2024-06-10 |
Biogen Ma Inc. |
Kontrola glikozylacji białka poprzez parametry procesu suplementacji pożywki hodowlanej i hodowli komórkowej
|
US20160237399A1
(en)
|
2015-02-18 |
2016-08-18 |
Biogen Ma Inc. |
Control of Protein Glycosylation by Culture Medium Supplementation and Cell Culture Process Parameters
|
CN114621346A
(zh)
|
2013-08-21 |
2022-06-14 |
德克萨斯州大学系统董事会 |
用于靶向连接蛋白半通道的组合物和方法
|
WO2015025054A1
(en)
|
2013-08-22 |
2015-02-26 |
Medizinische Universität Wien |
Dye-specific antibodies for prestained molecular weight markers and methods producing the same
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
WO2015035180A1
(en)
|
2013-09-05 |
2015-03-12 |
Genentech, Inc. |
Method for chromatography reuse
|
CA2923579C
(en)
|
2013-09-06 |
2023-09-05 |
Academia Sinica |
Human inkt cell activation using glycolipids with altered glycosyl groups
|
US11545241B1
(en)
|
2013-09-07 |
2023-01-03 |
Labrador Diagnostics Llc |
Systems and methods for analyte testing and data management
|
EP3760639A1
(en)
|
2013-09-08 |
2021-01-06 |
Kodiak Sciences Inc. |
Zwitterionic polymer conjugates
|
RU2675824C2
(ru)
|
2013-09-11 |
2018-12-25 |
Игл Байолоджикс, Инк. |
Жидкие белковые составы, содержащие ионные жидкости
|
CN104418947A
(zh)
|
2013-09-11 |
2015-03-18 |
香港大学 |
抗her2和抗-igf-ir的双特异性抗体及其用途
|
CN104193828B
(zh)
*
|
2013-09-12 |
2017-04-05 |
北京韩美药品有限公司 |
同时阻断her2和vegfr信号通路的重组融合蛋白
|
EP3044236A2
(en)
|
2013-09-12 |
2016-07-20 |
Halozyme, Inc. |
Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
|
EP3046940B1
(en)
|
2013-09-17 |
2019-07-03 |
F.Hoffmann-La Roche Ag |
Methods of using anti-lgr5 antibodies
|
NZ714555A
(en)
|
2013-09-17 |
2020-03-27 |
Obi Pharma Inc |
Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment
|
HUE057005T2
(hu)
|
2013-09-25 |
2022-04-28 |
Bioverativ Therapeutics Inc |
Oszlopon történõ vírusinaktiváló eljárások
|
WO2015048770A2
(en)
|
2013-09-30 |
2015-04-02 |
Beth Israel Deaconess Medical Center, Inc. |
Antibody therapies for human immunodeficiency virus (hiv)
|
EP3055329B1
(en)
|
2013-10-11 |
2018-06-13 |
F. Hoffmann-La Roche AG |
Multispecific domain exchanged common variable light chain antibodies
|
UA119047C2
(uk)
|
2013-10-11 |
2019-04-25 |
Берлін-Хемі Аг |
Кон'юговане антитіло до ly75 для лікування раку
|
BR112016007635A2
(pt)
|
2013-10-11 |
2017-09-12 |
Genentech Inc |
inibidores de nsp4 e métodos de uso
|
KR20160070136A
(ko)
|
2013-10-18 |
2016-06-17 |
제넨테크, 인크. |
항-rspo2 및/또는 항-rspo3 항체 및 그의 용도
|
WO2015061183A1
(en)
|
2013-10-21 |
2015-04-30 |
Dyax Corp. |
Assays for determining plasma kallikrein system biomarkers
|
IL284969B
(en)
|
2013-10-21 |
2022-07-01 |
Dyax Corp |
Diagnosis and treatment of autoimmune diseases
|
CA2924873A1
(en)
|
2013-10-23 |
2015-04-30 |
Genentech, Inc. |
Methods of diagnosing and treating eosinophilic disorders
|
WO2015066543A1
(en)
*
|
2013-11-01 |
2015-05-07 |
Board Of Regents, The University Of Texas System |
Targeting her2 and her3 with bispecific antibodies in cancerous cells
|
AU2014343636A1
(en)
|
2013-11-04 |
2016-06-02 |
Glenmark Pharmaceuticals S.A. |
Production of T cell retargeting hetero-dimeric immunoglobulins
|
WO2015069865A1
(en)
|
2013-11-06 |
2015-05-14 |
Janssen Biotech, Inc. |
Anti-ccl17 antibodies
|
CA3185700A1
(en)
|
2013-11-06 |
2015-05-14 |
Astute Medical, Inc. |
Assays for igfbp7 having improved performance in biological samples
|
CN104628846B
(zh)
|
2013-11-06 |
2019-12-06 |
三生国健药业(上海)股份有限公司 |
重组蛋白质的纯化方法
|
CN104623637A
(zh)
|
2013-11-07 |
2015-05-20 |
健能隆医药技术(上海)有限公司 |
Il-22二聚体在制备静脉注射药物中的应用
|
ES2839087T3
(es)
|
2013-11-12 |
2021-07-05 |
Ogd2 Pharma |
Anticuerpo derivado de IGG1 humana con actividad pro-apoptótica
|
EP3071974A2
(en)
|
2013-11-19 |
2016-09-28 |
Prothena Biosciences Limited |
Monitoring immunotherapy of lewy body disease from constipation symptoms
|
JP6483117B2
(ja)
|
2013-11-20 |
2019-03-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
Aplnrモジュレーター及びその使用
|
RU2697098C1
(ru)
|
2013-11-21 |
2019-08-12 |
Ф.Хоффманн-Ля Рош Аг |
Антитела к альфа-синуклеину и способы применения
|
CA2931356A1
(en)
*
|
2013-11-27 |
2015-06-04 |
Zymeworks Inc. |
Bispecific antigen-binding constructs targeting her2
|
JP6549143B2
(ja)
|
2013-12-09 |
2019-07-24 |
アラコス インコーポレイテッド |
抗シグレック−8抗体およびその使用の方法
|
KR20160097294A
(ko)
|
2013-12-09 |
2016-08-17 |
뉴욕 유니버시티 |
항-포도상구균 제제의 식세포 전달을 위한 조성물 및 방법
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
CN110590950A
(zh)
|
2013-12-13 |
2019-12-20 |
基因泰克公司 |
抗cd33抗体和免疫缀合物
|
BR112016013258A2
(pt)
|
2013-12-16 |
2018-01-16 |
Genentech Inc |
composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
MX2016007958A
(es)
|
2013-12-17 |
2016-08-03 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso.
|
KR102447878B1
(ko)
|
2013-12-17 |
2022-09-26 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
|
WO2015095423A2
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
WO2015095410A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
US20150174242A1
(en)
|
2013-12-19 |
2015-06-25 |
Mayo Foundation For Medical Education And Research |
Monovalent anti-cd3 adjuvants
|
ES2778498T3
(es)
|
2013-12-20 |
2020-08-10 |
Hoffmann La Roche |
Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
|
EP3083933A1
(en)
|
2013-12-20 |
2016-10-26 |
Biogen MA Inc. |
Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
|
JP7325166B2
(ja)
|
2013-12-20 |
2023-08-14 |
ジェネンテック, インコーポレイテッド |
二重特異性抗体
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
WO2015091738A1
(en)
|
2013-12-20 |
2015-06-25 |
F. Hoffmann-La Roche Ag |
Bispecific her2 antibodies and methods of use
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
DK3087098T3
(da)
|
2013-12-24 |
2020-06-08 |
Janssen Pharmaceutica Nv |
Anti-Vista-antistoffer og -fragmenter
|
SG11201605215YA
(en)
|
2013-12-25 |
2016-08-30 |
Daiichi Sankyo Co Ltd |
Anti-trop2 antibody-drug conjugate
|
PL3089996T3
(pl)
|
2014-01-03 |
2021-12-13 |
F. Hoffmann-La Roche Ag |
Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg
|
RU2694981C2
(ru)
|
2014-01-03 |
2019-07-18 |
Ф. Хоффманн-Ля Рош Аг |
Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения
|
EP3089759B1
(en)
|
2014-01-03 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Covalently linked polypeptide toxin-antibody conjugates
|
CA2932547C
(en)
|
2014-01-06 |
2023-05-23 |
F. Hoffmann-La Roche Ag |
Monovalent blood brain barrier shuttle modules
|
EP3094654B1
(en)
|
2014-01-14 |
2020-03-11 |
The Medical College of Wisconsin, Inc. |
Targeting clptm1l for treatment and prevention of cancer
|
RU2727639C2
(ru)
|
2014-01-15 |
2020-07-22 |
Ф.Хоффманн-Ля Рош Аг |
Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
JP2017507118A
(ja)
|
2014-01-16 |
2017-03-16 |
アカデミア シニカAcademia Sinica |
がんの処置および検出のための組成物および方法
|
ES2963718T3
(es)
|
2014-01-21 |
2024-04-01 |
Novartis Ag |
Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
|
KR102424183B1
(ko)
|
2014-01-21 |
2022-07-26 |
다케다 파머수티컬 컴패니 리미티드 |
혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
|
US20170043034A1
(en)
|
2014-01-24 |
2017-02-16 |
Genentech, Inc. |
Methods of using anti-steap1 antibodies and immunoconjugates
|
HUE050279T2
(hu)
|
2014-01-24 |
2020-11-30 |
Ngm Biopharmaceuticals Inc |
Béta-klotho 2-es doménjéhez kötõdõ antitestek és azok alkalmazási módszerei
|
KR102275925B1
(ko)
|
2014-01-31 |
2021-07-12 |
다이이찌 산쿄 가부시키가이샤 |
항-her2 항체-약물 접합체
|
BR112016014731A2
(pt)
|
2014-01-31 |
2017-09-19 |
Boehringer Ingelheim Int |
Anticorpos anti-baff
|
JP6736467B2
(ja)
|
2014-02-04 |
2020-08-05 |
ジェネンテック, インコーポレイテッド |
平滑化変異体及びその使用方法
|
SI3102595T1
(sl)
|
2014-02-06 |
2019-02-28 |
F. Hoffmann-La Roche Ag |
Fuzijske beljakovine z interlevkinom-2 in njihova uporaba
|
TWI769970B
(zh)
|
2014-02-08 |
2022-07-11 |
美商建南德克公司 |
治療阿茲海默症之方法
|
CN106163548A
(zh)
|
2014-02-08 |
2016-11-23 |
健泰科生物技术公司 |
治疗阿尔茨海默氏病的方法
|
PE20161335A1
(es)
|
2014-02-12 |
2016-12-07 |
Genentech Inc |
Anticuerpos anti-jagged1 y metodos de uso
|
KR20150097304A
(ko)
|
2014-02-18 |
2015-08-26 |
삼성전자주식회사 |
항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
|
PE20161171A1
(es)
|
2014-02-21 |
2016-11-08 |
Genentech Inc |
Anticuerpos bioespecificos anti-il-13/il-17 y sus usos referencia cruzada a solicitudes relacionadas
|
EP3110445A4
(en)
|
2014-02-25 |
2017-09-27 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
DK3122757T3
(da)
|
2014-02-28 |
2023-10-09 |
Hangzhou Dac Biotech Co Ltd |
Ladede linkere og anvendelse deraf til konjugering
|
US10183996B2
(en)
|
2014-02-28 |
2019-01-22 |
Allakos Inc. |
Methods and compositions for treating Siglec-8 associated diseases
|
EP2915569A1
(en)
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
IL-15/IL-15Ralpha based conjugates purification method
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
PL3116891T3
(pl)
|
2014-03-10 |
2020-07-27 |
Richter Gedeon Nyrt. |
Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania
|
CN106459199B
(zh)
|
2014-03-11 |
2021-01-01 |
瑞泽恩制药公司 |
抗-egfrviii抗体及其用途
|
US20170158755A1
(en)
|
2014-03-12 |
2017-06-08 |
Prothena Biosciences Limited |
Anti-laminin4 antibodies specific for lg1-3
|
TW201623331A
(zh)
|
2014-03-12 |
2016-07-01 |
普羅帝納生物科學公司 |
抗黑色素瘤細胞黏著分子(mcam)抗體類及使用彼等之相關方法
|
KR20160131073A
(ko)
|
2014-03-12 |
2016-11-15 |
프로테나 바이오사이언시즈 리미티드 |
Lg4-5에 대해 특이적인 항-라미닌4 항체
|
JP6728053B2
(ja)
|
2014-03-12 |
2020-07-22 |
プロセナ バイオサイエンシーズ リミテッド |
抗mcam抗体及び関連する使用方法
|
EP3116910A1
(en)
|
2014-03-13 |
2017-01-18 |
Prothena Biosciences Limited |
Combination treatment for multiple sclerosis
|
CN106132989B
(zh)
|
2014-03-14 |
2020-06-19 |
先天制药公司 |
具有增加的稳定性的人源化抗体
|
KR102475799B1
(ko)
|
2014-03-14 |
2022-12-08 |
다니엘 제이 카폰 |
비-펩티드 결합을 함유하는 하이브리드 면역글로불린
|
MA39746A
(fr)
|
2014-03-14 |
2021-04-28 |
Hoffmann La Roche |
Compositions de sécrétion de polypeptides hétérologues et procédés associés
|
JP2017513818A
(ja)
|
2014-03-15 |
2017-06-01 |
ノバルティス アーゲー |
キメラ抗原受容体を使用する癌の処置
|
WO2015142661A1
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
US20170107294A1
(en)
|
2014-03-21 |
2017-04-20 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
US10556945B2
(en)
|
2014-03-21 |
2020-02-11 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
RS65360B1
(sr)
|
2014-03-21 |
2024-04-30 |
Teva Pharmaceuticals Int Gmbh |
Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
|
MA39776A
(fr)
|
2014-03-24 |
2017-02-01 |
Hoffmann La Roche |
Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
|
WO2015148515A1
(en)
|
2014-03-24 |
2015-10-01 |
Biogen Ma Inc. |
Methods for overcoming glutamine deprivation during mammalian cell culture
|
US10428158B2
(en)
|
2014-03-27 |
2019-10-01 |
Dyax Corp. |
Compositions and methods for treatment of diabetic macular edema
|
MA39804A
(fr)
|
2014-03-27 |
2017-02-01 |
Hoffmann La Roche |
Méthodes permettant le diagnostic et le traitement d'une maladie inflammatoire de l'intestin
|
CN106415244B
(zh)
|
2014-03-27 |
2020-04-24 |
中央研究院 |
反应性标记化合物及其用途
|
WO2015145449A2
(en)
|
2014-03-27 |
2015-10-01 |
Yeda Research And Development Co. Ltd. |
T-cell receptor cdr3 peptides and antibodies
|
US9822186B2
(en)
|
2014-03-28 |
2017-11-21 |
Xencor, Inc. |
Bispecific antibodies that bind to CD38 and CD3
|
AU2015241038A1
(en)
|
2014-03-31 |
2016-10-13 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
|
EP3632934A1
(en)
|
2014-03-31 |
2020-04-08 |
F. Hoffmann-La Roche AG |
Anti-ox40 antibodies and methods of use
|
JP6666262B2
(ja)
|
2014-04-02 |
2020-03-13 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
多重特異性抗体の軽鎖誤対合を検出するための方法
|
HRP20240874T1
(hr)
|
2014-04-07 |
2024-10-11 |
Novartis Ag |
Liječenje raka korištenjem kimernog antigenskog receptora anti-cd19
|
CA2944402A1
(en)
|
2014-04-08 |
2015-10-15 |
Prothena Biosciences Limited |
Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
|
US11185594B2
(en)
|
2014-04-10 |
2021-11-30 |
Daiichi Sankyo Company, Limited |
(Anti-HER2 antibody)-drug conjugate
|
KR20160143808A
(ko)
|
2014-04-11 |
2016-12-14 |
메디뮨 엘엘씨 |
이중특이적 her2 항체
|
BR112016024088A2
(pt)
|
2014-04-16 |
2018-06-19 |
Biocon Ltd. |
formulações de proteína estáveis que compreendem um excesso molar de sorbitol
|
AU2015247459A1
(en)
|
2014-04-18 |
2016-10-27 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating sickle-cell disease
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
CA2946860A1
(en)
|
2014-04-25 |
2015-10-29 |
Genentech, Inc. |
Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
|
KR102430829B1
(ko)
|
2014-04-25 |
2022-08-09 |
리나트 뉴로사이언스 코프. |
약물이 고도로 로딩된 항체-약물 접합체
|
EP3134115A4
(en)
*
|
2014-04-25 |
2017-10-25 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
MD20160130A2
(ro)
|
2014-04-27 |
2017-04-30 |
Ccam Biotherapeutics Ltd. |
Anticorpi umanizaţi contra CEACAM1
|
WO2015168019A2
(en)
|
2014-04-30 |
2015-11-05 |
Pfizer Inc. |
Anti-ptk7 antibody-drug conjugates
|
CA2944712A1
(en)
|
2014-05-01 |
2015-11-05 |
Genentech, Inc. |
Anti-factor d antibody variants and uses thereof
|
EP4306544A3
(en)
|
2014-05-06 |
2024-03-20 |
F. Hoffmann-La Roche AG |
Production of heteromultimeric proteins using mammalian cells
|
HUE050007T2
(hu)
|
2014-05-16 |
2020-11-30 |
Ablynx Nv |
Immunglobulin variábilis domének
|
CA2946662A1
(en)
|
2014-05-22 |
2015-11-26 |
Genentech, Inc. |
Anti-gpc3 antibodies and immunoconjugates
|
JP2017524371A
(ja)
|
2014-05-23 |
2017-08-31 |
ジェネンテック, インコーポレイテッド |
Mitバイオマーカーとその使用方法
|
JP7062361B2
(ja)
|
2014-05-27 |
2022-05-06 |
アカデミア シニカ |
抗her2糖操作抗体群およびその使用
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
WO2015184004A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
EP3149045B1
(en)
|
2014-05-27 |
2023-01-18 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
CA2950433A1
(en)
|
2014-05-28 |
2015-12-03 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
KR102433464B1
(ko)
|
2014-05-28 |
2022-08-17 |
아게누스 인코포레이티드 |
항-gitr 항체 및 이의 사용 방법
|
PT3148581T
(pt)
|
2014-05-30 |
2020-01-06 |
Henlix Biotech Co Ltd |
Anticorpos antirrecetor do fator de crescimento epidérmico (egfr)
|
JP6997619B2
(ja)
|
2014-06-11 |
2022-01-17 |
キャシー・エイ・グリーン |
液性免疫の抑制または増進のための、vistaアゴニスト及びvistaアンタゴニストの使用
|
CN106459202A
(zh)
|
2014-06-11 |
2017-02-22 |
豪夫迈·罗氏有限公司 |
抗LgR5抗体及其用途
|
CN107073121A
(zh)
|
2014-06-13 |
2017-08-18 |
基因泰克公司 |
治疗及预防癌症药物抗性的方法
|
MX2016016531A
(es)
|
2014-06-13 |
2017-04-25 |
Acceleron Pharma Inc |
Metodos y composiciones para el tratamiento de las ulceras.
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
RU2705299C2
(ru)
|
2014-06-26 |
2019-11-06 |
Ф. Хоффманн-Ля Рош Аг |
Антитела против 5-бром-2'-дезоксиуридина и способы применения
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
WO2016004370A1
(en)
|
2014-07-03 |
2016-01-07 |
Genentech, Inc. |
Polypeptide expression systems
|
EP3166688B1
(en)
|
2014-07-08 |
2024-08-21 |
New York University |
Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
|
KR102360693B1
(ko)
|
2014-07-11 |
2022-02-08 |
벤타나 메디컬 시스템즈, 인코포레이티드 |
항-pd-l1 항체 및 이의 진단 용도
|
JP2017526641A
(ja)
|
2014-07-11 |
2017-09-14 |
ジェネンテック, インコーポレイテッド |
Notch経路阻害
|
EP3169801A1
(en)
|
2014-07-14 |
2017-05-24 |
F. Hoffmann-La Roche AG |
Diagnostic methods and compositions for treatment of glioblastoma
|
JP6671363B2
(ja)
|
2014-07-15 |
2020-03-25 |
イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミティッド |
Cd44の単離されたポリペプチドおよびその使用
|
CA2955154C
(en)
|
2014-07-21 |
2023-10-31 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
MX2017001011A
(es)
|
2014-07-21 |
2018-05-28 |
Novartis Ag |
Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
AU2015292811B2
(en)
|
2014-07-21 |
2019-12-19 |
Novartis Ag |
Treatment of cancer using a CLL-1 chimeric antigen receptor
|
WO2016014434A2
(en)
|
2014-07-22 |
2016-01-28 |
Sutro Biopharma, Inc. |
Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
|
WO2016014839A2
(en)
|
2014-07-23 |
2016-01-28 |
Ohio State Innovation Foundation |
Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (tag-72)
|
US10507241B2
(en)
|
2014-07-24 |
2019-12-17 |
Boehringer Ingelheim International Gmbh |
Biomarkers useful in the treatment of IL-23A related diseases
|
AU2015292326A1
(en)
|
2014-07-24 |
2017-02-23 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
EA034081B1
(ru)
|
2014-07-29 |
2019-12-25 |
Селлектис |
Ror1-(ntrkr1)-специфические химерные антигенные рецепторы для иммунотерапии рака
|
CA2952540C
(en)
|
2014-07-31 |
2022-06-21 |
Amgen Research (Munich) Gmbh |
Bispecific single chain antibody construct with enhanced tissue distribution
|
US20170209492A1
(en)
|
2014-07-31 |
2017-07-27 |
Novartis Ag |
Subset-optimized chimeric antigen receptor-containing t-cells
|
JP2017522893A
(ja)
|
2014-07-31 |
2017-08-17 |
セレクティスCellectis |
Ror1特異的多重鎖キメラ抗原受容体
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
EP3174901B1
(en)
|
2014-07-31 |
2019-06-26 |
Amgen Research (Munich) GmbH |
Optimized cross-species specific bispecific single chain antibody constructs
|
WO2016016442A1
(en)
|
2014-08-01 |
2016-02-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An anti-cd45rc antibody for use as drug
|
KR102317315B1
(ko)
|
2014-08-04 |
2021-10-27 |
에프. 호프만-라 로슈 아게 |
이중특이적 t 세포 활성화 항원 결합 분자
|
CA2957258C
(en)
|
2014-08-05 |
2023-11-07 |
MabQuest SA |
Immunological reagents
|
EP3180359A1
(en)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
EP2985294A1
(en)
|
2014-08-14 |
2016-02-17 |
Deutsches Krebsforschungszentrum |
Recombinant antibody molecule and its use for target cell restricted T cell activation
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
DK3186284T3
(da)
|
2014-08-28 |
2022-05-09 |
Bioatla Inc |
Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
|
WO2016030791A1
(en)
|
2014-08-28 |
2016-03-03 |
Pfizer Inc. |
Stability-modulating linkers for use with antibody drug conjugates
|
EP3699188A1
(en)
|
2014-09-04 |
2020-08-26 |
Cellectis |
5t4 (tpbg) specific chimeric antigen receptors for cancer immunotherapy
|
CN107073135B
(zh)
|
2014-09-08 |
2023-06-06 |
鲁塔纳有限公司 |
用于将分子递送至细胞的细胞质中的构建体
|
EP3191500A4
(en)
|
2014-09-08 |
2018-04-11 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
|
EP3191527B1
(en)
|
2014-09-10 |
2020-01-15 |
F.Hoffmann-La Roche Ag |
Galactoengineered immunoglobulin 1 antibodies
|
JP6943760B2
(ja)
|
2014-09-12 |
2021-10-06 |
ジェネンテック, インコーポレイテッド |
抗b7−h4抗体及び免疫複合体
|
WO2016040825A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anthracycline disulfide intermediates, antibody-drug conjugates and methods
|
US20160075772A1
(en)
|
2014-09-12 |
2016-03-17 |
Regeneron Pharmaceuticals, Inc. |
Treatment of Fibrodysplasia Ossificans Progressiva
|
EP3693391B1
(en)
|
2014-09-12 |
2024-08-21 |
Genentech, Inc. |
Anti-cll-1 antibodies and immunoconjugates
|
AR101844A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos y conjugados modificados genéticamente con cisteína
|
AU2015314954B2
(en)
|
2014-09-12 |
2021-05-13 |
Genentech, Inc. |
Anti-HER2 antibodies and immunoconjugates
|
AU2015317608B2
(en)
|
2014-09-17 |
2021-03-11 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
KR20170055521A
(ko)
|
2014-09-17 |
2017-05-19 |
제넨테크, 인크. |
항-her2 항체를 포함하는 면역콘주게이트
|
CR20170099A
(es)
|
2014-09-17 |
2017-07-19 |
Genentech Inc |
Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas
|
US10080790B2
(en)
|
2014-09-19 |
2018-09-25 |
The Regents Of The University Of Michigan |
Staphylococcus aureus materials and methods
|
PT3262071T
(pt)
|
2014-09-23 |
2020-06-16 |
H Hoffnabb La Roche Ag |
Métodos de utilização de imunoconjugados anti-cd79b
|
US9840557B2
(en)
|
2014-09-23 |
2017-12-12 |
Regeneron Pharmaceuticals, Inc. |
Anti-IL-25 antibodies and uses thereof
|
KR102497368B1
(ko)
|
2014-10-01 |
2023-02-10 |
이글 바이올로직스 인코포레이티드 |
점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형
|
US10385380B2
(en)
|
2014-10-02 |
2019-08-20 |
The Regents Of The University Of California |
Personalized protease assay to measure protease activity in neoplasms
|
AU2015327819B2
(en)
|
2014-10-03 |
2021-07-01 |
Massachusetts Institute Of Technology |
Antibodies that bind ebola glycoprotein and uses thereof
|
US9921230B2
(en)
|
2014-10-08 |
2018-03-20 |
Rhode Island Hospital |
Methods for diagnosis and treatment of concussion or brain injury
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック, インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
MA41685A
(fr)
|
2014-10-17 |
2017-08-22 |
Biogen Ma Inc |
Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
|
US9821059B2
(en)
|
2014-10-17 |
2017-11-21 |
Alteogen Inc. |
Composition for stabilizing protein and pharmaceutical formulation comprising the same
|
JP6849590B2
(ja)
|
2014-10-17 |
2021-03-24 |
コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. |
ブチリルコリンエステラーゼ両性イオン性ポリマーコンジュゲート
|
US10040844B2
(en)
|
2014-10-22 |
2018-08-07 |
The Regents Of The University Of California |
Proteolytic release of cell surface antigens for phage biopanning
|
CN114836385A
(zh)
|
2014-10-31 |
2022-08-02 |
宾夕法尼亚大学董事会 |
改变cart细胞中的基因表达及其用途
|
EP3223865A4
(en)
|
2014-10-31 |
2018-10-03 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind b7-h4
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
US20160161485A1
(en)
|
2014-11-03 |
2016-06-09 |
Genentech, Inc. |
Assays for detecting t cell immune subsets and methods of use thereof
|
JP2017536842A
(ja)
|
2014-11-03 |
2017-12-14 |
ジェネンテック, インコーポレイテッド |
Ox40アゴニスト治療薬の有効性及び評価を予測するための方法及びバイオマーカー
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
EP3753948A1
(en)
|
2014-11-05 |
2020-12-23 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
CA2966558C
(en)
|
2014-11-05 |
2024-03-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
CN107108740B
(zh)
|
2014-11-05 |
2021-09-17 |
豪夫迈·罗氏有限公司 |
抗fgfr2/3抗体及其使用方法
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
AU2015343494A1
(en)
|
2014-11-06 |
2017-04-27 |
Genentech, Inc. |
Combination therapy comprising OX40 binding agonists and TIGIT inhibitors
|
JP6576456B2
(ja)
|
2014-11-06 |
2019-09-18 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
修飾されたFcRn結合特性およびプロテインA結合特性を有するFc領域変種
|
BR112017006178A2
(pt)
|
2014-11-06 |
2018-05-02 |
F. Hoffmann-La Roche Ag |
região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
|
JP2018500882A
(ja)
|
2014-11-10 |
2018-01-18 |
ジェネンテック, インコーポレイテッド |
腎症の動物モデルおよびそれを治療するための薬剤
|
CN107172879B
(zh)
|
2014-11-10 |
2021-11-05 |
豪夫迈·罗氏有限公司 |
抗白细胞介素-33抗体及其用途
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
AU2015344769B2
(en)
|
2014-11-12 |
2020-07-09 |
Allogene Therapeutics, Inc. |
Inhibitory chimeric antigen receptors
|
AU2015346444A1
(en)
|
2014-11-12 |
2017-05-04 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
CN113372434B
(zh)
|
2014-11-14 |
2024-06-04 |
豪夫迈·罗氏有限公司 |
包含tnf家族配体三聚体的抗原结合分子
|
CN106999583A
(zh)
|
2014-11-17 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
|
EP3699198A1
(en)
|
2014-11-17 |
2020-08-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for tumor treatment using cd3xcd20 bispecific antibody
|
US10434177B2
(en)
|
2014-11-17 |
2019-10-08 |
Carnegie Mellon University |
Activatable two-component photosensitizers
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
WO2016081640A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
US10882920B2
(en)
|
2014-11-19 |
2021-01-05 |
Genentech, Inc. |
Antibodies against BACE1 and use thereof for neural disease immunotherapy
|
SG11201703237VA
(en)
|
2014-11-19 |
2017-06-29 |
Axon Neuroscience Se |
Humanized tau antibodies in alzheimer's disease
|
SI3221357T1
(sl)
|
2014-11-20 |
2020-09-30 |
F. Hoffmann-La Roche Ag |
Pogoste lahke verige in načini uporabe
|
EP3789402B1
(en)
|
2014-11-20 |
2022-07-13 |
F. Hoffmann-La Roche AG |
Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
|
WO2016081835A2
(en)
|
2014-11-21 |
2016-05-26 |
University Of Maryland, Baltimore |
Targeted structure-specific particulate delivery systems
|
JP2017536830A
(ja)
|
2014-11-26 |
2017-12-14 |
ゼンコー・インコーポレイテッドXencor、 Inc. |
Cd3及びcd38に結合するヘテロ二量体抗体
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
EA201791139A1
(ru)
|
2014-11-26 |
2018-04-30 |
Ксенкор, Инк. |
Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
|
JP2017537105A
(ja)
|
2014-11-26 |
2017-12-14 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
瘻孔を伴うクローン病の治療用ベドリズマブ
|
EP3223848A4
(en)
|
2014-11-27 |
2018-07-18 |
Zymeworks Inc. |
Methods of using bispecific antigen-binding constructs targeting her2
|
US10233256B2
(en)
*
|
2014-11-28 |
2019-03-19 |
The Israel Institute of Biological Research (IIBR) |
Antibodies directed to ricin toxin
|
US10208108B2
(en)
|
2014-11-28 |
2019-02-19 |
The Israel Institute of Biological Research (IIBR) |
Antibodies directed to ricin toxin
|
EP3029067A1
(en)
|
2014-12-01 |
2016-06-08 |
Deutsches Krebsforschungszentrum |
Use of blocking-reagents for reducing unspecific T cell-activation
|
EP3227341A1
(en)
|
2014-12-02 |
2017-10-11 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
|
EP3226911A1
(en)
|
2014-12-03 |
2017-10-11 |
F.Hoffmann-La Roche Ag |
Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
|
BR112017011478A2
(pt)
|
2014-12-03 |
2018-02-27 |
Genentech, Inc. |
composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
多重特異性抗体
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
DK3227336T3
(da)
|
2014-12-05 |
2019-09-16 |
Hoffmann La Roche |
Anti-CD79b-antistoffer og fremgangsmåder til anvendelse
|
JP2018505911A
(ja)
|
2014-12-05 |
2018-03-01 |
イミュネクスト,インコーポレーテッド |
推定上のvista受容体としてのvsig8の同定と、vista/vsig8調節剤を産生するためのその使用
|
CN107207591A
(zh)
|
2014-12-10 |
2017-09-26 |
豪夫迈·罗氏有限公司 |
血脑屏障受体抗体及使用方法
|
US10766959B2
(en)
|
2014-12-11 |
2020-09-08 |
Pierre Fabre Medicament |
Anti-C10ORF54 antibodies and uses thereof
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
CA3008162A1
(en)
|
2014-12-15 |
2016-06-23 |
The Regents Of The University Of California |
Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
|
US11384350B2
(en)
|
2014-12-15 |
2022-07-12 |
The Regents Of The University Of California |
Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
|
CA2966551A1
(en)
|
2014-12-18 |
2016-06-23 |
F. Hoffmann-La Roche Ag |
Assay and method for determining cdc eliciting antibodies
|
TWI779010B
(zh)
|
2014-12-19 |
2022-10-01 |
日商中外製藥股份有限公司 |
抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
|
EP3233912B1
(en)
|
2014-12-19 |
2021-05-19 |
Regenesance B.V. |
Antibodies that bind human c6 and uses thereof
|
PL3233921T3
(pl)
|
2014-12-19 |
2022-01-10 |
Chugai Seiyaku Kabushiki Kaisha |
Przeciwciała anty-c5 i sposoby ich stosowania
|
CA2973819A1
(en)
|
2014-12-19 |
2016-06-23 |
Alder Biopharmaceuticals, Inc. |
Humanized anti-acth antibodies and use thereof
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
ES2862701T3
(es)
|
2014-12-22 |
2021-10-07 |
Univ Rockefeller |
Anticuerpos agonistas anti-MERTK y usos de los mismos
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
JP2018511557A
(ja)
|
2015-01-22 |
2018-04-26 |
中外製薬株式会社 |
2種以上の抗c5抗体の組み合わせおよび使用方法
|
WO2016116626A1
(en)
|
2015-01-23 |
2016-07-28 |
Sanofi |
Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
|
EP3247281B1
(en)
|
2015-01-23 |
2020-12-02 |
The University of North Carolina at Chapel Hill |
Apparatuses, systems, and methods for preclinical ultrasound imaging of subjects
|
EP3248013B1
(en)
|
2015-01-24 |
2020-07-15 |
Academia Sinica |
Cancer markers and methods of use thereof
|
EP3248005B1
(en)
|
2015-01-24 |
2020-12-09 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
MX2017009181A
(es)
|
2015-01-26 |
2017-11-22 |
Cellectis |
Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer.
|
TWI769570B
(zh)
|
2015-01-28 |
2022-07-01 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
TWI781507B
(zh)
|
2015-01-28 |
2022-10-21 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
EP3250927B1
(en)
|
2015-01-28 |
2020-02-19 |
H. Hoffnabb-La Roche Ag |
Gene expression markers and treatment of multiple sclerosis
|
TWI718122B
(zh)
|
2015-01-28 |
2021-02-11 |
愛爾蘭商普羅佘納生物科技有限公司 |
抗甲狀腺素運送蛋白抗體
|
DK3250590T3
(da)
|
2015-01-30 |
2021-10-18 |
Academia Sinica |
Sammensætninger og fremgangsmåder, der vedrører universelle glycoformer, til øget anti-SSEA4-antistofeffektivitet
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
SG10202103879YA
(en)
|
2015-02-04 |
2021-05-28 |
Boehringer Ingelheim Int |
Methods of treating inflammatory diseases
|
EP3253784B1
(en)
|
2015-02-04 |
2020-05-06 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP3253778A1
(en)
|
2015-02-05 |
2017-12-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
KR20170138410A
(ko)
|
2015-02-23 |
2017-12-15 |
시걸 테라퓨틱스 에스에이에스 |
비-천연 세마포린 3 및 이의 의학적 용도
|
KR20170120601A
(ko)
|
2015-02-26 |
2017-10-31 |
제넨테크, 인크. |
인테그린 베타7 길항제 및 크론병을 치료하는 방법
|
BR112017015880A2
(pt)
|
2015-03-03 |
2018-07-31 |
Kymab Ltd |
anticorpos, usos e métodos
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
SG10202005917SA
(en)
|
2015-03-06 |
2020-07-29 |
Genentech Inc |
Ultrapurified dsba and dsbc and methods of making and using the same
|
SG10202103552XA
(en)
|
2015-03-09 |
2021-05-28 |
Intekrin Therapeutics Inc |
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
|
CA2977285A1
(en)
|
2015-03-16 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
|
EP3069734A1
(en)
|
2015-03-17 |
2016-09-21 |
Exiris S.r.l. |
Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers
|
KR102618312B1
(ko)
|
2015-03-17 |
2023-12-28 |
메모리얼 슬로안 케터링 캔서 센터 |
항muc16 항체 및 그의 용도
|
AU2016232839B2
(en)
|
2015-03-18 |
2021-02-25 |
Seagen Inc. |
CD48 antibodies and conjugates thereof
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
ME03819B
(me)
|
2015-03-23 |
2021-04-20 |
Jounce Therapeutics Inc |
Antitela za icos
|
ES2768784T3
(es)
|
2015-03-23 |
2020-06-23 |
Bayer Pharma AG |
Anticuerpos anti-CEACAM6 y usos de los mismos
|
CA2981312C
(en)
|
2015-03-30 |
2023-09-26 |
Regeneron Pharmaceuticals, Inc. |
Heavy chain constant regions with reduced binding to fc gamma receptors
|
IL305207A
(en)
|
2015-03-30 |
2023-10-01 |
Takeda Pharmaceuticals Co |
Plasma kallikrein inhibitors and their uses to prevent the outbreak of hereditary angioedema
|
MX2017012352A
(es)
|
2015-04-03 |
2018-01-26 |
Eureka Therapeutics Inc |
Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
|
US11279768B1
(en)
|
2015-04-03 |
2022-03-22 |
Precision Biologics, Inc. |
Anti-cancer antibodies, combination therapies, and uses thereof
|
EP3280433B1
(en)
|
2015-04-06 |
2021-09-15 |
Subdomain, LLC |
De novo binding domain containing polypeptides and uses thereof
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
AU2016246708B2
(en)
|
2015-04-06 |
2020-12-24 |
Acceleron Pharma Inc. |
ALK7:actRIIB heteromultimers and uses thereof
|
JP6955445B2
(ja)
|
2015-04-07 |
2021-10-27 |
ジェネンテック, インコーポレイテッド |
アゴニスト性の活性を有する抗原結合複合体及びその使用方法
|
US20180140602A1
(en)
|
2015-04-07 |
2018-05-24 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
IL254887B2
(en)
|
2015-04-07 |
2023-11-01 |
Alector Llc |
Anti-sortilin antibodies and methods of using them
|
RU2752918C2
(ru)
|
2015-04-08 |
2021-08-11 |
Новартис Аг |
Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) k cd19
|
SG10201912823PA
(en)
|
2015-04-13 |
2020-02-27 |
Pfizer |
Therapeutic antibodies and their uses
|
WO2016166139A1
(en)
|
2015-04-14 |
2016-10-20 |
Eberhard Karls Universität Tübingen |
Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
|
JP2018512422A
(ja)
|
2015-04-14 |
2018-05-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
疾患の処置法
|
CN107771081A
(zh)
|
2015-04-15 |
2018-03-06 |
瑞泽恩制药公司 |
用gdf8抑制剂增加力量和功能的方法
|
EP4276116A3
(en)
|
2015-04-17 |
2024-01-17 |
Amgen Research (Munich) GmbH |
Bispecific antibody constructs for cdh3 and cd3
|
SG11201708223QA
(en)
|
2015-04-17 |
2017-11-29 |
Bristol Myers Squibb Co |
Compositions comprising a combination of an anti-pd-1 antibody and another antibody
|
WO2016168771A2
(en)
|
2015-04-17 |
2016-10-20 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins with tunable affinities
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
AU2016252773B2
(en)
|
2015-04-24 |
2022-06-02 |
Genentech, Inc. |
Multispecific antigen-binding proteins
|
EP3286315B1
(en)
|
2015-04-24 |
2021-05-26 |
F. Hoffmann-La Roche AG |
Methods of identifying bacteria comprising binding polypeptides
|
WO2016176341A1
(en)
|
2015-04-29 |
2016-11-03 |
Regeneron Pharmaceuticals, Inc. |
Treatment of fibrodysplasia ossificans progressiva
|
EA201792388A1
(ru)
|
2015-04-30 |
2018-06-29 |
Президент Энд Феллоуз Оф Гарвард Колледж |
Анти-ap2 антитела и антигенсвязывающие фрагменты для лечения метаболических заболеваний
|
WO2016179003A1
(en)
|
2015-05-01 |
2016-11-10 |
Genentech, Inc. |
Masked anti-cd3 antibodies and methods of use
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
US20180140694A1
(en)
|
2015-05-04 |
2018-05-24 |
Bionor Immuno As |
Dosage regimen for hiv vaccine
|
US20160326234A1
(en)
*
|
2015-05-07 |
2016-11-10 |
Andrew Hiatt |
Monoclonal antibody cocktails for treatment of ebola infections
|
AU2016256911B2
(en)
|
2015-05-07 |
2022-03-31 |
Agenus Inc. |
Anti-OX40 antibodies and methods of use thereof
|
EP3236996B1
(en)
|
2015-05-08 |
2022-03-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
EP3294771A1
(en)
|
2015-05-11 |
2018-03-21 |
H. Hoffnabb-La Roche Ag |
Compositions and methods of treating lupus nephritis
|
SI3294770T2
(sl)
|
2015-05-12 |
2024-06-28 |
F. Hoffmann-La Roche Ag |
Terapevtski in diagnostični postopki za raka
|
HRP20231392T1
(hr)
|
2015-05-15 |
2024-04-26 |
The General Hospital Corporation |
Antagonistička protutijela na superobitelj receptora za faktor tumorske nekroze
|
EP3770168A1
(en)
|
2015-05-18 |
2021-01-27 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
US10752670B2
(en)
|
2015-05-20 |
2020-08-25 |
Cellectis |
Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
|
SG10202002131PA
(en)
|
2015-05-21 |
2020-05-28 |
Harpoon Therapeutics Inc |
Trispecific binding proteins and methods of use
|
MX2017015011A
(es)
|
2015-05-28 |
2018-03-23 |
Genentech Inc |
Ensayo a base de celulas para detectar homodimeros anti-cd3.
|
ES2789500T5
(es)
|
2015-05-29 |
2023-09-20 |
Hoffmann La Roche |
Procedimientos terapéuticos y de diagnóstico para el cáncer
|
MA53355A
(fr)
|
2015-05-29 |
2022-03-16 |
Agenus Inc |
Anticorps anti-ctla-4 et leurs procédés d'utilisation
|
EP3302563A1
(en)
|
2015-05-29 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Humanized anti-ebola virus glycoprotein antibodies and methods of use
|
LT3302551T
(lt)
|
2015-05-30 |
2024-09-10 |
F. Hoffmann-La Roche Ag |
Anksčiau negydyto metastazavusio her2 teigiamo krūties vėžio gydymo būdai
|
LT3303373T
(lt)
|
2015-05-30 |
2020-07-10 |
Molecular Templates, Inc. |
Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės
|
JP2018516933A
(ja)
|
2015-06-02 |
2018-06-28 |
ジェネンテック, インコーポレイテッド |
抗il−34抗体を使用して神経学的疾患を治療するための組成物及び方法
|
WO2016196726A1
(en)
|
2015-06-05 |
2016-12-08 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
AU2016274584A1
(en)
|
2015-06-08 |
2018-01-04 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies and PD-1 axis binding antagonists
|
KR20180011839A
(ko)
|
2015-06-08 |
2018-02-02 |
제넨테크, 인크. |
항-ox40 항체를 이용한 암의 치료 방법
|
TW201709932A
(zh)
|
2015-06-12 |
2017-03-16 |
西雅圖遺傳學公司 |
Cd123抗體及其共軛物
|
KR20180033502A
(ko)
|
2015-06-12 |
2018-04-03 |
알렉터 엘엘씨 |
항-cd33 항체 및 그의 사용 방법
|
EP3307779A2
(en)
|
2015-06-12 |
2018-04-18 |
Alector LLC |
Anti-cd33 antibodies and methods of use thereof
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
EP3307780A1
(en)
|
2015-06-15 |
2018-04-18 |
Genentech, Inc. |
Antibodies and immunoconjugates
|
CN107849145B
(zh)
|
2015-06-16 |
2021-10-26 |
基因泰克公司 |
抗cd3抗体及其使用方法
|
CN107847568B
(zh)
|
2015-06-16 |
2022-12-20 |
豪夫迈·罗氏有限公司 |
抗cll-1抗体和使用方法
|
AR105026A1
(es)
|
2015-06-16 |
2017-08-30 |
Genentech Inc |
ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
|
CN107771076A
(zh)
|
2015-06-17 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
|
JP2018524312A
(ja)
|
2015-06-17 |
2018-08-30 |
ジェネンテック, インコーポレイテッド |
抗her2抗体及び使用方法
|
JP6846362B2
(ja)
|
2015-06-17 |
2021-03-24 |
アラコス インコーポレイテッド |
線維性疾患を処置するための方法および組成物
|
US20180318438A1
(en)
|
2015-06-23 |
2018-11-08 |
Bayer Pharma Aktiengesellschaft |
Antibody drug conjugates of kinesin spindel protein (ksp) inhibitors with anti-tweakr-antibodies
|
JP6619460B2
(ja)
|
2015-06-24 |
2019-12-11 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ヒト化抗タウ(pS422)抗体及び使用法
|
NZ737205A
(en)
|
2015-06-24 |
2024-07-26 |
F Hoffmann La Roche Ag |
Anti-transferrin receptor antibodies with tailored affinity
|
CA2990360C
(en)
|
2015-06-24 |
2024-02-13 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
AU2016285596A1
(en)
|
2015-06-29 |
2018-01-18 |
Genentech, Inc. |
Type II anti-CD20 antibody for use in organ transplantation
|
CN116059395A
(zh)
|
2015-06-29 |
2023-05-05 |
第一三共株式会社 |
用于选择性制造抗体-药物缀合物的方法
|
CA3162586A1
(en)
|
2015-06-29 |
2017-01-05 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
IL256295B2
(en)
|
2015-06-30 |
2023-11-01 |
Seagen Inc |
Anti-NTB-A antibodies and related compositions and methods
|
BR112017027582A2
(pt)
|
2015-07-06 |
2018-08-28 |
Regeneron Pharma |
método para inibição do crescimento de uma célula tumoral ou promoção da eliminação de uma célula tumoral, e, composição farmacêutica.
|
SI3319995T1
(sl)
|
2015-07-07 |
2019-07-31 |
F. Hoffmann-La Roche Ag |
Kombinirana terapija s konjugatom protitelo anti-HER-2 in zdravilo ter zaviralcem bcl-2
|
JP6759326B2
(ja)
|
2015-07-12 |
2020-09-23 |
ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. |
細胞結合分子の共役のための架橋連結体
|
JO3711B1
(ar)
|
2015-07-13 |
2021-01-31 |
H Lundbeck As |
أجسام مضادة محددة لبروتين تاو وطرق استعمالها
|
GB201512203D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
GB201512215D0
(en)
|
2015-07-13 |
2015-08-19 |
Lundbeck & Co As H |
Agents,uses and methods
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
CA2994043A1
(en)
|
2015-07-31 |
2017-02-09 |
Glaxosmithkline Intellectual Property Development Limited |
Antibody variants
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
US10286080B2
(en)
|
2015-08-03 |
2019-05-14 |
Wayne State University |
IgA Fc-folate conjugates, pharmaceutical compositions and methods to treat cancer
|
KR20180035884A
(ko)
|
2015-08-04 |
2018-04-06 |
악셀레론 파마 인코포레이티드 |
골수증식성 장애를 치료하기 위한 방법
|
HU231463B1
(hu)
|
2015-08-04 |
2024-01-28 |
Richter Gedeon Nyrt. |
Módszer rekombináns proteinek galaktóz tartalmának növelésére
|
EP3331563B1
(en)
|
2015-08-05 |
2023-04-19 |
Janssen Biotech, Inc. |
Anti-cd154 antibodies and methods of using them
|
WO2017025458A1
(en)
|
2015-08-07 |
2017-02-16 |
Gamamabs Pharma |
Antibodies, antibody drug conjugates and methods of use
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
EP3334442A1
(en)
|
2015-08-11 |
2018-06-20 |
Cellectis |
Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
EP3334761B1
(en)
|
2015-08-13 |
2023-07-19 |
New York University |
Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
|
JP6913078B2
(ja)
|
2015-08-13 |
2021-08-04 |
ニューヨーク・ユニバーシティ |
タウの短縮型Asp421エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用
|
WO2017033152A1
(en)
|
2015-08-25 |
2017-03-02 |
Prothena Biosciences Limited |
Methods for detecting phosphorylated alpha-synuclein
|
CA2992306A1
(en)
|
2015-08-28 |
2017-03-09 |
Amunix Operating Inc. |
Chimeric polypeptide assembly and methods of making and using the same
|
EP3341415B1
(en)
|
2015-08-28 |
2021-03-24 |
H. Hoffnabb-La Roche Ag |
Anti-hypusine antibodies and uses thereof
|
PE20181322A1
(es)
|
2015-09-01 |
2018-08-14 |
Agenus Inc |
Anticuerpo anti-pd1 y sus metodos de uso
|
KR20180039172A
(ko)
|
2015-09-01 |
2018-04-17 |
베링거 인겔하임 인터내셔날 게엠베하 |
루푸스 신염의 치료를 위한 항-cd40 항체의 용도
|
CN108350605A
(zh)
|
2015-09-04 |
2018-07-31 |
台湾浩鼎生技股份有限公司 |
聚糖阵列以及使用方法
|
WO2017046774A2
(en)
|
2015-09-16 |
2017-03-23 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
|
CA2998716A1
(en)
|
2015-09-16 |
2017-03-23 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
|
TWI733695B
(zh)
|
2015-09-18 |
2021-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
治療發炎性疾病之方法
|
KR101920175B1
(ko)
|
2015-09-18 |
2018-11-19 |
추가이 세이야쿠 가부시키가이샤 |
Il-8에 결합하는 항체 및 그의 사용
|
AU2016328357B2
(en)
|
2015-09-22 |
2023-03-02 |
Ventana Medical Systems, Inc. |
Anti-OX40 antibodies and diagnostic uses thereof
|
EP3353212B1
(en)
|
2015-09-23 |
2021-11-03 |
Regeneron Pharmaceuticals, Inc. |
Optimized anti-cd3 bispecific antibodies and uses thereof
|
TWI748962B
(zh)
|
2015-09-23 |
2021-12-11 |
美商建南德克公司 |
抗vegf抗體之最佳化變異體
|
RU2757135C2
(ru)
|
2015-09-24 |
2021-10-11 |
АБВИТРО ЭлЭлСи |
Композиции антител к вич и способы их применения
|
CN113912724A
(zh)
|
2015-09-25 |
2022-01-11 |
豪夫迈·罗氏有限公司 |
抗tigit抗体和使用方法
|
WO2017058859A1
(en)
|
2015-09-29 |
2017-04-06 |
Celgene Corporation |
Pd-1 binding proteins and methods of use thereof
|
EP3355914B1
(en)
|
2015-09-29 |
2024-03-06 |
The General Hospital Corporation |
A composition comprising bcg for reducing cholesterol.
|
US10358497B2
(en)
|
2015-09-29 |
2019-07-23 |
Amgen Inc. |
Methods of treating cardiovascular disease with an ASGR inhibitor
|
MA43053A
(fr)
|
2015-09-30 |
2018-08-08 |
Janssen Biotech Inc |
Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
JP2018533930A
(ja)
|
2015-10-02 |
2018-11-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性t細胞活性化抗原結合分子
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
US20180282410A1
(en)
|
2015-10-02 |
2018-10-04 |
Hoffmann-La Roche Inc. |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
MY192668A
(en)
|
2015-10-02 |
2022-08-30 |
Hoffmann La Roche |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
AR106365A1
(es)
|
2015-10-02 |
2018-01-10 |
Hoffmann La Roche |
Moléculas biespecíficas de unión a antígeno activadoras de células t
|
EP3913000A1
(en)
|
2015-10-02 |
2021-11-24 |
F. Hoffmann-La Roche AG |
Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
JP7044700B2
(ja)
|
2015-10-02 |
2022-03-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ceaxcd3 t細胞活性化抗原結合分子
|
PL3356404T3
(pl)
|
2015-10-02 |
2022-01-03 |
F. Hoffmann-La Roche Ag |
Przeciwciała anty-pd1 i sposoby ich stosowania
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
MA43017A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf
|
JP6622392B2
(ja)
|
2015-10-02 |
2019-12-18 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Pd1とtim3に特異的な二重特異性抗体
|
WO2017062682A2
(en)
|
2015-10-06 |
2017-04-13 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
CN108271377B
(zh)
|
2015-10-07 |
2021-11-19 |
豪夫迈·罗氏有限公司 |
具有针对共刺激性tnf受体的四价的双特异性抗体
|
US11161912B2
(en)
|
2015-10-13 |
2021-11-02 |
Technion Research & Development Foundation Limited |
Heparanase-neutralizing monoclonal antibodies
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
GB201518675D0
(en)
|
2015-10-21 |
2015-12-02 |
Cellcap Technologies Ltd |
Detection of structural forms of proteins
|
TW201723190A
(zh)
|
2015-10-22 |
2017-07-01 |
永斯醫療股份有限公司 |
用於測定icos表現之基因印記
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
AU2016344459B2
(en)
|
2015-10-28 |
2023-10-05 |
Yale University |
Humanized anti-DKK2 antibody and uses thereof
|
MX2018005036A
(es)
|
2015-10-29 |
2018-08-01 |
Hoffmann La Roche |
Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
US10421821B2
(en)
|
2015-10-30 |
2019-09-24 |
Genentech, Inc. |
Anti-HtrA1 antibodies and methods of use thereof
|
US10654932B2
(en)
|
2015-10-30 |
2020-05-19 |
Genentech, Inc. |
Anti-factor D antibody variant conjugates and uses thereof
|
CA3003033A1
(en)
|
2015-10-30 |
2017-05-04 |
Galaxy Biotech, Llc |
Highly potent antibodies binding to death receptor 4 and death receptor 5
|
JP2018534930A
(ja)
|
2015-10-30 |
2018-11-29 |
ジェネンテック, インコーポレイテッド |
抗d因子抗体及びコンジュゲート
|
MX2018004831A
(es)
|
2015-11-02 |
2018-08-01 |
Genentech Inc |
Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina.
|
CN108350077A
(zh)
|
2015-11-03 |
2018-07-31 |
糖模拟物有限公司 |
产生单克隆抗体、造血干细胞的方法和组合物以及利用所述抗体和造血干细胞的方法
|
CR20180234A
(es)
|
2015-11-03 |
2018-09-11 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a pd-1 y sus usos
|
JP2019500011A
(ja)
|
2015-11-03 |
2019-01-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用
|
US11123430B2
(en)
|
2015-11-04 |
2021-09-21 |
Acceleron Pharma Inc. |
Methods for increasing red blood cell levels and treating ineffective erythropoiesis
|
KR20180104597A
(ko)
|
2015-11-07 |
2018-09-21 |
멀티비르 인코포레이티드 |
암 치료를 위한 종양 억제 유전자 요법 및 면역관문 봉쇄를 포함하는 조성물
|
CN118725134A
(zh)
|
2015-11-08 |
2024-10-01 |
豪夫迈·罗氏有限公司 |
筛选多特异性抗体的方法
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
EP3377533A2
(en)
|
2015-11-19 |
2018-09-26 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
CN106729743B
(zh)
|
2015-11-23 |
2021-09-21 |
四川科伦博泰生物医药股份有限公司 |
抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
|
CN116327924A
(zh)
|
2015-11-23 |
2023-06-27 |
戊瑞治疗有限公司 |
用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
|
AU2016359695A1
(en)
|
2015-11-23 |
2018-06-14 |
Acceleron Pharma Inc. |
Methods for treating eye disorders
|
TWI778491B
(zh)
|
2015-11-30 |
2022-09-21 |
美商輝瑞股份有限公司 |
位點專一性her2抗體藥物共軛體
|
US11253590B2
(en)
|
2015-12-02 |
2022-02-22 |
Stsciences, Inc. |
Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
|
WO2017096051A1
(en)
|
2015-12-02 |
2017-06-08 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
CA3009644A1
(en)
|
2015-12-04 |
2017-06-08 |
The Regents Of The University Of California |
Novel antibodies for the treatment of cancers
|
EP3387013B1
(en)
|
2015-12-07 |
2022-06-08 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and psma
|
US11052111B2
(en)
|
2015-12-08 |
2021-07-06 |
Chimera Bioengineering, Inc. |
Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
CN108602890A
(zh)
|
2015-12-11 |
2018-09-28 |
瑞泽恩制药公司 |
用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法
|
CN108602893A
(zh)
|
2015-12-11 |
2018-09-28 |
戴埃克斯有限公司 |
血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
|
EP3389714A4
(en)
|
2015-12-14 |
2019-11-13 |
MacroGenics, Inc. |
BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY TO PD-1 AND CTLA-4 AND METHODS OF USE
|
MA44077A
(fr)
|
2015-12-15 |
2021-05-05 |
Gilead Sciences Inc |
Anticorps neutralisants le virus de l'immunodéficience humaine
|
JP2019502698A
(ja)
|
2015-12-17 |
2019-01-31 |
ヤンセン バイオテツク,インコーポレーテツド |
Hla−drに特異的に結合する抗体及びその使用
|
FI3390442T3
(fi)
|
2015-12-18 |
2023-11-10 |
Chugai Pharmaceutical Co Ltd |
Anti-C5-vasta-aineita ja käyttömenetelmiä
|
CN105646704B
(zh)
*
|
2015-12-28 |
2019-11-15 |
广西医科大学 |
抗p185erbB2人鼠嵌合抗体ChAb26、乳腺特异性表达载体、转基因FVB小鼠及其制备方法
|
IL260323B1
(en)
|
2015-12-30 |
2024-09-01 |
Kodiak Sciences Inc |
Antibodies and their conjugates
|
US20200270365A1
(en)
|
2016-01-05 |
2020-08-27 |
Jiangsu Hengrui Medicine Co., Ltd. |
Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof
|
MX2018008347A
(es)
|
2016-01-08 |
2018-12-06 |
Hoffmann La Roche |
Metodos de tratamiento de canceres positivos para ace utilizando antagonistas de union a eje pd-1 y anticuerpos biespecificos anti-ace/anti-cd3.
|
TWI753875B
(zh)
|
2016-01-08 |
2022-02-01 |
美商美國全心醫藥生技股份有限公司 |
四價抗psgl-1抗體及其用途
|
EP3192810A1
(en)
|
2016-01-14 |
2017-07-19 |
Deutsches Krebsforschungszentrum |
Psma binding antibody and uses thereof
|
CN114019170A
(zh)
|
2016-01-20 |
2022-02-08 |
基因泰克公司 |
用于阿尔茨海默氏病的高剂量治疗
|
JP2019506398A
(ja)
|
2016-01-21 |
2019-03-07 |
ファイザー・インク |
上皮増殖因子受容体変異体iiiおよびcd3の単一および二重特異性抗体およびそれらの使用
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
EP3964529A1
(en)
|
2016-01-22 |
2022-03-09 |
Mabquest SA |
Non-blocking pd1 specific antibodies
|
US11214617B2
(en)
|
2016-01-22 |
2022-01-04 |
MabQuest SA |
Immunological reagents
|
US11513127B2
(en)
|
2016-01-25 |
2022-11-29 |
Genentech, Inc. |
Methods for assaying T-cell dependent bispecific antibodies
|
CN114796520A
(zh)
|
2016-01-27 |
2022-07-29 |
苏特罗生物制药公司 |
抗cd74抗体偶联物,包含抗cd74抗体偶联物的组合物以及抗cd74抗体偶联物的使用方法
|
EA201891753A1
(ru)
|
2016-02-03 |
2019-01-31 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки
|
KR20240118898A
(ko)
|
2016-02-03 |
2024-08-05 |
암젠 리서치 (뮌헨) 게엠베하 |
Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
WO2017139417A1
(en)
|
2016-02-08 |
2017-08-17 |
Vitrisa Therapeutics, Inc. |
Compositions with improved intravitreal half-life and uses thereof
|
WO2017137830A1
(en)
|
2016-02-12 |
2017-08-17 |
Janssen Pharmaceutica Nv |
Anti-vista (b7h5) antibodies
|
IL311107A
(en)
|
2016-02-17 |
2024-04-01 |
Seagen Inc |
BCMA antibodies and their use for the treatment of cancer and immune disorders
|
GB201603291D0
(en)
*
|
2016-02-25 |
2016-04-13 |
Binding Site Group The Ltd |
Antibodies
|
EP3419670A2
(en)
|
2016-02-26 |
2019-01-02 |
Regeneron Pharmaceuticals, Inc. |
Optimized transglutaminase site-specific antibody conjugation
|
AU2017224122B2
(en)
|
2016-02-26 |
2024-04-11 |
The Board Of Regents Of The University Of Texas System |
Connexin (Cx) 43 hemichannel-binding antibodies and uses thereof
|
US10941447B2
(en)
|
2016-02-29 |
2021-03-09 |
Rhode Island Hospital |
Diagnostics for pulmonary arterial hypertension and sudden cardiac death
|
CN114395624A
(zh)
|
2016-02-29 |
2022-04-26 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
MX2018010445A
(es)
|
2016-03-01 |
2019-10-17 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Anticuerpos especificos del receptor de poliovirus humano (rvp).
|
CN114272389B
(zh)
|
2016-03-02 |
2023-04-18 |
卫材研究发展管理有限公司 |
基于艾日布林的抗体-药物偶联物和使用方法
|
WO2017149513A1
(en)
|
2016-03-03 |
2017-09-08 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
TWI752012B
(zh)
|
2016-03-04 |
2022-01-11 |
美商Jn生物科學有限責任公司 |
針對tigit之抗體
|
EP3423482A1
(en)
|
2016-03-04 |
2019-01-09 |
Novartis AG |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
EP3216458A1
(en)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified vascular endothelial growth factor a (vegf-a) and its medical use
|
CA3016170A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
WO2017153955A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
WO2017153953A1
(en)
|
2016-03-09 |
2017-09-14 |
Prothena Biosciences Limited |
Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
|
EA201892071A1
(ru)
|
2016-03-14 |
2019-03-29 |
Милленниум Фармасьютикалз, Инк. |
Способ профилактики болезни "трансплантат против хозяина"
|
JP2019512493A
(ja)
|
2016-03-14 |
2019-05-16 |
ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. |
移植片対宿主病の処置または予防の方法
|
WO2017159699A1
(en)
|
2016-03-15 |
2017-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
|
WO2017161206A1
(en)
|
2016-03-16 |
2017-09-21 |
Halozyme, Inc. |
Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
|
CN109462996A
(zh)
|
2016-03-17 |
2019-03-12 |
西达-赛奈医疗中心 |
通过rnaset2诊断炎性肠病的方法
|
CN108884170A
(zh)
|
2016-03-22 |
2018-11-23 |
豪夫迈·罗氏有限公司 |
蛋白酶活化的t细胞双特异性分子
|
LT3433280T
(lt)
|
2016-03-22 |
2023-07-10 |
F. Hoffmann-La Roche Ag |
Proteazės aktyvuojamos t ląstelei bispecifinės molekulės
|
WO2017161976A1
(en)
|
2016-03-23 |
2017-09-28 |
Mabspace Biosciences (Suzhou) Co., Ltd |
Novel anti-pd-l1 antibodies
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
MX2018011629A
(es)
|
2016-03-24 |
2019-03-14 |
Bayer Pharma AG |
Complejos radiofarmaceuticos.
|
WO2017165734A1
(en)
|
2016-03-25 |
2017-09-28 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
TWI753892B
(zh)
|
2016-03-28 |
2022-02-01 |
美商英塞特公司 |
作為tam抑制劑之吡咯并三嗪化合物
|
CA3019560A1
(en)
|
2016-03-29 |
2017-10-05 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
EP3436475A1
(en)
|
2016-03-29 |
2019-02-06 |
STCube & Co., Inc. |
Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
KR20230148844A
(ko)
|
2016-03-29 |
2023-10-25 |
유니버시티 오브 써던 캘리포니아 |
암을 표적하는 키메라 항원 수용체
|
KR102418372B1
(ko)
|
2016-03-29 |
2022-07-08 |
주식회사 에스티큐브 |
글리코실화된 pd-l1에 특이적인 이중 기능 항체 및 이의 사용 방법
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
EP3436480A4
(en)
|
2016-03-30 |
2019-11-27 |
Musc Foundation for Research Development |
METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
|
US10883108B2
(en)
|
2016-03-31 |
2021-01-05 |
The Schepens Eye Research Institute, Inc. |
Endomucin inhibitor as an anti-angiogenic agent
|
KR101796277B1
(ko)
|
2016-04-12 |
2017-11-13 |
앱클론(주) |
안정성이 개선된 her2에 특이적으로 결합하는 항체
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
EP3560956A3
(en)
|
2016-04-15 |
2020-01-01 |
Boehringer Ingelheim International GmbH |
Methods of treating inflammatory diseases
|
CN109154613A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
WO2017181143A1
(en)
|
2016-04-15 |
2017-10-19 |
Generon (Shanghai) Corporation, Ltd. |
Use of il-22 in treating necrotizing enterocolitis
|
JP2019515670A
(ja)
|
2016-04-15 |
2019-06-13 |
ジェネンテック, インコーポレイテッド |
がんをモニタリングし治療するための方法
|
WO2017178288A1
(en)
|
2016-04-15 |
2017-10-19 |
Medimmune Limited |
ANTI-PrP ANTIBODIES AND USES THEREOF
|
WO2017181139A2
(en)
|
2016-04-15 |
2017-10-19 |
Michael Molloy |
Anti-human vista antibodies and use thereof
|
AU2017250358B2
(en)
|
2016-04-15 |
2023-06-01 |
Alpine Immune Sciences, Inc. |
ICOS ligand variant immunomodulatory proteins and uses thereof
|
EP3426686A4
(en)
|
2016-04-15 |
2019-11-06 |
Alder Biopharmaceuticals, Inc. |
HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF
|
MX2018012615A
(es)
|
2016-04-15 |
2019-05-30 |
Novartis Ag |
Composiciones y metodos para la expresion selectiva de proteinas.
|
US11078282B2
(en)
|
2016-04-15 |
2021-08-03 |
Alpine Immune Sciences, Inc. |
CD80 variant immunomodulatory proteins and uses thereof
|
WO2017184619A2
(en)
|
2016-04-18 |
2017-10-26 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human cd40 and uses thereof
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
US11583577B2
(en)
|
2016-04-22 |
2023-02-21 |
Obi Pharma, Inc. |
Cancer immunotherapy by immune activation or immune modulation via Globo series antigens
|
US11016085B2
(en)
|
2016-04-25 |
2021-05-25 |
The Johns Hopkins University |
ZNT8 assays for drug development and pharmaceutical compositions
|
ES2952951T3
(es)
|
2016-04-28 |
2023-11-07 |
Biomunex Pharmaceuticals |
Anticuerpos biespecíficos dirigidos a EGFR y HER2
|
EP3448891A1
(en)
|
2016-04-28 |
2019-03-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
WO2017191561A1
(en)
|
2016-05-02 |
2017-11-09 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
WO2017191101A1
(en)
|
2016-05-02 |
2017-11-09 |
F. Hoffmann-La Roche Ag |
The contorsbody - a single chain target binder
|
PE20190261A1
(es)
|
2016-05-02 |
2019-02-25 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau
|
US10752679B2
(en)
|
2016-05-02 |
2020-08-25 |
Prothena Biosciences Limited |
Tau immunotherapy
|
EP3241847A1
(en)
*
|
2016-05-06 |
2017-11-08 |
MAB Discovery GmbH |
Her-2 binding antibodies
|
EP3454863A1
(en)
|
2016-05-10 |
2019-03-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combinations therapies for the treatment of cancer
|
CN109071640B
(zh)
|
2016-05-11 |
2022-10-18 |
豪夫迈·罗氏有限公司 |
经修饰抗生腱蛋白抗体及使用方法
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
JP7285076B2
(ja)
|
2016-05-11 |
2023-06-01 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Tnfファミリーリガンドトリマーとテネイシン結合部分とを含む抗原結合分子
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
TWI844509B
(zh)
|
2016-05-13 |
2024-06-11 |
美商拜奧亞特拉公司 |
抗-ror2抗體、抗體片段、其免疫結合物及其用途
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
CN116715767A
(zh)
|
2016-05-13 |
2023-09-08 |
综合医院公司 |
拮抗性抗肿瘤坏死因子受体超家族抗体
|
JP7359547B2
(ja)
|
2016-05-17 |
2023-10-11 |
ジェネンテック, インコーポレイテッド |
免疫療法における診断及び使用のための間質遺伝子シグネチャー
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
IL263102B2
(en)
|
2016-05-20 |
2023-11-01 |
Harpoon Therapeutics Inc |
A serum albumin-binding protein with a single site
|
PL3458101T3
(pl)
|
2016-05-20 |
2021-05-31 |
F. Hoffmann-La Roche Ag |
Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
|
ES2905823T3
(es)
|
2016-05-20 |
2022-04-12 |
Biohaven Therapeutics Ltd |
Uso de riluzol, profármacos de riluzol o análogos de riluzol con inmunoterapias para tratar cánceres
|
EP3465221B1
(en)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
NZ749355A
(en)
|
2016-05-27 |
2023-04-28 |
Agenus Inc |
Anti-tim-3 antibodies and methods of use thereof
|
BR112019022558A2
(pt)
|
2016-06-02 |
2020-05-19 |
Hoffmann La Roche |
anticorpos, métodos para tratar ou retardar a progressão de uma doença proliferativa e para tratar ou retardar a progressão do câncer em um indivíduo, composições farmacêuticas, kit, usos de uma combinação de um anticorpo anti-cd20 e de um anticorpo e invenção
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
CN109952319B
(zh)
|
2016-06-02 |
2023-08-25 |
英美偌科有限公司 |
对gp100具有特异性的TCR-抗CD3 scFv融合蛋白的定量用药方案
|
WO2017208210A1
(en)
|
2016-06-03 |
2017-12-07 |
Prothena Biosciences Limited |
Anti-mcam antibodies and associated methods of use
|
EP3464345A1
(en)
|
2016-06-06 |
2019-04-10 |
F. Hoffmann-La Roche AG |
Fusion proteins for ophthalmology with increased eye retention
|
US10639378B2
(en)
|
2016-06-06 |
2020-05-05 |
Genentech, Inc. |
Silvestrol antibody-drug conjugates and methods of use
|
US10626184B2
(en)
|
2016-06-09 |
2020-04-21 |
Omeros Corporation |
Monoclonal antibodies, compositions and methods for detecting mucin-like protein (MLP) as a biomarker for ovarian and pancreatic cancer
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
SG11201810525XA
(en)
|
2016-06-10 |
2018-12-28 |
Regeneron Pharma |
Anti-gitr antibodies and uses thereof
|
RU2767357C2
(ru)
|
2016-06-14 |
2022-03-17 |
Ксенкор, Инк. |
Биспецифические антитела-ингибиторы контрольных точек
|
WO2017218698A1
(en)
|
2016-06-15 |
2017-12-21 |
Sutro Biopharma, Inc. |
Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
|
MX2018015173A
(es)
|
2016-06-17 |
2019-07-04 |
Genentech Inc |
Purificacion de anticuerpos multiespecificos.
|
EP3472210A1
(en)
|
2016-06-17 |
2019-04-24 |
Life Technologies Corporation |
Site-specific crosslinking of antibodies
|
EP3471773A4
(en)
|
2016-06-21 |
2020-07-08 |
Teneobio, Inc. |
ANTIBODIES BINDING CD3
|
CN109563160B
(zh)
|
2016-06-24 |
2023-02-28 |
豪夫迈·罗氏有限公司 |
抗聚泛素多特异性抗体
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
EP3478715A2
(en)
|
2016-07-02 |
2019-05-08 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
EP3478714A2
(en)
|
2016-07-02 |
2019-05-08 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
WO2018007924A2
(en)
|
2016-07-02 |
2018-01-11 |
Prothena Biosciences Limited |
Anti-transthyretin antibodies
|
WO2018007314A1
(en)
|
2016-07-04 |
2018-01-11 |
F. Hoffmann-La Roche Ag |
Novel antibody format
|
HUE055402T2
(hu)
|
2016-07-06 |
2021-11-29 |
Prothena Biosciences Ltd |
Esszé összes és S129 foszforilezett alfa-szinuklein kimutatására
|
WO2018009732A1
(en)
|
2016-07-08 |
2018-01-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
|
EP3481864A1
(en)
|
2016-07-08 |
2019-05-15 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
CA3030683C
(en)
|
2016-07-12 |
2023-11-21 |
Kite Pharma, Inc. |
Antigen binding molecules and methods of use thereof
|
DK3484916T3
(da)
|
2016-07-12 |
2021-04-06 |
H Lundbeck As |
Antistoffer specifikke for hyperphosphoryleret tau og fremgangsmåder til anvendelse deraf
|
KR102632202B1
(ko)
|
2016-07-14 |
2024-02-02 |
젠맵 에이/에스 |
Cd40 및 cd137에 대한 다중특이적 항체
|
PT3496739T
(pt)
|
2016-07-15 |
2021-06-21 |
Acceleron Pharma Inc |
Composições compreendendo polipéptidos actriia para uso no tratamento de hipertensão pulmonar
|
AU2017295886C1
(en)
|
2016-07-15 |
2024-05-16 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
BR112019000544A2
(pt)
|
2016-07-15 |
2019-04-24 |
Takeda Pharmaceutical Company Limited |
métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática
|
WO2018017673A1
(en)
|
2016-07-20 |
2018-01-25 |
Stcube, Inc. |
Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
EP3487521A4
(en)
|
2016-07-21 |
2020-07-01 |
Emory University |
ANTIBODIES AGAINST EBOLA VIRUS AND LIAISON AGENTS DERIVED THEREFROM
|
US10377833B2
(en)
|
2016-07-22 |
2019-08-13 |
Beijing Mabworks Biotech Co., Ltd. |
Bispecific anti-HER2 antibody
|
CN107446045A
(zh)
|
2016-07-22 |
2017-12-08 |
北京天广实生物技术股份有限公司 |
一种抗her2的抗体、其药物组合物及用途
|
JP2019531332A
(ja)
|
2016-07-22 |
2019-10-31 |
ドイチェス ツェントルム フュール ノイロデゲネラティフェ アークランクンゲン エー.ファウ.(デーツェットエンエー) |
Trem2切断モジュレーター及びその使用
|
US20190330318A1
(en)
|
2016-07-25 |
2019-10-31 |
Biogen Ma Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
BR112019001615A2
(pt)
|
2016-07-27 |
2019-04-30 |
Acceleron Pharma Inc. |
métodos e composições para tratar mielofibrose
|
US11642400B2
(en)
|
2016-07-27 |
2023-05-09 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
SG11201900677SA
(en)
|
2016-07-28 |
2019-02-27 |
Novartis Ag |
Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
CA3032120A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
EP3491026A4
(en)
|
2016-07-29 |
2020-07-29 |
OBI Pharma, Inc. |
HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
KR102591955B1
(ko)
|
2016-07-29 |
2023-10-19 |
추가이 세이야쿠 가부시키가이샤 |
증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
|
MX2019001184A
(es)
|
2016-07-29 |
2019-09-26 |
Juno Therapeutics Inc |
Anticuerpos anti-idiotípicos y métodos relacionados.
|
CN110267677A
(zh)
|
2016-08-01 |
2019-09-20 |
诺华股份有限公司 |
使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
JP7369620B2
(ja)
|
2016-08-03 |
2023-10-26 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
マクロファージ上のFc受容体結合の破壊による抗SlRPα抗体療法の効果増強
|
KR102538749B1
(ko)
|
2016-08-05 |
2023-06-01 |
추가이 세이야쿠 가부시키가이샤 |
Il-8 관련 질환의 치료용 또는 예방용 조성물
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
JP7250674B2
(ja)
|
2016-08-08 |
2023-04-03 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療及び診断方法
|
JP7093767B2
(ja)
|
2016-08-11 |
2022-06-30 |
ジェネンテック, インコーポレイテッド |
ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
|
CA3033665A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
SG11201900746RA
(en)
|
2016-08-12 |
2019-02-27 |
Janssen Biotech Inc |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
MX2019001572A
(es)
|
2016-08-15 |
2019-08-29 |
Genentech Inc |
Método de cromatografía para cuantificar un tensioactivo no iónico en una composición que comprende el tensioactivo no iónico y un polipéptido.
|
KR102585976B1
(ko)
|
2016-08-17 |
2023-10-05 |
컴퓨젠 엘티디. |
항-tigit 항체, 항-pvrig 항체 및 이들의 조합
|
KR102588027B1
(ko)
|
2016-08-22 |
2023-10-12 |
초 파마 인크. |
항체, 결합 단편 및 사용 방법
|
WO2018045110A1
(en)
|
2016-08-30 |
2018-03-08 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
AU2017319702A1
(en)
|
2016-09-02 |
2019-04-11 |
The Regents Of The University Of California |
Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
|
EP3510046A4
(en)
|
2016-09-07 |
2020-05-06 |
The Regents of the University of California |
ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES
|
PT4050034T
(pt)
|
2016-09-14 |
2024-05-27 |
Teneoone Inc |
Anticorpos de ligação a cd3
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
EP4339615A3
(en)
|
2016-09-16 |
2024-05-22 |
Shanghai Henlius Biotech, Inc. |
Anti-pd-1 antibodies
|
CN109689682B
(zh)
|
2016-09-19 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
基于补体因子的亲和层析
|
JP2019534859A
(ja)
|
2016-09-19 |
2019-12-05 |
セルジーン コーポレイション |
Pd−1結合タンパク質を使用して白斑を治療する方法
|
EA201990747A1
(ru)
|
2016-09-19 |
2019-10-31 |
|
Способы лечения иммунных нарушений с применением белков, связывающих pd–1
|
EP4360714A3
(en)
|
2016-09-21 |
2024-07-24 |
Nextcure, Inc. |
Antibodies for siglec-15 and methods of use thereof
|
SG10202102846SA
(en)
|
2016-09-21 |
2021-04-29 |
Aptevo Res & Development Llc |
Cd123 binding proteins and related compositions and methods
|
DK3515478T3
(da)
|
2016-09-21 |
2024-05-21 |
Nextcure Inc |
Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
|
PT3528838T
(pt)
|
2016-09-23 |
2023-09-04 |
Hoffmann La Roche |
Utilizações de antagonistas de il-13 para tratamento de dermatite atópica
|
CA3037732A1
(en)
|
2016-09-23 |
2018-03-29 |
Regeneron Pharmaceuticals, Inc. |
Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
|
MX2019003337A
(es)
|
2016-09-23 |
2019-09-26 |
Teva Pharmaceuticals Int Gmbh |
Tratamiento para migraña refractaria.
|
WO2018067331A1
(en)
|
2016-09-23 |
2018-04-12 |
Regeneron Pharmaceuticals, Inc. |
Bi specific anti-muc16-cd3 antibodies and nti-muc16 drug conjugates
|
TWI695010B
(zh)
|
2016-09-28 |
2020-06-01 |
美商凱特製藥公司 |
抗原結合分子類和使用彼等之方法
|
EP3519437B1
(en)
|
2016-09-30 |
2021-09-08 |
F. Hoffmann-La Roche AG |
Bispecific antibodies against p95her2
|
CN110139674B
(zh)
|
2016-10-05 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
制备抗体药物缀合物的方法
|
AU2017340504A1
(en)
|
2016-10-05 |
2019-04-11 |
Acceleron Pharma, Inc. |
Compositions and method for treating kidney disease
|
CA3038712A1
(en)
|
2016-10-06 |
2018-04-12 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
JP7217970B2
(ja)
|
2016-10-07 |
2023-02-06 |
ティーシーアール2 セラピューティクス インク. |
融合タンパク質を用いてt細胞受容体をリプログラミングするための組成物及び方法
|
CA3036941C
(en)
|
2016-10-07 |
2023-02-21 |
Daiichi Sankyo Company, Limited |
Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
|
TW202340473A
(zh)
|
2016-10-07 |
2023-10-16 |
瑞士商諾華公司 |
利用嵌合抗原受體之癌症治療
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
CA3037380A1
(en)
|
2016-10-11 |
2018-04-19 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
EP3526254A1
(en)
|
2016-10-12 |
2019-08-21 |
Sutro Biopharma, Inc. |
Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
|
EP3525815A2
(en)
|
2016-10-13 |
2019-08-21 |
Massachusetts Institute of Technology |
Antibodies that bind zika virus envelope protein and uses thereof
|
EP3848390A1
(en)
|
2016-10-14 |
2021-07-14 |
Boehringer Ingelheim International GmbH |
Methods of treating diseases
|
RU2019114175A
(ru)
|
2016-10-14 |
2020-11-16 |
Ксенкор, Инк. |
Биспецифические гетеродимерные слитые белки, содержащие fc-слитые белки il-15/il-15ra и фрагменты антитела к pd-1
|
CN118359705A
(zh)
|
2016-10-19 |
2024-07-19 |
英温拉公司 |
抗体构建体
|
TW202300515A
(zh)
|
2016-10-20 |
2023-01-01 |
法商賽諾菲公司 |
抗chikv抗體及其用途
|
WO2018077926A1
(en)
|
2016-10-25 |
2018-05-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Monoclonal antibodies binding to the cd160 transmembrane isoform
|
MY191324A
(en)
|
2016-10-26 |
2022-06-15 |
Cedars Sinai Medical Center |
Neutralizing anti-tl1a monoclonal antibodies
|
ES2908239T3
(es)
|
2016-10-28 |
2022-04-28 |
Astute Medical Inc |
Uso de anticuerpos contra timp-2 para la mejora de la función renal
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック, インコーポレイテッド |
抗mic抗体及び使用方法
|
US20190298836A1
(en)
|
2016-11-02 |
2019-10-03 |
Board Of Regents, The University Of Texas System |
Dissolvable films and methods of their use
|
CN110392694B
(zh)
|
2016-11-02 |
2023-08-04 |
震动疗法股份有限公司 |
针对pd-1的抗体及其用途
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
CN109906030B
(zh)
|
2016-11-04 |
2022-03-18 |
安健基因公司 |
用于产生仅重链抗体的经基因修饰的非人动物和方法
|
CN110505880A
(zh)
|
2016-11-04 |
2019-11-26 |
基因泰克公司 |
Her2阳性乳腺癌的治疗
|
AU2017353939A1
(en)
|
2016-11-07 |
2019-06-06 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
|
WO2018089373A2
(en)
|
2016-11-08 |
2018-05-17 |
Regeneron Pharmaceuticals, Inc. |
Steroids and protein-conjugates thereof
|
AU2016429272A1
(en)
|
2016-11-14 |
2019-05-02 |
Hangzhou Dac Biotech Co., Ltd. |
Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
|
WO2018091444A1
(en)
|
2016-11-15 |
2018-05-24 |
H. Lundbeck A/S |
Agents, uses and methods for the treatment of synucleinopathy
|
WO2018093797A1
(en)
|
2016-11-15 |
2018-05-24 |
The Schepens Eye Research Institute, Inc. |
Compositions and methods for the treatment of aberrant angiogenesis
|
US11466094B2
(en)
|
2016-11-15 |
2022-10-11 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
EP4015532A1
(en)
|
2016-11-21 |
2022-06-22 |
cureab GmbH |
Anti-gp73 antibodies and immunoconjugates
|
TWI767959B
(zh)
|
2016-11-21 |
2022-06-21 |
台灣浩鼎生技股份有限公司 |
共軛生物分子、醫藥組成物及方法
|
JP7291396B2
(ja)
|
2016-11-22 |
2023-06-15 |
ティーシーアール2 セラピューティクス インク. |
融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法
|
KR102275008B1
(ko)
|
2016-11-23 |
2021-07-13 |
하푼 테라퓨틱스, 인크. |
전립선 특이 막 항원 결합 단백질
|
JP7215997B2
(ja)
|
2016-11-23 |
2023-01-31 |
ハープーン セラピューティクス,インク. |
前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法
|
EP3548514A1
(en)
|
2016-11-29 |
2019-10-09 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating prlr positive breast cancer
|
TWI784988B
(zh)
|
2016-12-01 |
2022-12-01 |
美商再生元醫藥公司 |
治療發炎症狀的方法
|
BR112019011582A2
(pt)
|
2016-12-07 |
2019-10-22 |
Agenus Inc. |
anticorpos e métodos de utilização dos mesmos
|
WO2018106776A2
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
WO2018106781A1
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc |
Anti-tau antibodies and methods of use
|
SI3551660T1
(sl)
|
2016-12-07 |
2024-02-29 |
Agenus Inc. |
Protitelesa proti antictla-4 in načini njihove uporabe
|
TW201827076A
(zh)
|
2016-12-12 |
2018-08-01 |
美商建南德克公司 |
使用抗pd-l1抗體及抗雄激素治療癌症之方法
|
TW201828993A
(zh)
|
2016-12-12 |
2018-08-16 |
日商第一三共股份有限公司 |
抗體-藥物結合物與免疫檢查點抑制劑之組合
|
JP2020510624A
(ja)
|
2016-12-12 |
2020-04-09 |
マルチビア インコーポレイテッド |
がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
|
JP2020514256A
(ja)
|
2016-12-15 |
2020-05-21 |
ザ ナショナル インスティチュート フォー バイオテクノロジー イン ザ ネゲヴ,リミテッド |
抗pcnaモノクローナル抗体及びその使用
|
BR112018016717A2
(pt)
|
2016-12-16 |
2018-12-26 |
H Lundbeck As |
agentes, usos e métodos
|
WO2018114754A1
(en)
|
2016-12-19 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted 4-1bb (cd137) agonists
|
WO2018115960A1
(en)
|
2016-12-19 |
2018-06-28 |
Mosaic Biomedicals, S.L. |
Antibodies against lif and uses thereof
|
KR102716931B1
(ko)
|
2016-12-19 |
2024-10-15 |
펀다시오 프리바다 인스티튜시오 카탈라나 드 르세르카 아이 에스투디스 아반카츠 |
Lif에 대한 항체 및 이의 용도
|
ES2847973T3
(es)
|
2016-12-20 |
2021-08-04 |
Hoffmann La Roche |
Politerapia de anticuerpos biespecíficos anti-CD20/anti-CD3 y agonistas de 4-1BB (CD137)
|
WO2018114728A1
(en)
|
2016-12-20 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody
|
IL300729A
(en)
|
2016-12-21 |
2023-04-01 |
Teneobio Inc |
Anti-BCMA antibodies containing only heavy chains
|
CN110100007B
(zh)
|
2016-12-21 |
2024-05-28 |
豪夫迈·罗氏有限公司 |
用于体外糖工程化抗体的酶的再使用
|
AU2017384276B9
(en)
|
2016-12-21 |
2020-11-26 |
F. Hoffmann-La Roche Ag |
In vitro glycoengineering of antibodies
|
MX2019006123A
(es)
|
2016-12-21 |
2019-08-12 |
Hoffmann La Roche |
Metodo para glicomanipulacion in vitro de anticuerpos.
|
US10364286B2
(en)
|
2016-12-22 |
2019-07-30 |
H. Lundbeck A/S |
Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
TW201827077A
(zh)
|
2016-12-28 |
2018-08-01 |
美商建南德克公司 |
晚期her2表現癌症之治療
|
MX2019007795A
(es)
|
2017-01-03 |
2019-08-16 |
Hoffmann La Roche |
Moleculas de union a antigeno biespecificas que comprenden el clon 20h4.9 anti-4-1bb.
|
CN110267985B
(zh)
|
2017-01-04 |
2023-05-23 |
H.隆德贝克有限公司 |
用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
|
TW201825515A
(zh)
|
2017-01-04 |
2018-07-16 |
美商伊繆諾金公司 |
Met抗體以及其免疫結合物及用途
|
WO2018127791A2
(en)
|
2017-01-06 |
2018-07-12 |
Biosion, Inc. |
Erbb2 antibodies and uses therefore
|
US11274157B2
(en)
|
2017-01-12 |
2022-03-15 |
Eureka Therapeutics, Inc. |
Constructs targeting histone H3 peptide/MHC complexes and uses thereof
|
MA56006A
(fr)
|
2017-01-17 |
2022-05-04 |
Hoffmann La Roche |
Formulations sous-cutanées d'anticorps her2
|
BR112019012847A2
(pt)
|
2017-01-17 |
2019-12-10 |
Daiichi Sankyo Co Ltd |
anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor.
|
CN110418802A
(zh)
|
2017-01-20 |
2019-11-05 |
朱诺治疗学有限公司 |
细胞表面缀合物及相关的细胞组合物和方法
|
WO2018140510A1
(en)
|
2017-01-25 |
2018-08-02 |
Biogen Ma Inc. |
Compositions and methods for treatment of stroke and other cns disorders
|
ES2912408T3
(es)
|
2017-01-26 |
2022-05-25 |
Novartis Ag |
Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
|
KR20230043247A
(ko)
|
2017-01-31 |
2023-03-30 |
추가이 세이야쿠 가부시키가이샤 |
C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
|
WO2018144535A1
(en)
|
2017-01-31 |
2018-08-09 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
RU2771485C2
(ru)
|
2017-02-10 |
2022-05-04 |
Дженентек, Инк. |
Антитела против триптазы, их композиции и применения
|
WO2018146253A1
(en)
|
2017-02-10 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
|
ES2900233T3
(es)
|
2017-02-14 |
2022-03-16 |
Kite Pharma Inc |
Moléculas que se unen a CD70 y métodos de uso de las mismas
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
CA3235295A1
(en)
|
2017-02-20 |
2018-08-23 |
Dragonfly Therapeutics, Inc. |
Proteins binding her2, nkg2d and cd16
|
WO2018156785A1
(en)
|
2017-02-22 |
2018-08-30 |
Sutro Biopharma, Inc. |
Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
BR112019017628A2
(pt)
|
2017-02-24 |
2020-07-07 |
Macrogenics, Inc. |
molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
|
JP2018139530A
(ja)
|
2017-02-27 |
2018-09-13 |
帝人ファーマ株式会社 |
認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
|
WO2018157169A1
(en)
|
2017-02-27 |
2018-08-30 |
Caerus Therapeutics, Inc. |
Antibody constructs and methods of treating cancer
|
CA3053749A1
(en)
|
2017-02-28 |
2018-09-07 |
Kinki University |
Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
EP3589754B1
(en)
|
2017-03-01 |
2023-06-28 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
CN116531511A
(zh)
|
2017-03-02 |
2023-08-04 |
豪夫迈·罗氏有限公司 |
Her2阳性乳腺癌的辅助治疗
|
MX2019010458A
(es)
|
2017-03-03 |
2020-01-20 |
Rinat Neuroscience Corp |
Anticuerpos anti-gitr y metodos de uso de los mismos.
|
US20200239579A1
(en)
|
2017-03-09 |
2020-07-30 |
Genmab A/S |
Antibodies against pd-l1
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
JP7216424B2
(ja)
|
2017-03-15 |
2023-02-01 |
チンファ ユニバーシティ |
新規の抗TrkB抗体
|
EP3596116B1
(en)
|
2017-03-16 |
2023-09-06 |
Alpine Immune Sciences, Inc. |
Pd-l1 variant immunomodulatory proteins and uses thereof
|
CA3054068A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
JP2020511144A
(ja)
|
2017-03-16 |
2020-04-16 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Pd−l2バリアント免疫調節タンパク質及びその使用
|
JOP20180021A1
(ar)
|
2017-03-16 |
2019-01-30 |
Janssen Biotech Inc |
الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
|
KR20240150530A
(ko)
|
2017-03-22 |
2024-10-15 |
아센디스 파마 에이에스 |
히드로겔 가교된 히알루론산 전구약물 조성물 및 방법
|
TWI839327B
(zh)
|
2017-03-22 |
2024-04-21 |
美商建南德克公司 |
用於治療眼部病症之最佳化之抗體組合物
|
CN108623686A
(zh)
|
2017-03-25 |
2018-10-09 |
信达生物制药(苏州)有限公司 |
抗ox40抗体及其用途
|
CN110612309A
(zh)
|
2017-03-27 |
2019-12-24 |
细胞基因公司 |
用于降低免疫原性的方法和组合物
|
TW201900673A
(zh)
|
2017-03-27 |
2019-01-01 |
瑞士商赫孚孟拉羅股份公司 |
改良之抗原結合受體
|
WO2018183173A1
(en)
|
2017-03-27 |
2018-10-04 |
Boehringer Ingelheim International Gmbh |
Anti il-36r antibodies combination therapy
|
JP7196094B2
(ja)
|
2017-03-29 |
2022-12-26 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激tnf受容体のための二重特異性抗原結合分子
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
CN110382542B
(zh)
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
针对共刺激性tnf受体的双特异性抗原结合分子
|
MX2019011599A
(es)
|
2017-03-30 |
2019-12-19 |
Univ Queensland |
Moleculas quimericas y usos de las mismas.
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
JP7458188B2
(ja)
|
2017-03-31 |
2024-03-29 |
ブリストル-マイヤーズ スクイブ カンパニー |
腫瘍を処置する方法
|
WO2018178396A1
(en)
|
2017-03-31 |
2018-10-04 |
Genmab Holding B.V. |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
WO2018184965A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
WO2018184966A1
(en)
|
2017-04-03 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Antibodies binding to steap-1
|
AU2018249822A1
(en)
|
2017-04-03 |
2019-10-31 |
Coherus Biosciences Inc. |
PPArgamma agonist for treatment of progressive supranuclear palsy
|
US20200024351A1
(en)
|
2017-04-03 |
2020-01-23 |
Jounce Therapeutics, Inc. |
Compositions and Methods for the Treatment of Cancer
|
RS63663B1
(sr)
|
2017-04-03 |
2022-11-30 |
Hoffmann La Roche |
Imunokonjugati anti-pd-1 antitela sa mutantom il-2 ili sa il-15
|
RU2766234C2
(ru)
|
2017-04-04 |
2022-02-10 |
Ф. Хоффманн-Ля Рош Аг |
Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
|
KR102294136B1
(ko)
|
2017-04-05 |
2021-08-26 |
에프. 호프만-라 로슈 아게 |
항-lag3 항체
|
JP7315466B2
(ja)
|
2017-04-05 |
2023-07-26 |
アスチュート メディカル,インコーポレイテッド |
生体試料中において改善した性能を有する、timp2に関するアッセイ
|
CA3052532A1
(en)
|
2017-04-05 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specifically binding to pd1 and lag3
|
WO2018187791A1
(en)
|
2017-04-07 |
2018-10-11 |
Juno Therapeutics, Inc |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
CA3058477A1
(en)
|
2017-04-11 |
2018-10-18 |
Inhibrx, Inc. |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
CN108690138A
(zh)
*
|
2017-04-12 |
2018-10-23 |
鸿运华宁(杭州)生物医药有限公司 |
一种能与人cd19或cd20和人cd3结合的双特异性抗体及其应用
|
KR102629972B1
(ko)
|
2017-04-13 |
2024-01-29 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
CN110505883A
(zh)
|
2017-04-13 |
2019-11-26 |
豪夫迈·罗氏有限公司 |
供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂
|
AU2018250695A1
(en)
|
2017-04-14 |
2019-11-07 |
Kodiak Sciences Inc. |
Complement factor D antagonist antibodies and conjugates thereof
|
KR20200005540A
(ko)
|
2017-04-14 |
2020-01-15 |
제넨테크, 인크. |
암의 진단 및 치료 방법
|
RU2665790C1
(ru)
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело к pd-l1
|
AU2018254263B2
(en)
*
|
2017-04-19 |
2022-07-14 |
Apa- Advanced Technologies Ltd. |
Fusogenic liposomes, compositions, kits and use thereof for treating cancer
|
MA50958A
(fr)
|
2017-04-21 |
2020-10-14 |
Staten Biotechnology B V |
Anticorps anti-apoc3 et leurs méthodes d'utilisation
|
EP3624820A1
(en)
|
2017-04-21 |
2020-03-25 |
H. Hoffnabb-La Roche Ag |
Use of klk5 antagonists for treatment of a disease
|
AU2018258263A1
(en)
|
2017-04-24 |
2019-10-24 |
Genentech, Inc. |
ErbB2/Her2 mutations in the transmembrane or juxtamembrane domain
|
US11236151B2
(en)
|
2017-04-25 |
2022-02-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
|
WO2018200586A1
(en)
|
2017-04-26 |
2018-11-01 |
Eureka Therapeutics, Inc. |
Constructs specifically recognizing glypican 3 and uses thereof
|
US20230140818A1
(en)
|
2017-04-27 |
2023-05-04 |
The University Of Hong Kong |
Use of hcn inhibitors for treatment of cancer
|
EP3615572A1
(en)
|
2017-04-27 |
2020-03-04 |
Tesaro Inc. |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
US20200055948A1
(en)
|
2017-04-28 |
2020-02-20 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
US11021537B2
(en)
|
2017-05-01 |
2021-06-01 |
Agenus Inc. |
Anti-TIGIT antibodies and methods of use thereof
|
PE20200695A1
(es)
|
2017-05-02 |
2020-06-16 |
Prothena Biosciences Ltd |
Anticuerpos que reconocen tau
|
EP3618868A4
(en)
|
2017-05-05 |
2021-02-24 |
Allakos Inc. |
METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES
|
US11918650B2
(en)
|
2017-05-05 |
2024-03-05 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
CA3062418A1
(en)
|
2017-05-06 |
2018-11-15 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating eye disorders with aplnr antagonists and vegf inhibitors
|
EP3401328A1
(en)
|
2017-05-10 |
2018-11-14 |
Bayer Pharma Aktiengesellschaft |
One step antibody humanization by golden gate based germline framework region shuffling
|
WO2018209239A1
(en)
|
2017-05-11 |
2018-11-15 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
CA3063362A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
WO2018209298A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
TWI794230B
(zh)
|
2017-05-15 |
2023-03-01 |
日商第一三共股份有限公司 |
抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法
|
WO2018213097A1
(en)
|
2017-05-15 |
2018-11-22 |
University Of Rochester |
Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
|
BR112019023898A2
(pt)
|
2017-05-16 |
2020-06-09 |
Five Prime Therapeutics Inc |
método para tratamento de câncer gástrico, uso de um anticorpo e composição
|
CA3063324A1
(en)
|
2017-05-16 |
2018-11-22 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
JP7364471B2
(ja)
|
2017-05-18 |
2023-10-18 |
レゲネロン ファーマシューティカルス,インコーポレーテッド |
シクロデキストリンタンパク質薬物コンジュゲート
|
WO2018215535A1
(en)
|
2017-05-23 |
2018-11-29 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Novel cd73 antibody, preparation and uses thereof
|
EP3630292A2
(en)
|
2017-05-24 |
2020-04-08 |
Sutro Biopharma, Inc. |
Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
JP7366755B2
(ja)
|
2017-05-30 |
2023-10-23 |
ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ |
抗ダブルコルチン様キナーゼ1抗体および使用方法
|
EP3630834A1
(en)
|
2017-05-31 |
2020-04-08 |
STCube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
|
KR20200015602A
(ko)
|
2017-05-31 |
2020-02-12 |
주식회사 에스티큐브앤컴퍼니 |
Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
|
MX2019014265A
(es)
|
2017-06-01 |
2020-08-03 |
Compugen Ltd |
Tratamientos conjuntos triples con anticuerpos.
|
AU2018275359C1
(en)
|
2017-06-02 |
2022-02-03 |
Pfizer Inc. |
Antibodies specific for FLT3 and their uses
|
KR102692379B1
(ko)
|
2017-06-05 |
2024-08-05 |
얀센 바이오테크 인코포레이티드 |
Pd-1과 특이적으로 결합하는 항체 및 사용 방법
|
CN110997724A
(zh)
|
2017-06-06 |
2020-04-10 |
斯特库伯株式会社 |
使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
|
US10793634B2
(en)
|
2017-06-09 |
2020-10-06 |
Boehringer Ingelheim International Gmbh |
Anti-TrkB antibodies
|
US20210079057A1
(en)
|
2017-06-13 |
2021-03-18 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
JP7469225B2
(ja)
|
2017-06-15 |
2024-04-16 |
キャンサー アドヴァンシーズ インク. |
腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法
|
PE20200013A1
(es)
|
2017-06-20 |
2020-01-06 |
Amgen Inc |
Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
|
WO2018237006A1
(en)
|
2017-06-20 |
2018-12-27 |
Teneoone, Inc. |
ANTIBODIES ONLY TO HEAVY ANTI-BCMA CHAINS
|
IL271194B2
(en)
|
2017-06-20 |
2024-10-01 |
Teneobio Inc |
Anti-BCMA antibodies containing only heavy chains
|
TWI804499B
(zh)
|
2017-06-23 |
2023-06-11 |
美商維洛斯生物公司 |
Ror1抗體免疫接合物
|
WO2019005756A1
(en)
|
2017-06-28 |
2019-01-03 |
The Rockefeller University |
CONJUGATES AGONIST ANTIBODY ANTI-MERTK-MEDICINE
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
US11892457B2
(en)
|
2017-07-12 |
2024-02-06 |
The Johns Hopkins University |
Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
|
CR20200076A
(es)
|
2017-07-14 |
2020-06-10 |
Pfizer |
ANTICUERPOS CONTRA MAdCAM
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
|
US10894833B2
(en)
|
2017-07-20 |
2021-01-19 |
H. Lundbeck A/S |
Agents, uses and methods for treatment
|
WO2019018757A1
(en)
|
2017-07-21 |
2019-01-24 |
Genentech, Inc. |
THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
|
JP2020528061A
(ja)
|
2017-07-26 |
2020-09-17 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
BET阻害剤、Bcl−2阻害剤及び抗CD20抗体を用いた併用療法
|
US10961318B2
(en)
|
2017-07-26 |
2021-03-30 |
Forty Seven, Inc. |
Anti-SIRP-α antibodies and related methods
|
EP3658588A1
(en)
|
2017-07-26 |
2020-06-03 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
CN117050176A
(zh)
|
2017-07-31 |
2023-11-14 |
豪夫迈·罗氏有限公司 |
基于三维结构的人源化方法
|
CN110662765B
(zh)
|
2017-08-03 |
2023-09-29 |
艾利妥 |
抗cd33抗体及其使用方法
|
CA3071211A1
(en)
|
2017-08-04 |
2019-02-07 |
Genmab A/S |
Binding agents binding to pd-l1 and cd137 and use thereof
|
AU2018316343A1
(en)
|
2017-08-11 |
2020-02-13 |
Genentech, Inc. |
Anti-CD8 antibodies and uses thereof
|
EP3444275A1
(en)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoclonal antibody anti-fgfr4
|
CN110944667B
(zh)
|
2017-08-23 |
2024-08-27 |
第一三共株式会社 |
抗体-药物缀合物制剂及其冻干
|
WO2019046338A1
(en)
|
2017-08-28 |
2019-03-07 |
Angiex, Inc. |
ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE
|
KR102422860B1
(ko)
|
2017-08-31 |
2022-07-19 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트의 신규 제조 방법
|
JP7366745B2
(ja)
|
2017-08-31 |
2023-10-23 |
第一三共株式会社 |
抗体-薬物コンジュゲートの改良製造方法
|
MX2020002612A
(es)
|
2017-09-07 |
2020-07-13 |
Univ Res Inst Inc Augusta |
Anticuerpos de la proteina de muerte celular programada 1.
|
KR20200044094A
(ko)
|
2017-09-13 |
2020-04-28 |
테네오바이오, 인코포레이티드 |
엑토효소에 결합하는 중쇄 항체
|
WO2019055825A1
(en)
|
2017-09-15 |
2019-03-21 |
The Regents Of The University Of California |
INHIBITION OF AMINOACYLASE 3 (AA3) IN THE TREATMENT OF CANCER
|
EP3684814A1
(en)
|
2017-09-18 |
2020-07-29 |
Sutro Biopharma, Inc. |
Anti-folate receptor alpha antibody conjugates and their uses
|
WO2019059411A1
(en)
|
2017-09-20 |
2019-03-28 |
Chugai Seiyaku Kabushiki Kaisha |
DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
|
WO2019060713A1
(en)
|
2017-09-22 |
2019-03-28 |
Kite Pharma, Inc. |
ANTIGEN-BINDING MOLECULES AND METHODS OF USE THEREOF
|
CA3076313A1
(en)
|
2017-09-28 |
2019-04-04 |
Prothena Biosciences Limited |
Dosing regimes for treatment of synucleinopathies
|
US11364303B2
(en)
|
2017-09-29 |
2022-06-21 |
Pfizer Inc. |
Cysteine engineered antibody drug conjugates
|
IL301637B2
(en)
|
2017-09-29 |
2024-10-01 |
Daiichi Sankyo Co Ltd |
Conjugation of an antibody with a pyrrolobenzodiazepine derivative
|
UA128389C2
(uk)
|
2017-09-29 |
2024-07-03 |
Чугаі Сейяку Кабусікі Кайся |
Мультиспецифічна антигензв'язувальна молекула, яка має активність заміщувати кофакторну функцію фактора коагуляції крові viii (fviii), та фармацевтичний склад, який містить згадану молекулу як активний інгредієнт
|
EP3688029A1
(en)
|
2017-09-29 |
2020-08-05 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
US20200271657A1
(en)
|
2017-10-04 |
2020-08-27 |
Opko Pharmaceuticals, Llc |
Articles and methods directed to personalized therapy of cancer
|
KR20230020022A
(ko)
|
2017-10-10 |
2023-02-09 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Ctla-4 변이체 면역조절 단백질 및 이의 용도
|
CA3185107A1
(en)
|
2017-10-12 |
2019-04-18 |
Immunowake Inc. |
Vegfr-antibody light chain fusion protein
|
CN111630070B
(zh)
|
2017-10-13 |
2024-07-30 |
哈普恩治疗公司 |
三特异性蛋白质及使用方法
|
AU2018346955B2
(en)
|
2017-10-13 |
2024-08-29 |
Harpoon Therapeutics, Inc. |
B cell maturation antigen binding proteins
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
CN111247169A
(zh)
|
2017-10-15 |
2020-06-05 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
TW201925223A
(zh)
|
2017-10-18 |
2019-07-01 |
美商艾爾潘免疫科學有限公司 |
變異型icos 配位體免疫調節蛋白及相關組合物及方法
|
EP3697441B1
(en)
|
2017-10-20 |
2023-06-07 |
F. Hoffmann-La Roche AG |
Method for generating multispecific antibodies from monospecific antibodies
|
EP3700932A1
(en)
|
2017-10-27 |
2020-09-02 |
Kite Pharma, Inc. |
T cell receptor antigen binding molecules and methods of use thereof
|
BR112020007736A2
(pt)
|
2017-10-30 |
2020-10-20 |
F. Hoffmann-La Roche Ag |
composição e método de tratamento
|
CN111315772A
(zh)
|
2017-10-31 |
2020-06-19 |
斯塔顿生物技术有限公司 |
抗apoc3抗体及其使用方法
|
EP3704150A1
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
The compbody - a multivalent target binder
|
JP2021500902A
(ja)
|
2017-11-01 |
2021-01-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
新規tnfファミリーリガンド三量体含有抗原結合分子
|
US20210324108A1
(en)
|
2017-11-01 |
2021-10-21 |
Hoffmann-La Roche Inc. |
Bispecific 2+1 contorsbodies
|
JP7092881B2
(ja)
|
2017-11-01 |
2022-06-28 |
エフ.ホフマン-ラ ロシュ アーゲー |
TriFabコントースボディ
|
TW201930353A
(zh)
|
2017-11-01 |
2019-08-01 |
瑞士商赫孚孟拉羅股份公司 |
使用經靶向之ox40促效劑的組合療法
|
MX2020004567A
(es)
|
2017-11-06 |
2020-08-13 |
Genentech Inc |
Metodos diagnosticos y terapeuticos para el cancer.
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
JP7311425B2
(ja)
|
2017-11-08 |
2023-07-19 |
協和キリン株式会社 |
CD40とEpCAMに結合するバイスペシフィック抗体
|
CA3082383A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
KR20200087176A
(ko)
|
2017-11-14 |
2020-07-20 |
아르셀엑스, 인크. |
다기능성 면역 세포 요법
|
US12116417B2
(en)
|
2017-11-14 |
2024-10-15 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
CA3082643A1
(en)
|
2017-11-14 |
2019-05-23 |
The Schepens Eye Research Institute, Inc. |
Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
|
JP7285267B2
(ja)
|
2017-11-14 |
2023-06-01 |
アーセルクス インコーポレイテッド |
Dドメイン含有ポリペプチドおよびその使用
|
EP3717516A1
(en)
|
2017-12-01 |
2020-10-07 |
Pfizer Inc |
Anti-cxcr5 antibodies and compositions and uses thereof
|
CA3084495A1
(en)
|
2017-12-01 |
2019-06-06 |
Seattle Genetics, Inc. |
Humanized anti-liv1 antibodies for the treatment of breast cancer
|
KR20200091901A
(ko)
|
2017-12-01 |
2020-07-31 |
시애틀 지네틱스, 인크. |
암을 치료하기 위한 cd47 항체 및 이의 용도
|
AU2018383679A1
(en)
|
2017-12-11 |
2020-05-07 |
Amgen Inc. |
Continuous manufacturing process for bispecific antibody products
|
KR20200098590A
(ko)
|
2017-12-12 |
2020-08-20 |
마크로제닉스, 인크. |
이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
EA202091509A1
(ru)
|
2017-12-19 |
2020-09-22 |
Акуос, Инк. |
Aav-опосредованная доставка терапевтических антител во внутреннее ухо
|
CN117924477A
(zh)
|
2017-12-19 |
2024-04-26 |
洛克菲勒大学 |
具有改进的效应子功能的人IgG Fc结构域变体
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
SG11202005632SA
(en)
|
2017-12-21 |
2020-07-29 |
Hoffmann La Roche |
Antibodies binding to hla-a2/wt1
|
AU2018389111A1
(en)
|
2017-12-22 |
2020-06-18 |
Jounce Therapeutics, Inc. |
Antibodies to LILRB2
|
WO2019126472A1
(en)
|
2017-12-22 |
2019-06-27 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
WO2019126756A1
(en)
|
2017-12-22 |
2019-06-27 |
Teneobio, Inc. |
Heavy chain antibodies binding to cd22
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
CN115925943A
(zh)
|
2017-12-27 |
2023-04-07 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
WO2019129136A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
SG11202006042SA
(en)
|
2017-12-27 |
2020-07-29 |
Teneobio Inc |
Cd3-delta/epsilon heterodimer specific antibodies
|
KR20200104333A
(ko)
|
2017-12-28 |
2020-09-03 |
난징 레전드 바이오테크 씨오., 엘티디. |
Tigit에 대한 단일-도메인 항체 및 이의 변이체
|
CA3078849A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against pd-l1
|
EP3732196A4
(en)
|
2017-12-28 |
2022-01-05 |
Astute Medical, Inc. |
ANTIBODIES AND DOSAGES FOR CCL14
|
WO2019131988A1
(en)
|
2017-12-28 |
2019-07-04 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
CN111511400A
(zh)
|
2017-12-29 |
2020-08-07 |
豪夫迈·罗氏有限公司 |
抗vegf抗体及其使用方法
|
EP3732193A1
(en)
|
2017-12-29 |
2020-11-04 |
Alector LLC |
Anti-tmem106b antibodies and methods of use thereof
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
WO2019136179A1
(en)
|
2018-01-03 |
2019-07-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
WO2019134981A1
(en)
|
2018-01-05 |
2019-07-11 |
Ac Immune Sa |
Misfolded tdp-43 binding molecules
|
KR20200108002A
(ko)
|
2018-01-08 |
2020-09-16 |
리제너론 파마슈티칼스 인코포레이티드 |
스테로이드 및 이의 항체-접합체
|
CN111699200B
(zh)
|
2018-01-15 |
2023-05-26 |
南京传奇生物科技有限公司 |
针对pd-1的单域抗体和其变体
|
EP3740505A1
(en)
|
2018-01-16 |
2020-11-25 |
Lakepharma Inc. |
Bispecific antibody that binds cd3 and another target
|
US20190225689A1
(en)
|
2018-01-22 |
2019-07-25 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-pd-1 antibodies
|
US11402380B2
(en)
|
2018-01-25 |
2022-08-02 |
Emory University |
Assays for detecting antibodies capable of mediating antibody-dependent cell-mediated cytotoxicity
|
JP7542257B2
(ja)
|
2018-01-25 |
2024-08-30 |
エイシーエム バイオラブズ プライベート リミテッド |
可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法
|
JP7349995B2
(ja)
|
2018-01-26 |
2023-09-25 |
ジェネンテック, インコーポレイテッド |
IL-22 Fc融合タンパク質及び使用方法
|
PL3743088T3
(pl)
|
2018-01-26 |
2023-03-20 |
F. Hoffmann-La Roche Ag |
Kompozycje i sposoby stosowania il-22 fc
|
EP3746476A1
(en)
|
2018-01-31 |
2020-12-09 |
Alector LLC |
Anti-ms4a4a antibodies and methods of use thereof
|
BR112020015641A2
(pt)
|
2018-02-01 |
2021-01-05 |
Pfizer Inc. |
Anticorpos específicos para cd70 e seus usos
|
WO2019152742A1
(en)
|
2018-02-01 |
2019-08-08 |
Pfizer Inc. |
Chimeric antigen receptors targeting cd70
|
WO2019149269A1
(zh)
|
2018-02-01 |
2019-08-08 |
信达生物制药(苏州)有限公司 |
全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用
|
US11884733B2
(en)
|
2018-02-08 |
2024-01-30 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the NKG2D receptor
|
MX2020008289A
(es)
|
2018-02-08 |
2020-09-25 |
Genentech Inc |
Moleculas biespecificas de union al antigeno y metodos de uso.
|
JP7407118B2
(ja)
|
2018-02-08 |
2023-12-28 |
アムジェン インコーポレイテッド |
低pH医薬抗体製剤
|
CA3226165A1
(en)
|
2018-02-09 |
2019-08-15 |
Genentech, Inc. |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
MX2020007697A
(es)
|
2018-02-09 |
2020-09-14 |
Genmab As |
Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra grupo de diferenciacion 3 (cd3) y grupo de diferenciacion 20 (cd20) y sus usos.
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
US20200377609A1
(en)
|
2018-02-14 |
2020-12-03 |
Kite Pharma, Inc. |
Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule
|
JP7350756B2
(ja)
|
2018-02-14 |
2023-09-26 |
アバ セラピューティクス アーゲー |
抗ヒトpd-l2抗体
|
WO2019160904A1
(en)
|
2018-02-15 |
2019-08-22 |
Macrogenics, Inc. |
Variant cd3-binding domains and their use in combination therapies for the treatment of disease
|
RU2020128111A
(ru)
|
2018-02-21 |
2022-03-21 |
Дженентек, Инк. |
ВЕДЕНИЕ БЕЛКОВ СЛИЯНИЯ IL-22 Fc ДЛЯ ЛЕЧЕНИЯ
|
CN111727058A
(zh)
|
2018-02-23 |
2020-09-29 |
卡瑟里克斯私人有限公司 |
靶向tag-72的t细胞疾病治疗
|
JP7391027B2
(ja)
|
2018-02-26 |
2023-12-04 |
ジェネンテック, インコーポレイテッド |
抗tigit及び抗pd-l1アンタゴニスト抗体による治療のための投薬
|
CN112384515A
(zh)
|
2018-02-27 |
2021-02-19 |
因赛特公司 |
作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
|
US11059876B2
(en)
|
2018-02-28 |
2021-07-13 |
Pfizer Inc. |
IL-15 variants and uses thereof
|
WO2019169229A1
(en)
|
2018-03-01 |
2019-09-06 |
Nextcure, Inc. |
Klrg1 binding compositions and methods of use thereof
|
EA202092064A1
(ru)
|
2018-03-01 |
2020-12-21 |
Ридженерон Фармасьютикалз, Инк. |
Способы изменения состава тела
|
US12071476B2
(en)
|
2018-03-02 |
2024-08-27 |
Kodiak Sciences Inc. |
IL-6 antibodies and fusion constructs and conjugates thereof
|
EP3762426A2
(en)
|
2018-03-06 |
2021-01-13 |
Imcare Biotech, LLC |
Serine protease inhibitor kazal (spik) compositions and methods
|
AU2019233523A1
(en)
|
2018-03-12 |
2020-10-01 |
Genmab A/S |
Antibodies
|
BR112020017701A2
(pt)
|
2018-03-12 |
2020-12-29 |
Zoetis Services Llc |
Anticorpos anti-ngf e métodos dos mesmos
|
WO2019173911A1
(en)
|
2018-03-13 |
2019-09-19 |
Zymeworks Inc. |
Anti-her2 biparatopic antibody-drug conjugates and methods of use
|
TWI841551B
(zh)
|
2018-03-13 |
2024-05-11 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
BR112020015568A2
(pt)
|
2018-03-13 |
2020-12-29 |
F. Hoffmann-La Roche Ag |
Agonista de 4-1bb (cd137), produto farmacêutico, composição farmacêutica, uso de uma combinação de um agonista de 4-1bb e método para tratar ou retardar a progressão do câncer
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
EP3765515A2
(en)
|
2018-03-14 |
2021-01-20 |
Boehringer Ingelheim International GmbH |
Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
|
CA3093729A1
(en)
|
2018-03-15 |
2019-09-19 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
|
CA3094329A1
(en)
|
2018-03-19 |
2020-02-20 |
Multivir Inc. |
Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
|
GB201804701D0
(en)
|
2018-03-23 |
2018-05-09 |
Gammadelta Therapeutics Ltd |
Lymphocytes expressing heterologous targeting constructs
|
US11242393B2
(en)
|
2018-03-23 |
2022-02-08 |
Bristol-Myers Squibb Company |
Antibodies against MICA and/or MICB and uses thereof
|
US20210048437A1
(en)
|
2018-03-26 |
2021-02-18 |
Glycanostiion , s.r.o. |
Means and methods for glycoprofiling of a protein
|
WO2019190969A1
(en)
|
2018-03-26 |
2019-10-03 |
Sutro Biopharma, Inc. |
Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
|
EP3774863A1
(en)
|
2018-03-29 |
2021-02-17 |
Pfizer Inc |
Lfa3 variants and compositions and uses thereof
|
JP2021519073A
(ja)
|
2018-03-29 |
2021-08-10 |
ジェネンテック, インコーポレイテッド |
哺乳動物細胞におけるラクトジェニック活性の制御
|
US11958903B2
(en)
|
2018-03-30 |
2024-04-16 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
EP3774911A1
(en)
|
2018-03-30 |
2021-02-17 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
WO2019192432A1
(zh)
|
2018-04-02 |
2019-10-10 |
上海博威生物医药有限公司 |
结合淋巴细胞活化基因-3(lag-3)的抗体及其用途
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
WO2019195561A2
(en)
|
2018-04-06 |
2019-10-10 |
BioLegend, Inc. |
Anti-tetraspanin 33 agents and compositions and methods for making and using the same
|
EP3552631A1
(en)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antibody-drug conjugates and their uses for the treatment of cancer
|
US10640576B2
(en)
|
2018-04-10 |
2020-05-05 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
CN112218686A
(zh)
|
2018-04-11 |
2021-01-12 |
印希比股份有限公司 |
具有受限cd3结合的多特异性多肽构建体以及相关方法和用途
|
KR20210021287A
(ko)
|
2018-04-12 |
2021-02-25 |
메디뮨 리미티드 |
암을 치료하는 데 사용하기 위한 lif 억제제와 pd-1 축 억제제의 조합
|
PE20210652A1
(es)
|
2018-04-13 |
2021-03-26 |
Hoffmann La Roche |
Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl
|
CN113384711A
(zh)
|
2018-04-13 |
2021-09-14 |
基因泰克公司 |
稳定的抗cd79b免疫缀合物制剂
|
CN110612117B
(zh)
|
2018-04-17 |
2024-04-12 |
分子模板公司 |
包含去免疫化的志贺毒素a亚基支架的her2靶向分子
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
MX2020010910A
(es)
|
2018-04-18 |
2021-02-09 |
Xencor Inc |
Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
IL−15/IL−15RA Fc融合タンパク質およびTIM−3抗原結合ドメインを含む、TIM−3標的化ヘテロ二量体融合タンパク質
|
US11471506B2
(en)
|
2018-04-23 |
2022-10-18 |
Emory University |
VIP antagonists and uses in treating cancer
|
MA52366A
(fr)
|
2018-04-25 |
2021-03-03 |
Prometheus Biosciences Inc |
Anticorps anti-tl1a optimisés
|
EP3784274A1
(en)
|
2018-04-27 |
2021-03-03 |
Fondazione Ebri Rita Levi-Montalcini |
Antibody directed against a tau-derived neurotoxic peptide and uses thereof
|
EP3560945A1
(en)
|
2018-04-27 |
2019-10-30 |
F. Hoffmann-La Roche AG |
Methods for purification of polypeptides using polysorbates
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
JP7431750B2
(ja)
|
2018-04-30 |
2024-02-15 |
武田薬品工業株式会社 |
カンナビノイド受容体1型(cb1)結合性タンパク質及びその使用
|
US12037411B2
(en)
|
2018-04-30 |
2024-07-16 |
Regeneron Pharmaceuticals, Inc. |
Antibodies, and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates, and uses thereof
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
WO2019213416A1
(en)
|
2018-05-02 |
2019-11-07 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
JP7402541B2
(ja)
|
2018-05-03 |
2023-12-21 |
ユニバーシティ オブ ロチェスター |
抗インフルエンザノイラミニダーゼモノクローナル抗体およびその使用
|
EP3814379A4
(en)
|
2018-05-07 |
2022-03-30 |
Genmab A/S |
METHOD OF TREATMENT OF CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
|
EA202092136A1
(ru)
|
2018-05-07 |
2021-03-22 |
Генмаб А/С |
Способы лечения рака с помощью комбинации антитела к pd-1 и конъюгата антитела к тканевому фактору и лекарственного средства
|
US11155638B2
(en)
|
2018-05-08 |
2021-10-26 |
Rhode Island Hospital |
Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
|
KR20210009308A
(ko)
|
2018-05-09 |
2021-01-26 |
이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. |
인간 넥틴4에 특이적인 항체
|
US11377502B2
(en)
|
2018-05-09 |
2022-07-05 |
Regeneron Pharmaceuticals, Inc. |
Anti-MSR1 antibodies and methods of use thereof
|
JP7530638B2
(ja)
|
2018-05-10 |
2024-08-08 |
ニューラクル サイエンス カンパニー リミテッド |
配列類似性19、メンバーa5抗体を有する抗ファミリー及びその使用方法
|
MX2020012081A
(es)
|
2018-05-11 |
2021-04-28 |
Wuxi Biologics Shanghai Co Ltd |
Anticuerpos totalmente humanos contra ox40, metodo para preparar los mismos y su uso.
|
AU2019269131B2
(en)
|
2018-05-14 |
2024-02-22 |
Fundació Privada Institució Catalana De Recerca I Estudis Avançats |
Antibodies against LIF and dosage forms thereof
|
JP7477462B2
(ja)
|
2018-05-17 |
2024-05-01 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗cd63抗体、コンジュゲート、及び、それらの使用
|
TWI825098B
(zh)
|
2018-05-18 |
2023-12-11 |
德商葛萊高托普公司 |
抗muc1抗體
|
JP7391046B2
(ja)
|
2018-05-18 |
2023-12-04 |
インサイト・コーポレイション |
A2a/a2b阻害剤としての縮合ピリミジン誘導体
|
EP3797118A4
(en)
|
2018-05-22 |
2022-06-29 |
Beth Israel Deaconess Medical Center, Inc. |
Antibody therapies for human immunodeficiency virus (hiv)
|
JP7384835B2
(ja)
|
2018-05-23 |
2023-11-21 |
ファイザー・インク |
Cd3に特異的な抗体及びその使用
|
MX2020012607A
(es)
|
2018-05-23 |
2021-01-29 |
Pfizer |
Anticuerpos especificos para gucy2c y sus usos.
|
EA202092839A1
(ru)
|
2018-05-24 |
2021-02-12 |
Янссен Байотек, Инк. |
Агенты, связывающиеся с psma, и виды их применения
|
PE20210132A1
(es)
|
2018-05-24 |
2021-01-19 |
Janssen Biotech Inc |
Anticuerpos anti-cd3 y usos de estos
|
AU2019274652A1
(en)
|
2018-05-24 |
2020-11-26 |
Janssen Biotech, Inc. |
Monospecific and multispecific anti-TMEFF2 antibodies and there uses
|
US20210213063A1
(en)
|
2018-05-25 |
2021-07-15 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
CN112218893A
(zh)
|
2018-05-25 |
2021-01-12 |
艾利妥 |
抗-sirpa抗体及其使用方法
|
IL278988B2
(en)
|
2018-05-28 |
2024-10-01 |
Daiichi Sankyo Co Ltd |
Anti-HER2 drug and antibody conjugates for use in the treatment of cancer with a HER2 mutation
|
AU2019275737A1
(en)
|
2018-06-01 |
2021-01-21 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and uses thereof for treating disease or condition
|
CN112384531B
(zh)
|
2018-06-01 |
2024-05-14 |
诺华股份有限公司 |
针对bcma的结合分子及其用途
|
CN113039202A
(zh)
|
2018-06-01 |
2021-06-25 |
康姆普根有限公司 |
抗pvrig/抗tigit双特异性抗体和使用方法
|
EP3801632A1
(en)
|
2018-06-01 |
2021-04-14 |
Eisai R&D Management Co., Ltd. |
Splicing modulator antibody-drug conjugates and methods of use
|
EP3800999A4
(en)
|
2018-06-04 |
2022-06-01 |
Biogen MA Inc. |
ANTI-VLA-4 ANTIBODIES WITH REDUCED EFFECTOR FUNCTION
|
US20210238308A1
(en)
|
2018-06-04 |
2021-08-05 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule showing changed half-life in cytoplasm
|
SG11202011830SA
(en)
|
2018-06-13 |
2020-12-30 |
Novartis Ag |
Bcma chimeric antigen receptors and uses thereof
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
KR20210022065A
(ko)
|
2018-06-18 |
2021-03-02 |
메디뮨 리미티드 |
암을 치료하는 데 사용하기 위한 lif 억제제와 백금-기반 항신생물제의 조합
|
AU2019288136A1
(en)
|
2018-06-18 |
2021-01-07 |
Eureka Therapeutics, Inc. |
Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
|
EP3806889A4
(en)
|
2018-06-18 |
2022-07-13 |
Anwita Biosciences, Inc. |
CYTOKINE-BASED FUSION PROTEINS AND THEIR USES
|
TW202423480A
(zh)
|
2018-06-20 |
2024-06-16 |
美商英塞特公司 |
抗pd-1抗體及其用途
|
US11548947B2
(en)
|
2018-06-21 |
2023-01-10 |
Regeneron Pharmaceuticals, Inc. |
Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof
|
WO2019243636A1
(en)
|
2018-06-22 |
2019-12-26 |
Genmab Holding B.V. |
Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
|
US20210269509A1
(en)
|
2018-06-22 |
2021-09-02 |
Genmab A/S |
Method for producing a controlled mixture of two or more different antibodies
|
MA52968A
(fr)
|
2018-06-23 |
2021-04-28 |
Hoffmann La Roche |
Méthodes de traitement du cancer du poumon à l'aide d'un antagoniste de liaison à l'axe pd-1, d'un agent de platine et d'un inhibiteur de la topoisomérase ii
|
US11203645B2
(en)
|
2018-06-27 |
2021-12-21 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
TWI832871B
(zh)
|
2018-06-29 |
2024-02-21 |
美商英塞特公司 |
Axl/mer 抑制劑之調配物
|
CN112384532A
(zh)
|
2018-06-29 |
2021-02-19 |
艾利妥 |
抗SIRP-β1抗体及其使用方法
|
CA3101469A1
(en)
|
2018-06-29 |
2020-01-02 |
Boehringer Ingelheim International Gmbh |
Anti-cd40 antibodies for use in treating autoimmune disease
|
WO2020003210A1
(en)
|
2018-06-29 |
2020-01-02 |
Kangwon National University University-Industry Cooperation Foundation |
Anti-l1cam antibodies and uses thereof
|
AU2019299357A1
(en)
|
2018-07-02 |
2021-01-14 |
Amgen Inc. |
Anti-steap1 antigen-binding protein
|
TW202035447A
(zh)
|
2018-07-04 |
2020-10-01 |
瑞士商赫孚孟拉羅股份公司 |
新穎雙特異性促效性4-1bb抗原結合分子
|
EP3818063A1
(en)
|
2018-07-05 |
2021-05-12 |
Incyte Corporation |
Fused pyrazine derivatives as a2a / a2b inhibitors
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
US11396546B2
(en)
|
2018-07-13 |
2022-07-26 |
Alector Llc |
Anti-Sortilin antibodies and methods of use thereof
|
WO2020018556A1
(en)
|
2018-07-16 |
2020-01-23 |
Amgen Inc. |
Method of treating multiple myeloma
|
EP3823611A1
(en)
|
2018-07-18 |
2021-05-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAx抗-CD3抗體及其用途
|
US11214619B2
(en)
|
2018-07-20 |
2022-01-04 |
Surface Oncology, Inc. |
Anti-CD112R compositions and methods
|
SG11202011597RA
(en)
|
2018-07-20 |
2020-12-30 |
Teneobio Inc |
Heavy chain antibodies binding to cd19
|
BR112021000934A2
(pt)
|
2018-07-20 |
2021-04-27 |
Pierre Fabre Medicament |
receptor para vista
|
TW202035451A
(zh)
|
2018-07-24 |
2020-10-01 |
美商英伊布里克斯公司 |
含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
|
EP3828206A4
(en)
|
2018-07-25 |
2022-04-20 |
Daiichi Sankyo Company, Limited |
METHOD OF PREPARING AN ANTIBODY DRUG CONJUGATE
|
CA3107732A1
(en)
|
2018-07-27 |
2020-01-30 |
Daiichi Sankyo Company, Limited |
Protein recognizing drug moiety of antibody-drug conjugate
|
EP3830121A1
(en)
|
2018-07-30 |
2021-06-09 |
Amgen Research (Munich) GmbH |
Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
|
AR117628A1
(es)
|
2018-07-31 |
2021-08-18 |
Amgen Inc |
Formulaciones y composiciones farmacéuticas que comprenden una proteína de unión a antígeno enmascarada
|
BR112021001509A2
(pt)
|
2018-07-31 |
2021-04-27 |
Daiichi Sankyo Company, Limited |
agente terapêutico para um tumor de cérebro metastásico
|
HRP20240823T1
(hr)
|
2018-08-01 |
2024-09-27 |
Chugai Seiyaku Kabushiki Kaisha |
Farmaceutski pripravak, namijenjen upotrebi u liječenju ili sprječavanju bolesti povezane s c5 i postupak liječenja ili sprječavanja bolesti povezane s c5
|
CN110790840A
(zh)
|
2018-08-01 |
2020-02-14 |
三生国健药业(上海)股份有限公司 |
结合人her2的抗体、其制备方法和用途
|
UY38326A
(es)
|
2018-08-03 |
2020-01-31 |
Amgen Inc |
Constructos de anticuerpos para cldn18.2 y cd3
|
CA3106829A1
(en)
|
2018-08-03 |
2020-02-06 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing two antigen-binding domains that are linked to each other
|
TW202019487A
(zh)
|
2018-08-06 |
2020-06-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物及微管蛋白抑制劑之組合
|
SG11202100756RA
(en)
|
2018-08-10 |
2021-02-25 |
Genentech Inc |
Cell culture strategies for modulating protein glycosylation
|
US20210324099A1
(en)
|
2018-08-10 |
2021-10-21 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-cd137 antigen-binding molecule and utilization thereof
|
CN112601761A
(zh)
|
2018-08-13 |
2021-04-02 |
印希比股份有限公司 |
结合ox40的多肽及其用途
|
CN113166241A
(zh)
|
2018-08-16 |
2021-07-23 |
约翰霍普金斯大学 |
人类znt8抗体
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商23與我有限公司 |
抗il1rap抗體及其使用方法
|
US20210340628A1
(en)
|
2018-08-23 |
2021-11-04 |
Daiichi Sankyo Company, Limited |
Sensitivity marker for antibody-drug conjugate
|
CA3109513A1
(en)
|
2018-08-23 |
2020-02-27 |
Regeneron Pharmaceuticals, Inc. |
Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof
|
HRP20240821T1
(hr)
|
2018-08-27 |
2024-09-27 |
Affimed Gmbh |
Stanice nk čuvane zamrzavanjem, koje su prethodno ubačene uz protutijelni konstrukt
|
WO2020047176A1
(en)
|
2018-08-28 |
2020-03-05 |
Ambrx, Inc. |
Anti-cd3 antibody folate bioconjugates and their uses
|
CN113056304A
(zh)
|
2018-08-30 |
2021-06-29 |
戴埃克斯有限公司 |
用于治疗遗传性血管性水肿发作的血浆激肽释放酶抑制剂及其用途
|
US20210253666A1
(en)
|
2018-08-30 |
2021-08-19 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
JP2021535142A
(ja)
|
2018-08-31 |
2021-12-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
Cd3/c20二重特異性抗体のサイトカイン放出症候群を軽減する投与戦略
|
US20210317208A1
(en)
|
2018-08-31 |
2021-10-14 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
US20220008549A1
(en)
|
2018-09-06 |
2022-01-13 |
Daiichi Sankyo Company, Limited |
Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
|
SG11202100888WA
(en)
|
2018-09-07 |
2021-02-25 |
Pfizer |
Anti-avb8 antibodies and compositions and uses thereof
|
CN112789293B
(zh)
|
2018-09-10 |
2024-05-10 |
南京传奇生物科技有限公司 |
针对cll1的单结构域抗体及其构建体
|
EP3623383A1
(en)
|
2018-09-11 |
2020-03-18 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Improved bispecific flt3xcd3 antigen binding proteins
|
MX2021002749A
(es)
|
2018-09-11 |
2021-07-16 |
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts |
Proteínas de unión al antígeno anti-flt3 mejoradas.
|
EP4268831A3
(en)
|
2018-09-12 |
2024-05-22 |
Fred Hutchinson Cancer Center |
Reducing cd33 expression to selectively protect therapeutic cells
|
WO2020053325A1
(en)
|
2018-09-12 |
2020-03-19 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
|
JP2022500454A
(ja)
|
2018-09-17 |
2022-01-04 |
ストロ バイオファーマ インコーポレーテッド |
抗葉酸受容体抗体コンジュゲートによる併用療法
|
CA3117001C
(en)
|
2018-09-17 |
2023-09-19 |
Biocontac Co., Ltd. |
Antibody for specifically binding to lysyl-trna synthetase n-terminal domain exposed to extracellular membrane
|
EP3853252A1
(en)
|
2018-09-18 |
2021-07-28 |
Merrimack Pharmaceuticals, Inc. |
Anti-tnfr2 antibodies and uses thereof
|
CN113396160A
(zh)
|
2018-09-19 |
2021-09-14 |
国家医疗保健研究所 |
治疗对免疫检查点疗法具有抗性的癌症的方法和药物组合物
|
AU2019345151A1
(en)
|
2018-09-19 |
2021-04-29 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant CD80 fusion proteins and related constructs
|
WO2020061060A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
CN112912109A
(zh)
|
2018-09-20 |
2021-06-04 |
第一三共株式会社 |
通过施用抗her3抗体-药物缀合物治疗her3-突变的癌症
|
AU2019342133A1
(en)
|
2018-09-21 |
2021-04-22 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
AU2019343952A1
(en)
*
|
2018-09-21 |
2021-04-22 |
Mucommune, Llc |
Synthetic binding agents for limiting permeation through mucus
|
US20210355215A1
(en)
|
2018-09-21 |
2021-11-18 |
Teneobio, Inc. |
Methods for purifying heterodimeric, multispecific antibodies
|
EP3626265A1
(en)
|
2018-09-21 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human cd45rc antibodies and uses thereof
|
US10894824B2
(en)
|
2018-09-24 |
2021-01-19 |
Aerpio Pharmaceuticals, Inc. |
Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
|
IL281683B2
(en)
|
2018-09-25 |
2023-04-01 |
Harpoon Therapeutics Inc |
dll3 binding proteins and methods of use
|
EP3856343A1
(en)
|
2018-09-25 |
2021-08-04 |
Biolegend, Inc. |
Anti-tlr9 agents and compositions and methods for making and using the same
|
KR20210069058A
(ko)
|
2018-09-26 |
2021-06-10 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
항-ox40 항체, 이의 항원-결합 단편 및 약학적 용도
|
JP2022502052A
(ja)
|
2018-09-27 |
2022-01-11 |
ティゾナ セラピューティクス |
抗hla−g抗体、抗hla−g抗体を含む組成物、および抗hla−g抗体を使用する方法
|
US20210380675A1
(en)
|
2018-09-28 |
2021-12-09 |
Kyowa Kirin Co., Ltd. |
Il-36 antibodies and uses thereof
|
AR116548A1
(es)
|
2018-09-28 |
2021-05-19 |
Amgen Inc |
Anticuerpos contra bcma soluble
|
WO2020069409A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
WO2020069405A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
MA53806A
(fr)
|
2018-10-01 |
2022-01-05 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène comprenant un clone anti-fap 212
|
JP2022511396A
(ja)
|
2018-10-01 |
2022-01-31 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Cd40への三価結合を伴う二重特異性抗原結合分子
|
MA53811A
(fr)
|
2018-10-03 |
2022-03-16 |
Staten Biotechnology B V |
Anticorps spécifiques à l'apoc3 humaine et du cynomolgus et procédés pour leur utilisation
|
US11358999B2
(en)
|
2018-10-03 |
2022-06-14 |
Xencor, Inc. |
IL-12 heterodimeric Fc-fusion proteins
|
JP7522106B2
(ja)
|
2018-10-04 |
2024-07-24 |
ジェンマブ ホールディング ビー.ブイ. |
二重特異性抗cd37抗体を含む医薬組成物
|
BR112021005204A2
(pt)
|
2018-10-05 |
2021-06-08 |
Five Prime Therapeutics, Inc. |
formulações farmacêuticas e método para tratar um tumor sólido
|
CA3113306A1
(en)
|
2018-10-08 |
2020-04-16 |
Universitat Zurich |
Her2-binding tetrameric polypeptides
|
TW202028244A
(zh)
|
2018-10-09 |
2020-08-01 |
美商建南德克公司 |
用於確定突觸形成之方法及系統
|
TW202028245A
(zh)
|
2018-10-11 |
2020-08-01 |
美商英伊布里克斯公司 |
Dll3單域抗體及其治療性組合物
|
TW202021986A
(zh)
|
2018-10-11 |
2020-06-16 |
美商英伊布里克斯公司 |
5t4單域抗體及其治療性組合物
|
AU2019356564A1
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
AU2019356573A1
(en)
|
2018-10-11 |
2021-05-27 |
Inhibrx Biosciences, Inc. |
PD-1 single domain antibodies and therapeutic compositions thereof
|
WO2020076970A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
PL3856774T3
(pl)
|
2018-10-15 |
2023-03-06 |
F. Hoffmann-La Roche Ag |
Sposoby leczenia resztkowego nowotworu złośliwego piersi trastuzumabem emtanzyną
|
CN113196061A
(zh)
|
2018-10-18 |
2021-07-30 |
豪夫迈·罗氏有限公司 |
肉瘤样肾癌的诊断和治疗方法
|
MA53933A
(fr)
|
2018-10-21 |
2021-08-25 |
Slsg Ltd Llc |
Poly-immunothérapie pour le traitement du cancer du sein triple-négatif
|
AU2019365238A1
(en)
|
2018-10-24 |
2021-05-13 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
WO2020086408A1
(en)
|
2018-10-26 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A high-yield perfusion-based transient gene expression bioprocess
|
JP2022505445A
(ja)
|
2018-10-26 |
2022-01-14 |
テネオバイオ, インコーポレイテッド |
Cd38に結合する重鎖抗体
|
US20220170097A1
(en)
|
2018-10-29 |
2022-06-02 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法
|
CA3117856A1
(en)
|
2018-10-31 |
2020-05-07 |
Bayer Aktiengesellschaft |
Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
|
RU2724469C2
(ru)
|
2018-10-31 |
2020-06-23 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с cd20
|
CN113260626B
(zh)
|
2018-11-05 |
2024-09-13 |
豪夫迈·罗氏有限公司 |
在原核宿主细胞中产生双链蛋白质的方法
|
JP2022512860A
(ja)
|
2018-11-06 |
2022-02-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
白血病幹細胞を根絶することによる急性骨髄性白血病の治療のための方法および医薬組成物
|
MX2021005085A
(es)
|
2018-11-06 |
2021-11-04 |
Genmab As |
Formulacion de anticuerpo.
|
HU231514B1
(hu)
|
2018-11-07 |
2024-07-28 |
Richter Gedeon Nyrt. |
Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
|
BR112021009275A2
(pt)
|
2018-11-15 |
2022-01-04 |
Byondis Bv |
Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira.
|
EP3880714A4
(en)
|
2018-11-16 |
2022-07-20 |
Memorial Sloan Kettering Cancer Center |
ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF
|
KR20210116437A
(ko)
|
2018-11-20 |
2021-09-27 |
코넬 유니버시티 |
방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
|
WO2020104705A2
(en)
|
2018-11-23 |
2020-05-28 |
Katholieke Universiteit Leuven |
Predicting a treatment response in inflammatory bowel disease
|
MX2021006134A
(es)
|
2018-11-26 |
2021-06-23 |
Forty Seven Inc |
Anticuerpos humanizados contra c-kit.
|
AU2019390394B2
(en)
|
2018-11-28 |
2023-11-30 |
Forty Seven, Inc. |
Genetically modified HSPCs resistant to ablation regime
|
CA3120868A1
(en)
|
2018-11-30 |
2020-06-04 |
Alpine Immune Sciences, Inc. |
Cd86 variant immunomodulatory proteins and uses thereof
|
EP3891186A1
(en)
|
2018-12-05 |
2021-10-13 |
MorphoSys AG |
Multispecific antigen-binding molecules
|
CA3119798A1
(en)
|
2018-12-06 |
2020-06-11 |
Genentech, Inc. |
Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
|
US20200207812A1
(en)
|
2018-12-07 |
2020-07-02 |
Coherus Biosciences, Inc. |
Methods for producing recombinant proteins
|
US20220026445A1
(en)
|
2018-12-07 |
2022-01-27 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
CN113227119A
(zh)
|
2018-12-10 |
2021-08-06 |
基因泰克公司 |
用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
|
KR20210102341A
(ko)
|
2018-12-11 |
2021-08-19 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 컨쥬게이트와 parp 저해제의 조합
|
CN113271981A
(zh)
|
2018-12-13 |
2021-08-17 |
卫材R&D管理有限公司 |
荷伯希二烯抗体-药物缀合物及使用方法
|
US20220064260A1
(en)
|
2018-12-14 |
2022-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
|
JP2022513228A
(ja)
|
2018-12-14 |
2022-02-07 |
ベーリンガー・インゲルハイム・イオ・カナダ・インコーポレイテッド |
抗ペリオスチン抗体及びその使用
|
EP3669890A1
(en)
|
2018-12-18 |
2020-06-24 |
Croda International PLC |
Filamentous nanoparticles having vaccine adjuvant effect
|
KR20210132644A
(ko)
|
2018-12-18 |
2021-11-04 |
캐터펄트 테라퓨틱스 비.브이. |
이식편 대 숙주 질환(GvHD)의 예방 또는 치료를 위한 항-CCR7 mAb의 용도
|
CA3124168A1
(en)
|
2018-12-19 |
2020-06-25 |
Regeneron Pharmaceuticals, Inc. |
Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof
|
AU2019405736A1
(en)
|
2018-12-19 |
2021-06-24 |
Regeneron Pharmaceuticals, Inc. |
Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof
|
US20220289857A1
(en)
|
2018-12-20 |
2022-09-15 |
Kyowa Kirin Co., Ltd. |
Fn14 antibodies and uses thereof
|
JP2022514290A
(ja)
|
2018-12-20 |
2022-02-10 |
ジェネンテック, インコーポレイテッド |
改変抗体fcおよび使用方法
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
WO2020130125A1
(ja)
|
2018-12-21 |
2020-06-25 |
第一三共株式会社 |
抗体-薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
|
CN111349162A
(zh)
|
2018-12-21 |
2020-06-30 |
神州细胞工程有限公司 |
人源化抗pd-1抗体及其用途
|
BR112021012037A2
(pt)
|
2018-12-21 |
2021-11-03 |
Ose Immunotherapeutics |
Molécula anti-pd-1/il-7 bifuncional
|
EP3897847A1
(en)
|
2018-12-21 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Antibodies binding to cd3
|
AR123405A1
(es)
|
2018-12-21 |
2022-11-30 |
23Andme Inc |
Anticuerpos anti-il-36 y métodos de uso de estos
|
CA3123607A1
(en)
|
2018-12-21 |
2020-06-25 |
Regeneron Pharmaceuticals, Inc. |
Rifamycin analogs and antibody-drug conjugates thereof
|
SG11202106116QA
(en)
|
2018-12-21 |
2021-07-29 |
Genentech Inc |
Methods of producing polypeptides using a cell line resistant to apoptosis
|
SG11202105093RA
(en)
|
2018-12-21 |
2021-06-29 |
Hoffmann La Roche |
Tumor-targeted agonistic cd28 antigen binding molecules
|
EP3898676A1
(en)
|
2018-12-21 |
2021-10-27 |
OSE Immunotherapeutics |
Bifunctional anti-pd-1/sirpa molecule
|
WO2020127369A1
(en)
|
2018-12-21 |
2020-06-25 |
Ose Immunotherapeutics |
Bifunctional molecule directed against human pd-1
|
TW202030204A
(zh)
|
2018-12-21 |
2020-08-16 |
瑞士商赫孚孟拉羅股份公司 |
靶向腫瘤之超促效cd28抗原結合分子
|
BR112021012022A2
(pt)
|
2018-12-21 |
2021-11-03 |
Hoffmann La Roche |
Anticorpo que se liga ao vegf e à il-1beta e métodos de uso
|
MX2021007769A
(es)
|
2018-12-26 |
2021-09-23 |
Xilio Dev Inc |
Proteínas de unión anti-ctla4 enmascaradas activables.
|
CN113272327A
(zh)
|
2018-12-30 |
2021-08-17 |
豪夫迈·罗氏有限公司 |
抗兔cd19抗体及其使用方法
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
AU2020206672A1
(en)
|
2019-01-07 |
2021-07-15 |
Inhibrx Biosciences, Inc. |
Polypeptides comprising modified IL-2 polypeptides and uses thereof
|
CN113573729A
(zh)
|
2019-01-10 |
2021-10-29 |
詹森生物科技公司 |
前列腺新抗原及其用途
|
CA3125962A1
(en)
|
2019-01-13 |
2020-07-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to human nectin-2
|
AU2020208193A1
(en)
|
2019-01-14 |
2021-07-29 |
BioNTech SE |
Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
|
CN116333141A
(zh)
|
2019-01-15 |
2023-06-27 |
浙江道尔生物科技有限公司 |
抗cld18a2纳米抗体及其应用
|
CN113330030A
(zh)
|
2019-01-17 |
2021-08-31 |
拜耳公司 |
确定受试者是否适于用可溶性鸟苷酸环化酶(sGC)的激动剂治疗的方法
|
PT3911298T
(pt)
|
2019-01-17 |
2024-02-19 |
Immunocore Ltd |
Formulações
|
EP3914291A2
(en)
|
2019-01-22 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Immunoglobulin a antibodies and methods of production and use
|
WO2020154475A1
(en)
|
2019-01-23 |
2020-07-30 |
Molecular Templates, Inc. |
Proteins comprising modified immunoglobulin variable light chains
|
WO2022080481A1
(ja)
|
2020-10-16 |
2022-04-21 |
日本メジフィジックス株式会社 |
抗her2抗体の放射性複合体、及び、放射性医薬
|
EP3914616A1
(en)
|
2019-01-23 |
2021-12-01 |
Encefa |
Cd31 competitors and uses thereof
|
EP3914615A1
(en)
|
2019-01-23 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Methods of producing multimeric proteins in eukaryotic host cells
|
WO2020153467A1
(ja)
|
2019-01-24 |
2020-07-30 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
JP2020117502A
(ja)
|
2019-01-28 |
2020-08-06 |
ファイザー・インク |
変形性関節症の徴候および症状を処置する方法
|
AU2020216295A1
(en)
|
2019-01-28 |
2021-09-09 |
Maple Biotech Llc |
PSMP antagonists for use in treatment of fibrotic disease of the lung, kidney or liver
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
GB201901305D0
(en)
|
2019-01-30 |
2019-03-20 |
Immunocore Ltd |
Specific binding molecules
|
AU2020219732A1
(en)
|
2019-02-05 |
2021-08-05 |
Seagen Inc. |
Anti-CD228 antibodies and antibody-drug conjugates
|
US20240254208A2
(en)
|
2019-02-12 |
2024-08-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for using bispecific antibodies to bind complement and a target antigen
|
WO2020165374A1
(en)
|
2019-02-14 |
2020-08-20 |
Ose Immunotherapeutics |
Bifunctional molecule comprising il-15ra
|
JP7232925B2
(ja)
|
2019-02-15 |
2023-03-03 |
ウーシー バイオロジクス アイルランド リミテッド |
改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス
|
US12109273B2
(en)
|
2019-02-15 |
2024-10-08 |
Wuxi Xdc Singapore Private Limited |
Process for preparing antibody-drug conjugates with improved homogeneity
|
US20220135663A1
(en)
|
2019-02-18 |
2022-05-05 |
Pfizer Inc. |
Method of treatment of Chronic Low Back Pain
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
MX2021010003A
(es)
|
2019-02-26 |
2021-12-10 |
Inspirna Inc |
Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
|
MX2021010313A
(es)
|
2019-02-27 |
2021-09-23 |
Genentech Inc |
Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
|
CN113874083A
(zh)
|
2019-03-01 |
2021-12-31 |
梅里麦克制药股份有限公司 |
抗-tnfr2抗体及其用途
|
US20210238305A1
(en)
|
2019-03-01 |
2021-08-05 |
Remegen Co., Ltd. |
Antibody for her2 concomitant diagnosis immunohistochemical detection and application thereof
|
BR112021016984A2
(pt)
|
2019-03-01 |
2021-11-30 |
Allogene Therapeutics Inc |
Receptores de antígeno quimérico direcionados a dll3 e agentes de ligação
|
EP3930850A1
(en)
|
2019-03-01 |
2022-01-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
CA3131531A1
(en)
|
2019-03-03 |
2020-09-10 |
Prothena Biosciences Limited |
Antibodies recognizing tau
|
KR20210138588A
(ko)
|
2019-03-08 |
2021-11-19 |
제넨테크, 인크. |
세포외 소포 상에서 막 관련 단백질을 검출하고 정량하기 위한 방법
|
EP3938396A1
(en)
|
2019-03-11 |
2022-01-19 |
Jounce Therapeutics, Inc. |
Anti-icos antibodies for the treatment of cancer
|
SG11202109424RA
(en)
|
2019-03-14 |
2021-09-29 |
Genentech Inc |
Treatment of cancer with her2xcd3 bispecific antibodies in combination with anti-her2 mab
|
JP2022525164A
(ja)
|
2019-03-14 |
2022-05-11 |
武田薬品工業株式会社 |
遺伝性血管性浮腫の発作を処置するための血漿カリクレイン阻害剤およびその使用
|
BR112021018684A2
(pt)
|
2019-03-21 |
2021-11-23 |
Allogene Therapeutics Inc |
Métodos para aumentar a eficiência de esgotamento de células tcr¿¿+
|
BR112021017616A2
(pt)
|
2019-03-25 |
2021-11-09 |
Daiichi Sankyo Co Ltd |
Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina
|
WO2020196474A1
(ja)
|
2019-03-25 |
2020-10-01 |
第一三共株式会社 |
抗体-ピロロベンゾジアゼピン誘導体コンジュゲート
|
TWI841715B
(zh)
|
2019-03-27 |
2024-05-11 |
日商第一三共股份有限公司 |
抗體-吡咯并苯二氮呯衍生物結合物及parp抑制劑之組合及其用途
|
EP3947442A2
(en)
|
2019-03-28 |
2022-02-09 |
Danisco US Inc. |
Engineered antibodies
|
CA3135836A1
(en)
|
2019-04-01 |
2020-10-08 |
Lakepharma, Inc. |
Btla-binding (cd272) antibodies for modulating immune response and treating disease
|
HU231498B1
(hu)
|
2019-04-04 |
2024-05-28 |
Richter Gedeon Nyrt |
Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelőző flokkulálás alkalmazásával
|
CN113710707B
(zh)
|
2019-04-05 |
2024-05-31 |
特尼奥生物股份有限公司 |
结合于psma的重链抗体
|
WO2020208049A1
(en)
|
2019-04-12 |
2020-10-15 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising lipocalin muteins
|
SG11202111033VA
(en)
|
2019-04-17 |
2021-11-29 |
Alpine Immune Sciences Inc |
Methods and uses of variant icos ligand (icosl) fusion proteins
|
JP2022528804A
(ja)
|
2019-04-18 |
2022-06-15 |
ジェネンテック, インコーポレイテッド |
抗体力価試験
|
CN113747944A
(zh)
|
2019-04-19 |
2021-12-03 |
詹森生物科技公司 |
用抗psma/cd3抗体治疗前列腺癌的方法
|
US11732041B2
(en)
|
2019-04-19 |
2023-08-22 |
Allogene Therapeutics, Inc. |
Antibodies against 4G7-derived chimeric antigen receptors
|
CA3134522A1
(en)
|
2019-04-19 |
2020-10-22 |
Genentech, Inc. |
Anti-mertk antibodies and their methods of use
|
CA3137397A1
(en)
|
2019-04-19 |
2020-10-22 |
Chugai Seiyaku Kabushiki Kaisha |
Chimeric receptor that recognizes engineered site in antibody
|
RU2734432C1
(ru)
|
2019-04-23 |
2020-10-16 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с GITR
|
MX2021013005A
(es)
|
2019-04-26 |
2021-12-10 |
Allogene Therapeutics Inc |
Metodos de fabricacion de celulas car-t alogenicas.
|
CA3130449A1
(en)
|
2019-04-30 |
2020-11-05 |
Gigagen, Inc. |
Recombinant polyclonal proteins and methods of use thereof
|
CN113966344A
(zh)
|
2019-05-03 |
2022-01-21 |
细胞基因公司 |
抗-bcma抗体结合物、包含其的组合物及其制备及使用方法
|
EP3962951A1
(en)
|
2019-05-03 |
2022-03-09 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
EP3962947A2
(en)
|
2019-05-03 |
2022-03-09 |
F. Hoffmann-La Roche AG |
Methods of treating cancer with an anti-pd-l1 antibody
|
US11434297B2
(en)
|
2019-05-04 |
2022-09-06 |
Inhibrx, Inc. |
CD123-binding polypeptides and uses thereof
|
MX2021013416A
(es)
|
2019-05-04 |
2021-12-10 |
Inhibrx Inc |
Polipeptidos de union al antigeno cd33 y sus usos.
|
MX2021013417A
(es)
|
2019-05-04 |
2021-12-10 |
Inhibrx Inc |
Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
|
US20220315661A1
(en)
|
2019-05-09 |
2022-10-06 |
Genmab B.V. |
Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
|
MA55872A
(fr)
|
2019-05-09 |
2022-03-16 |
Boehringer Ingelheim Int |
Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires
|
MX2021013657A
(es)
|
2019-05-10 |
2022-02-21 |
Takeda Pharmaceuticals Co |
Conjugados de anticuerpo y farmaco.
|
CA3138045C
(en)
|
2019-05-14 |
2024-02-20 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma
|
CN114222803A
(zh)
|
2019-05-20 |
2022-03-22 |
尼尔瓦纳科学股份有限公司 |
窄发射染料、包含其的组合物以及制备和使用其的方法
|
TW202100184A
(zh)
|
2019-05-20 |
2021-01-01 |
瑞士商諾華公司 |
Mcl-1抑制劑抗體-藥物結合物及使用方法
|
JOP20210309A1
(ar)
|
2019-05-21 |
2023-01-30 |
Novartis Ag |
جزيئات ربط بـ cd19 واستخدامتها
|
TWI762925B
(zh)
|
2019-05-21 |
2022-05-01 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
US12037378B2
(en)
|
2019-05-21 |
2024-07-16 |
Novartis Ag |
Variant CD58 domains and uses thereof
|
AU2020278907A1
(en)
|
2019-05-23 |
2022-01-20 |
Ac Immune Sa |
Anti-TDP-43 binding molecules and uses thereof
|
TW202108627A
(zh)
|
2019-05-24 |
2021-03-01 |
大陸商三優生物醫藥(上海)有限公司 |
新型cldn18.2結合分子
|
US11535634B2
(en)
|
2019-06-05 |
2022-12-27 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
AR119264A1
(es)
|
2019-06-05 |
2021-12-09 |
Genentech Inc |
Método para reutilización de cromatografía
|
MX2021014931A
(es)
|
2019-06-07 |
2022-01-24 |
Amgen Inc |
Construcciones de union biespecificas con enlazadores selectivamente escindibles.
|
JP7512310B2
(ja)
|
2019-06-11 |
2024-07-08 |
アレクトル エルエルシー |
治療に使用するための抗ソルチリン抗体
|
MX2021015221A
(es)
|
2019-06-13 |
2022-03-17 |
Bolt Biotherapeutics Inc |
Compuestos de aminobenzazepina, inmunoconjugados y usos de estos.
|
US11781248B2
(en)
|
2019-06-13 |
2023-10-10 |
Allogene Therapeutics, Inc. |
Anti-TALEN antibodies and uses thereof
|
TW202045711A
(zh)
|
2019-06-13 |
2020-12-16 |
美商安進公司 |
生物製品製造中基於生物量之自動灌注控制
|
MX2021015337A
(es)
|
2019-06-14 |
2022-01-18 |
Teneobio Inc |
Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.
|
EP3986933A1
(en)
|
2019-06-21 |
2022-04-27 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
|
JP2022537269A
(ja)
|
2019-06-21 |
2022-08-25 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Muc16およびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用
|
JP2022538075A
(ja)
|
2019-06-26 |
2022-08-31 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗体結合cea及び4-1bblの融合
|
TW202115112A
(zh)
|
2019-06-27 |
2021-04-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗-angpt2抗體
|
EP3990492A1
(en)
|
2019-06-27 |
2022-05-04 |
F. Hoffmann-La Roche AG |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
BR112021026492A2
(pt)
|
2019-06-28 |
2022-02-08 |
Genentech Inc |
Formulações líquidas, formulação liofilizada, artigos de fabricação e método para preparar uma formulação líquida
|
CN114423785A
(zh)
|
2019-07-01 |
2022-04-29 |
通尼克斯制药有限公司 |
抗-cd154抗体及其用途
|
EP3994169A1
(en)
|
2019-07-02 |
2022-05-11 |
F. Hoffmann-La Roche AG |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
US20220257796A1
(en)
|
2019-07-02 |
2022-08-18 |
Fred Hutchinson Cancer Research Center |
Recombinant ad35 vectors and related gene therapy improvements
|
WO2021007338A1
(en)
|
2019-07-08 |
2021-01-14 |
Imcare Biotech, Llc. |
Anti-serine protease inhibitor kazal (spik) antibodies, immunoconjugates, and methods of use
|
CN113950485A
(zh)
|
2019-07-10 |
2022-01-18 |
中外制药株式会社 |
密蛋白-6结合分子及其用途
|
WO2021005232A1
(en)
|
2019-07-11 |
2021-01-14 |
Umc Utrecht Holding B.V. |
Intranasal administration of neutralising antiviral antibodies
|
CN114341187A
(zh)
|
2019-07-12 |
2022-04-12 |
中外制药株式会社 |
抗突变型fgfr3抗体及其用途
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
US20220273809A1
(en)
|
2019-07-19 |
2022-09-01 |
Genmab A/S |
Axl antibody-drug conjugates for use in treating cancer
|
EP4001306A4
(en)
|
2019-07-19 |
2023-11-15 |
Sinocelltech Ltd. |
HUMANIZED MONOCLONAL ANTIBODY AGAINST VEGF
|
CA3150046C
(en)
|
2019-07-19 |
2023-11-14 |
Sinocelltech Ltd |
Humanized anti-vegf fab antibody fragment and use thereof
|
CA3147750A1
(en)
|
2019-07-22 |
2021-01-28 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
US20220291203A1
(en)
|
2019-07-25 |
2022-09-15 |
Immunowake Inc. |
Methods of measuring cell-mediated killing by effectors
|
MX2022001068A
(es)
|
2019-07-26 |
2022-02-14 |
Sinocelltech Ltd |
Anticuerpo anti-il17a humanizado y uso del mismo.
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
EP4004041A1
(en)
|
2019-07-26 |
2022-06-01 |
Amgen Inc. |
Anti-il13 antigen binding proteins
|
MX2022001049A
(es)
|
2019-07-26 |
2022-05-03 |
Janssen Biotech Inc |
Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos.
|
CA3145278A1
(en)
|
2019-07-26 |
2021-02-04 |
Vanderbilt University |
Human monoclonal antibodies to enterovirus d68
|
WO2021022304A2
(en)
|
2019-07-30 |
2021-02-04 |
Qlsf Biotherapeutics, Inc. |
MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO LRRC15 AND CD3ε
|
EP4003519A2
(en)
|
2019-07-31 |
2022-06-01 |
Alector LLC |
Anti-ms4a4a antibodies and methods of use thereof
|
CN114174338A
(zh)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
KR20210016333A
(ko)
|
2019-07-31 |
2021-02-15 |
에프. 호프만-라 로슈 아게 |
항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생
|
KR20240001329A
(ko)
|
2019-07-31 |
2024-01-03 |
에프. 호프만-라 로슈 아게 |
항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생
|
PE20220394A1
(es)
|
2019-07-31 |
2022-03-18 |
Hoffmann La Roche |
Anticuerpos que se fijan a gprc5d
|
JP2022543062A
(ja)
|
2019-08-01 |
2022-10-07 |
インサイト・コーポレイション |
Ido阻害剤の投与レジメン
|
TWI832183B
(zh)
|
2019-08-06 |
2024-02-11 |
香港商新旭生技股份有限公司 |
結合至病理性tau種類之抗體及其用途
|
WO2021023860A1
(en)
|
2019-08-07 |
2021-02-11 |
Db Biotech, As |
Improved horseradish peroxidase polypeptides
|
JP7284256B2
(ja)
|
2019-08-12 |
2023-05-30 |
ビオンド バイオロジクス リミテッド |
Ilt2に対する抗体およびその使用
|
US12098212B2
(en)
|
2019-08-12 |
2024-09-24 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
|
EP4013506A1
(en)
|
2019-08-12 |
2022-06-22 |
Aptevo Research and Development LLC |
4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
|
US20220411505A1
(en)
|
2019-08-15 |
2022-12-29 |
Genmab A/S |
Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses
|
WO2021035170A1
(en)
|
2019-08-21 |
2021-02-25 |
Precision Biosciences, Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
WO2021042019A1
(en)
|
2019-08-30 |
2021-03-04 |
Agenus Inc. |
Anti-cd96 antibodies and methods of use thereof
|
EP4025254A1
(en)
|
2019-09-03 |
2022-07-13 |
Bolt Biotherapeutics, Inc. |
Aminoquinoline compounds, immunoconjugates, and uses thereof
|
EP4025303A1
(en)
|
2019-09-04 |
2022-07-13 |
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) |
Herv inhibitors for use in treating tauopathies
|
CN114341183B
(zh)
|
2019-09-04 |
2024-04-16 |
Inserm(法国国家健康医学研究院) |
Il20-rb特异性抗体及其用于治疗慢性阻塞性肺疾病急性恶化的用途
|
AU2020345787A1
(en)
|
2019-09-10 |
2022-03-24 |
Amgen Inc. |
Purification method for bispecific antigen-binding polypeptides with enhanced protein L capture dynamic binding capacity
|
JP2022547574A
(ja)
|
2019-09-11 |
2022-11-14 |
インケア バイオテック, エルエルシー |
抗セリンプロテアーゼインヒビターkazal(spik)抗体のエピトープ
|
WO2021048423A1
(en)
|
2019-09-12 |
2021-03-18 |
Genmab A/S |
Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
|
KR20220062304A
(ko)
|
2019-09-12 |
2022-05-16 |
제넨테크, 인크. |
루푸스 신장염을 치료하는 조성물과 방법
|
WO2021053556A1
(en)
|
2019-09-18 |
2021-03-25 |
Novartis Ag |
Nkg2d fusion proteins and uses thereof
|
JP2022549087A
(ja)
|
2019-09-18 |
2022-11-24 |
ジェネンテック, インコーポレイテッド |
抗klk7抗体、抗klk5抗体、多重特異性抗klk5/klk7抗体および使用方法
|
RU2753282C2
(ru)
|
2019-09-19 |
2021-08-12 |
Закрытое Акционерное Общество "Биокад" |
ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
|
US11814428B2
(en)
|
2019-09-19 |
2023-11-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-PTCRA antibody-drug conjugates and uses thereof
|
AU2020348393A1
(en)
|
2019-09-20 |
2022-02-24 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
EP3798235A1
(en)
|
2019-09-24 |
2021-03-31 |
Industrial Technology Research Institute |
Anti-tigit antibodies and methods of use
|
CN114423788A
(zh)
|
2019-09-24 |
2022-04-29 |
勃林格殷格翰国际有限公司 |
抗nrp1a抗体及其用于治疗眼或眼部疾病的用途
|
EP4041767A1
(en)
|
2019-09-26 |
2022-08-17 |
StCube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
CN114829401A
(zh)
|
2019-09-27 |
2022-07-29 |
南京金斯瑞生物科技有限公司 |
抗vhh域抗体及其用途
|
CN114746119A
(zh)
|
2019-09-27 |
2022-07-12 |
詹森生物科技公司 |
抗-ceacam抗体及其用途
|
EP4424321A2
(en)
|
2019-09-27 |
2024-09-04 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
AU2020359446A1
(en)
|
2019-09-30 |
2022-04-21 |
Bolt Biotherapeutics, Inc. |
Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
|
AU2020367945A1
(en)
|
2019-09-30 |
2022-05-12 |
Nekonal S.A.R.L. |
Anti-TIRC7 antigen binding proteins
|
CN115916233A
(zh)
|
2019-10-03 |
2023-04-04 |
Xencor股份有限公司 |
靶向IL-12异源二聚体Fc融合蛋白
|
MX2022003517A
(es)
|
2019-10-04 |
2022-04-25 |
Seagen Inc |
Anticuerpos anti-pd l1 y conjugados de anticuerpo-farmaco.
|
WO2021064184A1
(en)
|
2019-10-04 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
JP2022553129A
(ja)
|
2019-10-08 |
2022-12-22 |
ネクチン セラピューティクス エルティーディー. |
ポリオウイルス受容体(pvr)に対する抗体およびその使用
|
WO2021072277A1
(en)
|
2019-10-09 |
2021-04-15 |
Stcube & Co. |
Antibodies specific to glycosylated lag3 and methods of use thereof
|
US11912784B2
(en)
|
2019-10-10 |
2024-02-27 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
US20240092883A1
(en)
|
2019-10-11 |
2024-03-21 |
Coherus Biosciences, Inc. |
Methods of purifying ranibizumab or a ranibizumab variant
|
WO2021072182A1
(en)
|
2019-10-11 |
2021-04-15 |
Coherus Biosciences, Inc. |
Methods for producing ranibizumab
|
US20240092935A1
(en)
|
2019-10-11 |
2024-03-21 |
Beth Israel Deaconess Medical Center, Inc. |
Anti-tn antibodies and uses thereof
|
CN114945386A
(zh)
|
2019-10-18 |
2022-08-26 |
基因泰克公司 |
使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
|
WO2021081330A1
(en)
|
2019-10-23 |
2021-04-29 |
Kite Pharma, Inc. |
Anti-idiotypic antigen binding molecules and methods of use thereof
|
AU2020371725A1
(en)
|
2019-10-24 |
2022-05-26 |
Cedars-Sinai Medical Center |
Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
|
MX2022004875A
(es)
|
2019-10-25 |
2022-06-17 |
Bolt Biotherapeutics Inc |
Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos.
|
MX2022005240A
(es)
|
2019-11-04 |
2022-08-19 |
Seagen Inc |
Conjugados de farmaco-anticuerpo anti-cd30 y su uso para el tratamiento de infeccion por vih.
|
IL292757A
(en)
|
2019-11-05 |
2022-07-01 |
Merck Patent Gmbh |
Tigit antibodies and their uses
|
CN114787188A
(zh)
|
2019-11-05 |
2022-07-22 |
震动疗法股份有限公司 |
用抗pd-1抗体治疗癌症的方法
|
CN115066613A
(zh)
|
2019-11-06 |
2022-09-16 |
基因泰克公司 |
用于治疗血液癌症的诊断和治疗方法
|
EP4055051A1
(en)
|
2019-11-07 |
2022-09-14 |
Genmab A/S |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
TW202131954A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
利用鉑類劑與抗組織因子抗體-藥物共軛體之組合來治療癌症之方法
|
US20220396599A1
(en)
|
2019-11-13 |
2022-12-15 |
Amgen Inc. |
Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
|
EP4058466A1
(en)
|
2019-11-13 |
2022-09-21 |
Amunix Pharmaceuticals, Inc. |
Barcoded xten polypeptides and compositions thereof, and methods for making and using the same
|
JP2023502929A
(ja)
|
2019-11-15 |
2023-01-26 |
シージェン インコーポレイテッド |
Her2陽性乳がんを抗her2抗体-薬物コンジュゲートと併用してツカチニブで治療する方法
|
MX2022005317A
(es)
|
2019-11-15 |
2022-05-26 |
Hoffmann La Roche |
Prevencion de formacion de particulas visibles en soluciones acuosas de proteina.
|
IL293051A
(en)
|
2019-11-18 |
2022-07-01 |
Janssen Biotech Inc |
calr and jak2 mutant-based vaccines and their uses
|
US20230050773A1
(en)
|
2019-12-04 |
2023-02-16 |
Medimmune Limited |
Antibodies against lif and uses thereof
|
WO2021113644A1
(en)
|
2019-12-05 |
2021-06-10 |
Multivir Inc. |
Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
|
US20230057899A1
(en)
|
2019-12-05 |
2023-02-23 |
Compugen Ltd. |
Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing
|
US11919965B2
(en)
|
2019-12-06 |
2024-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies
|
EP4069742A1
(en)
|
2019-12-06 |
2022-10-12 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
|
CN115916817A
(zh)
|
2019-12-06 |
2023-04-04 |
朱诺治疗学股份有限公司 |
针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
CN114867494B9
(zh)
|
2019-12-13 |
2024-01-12 |
基因泰克公司 |
抗ly6g6d抗体及使用方法
|
MX2022007231A
(es)
|
2019-12-13 |
2022-07-12 |
Alector Llc |
Anticuerpos anti-mertk y metodos de uso de los mismos.
|
CA3164623A1
(en)
|
2019-12-17 |
2021-06-24 |
Pfizer Inc. |
Antibodies specific for cd47, pd-l1, and uses thereof
|
AU2020406085A1
(en)
|
2019-12-18 |
2022-05-26 |
F. Hoffmann-La Roche Ag |
Antibodies binding to HLA-A2/MAGE-A4
|
MX2022007613A
(es)
|
2019-12-18 |
2022-07-19 |
Teneofour Inc |
Union de anticuerpos de cadena pesada a cd38.
|
MX2022007688A
(es)
|
2019-12-20 |
2022-07-19 |
Amgen Inc |
Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
|
WO2021123173A1
(en)
|
2019-12-20 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Il-37 fusion proteins and uses thereof
|
KR20220119445A
(ko)
|
2019-12-20 |
2022-08-29 |
화이자 인코포레이티드 |
부위 특이적 her2 항체-약물 접합체를 사용한 치료
|
CN115515678A
(zh)
|
2019-12-23 |
2022-12-23 |
基因泰克公司 |
载脂蛋白l1特异性抗体及其使用方法
|
US20230074385A1
(en)
|
2019-12-23 |
2023-03-09 |
Eisai R&D Management Co., Ltd. |
Method for producing eribulin-based antibody-drug conjugate
|
CN113045655A
(zh)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
抗ox40抗体及其用途
|
JP2023508366A
(ja)
|
2019-12-27 |
2023-03-02 |
アフィメッド ゲゼルシャフト ミット ベシュレンクテル ハフツンク |
二重特異性fcyriii×cd30抗体構築体の製造方法
|
PE20221585A1
(es)
|
2019-12-27 |
2022-10-06 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla-4) y uso del mismo
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
US20210205311A1
(en)
|
2020-01-03 |
2021-07-08 |
Incyte Corporation |
Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors
|
IL294330A
(en)
|
2020-01-06 |
2022-08-01 |
Vaccinex Inc |
Anti-ccr8 antibodies and their uses
|
EP4087652A1
(en)
|
2020-01-08 |
2022-11-16 |
Regeneron Pharmaceuticals, Inc. |
Treatment of fibrodysplasia ossificans progressiva
|
WO2021140130A1
(en)
|
2020-01-09 |
2021-07-15 |
F. Hoffmann-La Roche Ag |
New 4-1bbl trimer-containing antigen binding molecules
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
AU2021209045A1
(en)
|
2020-01-13 |
2022-07-28 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
|
WO2021146383A1
(en)
|
2020-01-17 |
2021-07-22 |
BioLegend, Inc. |
Anti-tlr7 agents and compositions and methods for making and using the same
|
US20230093169A1
(en)
|
2020-01-22 |
2023-03-23 |
Amgen Research (Munch) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
WO2021148983A1
(en)
|
2020-01-24 |
2021-07-29 |
Pfizer Inc. |
Anti-e-selectin antibodies, compositions and methods of use
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021155071A1
(en)
|
2020-01-29 |
2021-08-05 |
Inhibrx, Inc. |
Cd28 single domain antibodies and multivalent and multispecific constructs thereof
|
JP2023512654A
(ja)
|
2020-01-31 |
2023-03-28 |
ジェネンテック, インコーポレイテッド |
Pd-1軸結合アンタゴニストおよびrnaワクチンを用いてネオエピトープ特異的t細胞を誘導する方法
|
WO2021155129A1
(en)
|
2020-01-31 |
2021-08-05 |
Seagen Inc. |
Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
|
WO2021155295A1
(en)
|
2020-01-31 |
2021-08-05 |
The Cleveland Clinic Foundation |
Anti-müllerian hormone receptor 2 antibodies and methods of use
|
JP2023513896A
(ja)
|
2020-02-04 |
2023-04-04 |
ジェンマブ エー/エス |
療法において使用するための抗体
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
AU2021218927A1
(en)
|
2020-02-10 |
2022-09-22 |
Shanghai Escugen Biotechnology Co., Ltd. |
Claudin 18.2 antibody and use thereof
|
KR20220139357A
(ko)
|
2020-02-10 |
2022-10-14 |
상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 |
Cldn18.2 항체 및 그의 사용
|
US20210277092A1
(en)
|
2020-02-11 |
2021-09-09 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
|
TW202140012A
(zh)
|
2020-02-12 |
2021-11-01 |
比利時商健生藥品公司 |
用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
TWI832035B
(zh)
|
2020-02-14 |
2024-02-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
EP4107173A1
(en)
|
2020-02-17 |
2022-12-28 |
Board of Regents, The University of Texas System |
Methods for expansion of tumor infiltrating lymphocytes and use thereof
|
US11180563B2
(en)
|
2020-02-21 |
2021-11-23 |
Harpoon Therapeutics, Inc. |
FLT3 binding proteins and methods of use
|
WO2021173844A1
(en)
|
2020-02-26 |
2021-09-02 |
Biograph 55, Inc. |
C19 c38 bispecific antibodies
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
WO2021174091A1
(en)
|
2020-02-28 |
2021-09-02 |
Tallac Therapeutics, Inc. |
Transglutaminase-mediated conjugation
|
JP2023516945A
(ja)
|
2020-02-28 |
2023-04-21 |
上海復宏漢霖生物技術股▲フン▼有限公司 |
抗cd137コンストラクト及びその使用
|
JP2023516941A
(ja)
|
2020-02-28 |
2023-04-21 |
上海復宏漢霖生物技術股▲フン▼有限公司 |
抗cd137コンストラクト、多重特異性抗体及びその使用
|
CA3168173A1
(en)
|
2020-03-06 |
2021-09-10 |
Robert Babb |
Anti-gitr antibodies and uses thereof
|
KR20220151195A
(ko)
|
2020-03-06 |
2022-11-14 |
오엔에이 테라퓨틱스 에스.엘. |
항-cd36 항체 및 암을 치료하기 위한 이의 용도
|
US20210275666A1
(en)
|
2020-03-06 |
2021-09-09 |
Incyte Corporation |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
|
CA3174908A1
(en)
|
2020-03-09 |
2021-09-16 |
Pfizer Inc. |
Fusion proteins and uses thereof
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
MX2022011156A
(es)
|
2020-03-13 |
2022-10-13 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y usos de estos.
|
KR20220154728A
(ko)
|
2020-03-13 |
2022-11-22 |
얀센 바이오테크 인코포레이티드 |
Siglec-3/cd33을 결합시키기 위한 물질 및 방법
|
IL296362A
(en)
|
2020-03-18 |
2022-11-01 |
Genmab As |
Antibodies that bind to b7h4
|
WO2021188851A1
(en)
|
2020-03-19 |
2021-09-23 |
Amgen Inc. |
Antibodies against mucin 17 and uses thereof
|
IL296427A
(en)
|
2020-03-19 |
2022-11-01 |
Genentech Inc |
Isoform-selective anti-tgf antibodies and methods of use
|
PE20230414A1
(es)
|
2020-03-24 |
2023-03-07 |
Genentech Inc |
Agentes de fijacion a tie2 y metodos de uso
|
CN115315512A
(zh)
|
2020-03-26 |
2022-11-08 |
基因泰克公司 |
具有降低的宿主细胞蛋白质的经修饰的哺乳动物细胞
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
BR112022018987A2
(pt)
|
2020-03-26 |
2022-11-01 |
Seagen Inc |
Métodos de tratamento de mieloma múltiplo
|
MX2022011892A
(es)
|
2020-03-26 |
2022-10-18 |
Univ Vanderbilt |
Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2).
|
EP4126940A1
(en)
|
2020-03-30 |
2023-02-08 |
F. Hoffmann-La Roche AG |
Antibody that binds to vegf and pdgf-b and methods of use
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
WO2021202590A1
(en)
|
2020-03-31 |
2021-10-07 |
Alector Llc |
Anti-mertk antibodies and methods of use thereof
|
WO2021202235A1
(en)
|
2020-04-01 |
2021-10-07 |
University Of Rochester |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
US20230174674A1
(en)
|
2020-04-04 |
2023-06-08 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
|
AU2020202454A1
(en)
|
2020-04-06 |
2021-10-21 |
H. Lundbeck A/S |
Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
|
JP2023520587A
(ja)
|
2020-04-06 |
2023-05-17 |
イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー. |
癌及び感染症の治療のためのNKp46に対する抗体及びそのコンストラクト
|
TW202204622A
(zh)
|
2020-04-09 |
2022-02-01 |
大陸商蘇州艾博生物科技有限公司 |
針對冠狀病毒之核酸疫苗
|
KR20220166819A
(ko)
|
2020-04-10 |
2022-12-19 |
바누디스 게엠베하 |
예방 및 치료에서의 천연 항체
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
WO2021209402A2
(en)
|
2020-04-15 |
2021-10-21 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
EP4135775A1
(en)
|
2020-04-16 |
2023-02-22 |
Regeneron Pharmaceuticals, Inc. |
Diels-alder conjugation methods
|
WO2021212053A2
(en)
|
2020-04-17 |
2021-10-21 |
Newyork University |
Therapeutic musk antibodies
|
US20230151098A1
(en)
|
2020-04-20 |
2023-05-18 |
Jounce Therapeutics, Inc. |
Compositions and Methods for Vaccination and the Treatment of Infectious Diseases
|
WO2021217051A1
(en)
|
2020-04-24 |
2021-10-28 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
JP2023523145A
(ja)
|
2020-04-27 |
2023-06-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
リポ蛋白(a)に対するイソ型非依存性抗体
|
EP4143345A1
(en)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
MX2022013455A
(es)
|
2020-04-28 |
2022-11-16 |
Sinocelltech Ltd |
Molecula truncada en el dominio extracelular de tgfbr2, proteina de fusion de molecula truncada en el dominio extracelular de tgfbr2 y anticuerpo anti-egfr, y uso antitumoral de la proteina de fusion.
|
MX2021015024A
(es)
|
2020-04-28 |
2022-01-18 |
Univ Rockefeller |
Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
|
WO2021222578A1
(en)
|
2020-04-29 |
2021-11-04 |
Teneobio, Inc. |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
PE20230431A1
(es)
|
2020-04-29 |
2023-03-08 |
Teneobio Inc |
Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas
|
EP4142791A1
(en)
|
2020-04-29 |
2023-03-08 |
TeneoOne, Inc. |
Methods of treating multiple myeloma
|
CN116963782A
(zh)
|
2020-05-03 |
2023-10-27 |
联宁(苏州)生物制药有限公司 |
包含抗trop-2抗体的抗体药物偶联物
|
CA3176436A1
(en)
|
2020-05-08 |
2021-11-11 |
Tahamtan Ahmadi |
Bispecific antibodies against cd3 and cd20
|
TW202208414A
(zh)
|
2020-05-08 |
2022-03-01 |
美商艾爾潘免疫科學有限公司 |
April及baff抑制性免疫調節蛋白及其使用方法
|
CA3176626A1
(en)
|
2020-05-08 |
2021-11-11 |
David Dornan |
Elastase-substrate, peptide linker immunoconjugates, and uses thereof
|
CN111995681B
(zh)
|
2020-05-09 |
2022-03-08 |
华博生物医药技术(上海)有限公司 |
抗tigit的抗体、其制备方法和应用
|
EP4149559A1
(en)
|
2020-05-13 |
2023-03-22 |
Seagen Inc. |
Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
JP2023520249A
(ja)
|
2020-05-15 |
2023-05-16 |
エフ. ホフマン-ラ ロシュ アーゲー |
非経口タンパク質溶液中の可視粒子形成の防止方法
|
EP4153130A1
(en)
|
2020-05-19 |
2023-03-29 |
F. Hoffmann-La Roche AG |
The use of chelators for the prevention of visible particle formation in parenteral protein solutions
|
MX2022014636A
(es)
|
2020-05-19 |
2023-02-23 |
Amgen Inc |
Construcciones de unión a mageb2.
|
PE20231076A1
(es)
|
2020-05-26 |
2023-07-17 |
Boehringer Ingelheim Int |
Anticuerpos anti-pd-1
|
EP4157881A4
(en)
|
2020-05-27 |
2024-10-09 |
Staidson Beijing Biopharmaceuticals Co Ltd |
ANTIBODIES THAT SPECIFICALLY RECOGNIZE NERVE GROWTH FACTOR AND THEIR USES
|
TW202210510A
(zh)
|
2020-05-27 |
2022-03-16 |
美商健生生物科技公司 |
包含cd3抗原結合域之蛋白質及其用途
|
CN115768416A
(zh)
|
2020-05-29 |
2023-03-07 |
思进公司 |
图卡替尼联合曲妥珠单抗和基于奥沙利铂的化学疗法治疗her2阳性癌症的方法
|
EP4157461A1
(en)
|
2020-05-29 |
2023-04-05 |
23Andme, Inc. |
Anti-cd200r1 antibodies and methods of use thereof
|
WO2021243320A2
(en)
|
2020-05-29 |
2021-12-02 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
WO2021247769A1
(en)
|
2020-06-02 |
2021-12-09 |
Dynamicure Biotechnology Llc |
Anti-cd93 constructs and uses thereof
|
CN113754775A
(zh)
*
|
2020-06-02 |
2021-12-07 |
三生国健药业(上海)股份有限公司 |
一种抗pd-l1和her2的双特异性抗体
|
AU2021284273A1
(en)
|
2020-06-02 |
2022-12-15 |
Arcus Biosciences, Inc. |
Antibodies to TIGIT
|
CN115803062A
(zh)
|
2020-06-03 |
2023-03-14 |
博泰康医药公司 |
滋养层细胞表面抗原2(trop-2)抗体
|
US20230203198A1
(en)
|
2020-06-04 |
2023-06-29 |
Amgen Inc. |
Bispecific binding constructs
|
IL298302A
(en)
|
2020-06-08 |
2023-01-01 |
Hoffmann La Roche |
Antibodies against hbv and methods of use
|
US20220119513A1
(en)
|
2020-06-08 |
2022-04-21 |
Zoetis Services Llc |
Anti-tgfb antibodies and therapeutic uses thereof
|
EP4165169A1
(en)
|
2020-06-11 |
2023-04-19 |
Novartis AG |
Zbtb32 inhibitors and uses thereof
|
EP4166656A4
(en)
*
|
2020-06-12 |
2024-08-07 |
Gencellmed Inc |
MULTI-TARGET RECOMBINANT HERPES SIMPLEX VIRUSES AND THEIR USE
|
CA3177152A1
(en)
|
2020-06-12 |
2021-12-16 |
David Scott Johnson |
Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
|
EP4165415A1
(en)
|
2020-06-12 |
2023-04-19 |
Genentech, Inc. |
Methods and compositions for cancer immunotherapy
|
IL299039A
(en)
|
2020-06-16 |
2023-02-01 |
Genentech Inc |
Methods and preparations for the treatment of triple-negative breast cancer
|
US11981932B2
(en)
|
2020-06-17 |
2024-05-14 |
Janssen Biotech, Inc. |
Materials and methods for the manufacture of pluripotent stem cells
|
KR20230024368A
(ko)
|
2020-06-18 |
2023-02-20 |
제넨테크, 인크. |
항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
|
CA3176579A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
CN115916827A
(zh)
|
2020-06-19 |
2023-04-04 |
豪夫迈·罗氏有限公司 |
免疫活化Fc结构域结合分子
|
CR20220637A
(es)
|
2020-06-19 |
2023-01-31 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y cd19
|
KR20230025673A
(ko)
|
2020-06-19 |
2023-02-22 |
에프. 호프만-라 로슈 아게 |
CD3 및 FolR1에 결합하는 항체
|
JP2023529982A
(ja)
|
2020-06-19 |
2023-07-12 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
プロテアーゼ活性化型t細胞二重特異性抗体
|
CN115734972A
(zh)
|
2020-06-22 |
2023-03-03 |
信达生物制药(苏州)有限公司 |
抗cd73抗体及其用途
|
EP4168443A1
(en)
|
2020-06-22 |
2023-04-26 |
Almirall S.A. |
Anti-il-36 antibodies and methods of use thereof
|
US20240228648A1
(en)
|
2020-06-23 |
2024-07-11 |
Jiangsu Kanion Pharmaceutical Co., Ltd. |
Anti-cd38 antibody and use thereof
|
CR20220627A
(es)
|
2020-06-23 |
2023-02-17 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se derigen a her2
|
WO2021260583A1
(en)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and dna-pk inhibitor
|
JP2023533458A
(ja)
|
2020-06-24 |
2023-08-03 |
プロシーナ バイオサイエンシーズ リミテッド |
ソルチリンを認識する抗体
|
CA3183867A1
(en)
|
2020-06-24 |
2021-12-30 |
Jerome Thomas Mettetal Ii |
Combination of antibody-drug conjugate and atr inhibitor
|
EP4172192A1
(en)
|
2020-06-24 |
2023-05-03 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
US20230233540A1
(en)
|
2020-06-24 |
2023-07-27 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and cdk9 inhibitor
|
WO2021260582A1
(en)
|
2020-06-24 |
2021-12-30 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and aurora b inhibitor
|
EP4171651A1
(en)
|
2020-06-24 |
2023-05-03 |
AstraZeneca UK Limited |
Combination of antibody-drug conjugate and atm inhibitor
|
JP2023531067A
(ja)
|
2020-06-25 |
2023-07-20 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd3/抗cd28二重特異性抗原結合分子
|
MX2022015375A
(es)
|
2020-06-29 |
2023-01-16 |
Genmab As |
Conjugados de farmaco-anticuerpo anti-factor de tejido y su uso en el tratamiento de cancer.
|
BR112022026888A2
(pt)
|
2020-06-29 |
2023-03-14 |
Genentech Inc |
Métodos de tratamento de câncer her2-positivo em um paciente, de terapia neoadjuvante de pacientes com câncer de mama inicial her2-positivo e de terapia neoadjuvante de câncer de mama inicial her2-positivo e método para tratar um paciente com câncer her2-positivo
|
US20230257472A1
(en)
|
2020-06-30 |
2023-08-17 |
Jiangsu Hengrui Medicine Co., Ltd. |
Anti-cd70 antibody and application thereof
|
MX2022016342A
(es)
|
2020-06-30 |
2023-01-24 |
Teneobio Inc |
Union de anticuerpos multiespecificos a bcma.
|
AU2021299552A1
(en)
|
2020-07-02 |
2023-02-02 |
Inhibrx Biosciences, Inc. |
Polypeptides comprising modified IL-2 polypeptides and uses thereof
|
EP4178529A1
(en)
|
2020-07-07 |
2023-05-17 |
F. Hoffmann-La Roche AG |
Alternative surfactants as stabilizers for therapeutic protein formulations
|
CN116390772A
(zh)
|
2020-07-07 |
2023-07-04 |
博泰康医药公司 |
新型美登素类似物作为adc有效载荷及其在癌症治疗中的用途
|
KR20240038138A
(ko)
|
2020-07-13 |
2024-03-22 |
리제너론 파마슈티칼스 인코포레이티드 |
단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도
|
WO2022013189A1
(en)
|
2020-07-14 |
2022-01-20 |
F. Hoffmann-La Roche Ag |
Assays for fixed dose combinations
|
AU2021308712A1
(en)
|
2020-07-16 |
2023-02-02 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
AU2021308586A1
(en)
|
2020-07-17 |
2023-03-02 |
Pfizer Inc. |
Therapeutic antibodies and their uses
|
MX2023000617A
(es)
|
2020-07-17 |
2023-02-13 |
Genentech Inc |
Anticuerpos anti-notch2 y metodos de uso.
|
US20230277679A1
(en)
|
2020-07-17 |
2023-09-07 |
Daiichi Sankyo Company, Limited |
Method for producing antibody-drug conjugate
|
US20230293714A1
(en)
|
2020-07-20 |
2023-09-21 |
Daiichi Sankyo Company, Limited |
Combination of anti-her2 antibody-drug conjugate with her dimerization inhibitor
|
AU2021312225A1
(en)
|
2020-07-21 |
2023-02-16 |
Genentech, Inc. |
Antibody-conjugated chemical inducers of degradation of BRM and methods thereof
|
JP2023534726A
(ja)
|
2020-07-23 |
2023-08-10 |
ジェンマブ ビー.ブイ. |
多発性骨髄腫の治療に使用するための抗dr5抗体と免疫調節イミド薬との併用
|
WO2022027037A1
(en)
|
2020-07-27 |
2022-02-03 |
Single Cell Technology, Inc. |
Anti-sars corona virus-2 spike protein antibodies
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
CN116723858A
(zh)
|
2020-07-29 |
2023-09-08 |
思进公司 |
图卡替尼联合曲妥珠单抗、紫杉烷和vegfr-2拮抗剂治疗her2阳性癌症的方法
|
TW202221028A
(zh)
|
2020-07-29 |
2022-06-01 |
美商健生生物科技公司 |
包括hla-g抗原結合域之蛋白及其用途
|
AU2021315665A1
(en)
|
2020-07-29 |
2023-03-16 |
Dynamicure Biotechnology Llc |
Anti-CD93 constructs and uses thereof
|
EP4189071A1
(en)
|
2020-08-03 |
2023-06-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
EP4188964A1
(en)
|
2020-08-03 |
2023-06-07 |
F. Hoffmann-La Roche AG |
Improved antigen binding receptors
|
US20230295330A1
(en)
|
2020-08-04 |
2023-09-21 |
Seagen Inc. |
Anti-cd228 antibodies and antibody-drug conjugates
|
BR112023002154A2
(pt)
|
2020-08-04 |
2023-03-14 |
Pfizer |
Tratamento com conjugados anticorpo-fármaco anti-her2 de local específico
|
WO2022031834A1
(en)
|
2020-08-05 |
2022-02-10 |
Gigagen, Inc. |
Recombinant polyclonal proteins targeting zika and methods of use thereof
|
WO2022029660A1
(en)
|
2020-08-05 |
2022-02-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
CN116194477A
(zh)
|
2020-08-06 |
2023-05-30 |
生物技术欧洲股份公司 |
冠状病毒s蛋白的结合剂
|
AU2021322239A1
(en)
|
2020-08-07 |
2023-02-23 |
Genentech, Inc. |
Flt3 ligand fusion proteins and methods of use
|
IL300588A
(en)
|
2020-08-12 |
2023-04-01 |
Biond Biologics Ltd |
Antibodies against ILT-2 and their use
|
MX2023001679A
(es)
|
2020-08-13 |
2023-02-22 |
Bolt Biotherapeutics Inc |
Inmunoconjugados de pirazolazepina y usos de estos.
|
WO2022034228A1
(en)
|
2020-08-14 |
2022-02-17 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
JP7392200B2
(ja)
|
2020-08-21 |
2023-12-05 |
シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド |
グリコシル化ceacam5に特異的に結合した抗体
|
WO2022043517A2
(en)
|
2020-08-27 |
2022-03-03 |
Cureab Gmbh |
Anti-golph2 antibodies for macrophage and dendritic cell differentiation
|
KR20230078657A
(ko)
|
2020-08-27 |
2023-06-02 |
에노시 테라퓨틱스 코퍼레이션 |
자가면역 질환 및 암을 치료하기 위한 방법 및 조성물
|
JP2023539201A
(ja)
|
2020-08-28 |
2023-09-13 |
ジェネンテック, インコーポレイテッド |
宿主細胞タンパク質のCRISPR/Cas9マルチプレックスノックアウト
|
WO2022044248A1
(ja)
|
2020-08-28 |
2022-03-03 |
中外製薬株式会社 |
ヘテロ二量体Fcポリペプチド
|
WO2022047316A1
(en)
|
2020-08-28 |
2022-03-03 |
Sana Biotechnology, Inc. |
Modified anti-viral binding agents
|
WO2022049220A2
(en)
|
2020-09-02 |
2022-03-10 |
Genmab A/S |
Antibody therapy
|
JP2023540526A
(ja)
|
2020-09-04 |
2023-09-25 |
ノヴァロック バイオセラピューティクス, リミテッド |
ネクチン-4抗体およびそれの使用
|
MX2023002330A
(es)
|
2020-09-04 |
2023-03-21 |
Merck Patent Gmbh |
Anticuerpos anti molecula de adhesion celular 5 relacionada con el antigeno carcinoembrionario (ceacam5) y conjugados y usos de los mismos.
|
CA3192256A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
AU2021342342A1
(en)
|
2020-09-10 |
2023-04-13 |
Genmab A/S |
Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
|
JP2023542289A
(ja)
|
2020-09-10 |
2023-10-06 |
ジェンマブ エー/エス |
濾胞性リンパ腫を治療するための併用療法におけるcd3及びcd20に対する二重特異性抗体
|
US20240034812A1
(en)
|
2020-09-10 |
2024-02-01 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
US20230355753A1
(en)
|
2020-09-10 |
2023-11-09 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
MX2023002544A
(es)
|
2020-09-10 |
2023-03-14 |
Genmab As |
Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para tratar linfoma folicular.
|
KR20230066094A
(ko)
|
2020-09-12 |
2023-05-12 |
아스트라제네카 유케이 리미티드 |
항-her2 항체-약물 접합체 치료법을 위한 채점 방법
|
JP2023541627A
(ja)
|
2020-09-14 |
2023-10-03 |
イシュノス サイエンシズ ソシエテ アノニム |
Il1rapに結合する抗体及びその使用
|
MX2023002984A
(es)
|
2020-09-15 |
2023-04-10 |
Bayer Ag |
Nuevos anticuerpos anti-a2ap y usos de los mismos.
|
TW202227478A
(zh)
|
2020-09-15 |
2022-07-16 |
德商拜恩迪克公司 |
對細胞靶向遞送的藥劑及方法
|
MX2023003214A
(es)
|
2020-09-18 |
2023-05-24 |
Regeneron Pharma |
Moleculas de union al antigeno que se unen a cd38 y/o cd28 y usos de las mismas.
|
JP2023542678A
(ja)
|
2020-09-21 |
2023-10-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
炎症状態の処置のための抗cd40抗体の使用。
|
CA3189473A1
(en)
|
2020-09-24 |
2022-03-31 |
Andreas Bultmann |
Novel human antibodies binding to human cd3 epsilon
|
JP2023543026A
(ja)
|
2020-09-28 |
2023-10-12 |
シージェン インコーポレイテッド |
がんの処置のためのヒト化抗liv1抗体
|
DE102020125465A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
TW202229312A
(zh)
|
2020-09-29 |
2022-08-01 |
德商英麥提克生物技術股份有限公司 |
由非hla-a*02顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
|
DE102020125457A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
JP2023547329A
(ja)
|
2020-10-02 |
2023-11-10 |
ジェンマブ エー/エス |
Ror2へと結合することができる抗体ならびにror2およびcd3に結合する二重特異性抗体
|
IL301547A
(en)
|
2020-10-05 |
2023-05-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-FCRH5/anti-CD3 antibodies
|
JP2023544839A
(ja)
|
2020-10-07 |
2023-10-25 |
ゾエティス・サービシーズ・エルエルシー |
抗ngf抗体及びその使用方法
|
WO2022074206A1
(en)
|
2020-10-08 |
2022-04-14 |
Affimed Gmbh |
Trispecific binders
|
CA3195117A1
(en)
|
2020-10-09 |
2022-04-14 |
Jerome Thomas Mettetal Ii |
Combination of antibody-drug conjugate and parp1 selective inhibitor
|
CN116635052A
(zh)
|
2020-10-13 |
2023-08-22 |
詹森生物科技公司 |
用于调节分化簇iv和/或viii的生物工程t细胞介导的免疫、材料和其他方法
|
TW202304983A
(zh)
|
2020-10-14 |
2023-02-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗her3抗體和抗her3抗體藥物偶聯物及其醫藥用途
|
US20240084014A1
(en)
|
2020-10-16 |
2024-03-14 |
Qlsf Biotherapeutics, Inc. |
Multispecific binding compounds that bind to pd-l1
|
WO2022086957A1
(en)
|
2020-10-20 |
2022-04-28 |
Genentech, Inc. |
Peg-conjugated anti-mertk antibodies and methods of use
|
AU2021366287A1
(en)
|
2020-10-20 |
2023-04-13 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments specifically binding to Gremlin-1 and uses thereof
|
WO2022084210A1
(en)
|
2020-10-20 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
|
WO2022084915A1
(en)
|
2020-10-22 |
2022-04-28 |
Janssen Biotech, Inc. |
Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
|
EP4232071A4
(en)
|
2020-10-23 |
2024-08-28 |
Asher Biotherapeutics Inc |
FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION
|
US20220127344A1
(en)
|
2020-10-23 |
2022-04-28 |
Boehringer Ingelheim International Gmbh |
Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
|
WO2022090801A2
(en)
|
2020-10-26 |
2022-05-05 |
Compugen Ltd. |
Pvrl2 and/or pvrig as biomarkers for treatment
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
AR124562A1
(es)
|
2020-10-28 |
2023-04-12 |
Hoffmann La Roche |
Receptores de unión al antígeno mejorada
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
JP7402381B2
(ja)
|
2020-11-04 |
2023-12-20 |
ジェネンテック, インコーポレイテッド |
抗cd20/抗cd3二重特異性抗体による処置のための投与
|
AU2021374594A1
(en)
|
2020-11-04 |
2023-06-01 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
WO2022098870A1
(en)
|
2020-11-04 |
2022-05-12 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
WO2022098628A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
JP2023547661A
(ja)
|
2020-11-06 |
2023-11-13 |
アムジエン・インコーポレーテツド |
Cd3に結合するポリペプチド構築物
|
AU2021374083A1
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
IL302569A
(en)
|
2020-11-06 |
2023-07-01 |
Novartis Ag |
CD19 binding molecules and their uses
|
EP4240770A1
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Research (Munich) GmbH |
Polypeptide constructs selectively binding to cldn6 and cd3
|
JP2023549116A
(ja)
|
2020-11-06 |
2023-11-22 |
アムジエン・インコーポレーテツド |
選択性が増大した多標的二重特異性抗原結合分子
|
AU2021373318A1
(en)
|
2020-11-06 |
2023-05-25 |
Amgen Inc. |
Antigen binding domain with reduced clipping rate
|
AU2021374958A1
(en)
|
2020-11-09 |
2023-06-22 |
Takeda Pharmaceutical Company Limited |
Antibody drug conjugates
|
CA3198330A1
(en)
|
2020-11-11 |
2022-05-19 |
Mayumi SUE |
Combination of an antibody-drug conjugate with anti-sirp.alpha. antibody
|
CN116437958A
(zh)
|
2020-11-11 |
2023-07-14 |
吉利德科学公司 |
鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法
|
EP4245322A1
(en)
|
2020-11-12 |
2023-09-20 |
Daiichi Sankyo Company, Limited |
Treatment for mesothelioma through administration of anti-b7-h3 antibody-drug conjugate
|
US20240033358A1
(en)
|
2020-11-13 |
2024-02-01 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
US20240002483A1
(en)
|
2020-11-16 |
2024-01-04 |
Hoffmann-La Roche Inc. |
Fab high mannose glycoforms
|
CN117916261A
(zh)
|
2020-11-16 |
2024-04-19 |
豪夫迈·罗氏有限公司 |
与靶向fap的cd40激动剂的组合疗法
|
CA3200671A1
(en)
|
2020-11-17 |
2022-05-27 |
Seagen Inc. |
Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
|
TW202233684A
(zh)
|
2020-11-18 |
2022-09-01 |
美商泰尼歐生物公司 |
結合於葉酸受體α之重鏈抗體
|
CN114829384B
(zh)
|
2020-11-19 |
2023-12-12 |
舒泰神(北京)生物制药股份有限公司 |
长效神经生长因子多肽及其用途
|
EP4247850A1
(en)
|
2020-11-20 |
2023-09-27 |
Simcere Innovation, Inc. |
Armed dual car-t compositions and methods for cancer immunotherapy
|
CA3198996A1
(en)
|
2020-11-24 |
2022-06-02 |
Matthew T. Burger |
Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
CN112480248B
(zh)
|
2020-11-24 |
2023-05-05 |
三优生物医药(上海)有限公司 |
与cld18a2特异性结合的分子
|
CN114539418A
(zh)
|
2020-11-26 |
2022-05-27 |
上海华奥泰生物药业股份有限公司 |
双特异性抗体及其用途
|
WO2022115120A1
(en)
|
2020-11-30 |
2022-06-02 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
US20220241411A1
(en)
|
2020-11-30 |
2022-08-04 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
WO2022119976A1
(en)
|
2020-12-01 |
2022-06-09 |
Aptevo Research And Development Llc |
Heterodimeric psma and cd3-binding bispecific antibodies
|
US20240101681A1
(en)
|
2020-12-02 |
2024-03-28 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
WO2022120033A1
(en)
|
2020-12-03 |
2022-06-09 |
Amgen Inc. |
Immunoglobuline constructs with multiple binding domains
|
JP2023551563A
(ja)
|
2020-12-04 |
2023-12-08 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
pH依存性変異体インターロイキン-2ポリペプチド
|
IL303350A
(en)
|
2020-12-04 |
2023-08-01 |
Macrogenics Inc |
Preparations containing an antibody against HER2/NEU and their use
|
JP2023551980A
(ja)
|
2020-12-07 |
2023-12-13 |
ジェンマブ エー/エス |
抗体およびタキソンの併用療法
|
IL303295A
(en)
|
2020-12-07 |
2023-07-01 |
UCB Biopharma SRL |
Multispecific antibodies and antibody combinations
|
BR112023008265A2
(pt)
|
2020-12-07 |
2024-02-06 |
UCB Biopharma SRL |
Anticorpos contra interleucina-22
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
TW202237639A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
EP4259662A1
(en)
|
2020-12-11 |
2023-10-18 |
Genentech, Inc. |
Combination therapies for treatment of her2 cancer
|
EP4259212A1
(en)
|
2020-12-11 |
2023-10-18 |
Bolt Biotherapeutics, Inc. |
Anti-her2 immunoconjugates, and uses thereof
|
JP2023552791A
(ja)
|
2020-12-11 |
2023-12-19 |
ボルト バイオセラピューティクス、インコーポレーテッド |
抗her2免疫複合体、及びその使用
|
AU2021401934A1
(en)
|
2020-12-14 |
2023-06-22 |
Allogene Therapeutics, Inc. |
Methods and reagents for characterizing car t cells for therapies
|
JP7326584B2
(ja)
|
2020-12-17 |
2023-08-15 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗hla-g抗体及びその使用
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
CA3196999A1
(en)
|
2020-12-28 |
2022-07-07 |
Masano HUANG |
Methods of treating tumors
|
IL303648A
(en)
|
2020-12-28 |
2023-08-01 |
Bristol Myers Squibb Co |
Antibody preparations and methods of using them
|
WO2022147092A1
(en)
|
2020-12-29 |
2022-07-07 |
Incyte Corporation |
Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
|
CA3203328A1
(en)
|
2020-12-29 |
2022-07-07 |
Dimitrios TSIANTOULAS |
Anti-april antibodies and uses thereof
|
JP2024502832A
(ja)
|
2020-12-31 |
2024-01-23 |
アラマー バイオサイエンシーズ, インコーポレイテッド |
高親和性及び/または特異性を有する結合剤分子ならびにその製造及び使用方法
|
EP4274658A1
(en)
|
2021-01-06 |
2023-11-15 |
F. Hoffmann-La Roche AG |
Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
|
EP4274587A1
(en)
|
2021-01-06 |
2023-11-15 |
Tonix Pharma Limited |
Methods of inducing immune tolerance with modified anti-cd154 antibodies
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
KR20230131205A
(ko)
|
2021-01-13 |
2023-09-12 |
에프. 호프만-라 로슈 아게 |
병용 요법
|
TW202241925A
(zh)
|
2021-01-15 |
2022-11-01 |
德商英麥提克生物技術股份有限公司 |
用於不同類型癌症免疫治療的hla展示肽
|
JP2024505636A
(ja)
|
2021-01-15 |
2024-02-07 |
ザ ロックフェラー ユニバーシティー |
抗sars-cov-2中和抗体
|
US20240101717A1
(en)
|
2021-01-22 |
2024-03-28 |
Bionecure Therapeutics, Inc. |
Anti-her-2/trop-2 constructs and uses thereof
|
PE20240761A1
(es)
|
2021-01-28 |
2024-04-17 |
Janssen Biotech Inc |
Proteinas de union a psma y usos de estas
|
WO2022161452A1
(zh)
|
2021-01-28 |
2022-08-04 |
南京桦冠生物技术有限公司 |
缀合物及其用途
|
EP4284512A1
(en)
|
2021-01-28 |
2023-12-06 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for treating cytokine release syndrome
|
TW202241454A
(zh)
|
2021-02-01 |
2022-11-01 |
日商第一三共股份有限公司 |
抗體-免疫賦活化劑共軛物之新穎製造方法
|
MX2023009100A
(es)
|
2021-02-03 |
2023-09-25 |
Mozart Therapeutics Inc |
Agentes aglutinantes y métodos para usar los mismos.
|
TW202245811A
(zh)
|
2021-02-03 |
2022-12-01 |
美商異基因治療有限公司 |
用於car t細胞藥物產品的調配物與製程
|
CN116848142A
(zh)
|
2021-02-04 |
2023-10-03 |
信达生物制药(苏州)有限公司 |
抗tnfr2抗体及其用途
|
JP2024505674A
(ja)
|
2021-02-05 |
2024-02-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗il1rap抗体
|
US20240270840A1
(en)
|
2021-02-11 |
2024-08-15 |
Nectin Therapeutics Ltd. |
Antibodies against cd112r and uses thereof
|
WO2022172085A2
(en)
|
2021-02-15 |
2022-08-18 |
Takeda Pharmaceutical Company Limited |
Cell therapy compositions and methods for modulating tgf-b signaling
|
US20240254246A1
(en)
|
2021-02-17 |
2024-08-01 |
Prometheus Biosciences, Inc. |
Anti-cd30l antibodies and uses thereof
|
WO2022178090A2
(en)
|
2021-02-19 |
2022-08-25 |
Theripion, Inc. |
Dnase fusion polypeptides and related compositions and methods
|
CN117098778A
(zh)
|
2021-02-19 |
2023-11-21 |
印希比股份有限公司 |
Dr5结合多肽的配制品
|
US12030888B2
(en)
|
2021-02-24 |
2024-07-09 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
CN117500835A
(zh)
|
2021-02-25 |
2024-02-02 |
特尼奥生物股份有限公司 |
抗psma抗体及car-t结构
|
US20220378929A1
(en)
|
2021-02-25 |
2022-12-01 |
MediBoston Limted |
Anti-her2 antibody-drug conjugates and uses thereof
|
KR20230150287A
(ko)
|
2021-02-26 |
2023-10-30 |
바이엘 악티엔게젤샤프트 |
비정상적 자궁 출혈의 치료에 사용하기 위한 il-11 또는 il-11ra의 억제제
|
JP2024508808A
(ja)
|
2021-02-26 |
2024-02-28 |
テネオバイオ, インコーポレイテッド |
抗muc1-c抗体及びcar-t構造
|
US20220306743A1
(en)
|
2021-03-01 |
2022-09-29 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
US20220340662A1
(en)
|
2021-03-01 |
2022-10-27 |
Xilio Development, Inc. |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
EP4301418A1
(en)
|
2021-03-03 |
2024-01-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates comprising an anti-bcma antibody
|
CN117715933A
(zh)
|
2021-03-05 |
2024-03-15 |
当康生物技术有限责任公司 |
抗vista的构建体及其用途
|
KR20230156051A
(ko)
|
2021-03-09 |
2023-11-13 |
에프. 호프만-라 로슈 아게 |
Pd-1-표적화 il-2 변이체 면역접합체 및 fap/4-1bb 결합 분자의 병용 요법
|
KR20230169135A
(ko)
|
2021-03-09 |
2023-12-15 |
젠맵 에이/에스 |
치료에 있어서 cd40 및 cd137에 대한 다중특이 결합제
|
AU2022232375A1
(en)
|
2021-03-09 |
2023-09-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
EP4304724A1
(en)
|
2021-03-09 |
2024-01-17 |
F. Hoffmann-La Roche AG |
Combination therapy of pd-1-targeted il-2 variant immunoconjugate and anti-tyrp1/anti-cd3 bispecific antibodies
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
CA3211581A1
(en)
|
2021-03-10 |
2022-09-15 |
Ellen WU |
Immunomodulatory molecules and uses thereof
|
MX2023010567A
(es)
|
2021-03-12 |
2023-09-21 |
Genmab As |
Variantes de anticuerpos no activadoras.
|
CN117062839A
(zh)
|
2021-03-12 |
2023-11-14 |
基因泰克公司 |
抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体和使用方法
|
WO2022191313A1
(ja)
|
2021-03-12 |
2022-09-15 |
第一三共株式会社 |
糖鎖及び糖鎖を含む医薬品の製造方法
|
BR112023018621A2
(pt)
|
2021-03-15 |
2023-10-24 |
Hoffmann La Roche |
Métodos para tratar nefrite lúpica, esgotar células b periféricas, kits para tratar nefrite lúpica e anticorpos anti-cd20 tipo ii
|
US12036286B2
(en)
|
2021-03-18 |
2024-07-16 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
EP4308606A1
(en)
|
2021-03-18 |
2024-01-24 |
Alector LLC |
Anti-tmem106b antibodies and methods of use thereof
|
WO2022195504A1
(en)
|
2021-03-19 |
2022-09-22 |
Pfizer Inc. |
Method of treating osteoarthritis pain with an anti ngf antibody
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
JP2024511418A
(ja)
|
2021-03-22 |
2024-03-13 |
ジュノー セラピューティクス インコーポレイテッド |
治療用細胞組成物の効力を決定する方法
|
EP4314280A1
(en)
|
2021-03-22 |
2024-02-07 |
Juno Therapeutics, Inc. |
Method to assess potency of viral vector particles
|
WO2022204274A1
(en)
|
2021-03-23 |
2022-09-29 |
Alector Llc |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
JP2024512567A
(ja)
|
2021-03-23 |
2024-03-19 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) |
T細胞リンパ腫の診断および治療方法
|
JP2024512035A
(ja)
|
2021-03-24 |
2024-03-18 |
ヤンセン バイオテツク,インコーポレーテツド |
Cd22及びcd79bを標的とする抗体
|
WO2022201053A1
(en)
|
2021-03-24 |
2022-09-29 |
Janssen Biotech, Inc. |
Proteins comprising cd3 antigen binding domains and uses thereof
|
EP4314049A1
(en)
|
2021-03-25 |
2024-02-07 |
Dynamicure Biotechnology LLC |
Anti-igfbp7 constructs and uses thereof
|
CA3212926A1
(en)
|
2021-03-26 |
2022-09-29 |
Gary Brandt |
2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
|
CN117940168A
(zh)
|
2021-03-26 |
2024-04-26 |
博尔特生物治疗药物有限公司 |
2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
|
MX2023011340A
(es)
|
2021-03-26 |
2023-12-14 |
Janssen Biotech Inc |
Anticuerpos humanizados contra el filamento helicoidal emparejado tau y usos de estos.
|
EP4314032A1
(en)
|
2021-03-30 |
2024-02-07 |
F. Hoffmann-La Roche AG |
Protease-activated polypeptides
|
PE20240357A1
(es)
|
2021-03-30 |
2024-02-27 |
Bayer Ag |
Anticuerpos anti-sema3a y usos de los mismos
|
US20240191272A1
(en)
|
2021-03-31 |
2024-06-13 |
Microbiopharm Japan Co., Ltd. |
Method for producing antibody-drug conjugate and enzyme used for the same
|
MX2023011690A
(es)
|
2021-04-02 |
2023-12-15 |
Amgen Inc |
Construcciones de unión a mageb2.
|
TW202304994A
(zh)
|
2021-04-02 |
2023-02-01 |
美商泰尼歐生物公司 |
促效性抗il-2r抗體及使用方法
|
EP4314068A1
(en)
|
2021-04-02 |
2024-02-07 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
AU2022255709A1
(en)
|
2021-04-06 |
2023-09-28 |
Teneobio, Inc. |
Anti-cd19 antibodies and car-t structures
|
EP4320153A1
(en)
|
2021-04-09 |
2024-02-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
CA3215049A1
(en)
|
2021-04-10 |
2022-10-13 |
Baiteng ZHAO |
Folr1 binding agents, conjugates thereof and methods of using the same
|
EP4322922A1
(en)
|
2021-04-12 |
2024-02-21 |
ACM Biolabs Pte Ltd |
Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
PE20240656A1
(es)
|
2021-04-16 |
2024-04-04 |
Teneobio Inc |
Anticuerpos anti-cd20 y estructuras car-t
|
IL307501A
(en)
|
2021-04-19 |
2023-12-01 |
Hoffmann La Roche |
Modified mammalian cells
|
CN117222412A
(zh)
|
2021-04-23 |
2023-12-12 |
豪夫迈·罗氏有限公司 |
Nk细胞接合剂相关的不良反应的预防或减轻
|
EP4326768A1
(en)
|
2021-04-23 |
2024-02-28 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
CN116917324A
(zh)
|
2021-04-26 |
2023-10-20 |
江苏恒瑞医药股份有限公司 |
抗Nectin-4抗体和抗Nectin-4抗体-药物偶联物及其医药用途
|
EP4329887A1
(en)
|
2021-04-28 |
2024-03-06 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
MX2023012699A
(es)
|
2021-04-30 |
2023-11-21 |
Hoffmann La Roche |
Dosificacion para el tratamiento con anticuerpo biespecifico anti-cd20/anti-cd3.
|
WO2022228705A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
US11931420B2
(en)
|
2021-04-30 |
2024-03-19 |
Celgene Corporation |
Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
|
MX2023012672A
(es)
|
2021-04-30 |
2024-01-18 |
Pf Medicament |
Nuevo anticuerpo anti-vista estable.
|
EP4334355A1
(en)
|
2021-05-03 |
2024-03-13 |
UCB Biopharma SRL |
Antibodies
|
US20240218057A1
(en)
|
2021-05-06 |
2024-07-04 |
The Rockefeller University |
Neutralizing anti- sars-cov-2 antibodies and methods of use thereof
|
CA3217180A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
IL308300A
(en)
|
2021-05-07 |
2024-01-01 |
Genmab As |
Pharmaceutical preparations containing bispecific antibodies that bind to B7H4 and CD3
|
CA3216795A1
(en)
|
2021-05-07 |
2022-11-10 |
Alpine Immune Sciences, Inc. |
Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
|
KR20240007184A
(ko)
|
2021-05-12 |
2024-01-16 |
제넨테크, 인크. |
미만성 거대 b세포 림프종을 치료하기 위해 항-cd79b 면역접합체를 사용하는 방법
|
CA3219425A1
(en)
|
2021-05-14 |
2022-11-17 |
Genentech, Inc. |
Agonists of trem2
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
KR20240009486A
(ko)
|
2021-05-19 |
2024-01-22 |
상하이 드 노보 파마테크 컴퍼니 리미티드 |
질소 함유 화합물, 이를 포함하는 접합체 및 이의 용도
|
WO2022245978A1
(en)
|
2021-05-19 |
2022-11-24 |
Sutro Biopharma, Inc. |
Anti-folate receptor conjugate combination therapy with bevacizumab
|
EP4341385A1
(en)
|
2021-05-21 |
2024-03-27 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
WO2022251311A1
(en)
|
2021-05-25 |
2022-12-01 |
Seagen Inc. |
Methods of quantifying anti-cd40 antibodies
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
MX2023014389A
(es)
|
2021-06-04 |
2024-03-04 |
Boehringer Ingelheim Int |
Anticuerpos anti-sirp-alfa.
|
WO2022255440A1
(en)
|
2021-06-04 |
2022-12-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
EP4351633A1
(en)
|
2021-06-08 |
2024-04-17 |
Biontech Cell & Gene Therapies Gmbh |
Agents and methods for activation and targeting of immune effector cells
|
WO2022258600A1
(en)
|
2021-06-09 |
2022-12-15 |
F. Hoffmann-La Roche Ag |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
CA3218481A1
(en)
|
2021-06-14 |
2022-12-22 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
WO2022262959A1
(en)
|
2021-06-15 |
2022-12-22 |
Astellas Pharma Europe Bv |
Bispecific binding agents binding to cldn18.2 and cd3
|
WO2022266221A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Monovalent anti-mertk antibodies and methods of use thereof
|
WO2022266223A1
(en)
|
2021-06-16 |
2022-12-22 |
Alector Llc |
Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
|
US20240279334A1
(en)
|
2021-06-17 |
2024-08-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
EP4355780A1
(en)
|
2021-06-18 |
2024-04-24 |
Alligator Bioscience AB |
Novel combination therapies and uses thereof
|
WO2022268740A1
(en)
|
2021-06-21 |
2022-12-29 |
Genmab A/S |
Combination dosage regime of cd137 and pd-l1 binding agents
|
EP4359440A1
(en)
|
2021-06-22 |
2024-05-01 |
Regeneron Pharmaceuticals, Inc. |
Anti-egfrviii antibody drug conjugates and uses thereof
|
WO2022271987A1
(en)
|
2021-06-23 |
2022-12-29 |
TeneoFour, Inc. |
Anti-cd38 antibodies and epitopes of same
|
WO2022269473A1
(en)
|
2021-06-23 |
2022-12-29 |
Janssen Biotech, Inc. |
Materials and methods for hinge regions in functional exogenous receptors
|
TW202317627A
(zh)
|
2021-06-25 |
2023-05-01 |
日商中外製藥股份有限公司 |
抗ctla-4抗體
|
EP4361176A1
(en)
|
2021-06-25 |
2024-05-01 |
Chugai Seiyaku Kabushiki Kaisha |
Use of anti-ctla-4 antibody
|
JP2024527551A
(ja)
|
2021-06-29 |
2024-07-25 |
シージェン インコーポレイテッド |
非フコシル化抗cd70抗体及びcd47アンタゴニストの組み合わせを用いるがんを処置する方法
|
MX2023015520A
(es)
|
2021-07-01 |
2024-01-22 |
Denali Therapeutics Inc |
Conjugados de oligonucleotidos dirigidos al receptor de transferrina.
|
WO2023275621A1
(en)
|
2021-07-01 |
2023-01-05 |
Compugen Ltd. |
Anti-tigit and anti-pvrig in monotherapy and combination treatments
|
TW202309078A
(zh)
|
2021-07-02 |
2023-03-01 |
美商建南德克公司 |
治療癌症之方法及組成物
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
TW202317633A
(zh)
|
2021-07-08 |
2023-05-01 |
美商舒泰神(加州)生物科技有限公司 |
特異性識別tnfr2的抗體及其用途
|
CA3225254A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
JP2024525769A
(ja)
|
2021-07-14 |
2024-07-12 |
舒泰神(北京)生物製薬股フン有限公司 |
Cd40を特異的に認識する抗体およびその使用
|
IL309856A
(en)
|
2021-07-14 |
2024-02-01 |
Genentech Inc |
Antibodies anti-C-C motif receptor 8 (CCR8) and methods of use
|
MX2024000678A
(es)
|
2021-07-15 |
2024-02-07 |
BioNTech SE |
Agentes que codifican elementos de union a cldn6 y cd3 para el tratamiento de canceres positivos para cldn6.
|
WO2023004304A1
(en)
|
2021-07-20 |
2023-01-26 |
Inhibrx, Inc. |
Cd8-binding polypeptides and uses thereof
|
TW202309102A
(zh)
|
2021-07-20 |
2023-03-01 |
美商英伊布里克斯公司 |
靶向cd8之經修飾il-2多肽及其用途
|
JP2024526880A
(ja)
|
2021-07-22 |
2024-07-19 |
ジェネンテック, インコーポレイテッド |
脳標的化組成物及びその使用方法
|
AU2022315528A1
(en)
|
2021-07-22 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
WO2023004197A1
(en)
|
2021-07-23 |
2023-01-26 |
Teneoten, Inc. |
Heavy chain antibodies binding to hepatitis b surface antigen
|
WO2023006809A1
(en)
|
2021-07-27 |
2023-02-02 |
Morphosys Ag |
Combinations of antigen binding molecules
|
WO2023007374A1
(en)
|
2021-07-27 |
2023-02-02 |
Pfizer Inc. |
Method of treatment of cancer pain with tanezumab
|
MX2024001214A
(es)
|
2021-07-28 |
2024-02-12 |
Hoffmann La Roche |
Metodos y composiciones para tratar cancer.
|
JP2024529381A
(ja)
|
2021-07-30 |
2024-08-06 |
アフィメド ゲーエムベーハー |
デュプレックスボディ
|
IL309934A
(en)
|
2021-07-30 |
2024-03-01 |
Ona Therapeutics S L |
Anti-CD36 antibodies and their use for cancer treatment
|
EP4380980A1
(en)
|
2021-08-03 |
2024-06-12 |
F. Hoffmann-La Roche AG |
Bispecific antibodies and methods of use
|
US20240336697A1
(en)
|
2021-08-07 |
2024-10-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
AU2022325950A1
(en)
|
2021-08-11 |
2024-02-22 |
Viela Bio, Inc. |
Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease
|
EP4384553A1
(en)
|
2021-08-13 |
2024-06-19 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
EP4388014A1
(en)
|
2021-08-19 |
2024-06-26 |
F. Hoffmann-La Roche AG |
Multivalent anti-variant fc-region antibodies and methods of use
|
GB202111905D0
(en)
|
2021-08-19 |
2021-10-06 |
UCB Biopharma SRL |
Antibodies
|
MX2024002187A
(es)
|
2021-08-20 |
2024-03-12 |
Tallac Therapeutics Inc |
Anticuerpos y conjugados de nectina-4.
|
JP2024534265A
(ja)
|
2021-08-23 |
2024-09-18 |
イミュニタス セラピューティクス,インコーポレーテッド |
抗cd161抗体及びその使用
|
JP2024529771A
(ja)
|
2021-08-26 |
2024-08-08 |
グリカノスティクス エス.アール.オー. |
がん診断のための糖タンパク質バイオマーカー
|
WO2023026245A1
(en)
|
2021-08-27 |
2023-03-02 |
H. Lundbeck A/S |
Treatment of cluster headache using anti-cgrp antibodies
|
MX2024002476A
(es)
|
2021-08-27 |
2024-05-20 |
Janssen Biotech Inc |
Anticuerpos anti-psma y usos de estos.
|
AU2022332303A1
(en)
|
2021-08-27 |
2024-02-01 |
Genentech, Inc. |
Methods of treating tau pathologies
|
EP4396223A1
(en)
|
2021-08-30 |
2024-07-10 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
JPWO2023032955A1
(xx)
|
2021-08-31 |
2023-03-09 |
|
|
WO2023031366A1
(en)
|
2021-09-02 |
2023-03-09 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Anti-cecam6 antibodies with reduced side-effects
|
JP2024533234A
(ja)
|
2021-09-06 |
2024-09-12 |
ジェンマブ エー/エス |
Cd27に結合する能力を有する抗体、そのバリアントおよびその使用
|
JP2024534976A
(ja)
|
2021-09-08 |
2024-09-26 |
ジョイント・ストック・カンパニー “バイオキャド” |
Mhcタンパク質に基づくヘテロ二量体を含む二重特異性抗体
|
AU2022346688A1
(en)
|
2021-09-14 |
2024-04-04 |
Glycanostics S.R.O |
Use of lectins to determine mammaglobin-a glycoforms in breast cancer
|
JP2024535060A
(ja)
|
2021-09-16 |
2024-09-26 |
アボレリス ファーマ |
抗ヒトcd45rc結合ドメインおよびその使用
|
TW202327650A
(zh)
|
2021-09-23 |
2023-07-16 |
美商思進公司 |
治療多發性骨髓瘤之方法
|
EP4405392A1
(en)
|
2021-09-24 |
2024-07-31 |
Janssen Biotech, Inc. |
Proteins comprising cd20 binding domains, and uses thereof
|
KR20240049832A
(ko)
|
2021-09-27 |
2024-04-17 |
조에티스 서비시즈 엘엘씨 |
항-TGFβ1,2,3 항체 및 이의 치료적 용도
|
WO2023053282A1
(ja)
|
2021-09-29 |
2023-04-06 |
中外製薬株式会社 |
がんの治療に用いるための細胞傷害誘導治療剤
|
WO2023056069A1
(en)
|
2021-09-30 |
2023-04-06 |
Angiex, Inc. |
Degrader-antibody conjugates and methods of using same
|
TW202330038A
(zh)
|
2021-09-30 |
2023-08-01 |
美商思進公司 |
用於治療癌症之b7-h4抗體-藥物結合物
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法
|
KR20240082387A
(ko)
|
2021-10-06 |
2024-06-10 |
젠맵 에이/에스 |
암을 치료하기 위한 항 pd-1 항체와 조합된 pd-l1 및 cd137에 대한 다중특이적 결합제
|
IL311771A
(en)
|
2021-10-06 |
2024-05-01 |
BioNTech SE |
Multispecific binding agents against PD-L1 and CD137 in combination
|
IL311805A
(en)
|
2021-10-08 |
2024-05-01 |
Genmab As |
Antibodies that bind to CD30 and CD3
|
CN116064598B
(zh)
|
2021-10-08 |
2024-03-12 |
苏州艾博生物科技有限公司 |
冠状病毒的核酸疫苗
|
JPWO2023058723A1
(xx)
|
2021-10-08 |
2023-04-13 |
|
|
AR127273A1
(es)
*
|
2021-10-09 |
2024-01-03 |
Hutchmed Ltd |
Anticuerpos biespecíficos que se unen específicamente a cd47 y her2 y usos de los mismos
|
KR20240082349A
(ko)
|
2021-10-14 |
2024-06-10 |
에프. 호프만-라 로슈 아게 |
새로운 인터루킨-7 면역접합체
|
EP4429706A1
(en)
|
2021-10-14 |
2024-09-18 |
F. Hoffmann-La Roche AG |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
WO2023069919A1
(en)
|
2021-10-19 |
2023-04-27 |
Alector Llc |
Anti-cd300lb antibodies and methods of use thereof
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
WO2023076599A1
(en)
|
2021-10-29 |
2023-05-04 |
Bolt Biotherapeutics, Inc. |
Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
|
KR20240099363A
(ko)
|
2021-10-29 |
2024-06-28 |
씨젠 인크. |
항-pd-1 항체와 항-cd30 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법
|
KR20240102981A
(ko)
|
2021-11-02 |
2024-07-03 |
비스테라, 인크. |
Fc감마r 및 c1q에 대한 결합이 제거된 fc 변이체
|
CA3237018A1
(en)
|
2021-11-03 |
2023-05-11 |
Joachim Koch |
Bispecific cd16a binders
|
AR127568A1
(es)
|
2021-11-03 |
2024-02-07 |
Affimed Gmbh |
Ligandos biespecíficos de cd16a
|
EP4426748A1
(en)
|
2021-11-05 |
2024-09-11 |
American Diagnostics & Therapy, LLC (ADXRX) |
Monoclonal antibodies against carcinoembryonic antigens, and their uses
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
EP4180061A1
(en)
|
2021-11-10 |
2023-05-17 |
Nerviano Medical Sciences S.r.l. |
Anthracycline derivative linker reagents, antibody-drug conjugates and methods
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
IL312692A
(en)
|
2021-11-16 |
2024-07-01 |
Genentech Inc |
Methods and compositions for the treatment of systemic lupus erythematosus (SLE) with musontuzumab
|
WO2023088959A1
(en)
|
2021-11-16 |
2023-05-25 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
WO2023089314A1
(en)
|
2021-11-18 |
2023-05-25 |
Oxford Biotherapeutics Limited |
Pharmaceutical combinations
|
CN118414173A
(zh)
|
2021-11-18 |
2024-07-30 |
阿斯利康(英国)有限公司 |
抗体-药物缀合物和parp1选择性抑制剂的组合
|
AU2022392804A1
(en)
|
2021-11-19 |
2024-05-02 |
Mirobio Limited |
Engineered PD-1 antibodies and uses thereof
|
MX2024006303A
(es)
|
2021-11-25 |
2024-06-12 |
Hoffmann La Roche |
Receptores de union al antigeno mejorados.
|
EP4437006A1
(en)
|
2021-11-26 |
2024-10-02 |
F. Hoffmann-La Roche AG |
Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
|
AU2022402850A1
(en)
|
2021-12-01 |
2024-06-06 |
Sutro Biopharma, Inc. |
Anti-folate receptor conjugate cancer therapy
|
WO2023099578A1
(en)
|
2021-12-01 |
2023-06-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neutralizing anti-cd95l monoclonal antibodies
|
JP7367262B1
(ja)
|
2021-12-01 |
2023-10-23 |
中外製薬株式会社 |
抗体含有製剤の調製方法
|
EP4445911A1
(en)
|
2021-12-06 |
2024-10-16 |
Beijing SoloBio Genetechnology Co., Ltd. |
Bispecific antibody that specifically binds to klebsiella pneumoniae o2 and o1 antigens, and composition
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
WO2023105528A1
(en)
|
2021-12-12 |
2023-06-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Antibodies specific to ceacam1
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
IL313169A
(en)
|
2021-12-15 |
2024-07-01 |
Genentech Inc |
Stabilized IL-18 polypeptides and their uses
|
EP4448579A1
(en)
|
2021-12-17 |
2024-10-23 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies and methods of use
|
WO2023109900A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
CR20240246A
(es)
|
2021-12-20 |
2024-07-19 |
Hoffmann La Roche |
Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
|
AU2022419233A1
(en)
|
2021-12-22 |
2024-07-04 |
Incyte Corporation |
Treatment paradigm for an anti-cd19 antibody therapy
|
WO2023116861A1
(zh)
|
2021-12-23 |
2023-06-29 |
江苏恒瑞医药股份有限公司 |
抗dll3抗体、其抗体-药物偶联物及其医药用途
|
TW202333800A
(zh)
|
2021-12-28 |
2023-09-01 |
英商阿斯特捷利康英國股份有限公司 |
抗體-藥物結合物及rasg12c抑制劑之組合
|
IL313929A
(en)
|
2021-12-28 |
2024-08-01 |
Astrazeneca Uk Ltd |
Combining an antibody-drug conjugate and an ATR inhibitor
|
TW202330619A
(zh)
|
2021-12-28 |
2023-08-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗ror1抗體和抗ror1抗體藥物偶聯物及其醫藥用途
|
WO2023133394A1
(en)
|
2022-01-05 |
2023-07-13 |
Inhibrx, Inc. |
Gamma delta t-cell-binding polypeptides and uses thereof
|
TW202334193A
(zh)
|
2022-01-05 |
2023-09-01 |
美商英伊布里克斯公司 |
靶向γδ T細胞之經修飾IL-2多肽及其用途
|
TW202337904A
(zh)
|
2022-01-07 |
2023-10-01 |
美商壯生和壯生企業創新公司 |
IL-1β結合蛋白之材料及方法
|
AU2023207960A1
(en)
|
2022-01-12 |
2024-07-11 |
Regeneron Pharmaceuticals, Inc. |
Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
|
TW202340251A
(zh)
|
2022-01-19 |
2023-10-16 |
美商建南德克公司 |
抗notch2抗體及結合物及其使用方法
|
WO2023138682A1
(zh)
|
2022-01-24 |
2023-07-27 |
北京桦冠生物技术有限公司 |
缀合物及其用途
|
AR128331A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
|
AR128330A1
(es)
|
2022-01-26 |
2024-04-17 |
Genentech Inc |
Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
IL314344A
(en)
|
2022-01-28 |
2024-09-01 |
Genmab As |
Bispecific antibodies against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
|
MX2024008832A
(es)
|
2022-01-28 |
2024-07-25 |
Genmab As |
Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para tratar linfoma difuso de celulas b grandes.
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
AU2023215613A1
(en)
|
2022-02-02 |
2024-08-08 |
BioNTech SE |
Agents and methods for targeted delivery to cells
|
AU2023216437A1
(en)
|
2022-02-02 |
2024-08-15 |
BioNTech SE |
Agents and methods for targeted delivery of nucleic acids to cells
|
WO2023148275A1
(en)
|
2022-02-02 |
2023-08-10 |
BioNTech SE |
Cyclic epitope tags
|
WO2023152581A1
(en)
|
2022-02-09 |
2023-08-17 |
Janssen Biotech, Inc. |
Method of treating cancer with psmaxcd3 antibody
|
KR20240149420A
(ko)
|
2022-02-09 |
2024-10-14 |
얀센 바이오테크 인코포레이티드 |
V 베타 17 이중특이성 t 세포 인게이저 및 생물공학적 바이러스 특이적 림프구를 포함하는 조성물 및 방법
|
AR128540A1
(es)
|
2022-02-16 |
2024-05-22 |
Ac Immune Sa |
Moléculas de unión anti-tdp-43 humanizadas y usos de las mismas
|
WO2023156437A1
(en)
|
2022-02-16 |
2023-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-robo4 human monoclonal antibodies and uses thereof for the treatment of cancer
|
WO2023156587A1
(en)
|
2022-02-18 |
2023-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
|
TW202400228A
(zh)
|
2022-02-25 |
2024-01-01 |
美商再生元醫藥公司 |
減輕細胞激素釋放症候群的給藥方案
|
WO2023161412A1
(en)
|
2022-02-25 |
2023-08-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies for preventing the cleavage of cd95l by metalloproteases
|
WO2023166081A1
(en)
|
2022-03-02 |
2023-09-07 |
Heidelberg Immunotherapeutics Gmbh |
Vaccine comprising an antibody or an fc-containing fusion protein comprising an fc part of an antibody
|
IL315341A
(en)
|
2022-03-02 |
2024-10-01 |
Daiichi Sankyo Co Ltd |
A method for producing a molecule containing Fc
|
AU2023228330A1
(en)
|
2022-03-02 |
2024-09-19 |
Biomunex Pharmaceuticals |
Bispecific antibodies binding to her-3 and to either her-2 or egfr
|
WO2023168426A1
(en)
|
2022-03-03 |
2023-09-07 |
Enosi Therapeutics Corporation |
Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
AU2023230951A1
(en)
|
2022-03-09 |
2024-09-05 |
Merck Patent Gmbh |
Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
|
WO2023170239A1
(en)
|
2022-03-09 |
2023-09-14 |
Merck Patent Gmbh |
Methods and tools for conjugation to antibodies
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
TW202346355A
(zh)
|
2022-03-11 |
2023-12-01 |
比利時商健生藥品公司 |
多特異性抗體及其用途(二)
|
WO2023170295A1
(en)
|
2022-03-11 |
2023-09-14 |
Janssen Pharmaceutica Nv |
Multispecific antibodies and uses thereof
|
IL314828A
(en)
|
2022-03-11 |
2024-10-01 |
Mablink Bioscience |
Antibody-drug conjugates and their uses
|
TW202400636A
(zh)
|
2022-03-11 |
2024-01-01 |
比利時商健生藥品公司 |
多特異性抗體及其用途(一)
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
IL314907A
(en)
|
2022-03-15 |
2024-10-01 |
Yeda Res & Dev |
Antibodies against GITR and their uses
|
WO2023175483A1
(en)
|
2022-03-16 |
2023-09-21 |
Astrazeneca Uk Limited |
A scoring method for an anti-trop2 antibody‑drug conjugate therapy
|
US20240103010A1
(en)
|
2022-03-18 |
2024-03-28 |
Compugen Ltd. |
Pvrl2 and/or pvrig as biomarkers for treatment
|
WO2023180346A1
(en)
|
2022-03-22 |
2023-09-28 |
Morphosys Ag |
Deimmunized antibodies specific for cd3
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
AU2023240941A1
(en)
|
2022-03-25 |
2024-09-19 |
Shanghai Henlius Biologics Co., Ltd. |
Anti-msln antibodies and methods of use
|
AR128876A1
(es)
|
2022-03-28 |
2024-06-19 |
Hoffmann La Roche |
Anticuerpos biespecíficos de linfocitos t activables con proteasa folr1 mejorados
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
AR128956A1
(es)
|
2022-04-01 |
2024-06-26 |
Genentech Inc |
Derivados de hidroxipropilmetilcelulosa para estabilizar polipéptidos
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023196903A1
(en)
|
2022-04-06 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
|
WO2023196866A1
(en)
|
2022-04-06 |
2023-10-12 |
Mirobio Limited |
Engineered cd200r antibodies and uses thereof
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
WO2023196943A1
(en)
|
2022-04-08 |
2023-10-12 |
Inhibrx, Inc. |
Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
WO2023201226A1
(en)
|
2022-04-11 |
2023-10-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
WO2023201299A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
WO2023198839A2
(en)
|
2022-04-13 |
2023-10-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
AU2023251832A1
(en)
|
2022-04-13 |
2024-10-17 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
WO2023203177A1
(en)
|
2022-04-20 |
2023-10-26 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
|
TW202400140A
(zh)
|
2022-04-27 |
2024-01-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合
|
WO2023212675A1
(en)
|
2022-04-28 |
2023-11-02 |
Allogene Therapeutics Inc. |
Methods for donor cell analysis
|
WO2023212294A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Angiopoietin-related protein 7-specific antibodies and uses thereof
|
WO2023212293A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Complement factor h related 4-specific antibodies and uses thereof
|
WO2023212298A1
(en)
|
2022-04-29 |
2023-11-02 |
Broadwing Bio Llc |
Bispecific antibodies and methods of treating ocular disease
|
WO2023213814A1
(en)
|
2022-05-02 |
2023-11-09 |
Pierre Fabre Medicament |
New formulation of anti vista antibody
|
TW202406934A
(zh)
|
2022-05-03 |
2024-02-16 |
美商建南德克公司 |
抗Ly6E抗體、免疫結合物及其用途
|
WO2023215810A1
(en)
|
2022-05-05 |
2023-11-09 |
Inhibrx, Inc. |
Albumin-binding polypeptides and uses thereof
|
WO2023213960A1
(en)
|
2022-05-06 |
2023-11-09 |
Genmab A/S |
Methods of treating cancer with anti-tissue factor antibody-drug conjugates
|
TW202400650A
(zh)
|
2022-05-11 |
2024-01-01 |
日商第一三共股份有限公司 |
抗體與cd47抑制劑之組合
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
AR129268A1
(es)
|
2022-05-11 |
2024-08-07 |
Hoffmann La Roche |
Anticuerpo que se une a vegf-a e il6 y métodos de uso
|
WO2023218320A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Anti-lymphotoxin beta receptor antibodies and methods of use thereof
|
WO2023218051A1
(en)
|
2022-05-12 |
2023-11-16 |
Genmab A/S |
Binding agents capable of binding to cd27 in combination therapy
|
TW202413412A
(zh)
|
2022-05-12 |
2024-04-01 |
丹麥商珍美寶股份有限公司 |
在組合療法中能夠結合到cd27之結合劑
|
WO2023218027A1
(en)
|
2022-05-12 |
2023-11-16 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
WO2023218099A1
(en)
|
2022-05-13 |
2023-11-16 |
argenx BV |
In utero treatment of a fetus having genetic disease/neuromuscular disease
|
WO2023222557A1
(en)
|
2022-05-17 |
2023-11-23 |
Bayer Aktiengesellschaft |
Radiopharmaceutical complexes targeting prostate-specific membrane antigen and its combinations
|
EP4279092A1
(en)
|
2022-05-17 |
2023-11-22 |
Bayer AG |
Radiopharmaceutical complexes targeting prostate-specific membrane antigen
|
WO2023225098A1
(en)
|
2022-05-18 |
2023-11-23 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
|
WO2023225359A1
(en)
|
2022-05-20 |
2023-11-23 |
Novartis Ag |
Antibody-drug conjugates of antineoplastic compounds and methods of use thereof
|
WO2023230432A1
(en)
|
2022-05-23 |
2023-11-30 |
Inhibrx, Inc. |
Dr5 agonist and iap antagonist combination therapy
|
WO2023228082A1
(en)
|
2022-05-26 |
2023-11-30 |
Pfizer Inc. |
Anti-tnfr2 antibodies and methods of use thereof
|
WO2023230532A1
(en)
|
2022-05-26 |
2023-11-30 |
Compugen Ltd. |
Anti-tigit antibody formulation
|
TW202405002A
(zh)
|
2022-05-31 |
2024-02-01 |
美商輝瑞大藥廠 |
抗-bmp9抗體及其使用方法
|
WO2023235699A1
(en)
|
2022-05-31 |
2023-12-07 |
Jounce Therapeutics, Inc. |
Antibodies to lilrb4 and uses thereof
|
WO2023235847A1
(en)
|
2022-06-02 |
2023-12-07 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023239803A1
(en)
|
2022-06-08 |
2023-12-14 |
Angiex, Inc. |
Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
|
WO2023240218A1
(en)
|
2022-06-09 |
2023-12-14 |
Allogene Therapeutics Inc. |
Methods for detecting genomic abnormalities in cells
|
TW202421661A
(zh)
|
2022-06-10 |
2024-06-01 |
愛爾蘭商赫瑞森治療學愛爾蘭指定活動公司 |
Igf1r抗體
|
TW202409086A
(zh)
|
2022-06-11 |
2024-03-01 |
美商英伊布里克斯公司 |
FcRn-結合多肽及其用途
|
WO2023245008A1
(en)
|
2022-06-13 |
2023-12-21 |
Genentech, Inc. |
Methods of delaying or preventing the onset of alzheimer's disease using crenezumab
|
WO2023242769A1
(en)
|
2022-06-17 |
2023-12-21 |
Pfizer Inc. |
Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof
|
WO2023247050A1
(en)
|
2022-06-23 |
2023-12-28 |
Alligator Bioscience Ab |
Combination therapies
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
WO2024006542A1
(en)
|
2022-06-30 |
2024-01-04 |
Sutro Biopharma, Inc. |
Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
|
TW202417042A
(zh)
|
2022-07-13 |
2024-05-01 |
美商建南德克公司 |
用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020051A1
(en)
|
2022-07-19 |
2024-01-25 |
BioLegend, Inc. |
Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
TW202417504A
(zh)
|
2022-07-22 |
2024-05-01 |
美商建南德克公司 |
抗steap1抗原結合分子及其用途
|
WO2024018426A1
(en)
|
2022-07-22 |
2024-01-25 |
Janssen Biotech, Inc. |
Enhanced transfer of genetic instructions to effector immune cells
|
US20240228664A9
(en)
|
2022-07-22 |
2024-07-11 |
Bristol-Myers Squibb Company |
Antibodies Binding to Human PAD4 and Uses Thereof
|
GB202210965D0
(en)
|
2022-07-27 |
2022-09-07 |
Alligator Bioscience Ab |
Novel dosages
|
GB202210957D0
(en)
|
2022-07-27 |
2022-09-07 |
Alligator Bioscience Ab |
Novel dosages
|
WO2024023750A1
(en)
|
2022-07-28 |
2024-02-01 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
|
WO2024026447A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Anti-gpnmb antibodies and methods of use thereof
|
WO2024026472A2
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Transferrin receptor antigen-binding domains and uses therefor
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
WO2024030856A2
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
US20240052047A1
(en)
|
2022-08-03 |
2024-02-15 |
Pfizer Inc. |
Anti- il27r antibodies and methods of use thereof
|
WO2024028731A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Transferrin receptor binding proteins for treating brain tumors
|
WO2024028732A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Cd98 binding constructs for treating brain tumors
|
WO2024036139A2
(en)
|
2022-08-09 |
2024-02-15 |
Qlsf Biotherapeutics, Inc. |
Antibodies binding to clec12a
|
US20240085403A1
(en)
|
2022-08-16 |
2024-03-14 |
Allogene Therapeutics, Inc. |
Method for inhibiting adventitious viral infection
|
WO2024040114A2
(en)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
|
WO2024038165A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Ltd |
T cell receptor fusion proteins specific for mage a4
|
TW202417034A
(zh)
|
2022-08-19 |
2024-05-01 |
大陸商億一生物醫藥開發(上海)有限公司 |
包含g—csf之調配物及其用途
|
WO2024050524A1
(en)
|
2022-09-01 |
2024-03-07 |
University Of Georgia Research Foundation, Inc. |
Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024054929A1
(en)
|
2022-09-07 |
2024-03-14 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024064600A2
(en)
|
2022-09-19 |
2024-03-28 |
Allogene Therapeutics Inc. |
B-cell maturation antigen (bcma) anti-idiotypic antibodies
|
WO2024061223A1
(zh)
*
|
2022-09-20 |
2024-03-28 |
普米斯生物技术(珠海)有限公司 |
抗体及其在抗肿瘤中的应用
|
WO2024061224A1
(zh)
*
|
2022-09-20 |
2024-03-28 |
普米斯生物技术(珠海)有限公司 |
抗her2抗体及其用途
|
TW202421193A
(zh)
|
2022-09-28 |
2024-06-01 |
美商英塞特公司 |
抗pd-1/lag-3雙特異性抗體及其用途
|
WO2024068572A1
(en)
|
2022-09-28 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Improved protease-activatable t cell bispecific antibodies
|
WO2024068705A1
(en)
|
2022-09-29 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Protease-activated polypeptides
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
EP4345113A1
(en)
|
2022-09-30 |
2024-04-03 |
SDS Optic Spolka Akcyjna |
Anti-her2 antibody, a nucleic acid molecule encoding the variable region of said antibody, a method of detecting her2 in a biological sample, an immuno-enzymatic elisa assay and use of said anti-her2 antibody or fragments therefof
|
WO2024077018A2
(en)
|
2022-10-04 |
2024-04-11 |
Alpine Immune Sciences, Inc. |
Methods and uses of taci-fc fusion immunomodulatory protein
|
WO2024077044A1
(en)
|
2022-10-05 |
2024-04-11 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
WO2024077118A2
(en)
|
2022-10-06 |
2024-04-11 |
Bicara Therapeutics Inc. |
Multispecific proteins and related methods
|
WO2024077239A1
(en)
|
2022-10-07 |
2024-04-11 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|
WO2024079015A1
(en)
|
2022-10-10 |
2024-04-18 |
F. Hoffmann-La Roche Ag |
Combination therapy of a gprc5d tcb and imids
|
TW202423970A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Gprc5d tcb及cd38抗體之組合療法
|
WO2024081180A1
(en)
|
2022-10-10 |
2024-04-18 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing alloantibody levels in subjects in need of solid organ transplantation
|
TW202423969A
(zh)
|
2022-10-10 |
2024-06-16 |
瑞士商赫孚孟拉羅股份公司 |
Gprc5d tcb及蛋白酶體抑制劑之組合療法
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|
GB202215115D0
(en)
|
2022-10-13 |
2022-11-30 |
Univ Nottingham |
VEGF antibodies
|
WO2024083790A1
(en)
|
2022-10-17 |
2024-04-25 |
Institut Gustave Roussy |
Cd207 dendritic cells as a biomarker for tumoural progression and therapeutic target
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
TW202426505A
(zh)
|
2022-10-25 |
2024-07-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
WO2024094822A1
(en)
|
2022-11-02 |
2024-05-10 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20 for treating richter's syndrome
|
WO2024097816A1
(en)
|
2022-11-03 |
2024-05-10 |
Seagen Inc. |
Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer
|
WO2024094741A1
(en)
|
2022-11-03 |
2024-05-10 |
F. Hoffmann-La Roche Ag |
Combination therapy with anti-cd19/anti-cd28 bispecific antibody
|
WO2024097741A1
(en)
|
2022-11-04 |
2024-05-10 |
Gilead Sciences, Inc. |
Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
WO2024100200A1
(en)
|
2022-11-09 |
2024-05-16 |
Cis Pharma Ag |
Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
WO2024104933A1
(en)
|
2022-11-15 |
2024-05-23 |
F. Hoffmann-La Roche Ag |
Antigen binding molecules
|
WO2024105223A1
(en)
|
2022-11-17 |
2024-05-23 |
Polygon Therapeutics |
Anti-cd8 alpha depleting antibodies
|
WO2024108053A1
(en)
|
2022-11-17 |
2024-05-23 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
WO2024118593A1
(en)
|
2022-11-28 |
2024-06-06 |
Allogene Therapeutics Inc. |
Claudin 18.2 targeting chimeric antigen receptors and binding agents and uses thereof
|
WO2024116094A1
(en)
|
2022-11-30 |
2024-06-06 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugates and dnmt inhibitors
|
WO2024115725A1
(en)
|
2022-12-01 |
2024-06-06 |
BioNTech SE |
Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
|
WO2024129594A1
(en)
|
2022-12-12 |
2024-06-20 |
Genentech, Inc. |
Optimizing polypeptide sialic acid content
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
US20240228639A1
(en)
|
2022-12-14 |
2024-07-11 |
Allogene Therapeutics, Inc. |
Cd70 anti-idiotype antibodies
|
WO2024126457A1
(en)
|
2022-12-14 |
2024-06-20 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|
WO2024133052A1
(en)
|
2022-12-19 |
2024-06-27 |
Universität Basel Vizerektorat Forschung |
T-cell receptor fusion protein
|
US20240269308A1
(en)
|
2022-12-21 |
2024-08-15 |
Regeneron Pharmaceuticals, Inc. |
Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
|
WO2024138128A2
(en)
|
2022-12-23 |
2024-06-27 |
Genentech, Inc. |
Cereblon degrader conjugates, and uses thereof
|
WO2024148232A2
(en)
|
2023-01-06 |
2024-07-11 |
Alector Llc |
Anti-il18 binding protein antibodies and methods of use thereof
|
WO2024151515A2
(en)
|
2023-01-09 |
2024-07-18 |
Odyssey Therapeutics, Inc. |
Anti-tnfr2 antigen-binding proteins and uses thereof
|
WO2024155807A1
(en)
|
2023-01-18 |
2024-07-25 |
Genentech, Inc. |
Multispecific antibodies and uses thereof
|
WO2024153722A1
(en)
|
2023-01-20 |
2024-07-25 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
WO2024156672A1
(en)
|
2023-01-25 |
2024-08-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to csf1r and cd3
|
WO2024163009A1
(en)
|
2023-01-31 |
2024-08-08 |
Genentech, Inc. |
Methods and compositions for treating urothelial bladder cancer
|
WO2024163494A1
(en)
|
2023-01-31 |
2024-08-08 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating non-small cell lung cancer and triple-negative breast cancer
|
WO2024167885A1
(en)
|
2023-02-06 |
2024-08-15 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory compositions and related methods
|
WO2024165146A1
(en)
|
2023-02-07 |
2024-08-15 |
Biontech Cell & Gene Therapies Gmbh |
Immune effector cells stably and transiently expressing nucleic acids
|
WO2024165045A1
(en)
|
2023-02-09 |
2024-08-15 |
Beigene, Ltd. |
Self-stabilizing linker conjugates
|
US20240327538A1
(en)
|
2023-02-10 |
2024-10-03 |
Amunix Pharmaceuticals, Inc. |
Compositions targeting prostate-specific membrane antigen and methods for making and using the same
|
WO2024173387A1
(en)
|
2023-02-14 |
2024-08-22 |
Bolt Biotherapeutics, Inc. |
Aza-benzazepine immunoconjugates, and uses thereof
|
WO2024170543A1
(en)
|
2023-02-14 |
2024-08-22 |
Institut National de la Santé et de la Recherche Médicale |
Anti-cd44 antibodies and uses thereof
|
WO2024170756A1
(en)
|
2023-02-17 |
2024-08-22 |
Ablynx N.V. |
Polypeptides binding to the neonatal fc receptor
|
WO2024173830A2
(en)
|
2023-02-17 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
Induced nk cells responsive to cd3/taa bispecific antibodies
|
WO2024186690A2
(en)
|
2023-03-03 |
2024-09-12 |
Enosi Therapeutics Corporation |
Oligo-trap fusion proteins (ofps) and uses thereof
|
WO2024186626A1
(en)
|
2023-03-03 |
2024-09-12 |
Bolt Biotherapeutics, Inc. |
Aza-bicyclic sting agonist immunoconjugates, and uses thereof
|
WO2024184287A1
(en)
|
2023-03-06 |
2024-09-12 |
F. Hoffmann-La Roche Ag |
Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
|
WO2024184494A1
(en)
|
2023-03-08 |
2024-09-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules and uses thereof
|
WO2024187062A1
(en)
|
2023-03-08 |
2024-09-12 |
Amgen Inc. |
Controlled-ice nucleation lyophilization process for bispecific molecules
|
US20240343820A1
(en)
|
2023-03-09 |
2024-10-17 |
Kite Pharma, Inc. |
Antigen binding molecules and methods of use
|
WO2024191785A1
(en)
|
2023-03-10 |
2024-09-19 |
Genentech, Inc. |
Fusions with proteases and uses thereof
|
WO2024188965A1
(en)
|
2023-03-13 |
2024-09-19 |
F. Hoffmann-La Roche Ag |
Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
|
WO2024191983A1
(en)
|
2023-03-13 |
2024-09-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with bispecific anti-cd22 x anti-cd28 molecules
|
WO2024192065A1
(en)
|
2023-03-14 |
2024-09-19 |
Odyssey Therapeutics, Inc. |
Anti-cd25 antigen-binding proteins and uses thereof
|
WO2024188356A1
(en)
|
2023-03-16 |
2024-09-19 |
Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. |
Ilt7-targeting antibodies and uses thereof
|
WO2024194685A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
WO2024194686A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
WO2024194851A1
(en)
|
2023-03-23 |
2024-09-26 |
Beigene Switzerland Gmbh |
Bioactive conjugate, preparation method therefor and use thereof
|
WO2024200637A2
(en)
|
2023-03-29 |
2024-10-03 |
Boehringer Ingelheim International Gmbh |
Dosing schedule of a her2 inhibitor
|
US20240327522A1
(en)
|
2023-03-31 |
2024-10-03 |
Genentech, Inc. |
Anti-alpha v beta 8 integrin antibodies and methods of use
|
WO2024208777A1
(en)
|
2023-04-03 |
2024-10-10 |
F. Hoffmann-La Roche Ag |
All-in-one agonistic antibodies
|
WO2024208776A1
(en)
|
2023-04-03 |
2024-10-10 |
F. Hoffmann-La Roche Ag |
Agonistic split antibodies
|
WO2024211236A2
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2024208898A1
(en)
|
2023-04-05 |
2024-10-10 |
Genmab A/S |
Pharmaceutical compositions comprising antibodies binding to cd30 and cd3
|
WO2024211235A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2024211234A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2024209072A1
(en)
|
2023-04-06 |
2024-10-10 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 for treating cancer
|
CN117224689B
(zh)
*
|
2023-11-16 |
2024-02-23 |
上海复宏汉霖生物技术股份有限公司 |
联合抗her2抗体和化疗剂治疗胃癌的用途
|